Patient ID,NRIC_Last5,Full Patient Name,DOTS (dd/mm/yyyy),Blood Test Date (dd/mm/yyyy),Care Setting,Immunosuppressant Used,Serum Creatinine (µmol/L),eGFR (mL/min/1.73 m²),Albumin (g/L),Urea (mmol/L),Sodium (mmol/L),Potassium (mmol/L),Bicarbonate (mmol/L),ALT (U/L),AST (U/L),ALP (U/L),GGT (U/L),Total Bilirubin (µmol/L),Total Cholesterol (mmol/L),LDL-C (mmol/L),HDL-C (mmol/L),Triglycerides (mmol/L),WBC (×10⁹/L),Haemoglobin (g/dL),Platelets (×10⁹/L),Drug Trough C0 (ng/mL),Drug C2 (ng/mL),Estimated Dose (mg/day),Genotypes (CYP3A5),Genotypes (ABCB1 3435C>T),Weight (kg),Genotypes (CYP3A4),CYP3A5 phenotype,CYP3A4 phenotype,ABCB1 3435C>T phenotype,Tac Genetic Dose Factor,AI Predicted Dose (mg/day),Target Trough Range (ng/mL),Prediction Confidence
RT1001,3401P,Ng Yong Jun,30/5/2025,1/6/2025,Inpatient,Sirolimus,132.1,59.2,36.0,6.7,138,3.6,20,31,11,84,81,15,4.4,2.0,1.5,2.2,6.1,13.8,170,9.03,,3.38,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,1/7/2025,Outpatient,Sirolimus,96.2,99.9,40.0,9.2,137,4.1,21,29,8,93,60,8,7.3,5.0,1.2,2.2,7.1,14.2,284,8.72,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,1/8/2025,Outpatient,Sirolimus,76.5,106.4,38.7,2.6,136,3.7,23,23,15,119,74,18,5.6,3.8,1.2,1.4,3.7,12.3,241,7.77,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,2/6/2025,Inpatient,Sirolimus,132.0,65.6,36.7,9.5,141,4.3,24,47,33,78,56,13,6.4,4.6,1.4,1.0,9.4,13.7,153,9.77,,3.38,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,2/7/2025,Outpatient,Sirolimus,111.7,111.8,39.6,8.7,137,3.5,22,18,23,68,58,19,5.8,4.1,0.9,1.8,7.1,13.0,238,8.18,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,2/8/2025,Outpatient,Sirolimus,70.8,120.0,36.9,4.7,134,3.9,24,8,21,84,49,3,6.4,4.8,1.1,1.2,4.9,13.1,275,5.62,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,3/6/2025,Inpatient,Sirolimus,110.7,47.0,36.2,9.9,138,3.7,25,16,34,122,72,14,5.7,3.6,1.3,1.8,7.9,12.4,151,8.97,,3.38,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,3/7/2025,Outpatient,Sirolimus,107.0,89.9,40.5,5.4,138,4.5,23,29,8,61,58,19,6.3,4.2,1.0,2.2,7.4,13.6,350,6.28,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,3/8/2025,Outpatient,Sirolimus,80.7,109.3,40.9,6.0,142,4.2,24,10,8,96,60,9,6.1,3.8,1.2,2.4,4.7,12.8,250,6.06,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,4/6/2025,Inpatient,Sirolimus,130.2,53.8,35.6,9.7,138,4.5,24,31,16,117,90,16,5.5,3.7,1.1,1.6,6.7,12.3,229,9.46,,3.38,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,4/7/2025,Outpatient,Sirolimus,99.0,93.4,38.9,5.9,138,4.4,24,21,28,88,66,18,5.4,3.7,1.0,1.4,5.8,12.6,158,8.17,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,4/8/2025,Outpatient,Sirolimus,75.2,119.7,39.5,5.0,141,3.6,27,20,12,92,61,13,6.6,4.3,1.1,2.6,7.4,11.7,261,7.38,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,5/6/2025,Inpatient,Sirolimus,131.9,60.4,36.4,8.8,142,3.9,24,38,30,74,88,18,5.2,3.1,1.3,1.9,5.4,12.4,218,5.56,,3.38,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,5/7/2025,Outpatient,Sirolimus,126.6,71.0,40.6,9.5,136,4.0,25,33,9,95,58,21,6.1,3.9,1.4,1.9,6.2,12.3,233,7.39,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,5/8/2025,Outpatient,Sirolimus,71.3,111.2,40.7,6.0,138,3.8,25,10,8,90,63,14,5.3,3.4,1.0,1.9,8.3,13.9,156,4.46,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,6/6/2025,Inpatient,Sirolimus,120.2,81.5,36.1,11.5,139,3.9,21,22,32,102,51,10,5.6,3.5,1.2,2.0,7.2,12.5,236,6.48,,3.38,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,6/7/2025,Outpatient,Sirolimus,108.1,91.3,39.3,4.7,138,5.0,26,12,14,89,58,22,6.0,3.6,1.3,2.3,6.7,11.2,203,9.62,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,6/8/2025,Outpatient,Sirolimus,75.8,120.0,39.1,5.0,138,4.0,23,8,13,86,79,11,6.0,4.1,0.9,2.2,7.1,13.5,254,10.59,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,7/6/2025,Inpatient,Sirolimus,125.3,50.6,37.8,8.6,135,3.8,24,27,31,100,68,16,5.9,3.6,1.6,1.5,5.4,13.3,231,9.11,,3.38,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,7/7/2025,Outpatient,Sirolimus,98.7,89.1,40.9,8.3,133,4.3,22,24,8,80,81,11,6.1,4.2,1.1,1.6,6.2,13.3,291,6.76,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,7/8/2025,Outpatient,Sirolimus,71.1,113.9,40.7,6.0,140,4.6,27,26,12,98,55,14,6.2,4.2,0.9,2.5,4.7,12.1,213,4.81,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,8/6/2025,Inpatient,Sirolimus,125.8,73.4,35.9,11.8,140,3.8,23,32,34,88,76,10,5.4,3.6,1.0,1.9,7.2,13.4,220,8.21,,3.38,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,8/7/2025,Outpatient,Sirolimus,91.8,106.9,40.8,7.9,137,3.9,23,17,17,61,44,13,5.3,3.2,1.1,2.2,8.1,12.4,217,5.11,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,8/8/2025,Outpatient,Sirolimus,68.2,110.0,38.4,5.6,139,4.2,25,8,8,73,79,12,5.3,2.9,1.4,2.3,5.4,14.5,288,8.66,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,9/6/2025,Inpatient,Sirolimus,132.7,63.6,36.5,6.2,136,3.9,21,30,33,76,48,15,5.6,3.2,1.4,2.0,8.5,13.3,242,6.02,,3.38,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,9/7/2025,Outpatient,Sirolimus,81.9,99.6,38.9,7.7,139,4.0,23,8,8,48,24,12,6.1,3.8,1.5,1.8,5.1,12.8,275,7.24,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,9/8/2025,Outpatient,Sirolimus,71.7,120.0,39.9,6.9,136,3.9,24,13,10,96,74,13,6.1,4.3,1.0,1.7,6.5,12.2,260,8.74,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,1/6/2025,Inpatient,Sirolimus,140.8,65.1,38.4,12.5,131,4.3,27,51,40,88,92,11,7.0,4.8,1.1,2.4,8.1,14.1,281,6.88,,5.36,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,1/7/2025,Outpatient,Sirolimus,95.3,85.0,40.0,4.7,139,4.6,27,32,28,73,43,12,7.1,4.9,1.4,1.9,7.5,12.2,195,4.87,,3.63,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,10/6/2025,Inpatient,Sirolimus,122.6,53.0,36.3,5.8,140,4.7,24,37,20,72,76,15,5.5,3.5,1.2,1.8,6.9,14.0,276,8.9,,3.38,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,10/7/2025,Outpatient,Sirolimus,104.8,76.4,38.8,5.7,138,4.2,26,17,16,112,100,11,5.7,3.5,1.2,2.1,7.1,13.3,260,6.55,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,10/8/2025,Outpatient,Sirolimus,65.8,120.0,39.3,4.7,133,4.2,25,8,9,63,77,15,5.9,3.7,1.1,2.3,8.5,13.7,294,3.74,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,10/6/2025,Inpatient,Sirolimus,98.8,89.9,35.5,5.4,136,4.4,21,20,31,80,65,11,3.8,2.0,1.0,1.7,9.1,13.2,246,8.21,,5.22,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,11/6/2025,Inpatient,Sirolimus,124.6,74.8,37.8,7.9,137,4.1,25,32,25,113,85,15,7.5,5.4,1.4,1.8,6.2,11.7,195,7.26,,3.38,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,11/7/2025,Outpatient,Sirolimus,106.8,95.7,40.1,7.3,137,4.2,25,30,21,94,49,17,5.8,3.9,1.0,1.9,5.7,11.5,229,8.93,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,11/8/2025,Outpatient,Sirolimus,67.5,119.8,40.3,3.5,140,4.2,23,8,19,125,71,12,5.6,3.1,1.1,2.9,5.9,14.1,286,5.92,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,12/6/2025,Inpatient,Sirolimus,110.9,58.5,37.3,7.6,136,3.6,26,22,31,128,42,14,5.7,3.5,1.4,1.6,7.9,12.6,202,7.77,,3.38,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,12/7/2025,Outpatient,Sirolimus,75.2,90.3,38.8,5.0,137,3.4,23,20,23,90,58,9,5.9,4.0,1.1,1.7,7.7,12.7,267,7.37,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,12/8/2025,Outpatient,Sirolimus,64.0,114.4,40.3,5.1,137,4.3,27,8,10,81,81,12,5.4,2.9,1.2,2.6,7.9,14.4,242,5.03,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,12/8/2025,Outpatient,Sirolimus,70.9,70.0,40.6,4.2,136,3.7,24,51,37,111,44,10,4.8,2.4,1.3,2.4,3.9,14.0,189,5.79,,3.79,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,13/6/2025,Outpatient,Sirolimus,123.1,68.9,39.8,4.6,134,3.9,23,25,34,132,50,14,6.2,4.1,1.2,2.2,4.1,13.8,279,9.04,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,13/7/2025,Outpatient,Sirolimus,103.3,87.3,40.4,7.2,137,4.2,24,17,15,100,80,11,6.4,4.6,0.9,2.0,5.7,13.8,280,7.87,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,13/8/2025,Outpatient,Sirolimus,60.0,120.0,37.7,6.8,137,3.7,27,15,8,84,10,13,5.9,3.6,1.3,2.2,4.7,14.2,279,4.79,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,14/6/2025,Outpatient,Sirolimus,130.9,79.8,41.3,9.1,143,4.0,25,27,30,121,67,19,5.8,3.5,1.3,1.9,5.8,13.0,156,6.93,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,14/7/2025,Outpatient,Sirolimus,101.8,94.4,38.4,6.3,140,3.8,25,22,21,87,36,10,5.2,2.9,1.3,2.4,5.7,12.4,173,5.25,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,14/8/2025,Outpatient,Sirolimus,61.7,120.0,40.4,3.0,138,3.9,25,17,8,64,43,15,6.2,3.6,1.3,2.7,7.6,12.8,324,6.42,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,15/6/2025,Outpatient,Sirolimus,113.0,70.4,40.0,9.0,139,4.3,21,21,13,91,86,15,6.2,3.9,1.3,2.1,3.7,14.2,220,6.16,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,15/7/2025,Outpatient,Sirolimus,107.6,105.7,39.8,6.9,140,4.1,23,20,17,69,68,22,5.1,2.8,1.0,2.7,5.0,14.3,252,7.45,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,15/8/2025,Outpatient,Sirolimus,60.0,120.0,39.3,3.6,136,4.7,25,13,12,83,56,12,5.8,3.7,1.1,2.3,6.2,12.9,199,5.41,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,15/7/2025,Outpatient,Sirolimus,108.0,76.2,43.7,6.7,136,4.8,27,34,16,91,56,19,4.9,2.3,1.2,3.1,5.0,14.6,278,8.57,,4.18,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,16/6/2025,Outpatient,Sirolimus,122.0,80.4,40.4,7.0,141,3.9,23,26,23,103,61,16,5.3,3.4,1.1,1.6,2.7,11.9,213,7.09,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,16/7/2025,Outpatient,Sirolimus,83.9,95.2,40.9,9.7,134,3.4,23,28,19,112,49,15,5.5,3.1,1.3,2.5,7.8,10.9,247,8.12,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,16/8/2025,Outpatient,Sirolimus,75.2,120.0,39.9,6.3,144,3.5,25,18,11,67,60,6,6.0,4.1,1.2,1.7,6.7,14.3,221,2.32,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,17/6/2025,Outpatient,Sirolimus,109.6,61.8,40.0,9.2,135,4.4,23,23,39,85,87,13,5.8,3.6,1.4,1.8,6.9,13.4,242,8.91,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,17/7/2025,Outpatient,Sirolimus,95.3,95.0,40.2,3.8,138,4.1,23,22,11,91,31,11,6.4,4.3,1.1,2.1,4.4,13.0,315,4.27,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,17/8/2025,Outpatient,Sirolimus,60.0,120.0,38.6,6.4,140,4.2,28,8,8,57,63,12,6.4,4.8,0.8,1.9,8.3,12.9,301,6.72,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,17/6/2025,Outpatient,Sirolimus,86.4,97.7,40.1,7.7,138,3.9,27,26,24,95,76,16,4.7,2.2,1.5,2.1,7.4,11.7,178,9.41,,4.24,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,18/6/2025,Outpatient,Sirolimus,96.3,55.5,41.3,6.4,141,4.6,28,17,18,77,75,13,5.6,3.6,1.1,2.0,6.0,13.7,310,7.18,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,18/7/2025,Outpatient,Sirolimus,95.3,104.8,42.1,7.2,132,3.8,26,15,16,92,56,14,5.6,3.6,1.0,2.1,6.1,11.2,258,6.57,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,18/8/2025,Outpatient,Sirolimus,60.0,120.0,39.4,3.6,141,3.4,26,8,12,48,11,12,6.1,3.8,1.4,1.9,6.8,14.1,225,4.02,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,19/6/2025,Outpatient,Sirolimus,104.7,77.9,38.8,7.5,139,4.7,26,30,38,77,67,19,5.5,3.2,1.2,2.4,6.7,13.2,264,6.48,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,19/7/2025,Outpatient,Sirolimus,79.2,116.1,40.5,6.2,142,3.8,23,11,15,84,60,13,5.7,3.6,1.0,2.4,3.8,14.1,174,7.55,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,19/8/2025,Outpatient,Sirolimus,64.7,120.0,39.1,4.8,136,3.8,28,8,8,94,75,10,4.9,2.2,1.4,3.0,7.2,13.5,256,8.37,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,19/8/2025,Outpatient,Sirolimus,101.4,73.8,42.4,2.7,139,4.2,25,14,19,106,63,9,6.5,4.4,1.3,2.1,8.9,13.3,247,6.01,,4.71,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,2/6/2025,Inpatient,Sirolimus,88.2,42.2,42.8,8.0,134,3.8,26,45,38,102,71,17,6.9,4.7,1.2,2.3,6.5,13.4,144,7.78,,3.83,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,20/6/2025,Outpatient,Sirolimus,127.1,88.7,39.1,6.0,137,4.4,21,46,20,55,50,17,5.8,3.5,1.4,1.9,5.9,13.9,349,5.53,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,20/7/2025,Outpatient,Sirolimus,72.7,103.7,38.6,7.9,136,3.8,27,13,16,99,47,15,6.2,3.9,1.3,2.2,5.6,13.2,189,5.54,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,20/8/2025,Outpatient,Sirolimus,60.0,114.4,39.9,6.4,135,4.6,25,9,8,61,44,4,6.4,4.1,1.2,2.2,5.8,12.1,320,6.0,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,21/6/2025,Outpatient,Sirolimus,113.9,75.7,38.6,8.1,138,3.8,27,15,8,110,74,12,6.6,4.0,1.3,2.8,4.1,14.2,206,7.85,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,21/7/2025,Outpatient,Sirolimus,88.5,95.2,42.0,6.3,137,4.3,24,10,19,70,32,14,6.2,4.1,1.2,2.2,7.9,13.1,215,8.05,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,21/8/2025,Outpatient,Sirolimus,60.0,120.0,41.4,3.1,134,4.2,28,8,8,75,47,13,6.2,4.1,1.2,2.2,5.8,13.4,372,5.23,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,22/6/2025,Outpatient,Sirolimus,119.5,69.9,41.0,9.0,137,5.2,25,18,21,68,54,12,5.2,2.7,1.3,2.7,6.8,15.3,181,11.94,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,22/7/2025,Outpatient,Sirolimus,80.7,107.9,40.5,6.3,134,3.9,21,11,12,90,79,17,6.0,3.9,1.0,2.4,8.4,14.4,353,6.54,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,22/8/2025,Outpatient,Sirolimus,60.4,120.0,41.1,2.0,137,3.5,24,8,13,82,35,16,6.1,4.0,1.3,1.9,5.0,13.2,265,5.59,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,22/7/2025,Outpatient,Sirolimus,110.8,62.0,40.8,3.8,139,4.0,24,37,26,90,51,12,5.8,3.4,1.4,2.3,5.3,13.6,273,8.25,,3.66,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,23/6/2025,Outpatient,Sirolimus,104.2,87.7,40.7,10.7,143,3.8,22,14,26,71,45,16,5.5,3.4,1.2,2.1,10.4,13.4,301,6.91,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,23/7/2025,Outpatient,Sirolimus,85.9,91.0,40.0,6.5,135,3.7,27,18,19,82,41,12,5.3,2.7,1.4,2.6,6.9,14.1,277,5.54,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,23/8/2025,Outpatient,Sirolimus,60.0,120.0,40.1,4.8,141,4.3,26,13,15,124,59,11,6.3,4.1,1.1,2.3,5.9,12.2,183,6.34,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,24/6/2025,Outpatient,Sirolimus,113.4,78.8,40.3,7.5,135,4.4,20,34,22,107,57,9,5.8,3.6,1.4,1.7,5.6,13.7,254,5.47,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,24/7/2025,Outpatient,Sirolimus,93.4,95.7,40.1,4.4,138,3.8,24,17,10,80,55,13,5.8,3.5,1.2,2.6,4.6,14.7,211,6.64,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,24/8/2025,Outpatient,Sirolimus,64.5,120.0,41.7,4.5,138,3.8,26,16,8,59,80,10,6.1,3.7,1.3,2.3,10.5,13.7,294,9.35,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,24/6/2025,Outpatient,Sirolimus,89.7,72.9,40.3,8.2,142,4.0,25,27,32,91,74,7,6.5,4.2,1.4,2.0,4.6,11.6,259,6.97,,3.05,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,25/6/2025,Outpatient,Sirolimus,107.5,89.7,41.1,8.1,139,4.8,25,24,21,98,71,14,5.4,3.2,1.3,1.9,7.1,13.8,307,9.26,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,25/7/2025,Outpatient,Sirolimus,88.8,112.7,40.0,6.0,136,3.8,25,11,8,84,51,16,7.0,4.2,1.7,2.3,7.0,13.1,151,4.39,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,25/8/2025,Outpatient,Sirolimus,60.0,120.0,38.9,6.2,137,4.0,24,8,8,93,50,14,6.5,4.2,1.2,2.4,5.8,14.4,270,8.42,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,26/6/2025,Outpatient,Sirolimus,106.0,72.5,40.5,5.6,139,4.3,26,26,13,99,77,12,6.0,4.1,0.9,2.2,8.3,12.0,277,7.08,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,26/7/2025,Outpatient,Sirolimus,96.7,98.4,41.3,4.6,137,4.3,24,24,24,113,34,7,6.4,3.9,1.2,2.8,3.1,13.0,206,8.41,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,26/8/2025,Outpatient,Sirolimus,61.5,120.0,40.4,4.2,136,3.5,26,8,13,64,24,14,6.1,4.0,1.1,2.3,7.3,12.6,225,7.3,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,26/8/2025,Outpatient,Sirolimus,118.3,62.9,37.2,6.4,133,3.9,29,17,24,71,59,19,6.8,4.2,1.3,2.9,5.8,13.7,258,3.84,,3.4,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,27/6/2025,Outpatient,Sirolimus,117.5,90.7,41.0,7.3,138,4.2,25,20,34,97,58,18,5.4,3.1,1.2,2.6,5.5,12.5,315,8.82,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,27/7/2025,Outpatient,Sirolimus,84.1,120.0,41.0,4.3,136,4.1,25,8,9,87,62,17,6.4,3.8,1.4,2.5,6.8,13.5,261,6.36,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,27/8/2025,Outpatient,Sirolimus,60.0,120.0,39.7,5.6,137,3.6,26,8,8,86,103,11,6.6,4.2,1.4,2.2,7.1,12.7,189,4.03,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,28/6/2025,Outpatient,Sirolimus,106.1,71.2,39.3,5.3,134,5.0,26,25,9,83,59,20,6.4,4.2,1.2,2.1,5.1,14.7,271,8.59,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,28/7/2025,Outpatient,Sirolimus,60.3,105.4,39.3,4.1,139,4.2,25,8,8,88,62,10,5.8,3.8,1.2,1.7,5.1,14.0,161,6.67,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,29/6/2025,Outpatient,Sirolimus,120.0,74.4,39.8,6.3,135,4.3,23,34,8,128,19,13,6.4,4.5,0.8,2.5,3.6,12.8,340,6.9,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,29/7/2025,Outpatient,Sirolimus,63.9,119.0,38.3,7.5,136,3.3,25,8,13,95,58,17,5.7,3.9,0.9,1.9,6.0,13.5,264,6.08,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,29/7/2025,Outpatient,Sirolimus,61.7,78.1,38.2,7.3,140,5.0,21,21,25,84,32,14,6.4,4.4,1.0,2.1,5.9,14.7,200,6.88,,3.58,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,3/6/2025,Inpatient,Sirolimus,122.7,32.2,40.9,14.1,142,4.0,24,8,20,171,112,21,6.7,4.3,1.2,2.6,5.9,12.1,259,6.87,,5.4,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,30/5/2025,Inpatient,Sirolimus,133.2,69.2,36.4,9.5,137,4.2,23,47,30,78,61,14,5.9,4.0,1.1,1.7,7.5,12.1,257,9.21,,3.38,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,30/6/2025,Outpatient,Sirolimus,100.6,77.7,41.3,7.5,138,3.6,22,27,16,57,61,13,7.2,5.0,1.4,1.6,6.4,12.4,212,6.23,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,30/7/2025,Outpatient,Sirolimus,70.3,103.0,40.5,4.4,141,4.2,24,13,22,111,55,11,6.8,4.8,1.0,2.2,7.1,13.5,228,6.51,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,31/5/2025,Inpatient,Sirolimus,129.3,61.3,36.1,12.0,138,4.0,21,28,38,122,82,16,4.9,2.6,1.3,2.2,6.6,12.5,244,7.0,,3.38,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,31/7/2025,Outpatient,Sirolimus,85.4,118.8,40.0,5.0,138,4.7,26,17,18,87,42,8,6.2,3.9,1.1,2.4,6.8,15.0,266,6.91,,2.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,31/5/2025,Inpatient,Sirolimus,139.6,50.8,34.9,9.0,136,4.2,23,17,30,91,23,20,5.6,3.9,1.2,1.2,8.9,13.2,229,6.62,,3.69,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,4/6/2025,Inpatient,Sirolimus,131.2,56.8,32.0,8.0,146,5.0,22,34,24,85,54,11,5.4,3.2,1.2,2.1,7.9,11.7,163,6.79,,2.94,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,5/6/2025,Inpatient,Sirolimus,91.5,99.3,34.4,9.2,139,4.5,24,16,12,71,30,22,6.3,4.3,0.9,2.5,5.2,11.7,240,6.34,,2.85,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,5/8/2025,Outpatient,Sirolimus,89.9,96.7,40.8,9.3,140,4.0,20,8,35,105,50,14,5.6,3.7,1.0,2.1,4.0,12.6,221,8.11,,3.92,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,6/6/2025,Inpatient,Sirolimus,70.0,87.3,29.7,8.6,146,3.9,26,26,29,100,46,7,5.9,4.0,0.9,2.1,8.2,11.6,312,9.86,,4.72,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,7/6/2025,Inpatient,Sirolimus,95.0,76.6,33.2,5.2,134,3.0,21,32,19,81,70,17,6.4,3.7,1.3,3.2,6.8,14.5,252,9.66,,3.83,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,8/6/2025,Inpatient,Sirolimus,153.1,58.9,38.7,8.2,140,5.1,25,53,28,95,39,12,4.6,2.7,0.8,2.6,11.3,11.6,193,9.14,,4.13,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,8/7/2025,Outpatient,Sirolimus,75.1,77.1,40.7,6.1,142,4.5,26,24,15,103,66,23,6.1,4.2,1.1,1.8,8.2,12.1,208,6.76,,3.78,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1001,3401P,Ng Yong Jun,30/5/2025,9/6/2025,Inpatient,Sirolimus,77.2,63.8,30.9,11.3,138,5.1,24,43,26,126,83,21,6.4,4.5,1.1,1.7,7.7,11.8,145,5.77,,4.68,*3/*3,CC,97.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,1/7/2025,Outpatient,Cyclosporin,107.8,74.3,42.1,9.3,140,3.8,20,31,27,91,89,10,5.3,3.3,1.4,1.3,6.8,12.5,317,228.02,1007.51,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,1/8/2025,Outpatient,Cyclosporin,84.2,108.8,39.8,4.3,139,4.3,25,23,16,115,64,10,5.2,3.6,1.0,1.5,5.6,14.6,237,129.78,855.0,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,1/9/2025,Outpatient,Cyclosporin,60.0,120.0,38.9,4.6,138,3.8,25,15,9,120,38,11,5.0,3.3,1.1,1.5,6.2,12.5,290,123.04,1053.79,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,2/7/2025,Outpatient,Cyclosporin,97.7,86.2,40.6,10.2,135,3.6,21,29,30,95,93,11,5.1,3.1,1.2,1.7,7.1,13.1,274,222.28,1148.46,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,2/8/2025,Outpatient,Cyclosporin,60.0,120.0,40.5,7.4,138,3.4,25,18,15,106,79,13,5.4,3.5,1.2,1.6,8.3,13.4,188,139.74,1080.77,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,3/7/2025,Outpatient,Cyclosporin,101.9,90.6,41.5,8.7,139,5.0,25,33,13,109,89,14,5.9,4.0,1.3,1.3,6.2,13.4,298,136.74,952.4,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,3/8/2025,Outpatient,Cyclosporin,65.4,120.0,37.6,7.5,140,4.5,25,11,13,66,52,14,5.0,2.8,1.4,1.6,6.6,13.7,211,143.76,673.02,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,4/6/2025,Inpatient,Cyclosporin,117.3,64.0,36.6,11.2,136,4.5,26,30,23,67,65,17,5.0,3.2,0.9,1.8,6.6,12.1,92,158.61,1098.27,249.92,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,4/7/2025,Outpatient,Cyclosporin,118.6,83.3,39.7,10.5,135,4.3,23,23,16,117,79,16,5.3,3.3,1.2,1.8,6.1,13.1,176,221.01,821.12,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,4/8/2025,Outpatient,Cyclosporin,70.3,120.0,40.8,8.0,141,4.1,23,8,10,56,44,6,5.4,3.4,1.3,1.5,8.4,14.3,230,183.64,1168.23,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,5/6/2025,Inpatient,Cyclosporin,122.2,74.3,36.8,7.1,139,4.5,26,32,30,105,86,10,5.8,3.8,1.3,1.6,9.3,13.4,257,172.29,1150.47,249.92,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,5/7/2025,Outpatient,Cyclosporin,99.2,88.7,41.0,4.2,136,3.8,22,23,29,84,72,16,5.0,3.1,1.2,1.4,3.8,14.0,268,199.62,714.37,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,5/8/2025,Outpatient,Cyclosporin,72.8,112.7,38.8,7.6,143,4.3,26,8,18,75,85,16,5.5,3.2,1.5,1.8,5.9,14.6,295,194.01,796.27,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,6/6/2025,Inpatient,Cyclosporin,104.8,77.9,37.9,7.8,137,3.6,22,39,26,117,87,17,5.3,3.3,1.3,1.6,9.9,13.1,209,208.09,1111.41,249.92,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,6/7/2025,Outpatient,Cyclosporin,89.4,81.6,41.8,8.3,133,4.9,25,18,23,99,39,14,5.4,3.2,1.4,1.8,5.7,12.5,294,152.74,1154.98,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,6/8/2025,Outpatient,Cyclosporin,60.0,110.1,40.7,3.5,137,3.7,21,18,19,82,41,12,5.6,3.9,1.0,1.4,7.6,12.2,180,140.7,985.38,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,7/6/2025,Inpatient,Cyclosporin,104.2,61.1,38.2,6.0,139,4.0,21,35,22,86,50,15,5.8,3.8,1.2,1.9,9.4,13.2,152,183.82,1106.9,249.92,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,7/7/2025,Outpatient,Cyclosporin,96.0,95.7,40.3,5.4,137,4.2,24,18,17,127,59,17,5.3,3.0,1.4,2.0,6.1,13.0,208,185.4,974.23,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,7/8/2025,Outpatient,Cyclosporin,66.7,120.0,41.5,5.6,139,3.5,27,23,15,81,58,15,4.9,2.7,1.3,2.0,4.0,12.2,177,180.05,788.15,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,8/6/2025,Inpatient,Cyclosporin,121.6,60.9,36.3,10.5,136,4.5,24,37,43,99,54,9,5.3,3.8,1.1,0.8,7.8,13.2,205,223.67,889.91,249.92,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,8/7/2025,Outpatient,Cyclosporin,88.8,91.2,40.6,6.1,139,4.5,22,34,11,105,86,10,4.8,3.2,1.0,1.4,6.5,14.2,260,194.49,1031.02,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,8/8/2025,Outpatient,Cyclosporin,76.3,113.3,40.5,2.5,142,4.0,25,15,8,120,74,11,5.5,3.1,1.5,2.0,5.4,15.3,302,184.37,1136.25,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,9/6/2025,Inpatient,Cyclosporin,123.8,67.4,36.2,7.5,137,4.1,22,25,23,80,100,15,4.6,2.7,1.3,1.4,5.5,12.5,227,172.94,1157.8,249.92,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,9/7/2025,Outpatient,Cyclosporin,100.9,90.8,39.5,7.3,140,4.5,21,25,18,98,70,18,4.5,3.0,1.1,1.0,7.2,13.5,235,166.4,1075.25,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,9/8/2025,Outpatient,Cyclosporin,67.7,120.0,38.8,4.9,141,4.2,24,19,27,82,54,11,5.1,3.3,1.1,1.7,5.2,14.0,187,185.11,882.35,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,10/6/2025,Inpatient,Cyclosporin,109.8,56.8,36.3,6.5,140,3.6,26,28,17,94,56,20,3.9,2.1,1.1,1.5,9.4,12.0,228,220.68,1041.5,249.92,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,10/7/2025,Outpatient,Cyclosporin,103.1,93.4,39.7,8.8,137,4.2,25,18,15,75,72,15,5.3,3.3,1.2,1.8,6.2,12.5,234,168.4,940.71,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,10/8/2025,Outpatient,Cyclosporin,61.9,111.4,39.5,2.0,133,4.2,23,8,14,90,10,13,5.3,3.3,1.3,1.6,7.6,14.0,200,142.02,1055.87,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,10/6/2025,Inpatient,Cyclosporin,139.4,68.3,37.0,12.4,133,4.5,21,53,25,98,64,15,5.0,3.3,1.1,1.3,6.3,13.0,210,129.57,928.7,249.92,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,11/6/2025,Inpatient,Cyclosporin,116.9,70.6,39.2,7.8,144,4.4,25,40,33,66,54,10,4.5,2.8,1.1,1.5,8.1,14.2,167,240.65,1288.6,249.92,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,11/7/2025,Outpatient,Cyclosporin,86.3,85.7,40.6,7.0,139,4.1,30,9,27,59,108,17,4.9,3.2,0.9,1.8,4.1,14.5,226,118.69,992.13,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,11/8/2025,Outpatient,Cyclosporin,69.5,110.7,40.2,3.5,143,4.0,23,21,20,90,84,15,5.2,3.2,1.1,1.8,5.8,14.1,251,146.22,1013.31,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,11/6/2025,Inpatient,Cyclosporin,133.3,70.9,36.1,8.5,132,4.0,21,46,44,90,80,19,5.6,3.8,1.4,1.0,5.2,13.9,229,162.58,990.87,249.92,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,12/6/2025,Inpatient,Cyclosporin,120.5,64.7,36.3,9.5,134,4.4,26,43,40,65,41,16,5.4,4.0,1.0,1.0,6.9,14.1,215,246.82,1040.25,249.92,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,12/7/2025,Outpatient,Cyclosporin,90.1,88.4,40.3,8.7,137,4.3,25,26,31,103,92,11,5.4,3.4,1.5,1.2,7.1,14.2,281,194.8,684.88,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,12/8/2025,Outpatient,Cyclosporin,67.5,120.0,39.9,3.8,141,3.9,26,8,8,69,50,17,5.1,3.3,1.0,1.8,7.3,12.7,288,181.48,741.72,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,12/6/2025,Inpatient,Cyclosporin,143.6,88.8,37.0,8.0,142,4.8,21,25,33,90,60,23,5.8,4.2,1.0,1.3,8.8,13.1,157,234.83,1116.71,249.92,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,12/7/2025,Outpatient,Cyclosporin,88.5,78.1,39.8,7.6,133,4.1,23,32,23,118,62,15,4.0,1.9,1.1,2.0,9.9,14.7,304,164.08,880.77,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,13/6/2025,Inpatient,Cyclosporin,122.5,77.6,38.4,5.0,141,4.1,23,39,21,82,89,14,5.1,3.4,1.0,1.4,8.6,12.8,252,249.17,1035.91,249.92,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,13/7/2025,Outpatient,Cyclosporin,107.1,102.3,39.0,6.3,141,4.7,21,25,24,76,83,11,4.5,2.5,1.3,1.4,5.6,12.7,313,136.38,824.97,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,13/8/2025,Outpatient,Cyclosporin,60.0,120.0,39.8,3.0,139,4.3,25,23,8,65,43,6,5.1,2.9,1.4,1.7,5.2,13.9,279,158.8,820.0,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,13/6/2025,Inpatient,Cyclosporin,105.7,70.4,36.6,7.7,138,4.3,22,20,19,82,65,8,4.9,3.3,0.9,1.6,8.5,10.8,176,205.82,1370.44,249.92,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,14/6/2025,Inpatient,Cyclosporin,113.8,107.8,36.3,8.0,140,3.7,25,34,46,100,89,14,4.5,2.6,1.3,1.4,9.1,12.9,284,186.92,1020.82,249.92,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,14/7/2025,Outpatient,Cyclosporin,82.0,89.1,39.7,6.8,139,3.8,24,21,17,111,88,18,4.9,3.2,1.1,1.2,8.8,14.0,294,176.61,1072.39,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,14/8/2025,Outpatient,Cyclosporin,60.6,119.4,38.1,4.9,137,4.1,26,8,9,98,36,16,5.9,3.8,1.3,1.7,2.8,13.3,276,138.15,895.2,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,14/6/2025,Inpatient,Cyclosporin,87.5,80.1,30.5,7.1,140,3.2,22,25,14,121,37,5,5.1,3.8,0.7,1.2,7.2,14.1,286,235.87,1622.79,249.92,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,15/6/2025,Inpatient,Cyclosporin,115.8,59.2,36.5,5.1,139,4.6,27,37,18,92,75,18,4.6,2.4,1.4,1.7,7.6,13.0,210,217.24,1099.61,249.92,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,15/7/2025,Outpatient,Cyclosporin,93.8,94.7,39.5,4.8,138,4.0,25,34,22,78,46,17,5.2,2.8,1.4,2.3,8.6,13.6,210,210.71,924.45,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,15/8/2025,Outpatient,Cyclosporin,60.0,120.0,39.5,6.6,137,3.8,28,15,8,105,78,21,4.4,2.5,1.1,1.8,6.2,13.7,215,162.51,1004.79,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,16/6/2025,Inpatient,Cyclosporin,98.1,71.2,37.6,6.7,137,4.0,24,37,25,77,74,14,5.3,3.4,1.0,1.9,7.7,13.4,269,171.84,899.59,249.92,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,16/7/2025,Outpatient,Cyclosporin,83.6,95.7,39.2,5.6,143,3.8,23,18,9,108,54,12,5.1,3.0,1.1,2.1,9.0,13.8,307,178.97,809.91,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,16/8/2025,Outpatient,Cyclosporin,65.8,120.0,38.9,4.3,135,3.5,22,8,10,120,44,12,5.3,3.5,1.2,1.2,5.8,12.6,300,181.19,375.45,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,16/8/2025,Outpatient,Cyclosporin,116.5,77.6,44.4,7.6,135,3.9,23,40,25,106,72,17,5.9,4.2,1.0,1.5,7.3,12.4,246,126.16,690.38,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,17/6/2025,Inpatient,Cyclosporin,130.7,59.4,37.1,8.1,137,3.8,24,40,27,95,89,15,5.7,4.1,1.2,0.8,7.9,12.1,230,205.25,1161.5,249.92,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,17/7/2025,Outpatient,Cyclosporin,94.6,114.1,40.6,6.9,138,4.4,25,10,13,83,65,14,5.3,3.3,1.3,1.5,3.4,14.0,305,160.57,787.74,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,17/8/2025,Outpatient,Cyclosporin,66.8,120.0,39.0,3.4,134,4.5,28,8,24,65,46,13,5.3,3.6,1.0,1.5,5.1,13.9,312,206.36,972.3,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,18/6/2025,Outpatient,Cyclosporin,120.3,95.4,39.8,8.9,138,4.5,20,35,28,89,80,15,4.9,3.3,1.0,1.4,6.3,14.0,222,235.89,890.64,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,18/7/2025,Outpatient,Cyclosporin,95.7,101.3,40.3,6.6,145,4.5,24,29,14,98,70,15,5.9,4.1,1.3,1.2,8.8,13.6,229,164.33,1074.01,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,18/8/2025,Outpatient,Cyclosporin,74.9,120.0,41.0,5.3,140,4.0,25,15,13,104,70,8,4.1,1.9,1.4,1.7,6.1,14.3,245,130.77,740.28,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,19/6/2025,Outpatient,Cyclosporin,99.9,69.8,41.1,8.8,137,4.3,25,48,24,89,50,17,5.3,3.1,1.3,2.0,6.5,12.2,309,225.52,911.51,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,19/7/2025,Outpatient,Cyclosporin,86.5,112.8,40.3,5.9,140,3.3,26,22,27,83,16,22,5.3,3.4,1.2,1.5,5.9,13.0,202,148.24,1295.31,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,19/8/2025,Outpatient,Cyclosporin,60.0,120.0,40.0,3.6,139,3.8,22,24,19,106,56,9,5.6,3.8,1.0,2.0,5.8,13.4,234,86.95,640.08,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,19/7/2025,Outpatient,Cyclosporin,103.2,78.0,38.2,8.3,138,3.8,25,25,33,112,30,12,5.0,3.4,1.1,1.1,7.9,13.2,261,140.47,757.54,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,2/8/2025,Outpatient,Cyclosporin,61.8,71.5,43.0,6.1,140,4.0,22,15,22,103,71,19,5.2,3.8,0.9,1.0,6.5,14.9,257,103.15,782.31,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,20/6/2025,Outpatient,Cyclosporin,113.1,59.1,39.6,9.1,137,4.6,24,29,15,104,88,10,5.1,3.2,1.0,1.9,7.6,13.4,308,154.72,1061.74,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,20/7/2025,Outpatient,Cyclosporin,88.3,113.2,39.4,5.1,138,4.1,25,24,25,113,60,8,5.2,2.8,1.4,2.0,7.9,13.3,280,160.72,824.0,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,20/8/2025,Outpatient,Cyclosporin,60.6,120.0,39.8,3.3,138,3.7,24,8,8,85,62,12,5.2,3.0,1.4,1.7,4.0,13.0,280,167.88,781.37,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,21/6/2025,Outpatient,Cyclosporin,111.8,84.3,40.2,8.2,137,4.4,26,26,19,77,42,15,5.4,3.7,1.0,1.6,5.7,14.9,188,150.34,1174.8,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,21/7/2025,Outpatient,Cyclosporin,80.0,97.2,39.7,4.1,141,4.0,26,33,17,76,59,16,5.3,3.4,1.3,1.5,6.2,13.0,311,172.62,858.56,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,21/8/2025,Outpatient,Cyclosporin,60.0,118.3,39.7,4.8,143,4.2,24,8,8,100,68,21,5.9,4.2,1.0,1.5,6.4,13.9,261,194.31,813.01,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,21/6/2025,Outpatient,Cyclosporin,114.7,79.9,40.8,4.6,140,4.1,25,20,30,117,74,10,4.9,3.3,1.1,1.2,5.9,14.3,251,123.62,627.05,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,22/6/2025,Outpatient,Cyclosporin,102.5,57.6,40.9,8.7,138,4.1,25,38,32,110,40,17,5.7,3.5,1.5,1.4,5.0,12.4,287,206.88,1065.16,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,22/7/2025,Outpatient,Cyclosporin,80.8,116.6,40.9,6.2,137,4.5,25,27,16,96,52,11,4.6,2.8,1.1,1.5,7.0,13.7,301,231.02,1087.84,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,22/8/2025,Outpatient,Cyclosporin,60.0,120.0,39.7,6.2,135,4.2,25,18,20,82,67,10,5.5,3.3,1.5,1.5,7.4,13.0,289,218.12,771.42,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,23/6/2025,Outpatient,Cyclosporin,99.3,90.2,38.6,7.4,143,4.3,26,39,15,109,77,10,4.7,2.8,1.3,1.3,4.1,16.0,307,138.76,1170.79,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,23/7/2025,Outpatient,Cyclosporin,79.1,118.9,38.3,6.4,140,4.8,24,28,8,66,55,11,5.3,3.9,1.0,0.9,5.5,15.1,185,166.58,715.35,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,23/8/2025,Outpatient,Cyclosporin,60.0,120.0,40.5,5.2,138,3.9,27,8,8,61,28,12,5.5,3.8,1.1,1.3,7.5,13.7,193,194.49,647.04,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,23/8/2025,Outpatient,Cyclosporin,89.9,83.5,41.8,6.2,138,3.8,26,41,35,83,59,8,5.4,4.0,0.9,1.1,5.8,12.5,229,136.1,731.1,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,24/6/2025,Outpatient,Cyclosporin,96.5,84.4,40.2,8.9,136,4.9,22,14,14,117,65,18,5.7,3.4,1.6,1.5,5.5,14.9,244,189.82,807.88,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,24/7/2025,Outpatient,Cyclosporin,68.8,120.0,40.2,6.5,140,4.6,26,30,12,91,41,15,5.5,3.7,1.1,1.7,6.9,12.6,214,154.79,999.51,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,24/8/2025,Outpatient,Cyclosporin,67.1,120.0,39.5,7.3,139,4.6,26,8,8,99,68,7,6.1,4.2,1.1,1.7,9.5,15.0,225,205.57,748.83,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,25/6/2025,Outpatient,Cyclosporin,123.7,88.9,40.4,7.1,144,3.9,21,35,25,83,27,16,4.9,2.8,1.3,1.9,4.2,13.8,303,104.77,1437.65,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,25/7/2025,Outpatient,Cyclosporin,80.7,109.3,39.8,5.5,139,3.9,25,26,15,60,34,18,5.6,3.9,0.9,1.8,4.2,13.8,280,237.39,989.5,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,25/8/2025,Outpatient,Cyclosporin,60.0,120.0,41.0,7.6,137,4.4,23,8,31,105,30,14,5.2,3.5,1.1,1.4,8.1,12.5,205,146.87,866.84,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,26/6/2025,Outpatient,Cyclosporin,78.6,77.5,38.2,6.0,143,4.3,23,18,38,101,60,11,4.7,2.7,1.1,2.1,7.2,13.6,233,168.47,959.51,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,26/7/2025,Outpatient,Cyclosporin,86.1,110.3,38.5,5.3,136,4.0,25,11,11,90,55,12,5.6,4.1,1.0,1.2,7.2,12.7,299,103.97,1031.43,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,26/8/2025,Outpatient,Cyclosporin,64.2,120.0,39.2,5.2,139,4.1,26,8,8,119,55,6,5.2,3.5,1.1,1.2,6.4,12.4,272,207.23,976.25,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,26/7/2025,Outpatient,Cyclosporin,121.2,91.2,38.5,9.5,139,4.7,23,8,30,138,56,12,4.6,2.7,0.8,2.4,6.1,15.8,239,143.31,1055.9,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,27/6/2025,Outpatient,Cyclosporin,83.0,77.3,38.9,8.6,139,4.6,22,35,24,74,59,12,5.0,2.6,1.5,2.0,5.7,13.3,291,154.38,880.5,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,27/7/2025,Outpatient,Cyclosporin,83.7,101.0,39.8,5.9,138,3.6,25,8,12,113,40,17,5.5,3.6,1.0,1.9,3.9,14.8,272,148.0,1030.03,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,27/8/2025,Outpatient,Cyclosporin,60.0,120.0,40.5,3.5,146,4.1,24,10,8,48,50,21,5.1,2.9,1.4,1.9,5.3,13.1,222,135.02,669.76,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,28/6/2025,Outpatient,Cyclosporin,104.5,84.4,39.5,5.1,141,4.2,22,30,14,112,42,12,5.5,3.8,1.2,1.1,7.3,14.2,229,231.19,813.74,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,28/7/2025,Outpatient,Cyclosporin,85.6,119.7,40.1,6.2,138,4.0,26,24,17,119,65,5,5.3,3.5,1.2,1.5,7.5,13.8,276,201.07,921.2,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,28/8/2025,Outpatient,Cyclosporin,67.0,120.0,38.4,6.3,139,4.5,24,8,10,103,84,12,5.7,3.8,1.3,1.4,6.7,12.3,218,80.0,865.58,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,28/6/2025,Outpatient,Cyclosporin,96.0,69.0,43.8,5.2,146,4.4,20,18,11,63,65,16,5.6,3.2,1.6,1.5,6.9,11.5,237,150.72,904.58,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,29/6/2025,Outpatient,Cyclosporin,114.1,95.6,39.1,8.5,141,4.0,22,27,36,101,68,11,5.2,3.5,1.0,1.6,5.0,13.3,227,216.14,675.91,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,29/7/2025,Outpatient,Cyclosporin,75.1,102.4,39.5,6.6,138,4.1,26,15,8,74,61,7,6.0,4.1,1.2,1.4,3.9,14.8,278,159.14,1148.25,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,29/8/2025,Outpatient,Cyclosporin,60.0,120.0,39.8,3.9,140,3.9,26,28,11,91,42,8,5.1,3.6,0.8,1.7,3.8,14.9,192,191.53,844.43,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,30/6/2025,Outpatient,Cyclosporin,100.3,81.2,37.8,4.0,141,3.6,25,46,23,70,44,18,5.2,3.0,1.5,1.4,7.5,14.6,294,143.3,1193.43,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,30/7/2025,Outpatient,Cyclosporin,84.3,105.4,41.1,6.4,137,3.8,23,8,11,120,45,19,5.2,3.2,1.3,1.8,6.1,12.9,267,200.81,850.4,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,30/8/2025,Outpatient,Cyclosporin,60.0,120.0,40.9,4.1,139,3.8,25,8,11,83,53,14,5.2,3.3,1.1,1.7,7.7,12.7,305,170.81,780.62,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,30/8/2025,Outpatient,Cyclosporin,96.0,60.8,40.1,6.0,138,4.0,24,29,8,77,80,11,4.0,2.4,1.1,1.1,6.0,15.0,218,131.18,1090.92,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,31/7/2025,Outpatient,Cyclosporin,61.4,120.0,40.9,6.8,138,3.5,27,24,9,94,64,16,5.3,3.4,1.3,1.3,4.8,11.7,173,197.11,888.81,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,31/8/2025,Outpatient,Cyclosporin,60.0,116.6,42.3,5.7,138,3.8,25,8,8,82,92,6,5.1,3.2,1.1,1.7,8.4,12.0,340,157.72,721.44,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,5/6/2025,Inpatient,Cyclosporin,77.1,57.2,32.3,12.0,138,4.1,22,35,23,73,48,18,5.2,3.6,0.9,1.5,9.5,15.3,191,166.18,851.39,249.92,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,5/7/2025,Outpatient,Cyclosporin,112.9,78.6,35.8,8.3,138,4.0,23,36,30,127,57,11,4.0,2.0,1.3,1.7,4.9,12.8,245,107.56,674.15,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,6/6/2025,Inpatient,Cyclosporin,120.0,73.6,39.3,7.2,148,4.4,25,39,25,127,86,20,5.7,3.7,1.2,1.8,9.0,13.2,176,252.69,881.78,249.92,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,7/6/2025,Inpatient,Cyclosporin,93.1,87.0,39.4,9.8,135,4.7,23,37,27,84,51,21,5.7,3.8,1.1,1.8,6.2,14.1,112,229.35,1419.97,249.92,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,8/6/2025,Inpatient,Cyclosporin,130.6,42.4,37.2,7.2,138,4.5,24,48,35,95,43,21,5.3,4.1,1.0,0.5,8.0,12.3,292,185.99,946.35,249.92,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,9/6/2025,Inpatient,Cyclosporin,123.1,75.5,32.4,8.1,138,4.4,22,25,30,126,32,16,4.4,2.7,1.1,1.5,11.7,13.2,222,226.38,1075.97,249.92,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1015,2330K,Daniel Anderson,4/6/2025,9/8/2025,Outpatient,Cyclosporin,130.1,64.1,36.1,8.7,141,4.4,23,28,21,113,65,7,5.0,3.3,1.3,1.0,7.2,14.1,240,164.56,560.28,215.84,*3/*3,CC,56.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,200.0,100–200,0.75
RT1017,5156S,Farah Binte Hassan,25/7/2025,1/8/2025,Inpatient,Tacrolimus,133.3,67.3,36.6,7.9,142,3.9,23,37,44,96,74,17,5.1,3.1,1.2,2.0,6.8,11.4,255,8.33,,5.59,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,1/9/2025,Outpatient,Tacrolimus,87.0,74.6,39.6,9.1,139,3.7,26,27,13,110,63,11,4.7,2.7,1.2,1.7,5.1,13.4,315,11.05,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,1/10/2025,Outpatient,Tacrolimus,75.0,120.0,41.0,5.4,139,3.9,23,11,8,74,66,12,5.6,3.8,1.2,1.4,5.8,13.4,95,7.16,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,2/8/2025,Inpatient,Tacrolimus,115.0,61.5,38.4,6.9,136,4.0,24,34,27,52,52,19,5.0,3.1,1.2,1.4,5.0,13.3,238,10.96,,5.59,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,2/9/2025,Outpatient,Tacrolimus,96.0,82.4,39.3,7.2,144,4.2,24,34,27,87,38,9,5.2,3.4,1.1,1.4,7.8,12.8,250,7.33,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,2/10/2025,Outpatient,Tacrolimus,72.1,120.0,39.4,4.7,138,4.1,24,17,18,88,52,10,5.2,3.0,1.5,1.8,4.3,13.4,211,8.45,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,3/8/2025,Inpatient,Tacrolimus,119.0,71.3,35.4,7.4,140,4.0,23,33,34,90,61,14,5.0,2.8,1.2,2.0,6.5,12.5,254,9.54,,5.59,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,3/9/2025,Outpatient,Tacrolimus,87.5,105.1,39.0,7.0,137,4.0,30,26,20,103,40,18,5.1,3.3,1.2,1.3,4.2,14.1,309,11.16,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,3/10/2025,Outpatient,Tacrolimus,73.7,120.0,41.4,2.8,141,4.0,24,8,16,96,58,13,6.0,4.2,0.9,1.9,3.5,14.1,264,7.86,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,4/8/2025,Inpatient,Tacrolimus,118.1,62.8,38.8,9.0,140,3.8,22,33,29,90,97,16,5.2,3.6,0.9,1.5,8.6,13.2,172,10.32,,5.59,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,4/9/2025,Outpatient,Tacrolimus,93.7,90.4,39.7,8.3,135,3.7,22,21,13,81,68,13,5.1,3.6,0.9,1.3,4.0,14.7,212,8.11,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,4/10/2025,Outpatient,Tacrolimus,79.4,120.0,39.4,4.3,139,4.7,25,25,14,55,102,15,5.8,4.2,0.9,1.6,5.9,13.8,380,9.86,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,5/8/2025,Inpatient,Tacrolimus,109.6,60.1,37.4,9.5,140,3.9,24,44,32,101,58,11,5.9,3.9,1.4,1.4,6.2,12.4,203,9.25,,5.59,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,5/9/2025,Outpatient,Tacrolimus,86.9,92.3,40.2,6.5,137,4.1,23,14,13,55,69,14,5.1,3.2,1.4,0.9,7.7,13.3,315,7.68,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,5/10/2025,Outpatient,Tacrolimus,65.8,120.0,39.3,3.0,137,3.8,26,9,10,64,35,8,5.5,3.5,1.1,2.0,8.5,12.5,308,9.47,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,6/8/2025,Inpatient,Tacrolimus,122.1,76.7,36.5,8.7,140,3.7,23,26,20,73,97,19,5.7,3.5,1.4,1.9,9.4,13.7,266,9.93,,5.59,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,6/9/2025,Outpatient,Tacrolimus,106.0,114.6,40.8,5.4,140,3.8,23,22,20,62,64,14,5.3,3.2,1.2,1.8,6.8,13.2,281,9.29,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,6/10/2025,Outpatient,Tacrolimus,61.4,119.6,38.7,7.1,134,3.9,26,9,8,65,31,13,5.1,2.7,1.5,1.7,4.2,12.7,221,5.88,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,7/8/2025,Inpatient,Tacrolimus,114.7,74.9,37.5,6.5,143,4.6,23,25,25,40,31,14,5.4,3.7,0.8,2.1,4.9,12.1,280,10.41,,5.59,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,7/9/2025,Outpatient,Tacrolimus,107.7,108.6,39.9,8.2,141,4.5,23,28,17,88,96,13,5.6,4.0,0.9,1.6,5.0,12.7,157,7.4,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,7/10/2025,Outpatient,Tacrolimus,65.2,120.0,39.6,3.5,146,3.7,23,12,10,80,41,11,5.2,3.1,1.3,1.8,4.3,13.1,352,7.15,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,8/8/2025,Outpatient,Tacrolimus,116.7,79.4,40.4,8.0,141,4.7,22,16,27,112,67,13,5.9,4.0,1.1,1.6,5.1,13.9,311,7.73,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,8/9/2025,Outpatient,Tacrolimus,79.6,98.9,41.2,5.0,135,4.1,25,29,17,106,46,10,5.5,3.5,1.2,1.6,6.1,14.7,317,6.94,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,8/10/2025,Outpatient,Tacrolimus,60.0,120.0,41.6,5.5,141,4.4,27,14,14,112,56,16,4.8,2.7,1.3,1.9,7.7,12.8,268,11.28,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,9/8/2025,Outpatient,Tacrolimus,131.2,74.5,40.5,6.4,140,4.3,25,28,24,68,77,11,5.0,2.7,1.5,1.6,5.2,14.0,219,10.18,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,9/9/2025,Outpatient,Tacrolimus,95.8,101.7,38.1,4.8,138,4.3,23,25,9,95,49,16,4.9,3.1,1.1,1.6,6.2,12.4,305,9.23,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,9/10/2025,Outpatient,Tacrolimus,60.0,120.0,40.0,6.1,142,3.6,22,11,16,94,50,16,5.5,4.0,0.9,1.2,7.5,12.5,287,8.96,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,1/8/2025,Inpatient,Tacrolimus,90.5,55.3,31.0,7.1,137,4.2,18,49,30,79,75,22,5.7,4.1,1.2,1.1,13.6,12.1,281,11.63,,5.59,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,10/8/2025,Outpatient,Tacrolimus,108.1,68.0,41.1,8.8,140,4.0,24,18,30,95,57,13,5.8,3.7,1.3,1.7,5.0,13.7,272,8.88,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,10/9/2025,Outpatient,Tacrolimus,100.2,90.4,40.7,5.4,143,4.1,24,29,27,108,62,19,5.5,3.4,1.3,1.8,4.3,14.5,287,6.49,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,10/10/2025,Outpatient,Tacrolimus,66.0,120.0,41.2,4.6,138,3.9,23,13,11,92,39,10,5.4,3.1,1.6,1.5,6.1,14.0,262,9.35,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,11/8/2025,Outpatient,Tacrolimus,124.1,76.4,39.7,6.2,140,4.2,25,29,25,90,60,15,5.5,3.7,1.2,1.2,4.8,13.5,277,9.37,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,11/9/2025,Outpatient,Tacrolimus,78.1,110.4,39.9,8.8,134,3.8,26,9,17,105,103,18,5.3,3.4,1.1,1.8,7.3,14.6,287,11.12,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,11/10/2025,Outpatient,Tacrolimus,73.6,120.0,40.7,5.4,136,3.4,26,15,8,85,58,14,4.5,2.6,1.1,1.5,6.5,14.6,237,11.27,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,12/8/2025,Outpatient,Tacrolimus,111.7,67.3,40.7,7.4,136,3.5,26,19,15,100,46,17,5.5,3.5,1.1,2.0,3.8,13.1,358,9.03,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,12/9/2025,Outpatient,Tacrolimus,98.6,96.5,40.0,8.9,139,4.0,26,14,11,86,60,10,5.2,3.4,1.2,1.6,7.2,11.8,313,9.07,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,12/10/2025,Outpatient,Tacrolimus,60.0,120.0,39.8,6.7,142,3.8,24,11,16,70,61,13,5.5,3.1,1.2,2.4,6.6,13.2,204,9.27,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,13/8/2025,Outpatient,Tacrolimus,108.4,68.5,40.1,6.7,140,3.7,27,35,24,100,50,9,4.4,2.2,1.3,1.8,7.5,12.5,249,11.18,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,13/9/2025,Outpatient,Tacrolimus,88.4,95.5,40.3,4.0,133,4.3,29,18,26,92,82,15,5.3,3.0,1.6,1.6,6.0,14.8,282,7.9,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,13/10/2025,Outpatient,Tacrolimus,60.0,120.0,39.4,3.5,138,3.8,29,8,8,88,55,11,5.3,3.5,0.9,1.9,3.8,13.6,241,8.21,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,13/9/2025,Outpatient,Tacrolimus,90.0,81.7,39.8,6.3,141,4.3,25,38,17,106,67,11,5.6,4.1,1.2,0.8,7.6,14.0,175,7.38,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,14/8/2025,Outpatient,Tacrolimus,108.1,75.9,40.4,7.9,144,4.6,24,39,18,144,83,18,4.9,2.5,1.6,1.7,8.8,14.5,277,10.65,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,14/9/2025,Outpatient,Tacrolimus,87.9,102.5,39.4,8.8,134,4.1,25,17,8,77,61,13,5.3,3.2,1.2,1.9,7.9,13.7,298,7.18,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,14/10/2025,Outpatient,Tacrolimus,80.3,120.0,41.1,5.4,136,4.1,25,9,8,80,34,14,5.7,3.6,1.5,1.3,8.1,13.0,245,3.0,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,15/8/2025,Outpatient,Tacrolimus,99.6,89.2,40.4,8.0,136,4.1,22,28,21,98,45,19,5.7,4.1,1.2,1.1,4.6,15.1,248,10.02,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,15/9/2025,Outpatient,Tacrolimus,89.4,105.8,40.2,7.1,140,3.5,26,15,29,117,78,15,5.0,3.2,1.1,1.6,4.4,13.4,184,8.49,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,15/10/2025,Outpatient,Tacrolimus,60.0,111.9,39.9,5.0,138,4.2,23,9,16,110,56,11,5.6,3.8,1.0,1.9,7.1,13.4,315,10.26,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,16/8/2025,Outpatient,Tacrolimus,131.5,74.1,39.3,8.5,139,4.3,21,41,25,64,71,17,5.1,2.8,1.3,2.3,6.9,13.7,299,9.51,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,16/9/2025,Outpatient,Tacrolimus,72.1,95.6,40.9,8.1,137,4.2,24,24,19,102,94,9,5.5,3.9,1.1,0.8,5.2,13.6,285,11.4,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,16/10/2025,Outpatient,Tacrolimus,60.0,120.0,39.4,2.4,134,4.3,23,8,30,98,33,19,4.6,2.7,1.3,1.3,6.8,12.3,221,10.57,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,16/8/2025,Outpatient,Tacrolimus,89.8,74.8,39.6,7.2,138,4.6,23,31,34,93,55,18,5.1,3.7,1.1,0.5,9.3,14.3,286,8.38,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,17/8/2025,Outpatient,Tacrolimus,100.9,75.6,40.3,8.2,140,3.7,26,34,32,90,84,12,5.0,3.1,1.3,1.3,6.1,11.5,234,9.88,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,17/9/2025,Outpatient,Tacrolimus,76.2,103.7,39.7,5.5,138,4.8,26,20,18,79,84,19,5.4,3.8,0.9,1.6,5.9,13.9,261,12.13,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,17/10/2025,Outpatient,Tacrolimus,60.0,120.0,41.6,5.3,137,4.2,23,8,20,79,58,6,5.3,3.3,1.0,2.4,6.0,13.3,251,6.62,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,18/8/2025,Outpatient,Tacrolimus,91.5,85.2,42.0,8.6,132,4.3,22,25,29,110,88,16,5.0,2.9,1.2,2.0,6.6,10.8,159,10.23,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,18/9/2025,Outpatient,Tacrolimus,79.2,115.9,41.0,4.8,140,4.0,24,18,8,69,86,15,5.3,3.5,1.2,1.3,7.8,13.4,249,10.94,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,18/10/2025,Outpatient,Tacrolimus,60.0,120.0,38.6,6.3,138,3.6,23,9,19,83,17,8,4.8,3.1,1.1,1.3,5.7,13.0,215,7.95,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,19/8/2025,Outpatient,Tacrolimus,114.4,83.2,39.8,9.4,138,4.6,26,13,18,84,72,16,5.1,3.0,1.2,1.8,6.4,12.5,296,9.21,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,19/9/2025,Outpatient,Tacrolimus,91.3,111.7,41.7,8.8,136,4.0,28,18,8,57,59,6,5.6,3.4,1.3,1.9,3.8,14.2,252,6.39,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,19/10/2025,Outpatient,Tacrolimus,60.0,120.0,39.5,5.4,141,4.0,25,15,11,94,73,7,5.2,2.9,1.5,1.6,5.1,13.0,180,9.89,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,2/8/2025,Inpatient,Tacrolimus,70.0,63.0,39.1,6.3,138,5.1,24,28,9,61,36,20,4.4,2.6,0.8,2.2,8.8,12.4,261,11.27,,5.59,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,20/8/2025,Outpatient,Tacrolimus,100.3,75.4,40.7,5.6,134,4.3,22,27,35,93,75,11,5.5,3.5,1.2,1.6,5.3,12.7,249,8.78,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,20/9/2025,Outpatient,Tacrolimus,79.4,99.2,39.7,5.8,142,3.9,22,33,20,109,102,9,5.6,3.9,1.1,1.2,5.4,14.0,193,7.89,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,20/10/2025,Outpatient,Tacrolimus,60.0,120.0,39.6,3.3,138,4.0,26,24,8,81,73,10,5.3,3.1,1.3,1.8,6.5,13.7,330,8.77,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,20/9/2025,Outpatient,Tacrolimus,106.6,87.7,35.8,7.3,140,4.2,24,26,23,89,36,3,5.4,3.0,1.2,2.5,6.9,12.4,207,7.22,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,21/8/2025,Outpatient,Tacrolimus,108.8,82.0,37.8,7.8,141,3.7,24,34,15,97,67,11,5.1,3.2,1.3,1.4,3.4,12.9,200,8.52,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,21/9/2025,Outpatient,Tacrolimus,65.2,99.3,41.2,8.5,141,3.9,23,32,9,118,11,14,6.2,4.5,1.1,1.5,7.1,11.8,238,7.3,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,21/10/2025,Outpatient,Tacrolimus,60.0,120.0,39.0,4.2,135,3.7,25,8,16,100,58,13,6.3,4.4,1.3,1.3,4.5,15.3,200,10.05,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,22/8/2025,Outpatient,Tacrolimus,106.6,93.2,39.6,6.4,139,4.2,23,26,22,93,69,15,5.2,2.6,1.5,2.4,6.4,13.4,287,8.21,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,22/9/2025,Outpatient,Tacrolimus,77.8,104.7,42.3,2.7,136,4.2,26,26,17,76,46,20,5.4,3.6,1.2,1.2,6.6,13.5,264,9.93,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,22/10/2025,Outpatient,Tacrolimus,60.0,120.0,41.0,3.9,139,4.5,26,8,8,107,71,10,5.4,3.6,1.0,1.6,5.6,13.4,223,5.95,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,23/8/2025,Outpatient,Tacrolimus,65.5,95.1,38.2,6.8,142,4.8,25,15,27,69,47,16,5.4,3.6,1.2,1.3,6.2,14.1,282,9.04,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,23/9/2025,Outpatient,Tacrolimus,75.3,108.3,41.0,5.3,141,4.1,26,8,26,79,77,20,5.6,3.5,1.3,1.6,4.7,14.3,237,8.38,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,23/8/2025,Outpatient,Tacrolimus,98.3,71.1,38.2,8.5,138,4.1,22,22,29,77,48,11,5.2,3.4,1.3,1.2,5.2,12.6,235,7.34,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,24/8/2025,Outpatient,Tacrolimus,133.8,96.6,39.0,8.5,137,5.1,24,26,21,76,96,19,4.8,2.9,1.1,1.5,2.4,14.6,287,7.31,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,24/9/2025,Outpatient,Tacrolimus,78.8,106.5,40.6,5.6,136,3.8,27,19,18,81,48,14,5.1,3.2,1.3,1.4,5.4,13.5,317,9.22,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,25/7/2025,Inpatient,Tacrolimus,126.7,67.7,35.6,8.0,140,4.6,24,19,18,97,69,17,5.2,3.4,1.0,1.8,7.4,12.7,281,9.56,,5.59,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,25/8/2025,Outpatient,Tacrolimus,95.3,101.1,42.3,7.4,136,3.2,23,16,23,101,60,9,5.5,3.2,1.4,1.7,4.6,14.6,333,9.48,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,25/9/2025,Outpatient,Tacrolimus,79.8,100.2,40.5,4.3,138,4.2,23,20,8,96,84,14,4.7,2.7,1.4,1.3,5.4,12.8,232,9.39,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,25/10/2025,Outpatient,Tacrolimus,109.4,80.8,37.4,7.9,142,4.1,22,52,27,117,67,8,5.2,3.1,1.4,1.5,6.4,14.2,261,5.82,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,26/7/2025,Inpatient,Tacrolimus,114.8,59.2,35.9,9.6,136,4.3,22,27,27,105,62,17,6.0,4.1,1.5,1.0,6.5,13.5,258,14.27,,5.59,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,26/8/2025,Outpatient,Tacrolimus,93.4,83.2,40.7,6.7,139,4.2,25,20,31,86,39,9,5.3,3.4,1.3,1.4,4.2,13.6,263,9.41,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,26/9/2025,Outpatient,Tacrolimus,77.5,108.2,40.2,5.9,138,3.9,24,27,13,91,41,13,5.0,3.0,1.1,1.9,5.3,14.8,279,8.54,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,26/7/2025,Inpatient,Tacrolimus,131.3,79.4,34.4,10.2,138,3.7,21,8,26,113,36,25,6.4,4.9,1.2,0.6,7.1,14.1,218,6.42,,5.59,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,27/7/2025,Inpatient,Tacrolimus,137.4,56.5,36.1,7.1,142,4.2,23,41,32,108,71,19,5.4,3.4,1.3,1.5,4.4,12.7,239,7.36,,5.59,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,27/8/2025,Outpatient,Tacrolimus,112.6,80.0,40.1,6.0,140,4.1,25,29,24,115,84,17,4.9,2.7,1.4,1.8,5.6,13.3,260,9.62,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,27/9/2025,Outpatient,Tacrolimus,72.6,119.7,38.6,5.7,140,4.2,23,30,15,101,76,15,4.8,2.8,1.6,0.8,5.1,13.7,272,7.83,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,27/7/2025,Inpatient,Tacrolimus,115.1,58.3,40.3,6.8,135,4.1,25,66,31,51,59,23,5.0,3.0,1.1,2.2,8.1,13.0,312,12.41,,5.59,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,27/9/2025,Outpatient,Tacrolimus,73.7,85.8,40.9,8.2,139,3.5,23,24,23,63,44,9,5.3,3.7,0.9,1.5,6.0,12.1,279,6.45,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,28/7/2025,Inpatient,Tacrolimus,133.8,83.1,37.6,6.7,141,3.9,23,27,27,72,65,21,5.0,3.0,1.3,1.4,7.2,12.3,268,10.11,,5.59,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,28/8/2025,Outpatient,Tacrolimus,96.4,82.8,41.0,5.5,139,4.4,22,35,28,105,76,21,5.6,3.8,1.0,1.8,6.5,13.4,274,8.13,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,28/9/2025,Outpatient,Tacrolimus,99.2,111.4,38.3,4.1,137,4.1,27,9,30,92,47,5,4.8,3.1,1.1,1.2,2.8,13.4,156,11.49,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,28/7/2025,Inpatient,Tacrolimus,126.2,71.6,34.2,5.8,137,5.0,21,30,38,93,83,10,5.2,3.7,0.9,1.4,7.6,14.0,223,11.04,,5.59,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,29/7/2025,Inpatient,Tacrolimus,124.2,60.5,35.9,6.9,134,4.6,23,42,28,121,51,19,4.6,2.2,1.5,2.0,7.5,13.0,207,9.91,,5.59,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,29/8/2025,Outpatient,Tacrolimus,95.6,84.4,40.2,7.5,138,4.1,24,22,12,88,26,19,5.0,2.9,1.4,1.7,4.9,13.4,302,5.59,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,29/9/2025,Outpatient,Tacrolimus,74.6,117.4,39.7,2.7,141,3.7,23,8,22,84,46,9,5.3,3.2,1.3,1.8,6.7,13.1,250,10.02,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,29/7/2025,Inpatient,Tacrolimus,134.7,31.2,34.7,9.9,134,4.6,25,23,29,50,69,14,4.1,2.7,0.9,1.2,7.4,10.7,221,6.48,,5.59,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,30/7/2025,Inpatient,Tacrolimus,120.0,45.0,35.8,11.1,142,4.4,25,21,22,108,95,14,5.5,3.4,1.1,2.2,7.3,12.9,180,6.17,,5.59,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,30/8/2025,Outpatient,Tacrolimus,110.2,89.1,40.0,6.3,137,4.8,24,27,21,102,42,13,5.4,3.3,1.2,2.1,6.7,14.4,276,10.24,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,30/9/2025,Outpatient,Tacrolimus,82.9,111.9,42.1,6.5,137,4.3,25,11,22,107,61,16,5.7,3.8,1.3,1.4,6.4,11.6,273,9.51,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,30/7/2025,Inpatient,Tacrolimus,119.8,51.7,34.2,10.5,140,4.7,23,51,48,105,60,13,4.9,2.8,1.4,1.6,5.2,12.7,232,9.2,,5.59,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,30/8/2025,Outpatient,Tacrolimus,114.4,92.2,40.8,7.0,139,4.3,23,36,45,84,74,12,5.3,3.9,0.9,1.1,5.7,11.9,308,4.98,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,31/7/2025,Inpatient,Tacrolimus,119.0,61.7,37.1,8.7,132,4.4,27,44,29,111,70,12,5.7,3.8,1.3,1.4,8.9,12.5,189,10.45,,5.59,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,31/8/2025,Outpatient,Tacrolimus,107.3,108.6,39.8,5.7,130,4.1,24,17,24,70,83,12,4.8,2.8,1.3,1.5,4.8,15.9,284,12.72,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,31/7/2025,Inpatient,Tacrolimus,116.7,74.3,33.6,4.8,137,3.8,24,28,21,74,45,19,4.6,3.1,1.0,1.1,7.7,13.0,172,12.42,,5.59,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,4/10/2025,Outpatient,Tacrolimus,90.6,63.9,39.3,10.8,136,4.1,25,44,26,83,76,9,5.3,3.2,1.4,1.6,7.1,14.2,195,7.57,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,6/9/2025,Outpatient,Tacrolimus,107.2,90.0,41.9,7.2,138,3.5,26,28,17,86,61,17,4.4,2.8,1.1,1.1,6.1,12.2,231,9.36,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1017,5156S,Farah Binte Hassan,25/7/2025,9/8/2025,Outpatient,Tacrolimus,128.7,82.9,36.8,9.2,142,4.0,24,39,27,122,96,14,5.3,3.3,1.2,1.8,5.9,11.8,277,8.73,,4.82,*1/*3,CT,62.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1019,7067A,Ananya Nair,2/7/2025,1/8/2025,Outpatient,Everolimus,89.8,91.2,40.1,5.4,137,4.2,23,28,25,63,73,18,6.6,4.2,1.3,2.3,7.4,13.3,241,3.82,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,1/9/2025,Outpatient,Everolimus,64.0,120.0,39.1,4.4,136,3.9,25,16,8,86,60,14,6.0,3.9,1.2,2.0,5.6,12.2,257,5.55,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,2/7/2025,Inpatient,Everolimus,135.5,55.8,37.4,8.5,139,4.7,21,29,32,96,56,15,6.6,4.3,1.1,2.8,6.9,11.0,251,6.29,,3.03,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,2/8/2025,Outpatient,Everolimus,95.4,105.1,38.7,7.6,142,4.6,26,12,8,101,44,17,6.7,4.6,1.1,2.3,6.9,14.3,299,5.58,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,2/9/2025,Outpatient,Everolimus,73.8,119.8,40.9,6.5,136,3.3,26,8,8,122,83,18,6.7,4.7,1.1,1.9,7.4,11.8,245,1.73,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,3/7/2025,Inpatient,Everolimus,124.0,54.3,35.1,9.7,137,4.3,21,30,28,111,54,15,6.5,4.1,1.1,2.8,6.8,12.6,192,4.62,,3.03,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,3/8/2025,Outpatient,Everolimus,102.9,81.8,40.7,7.7,140,3.9,24,37,28,88,58,14,7.6,5.6,1.2,1.8,4.3,14.4,307,2.66,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,3/9/2025,Outpatient,Everolimus,69.3,105.4,40.6,4.5,136,3.7,24,27,13,82,64,15,7.1,4.6,1.1,3.2,6.0,13.5,237,3.31,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,4/7/2025,Inpatient,Everolimus,128.7,54.4,36.8,7.3,136,4.1,24,34,19,90,45,15,6.5,3.9,1.4,2.6,8.8,12.1,200,4.04,,3.03,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,4/8/2025,Outpatient,Everolimus,108.5,92.3,40.1,6.6,136,3.9,24,15,19,92,86,17,6.3,4.2,1.2,2.0,5.7,15.1,204,3.58,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,4/9/2025,Outpatient,Everolimus,72.2,91.7,41.2,6.1,139,4.0,24,20,10,69,10,13,6.3,3.9,1.2,2.6,6.7,13.2,309,4.52,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,5/7/2025,Inpatient,Everolimus,134.1,61.4,35.8,7.2,139,5.0,24,37,21,114,39,24,6.1,4.6,1.0,1.3,7.7,13.0,239,5.35,,3.03,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,5/8/2025,Outpatient,Everolimus,96.0,91.1,41.7,7.5,137,4.7,23,20,13,97,27,25,6.5,4.1,1.1,2.8,7.8,12.3,315,4.13,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,5/9/2025,Outpatient,Everolimus,66.1,89.4,40.1,7.5,139,4.6,25,28,8,135,81,17,7.2,4.8,1.5,2.1,3.6,14.3,278,4.29,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,6/7/2025,Inpatient,Everolimus,123.7,69.0,36.8,8.0,136,4.4,25,25,26,86,88,16,6.4,4.3,1.1,2.2,8.1,12.9,274,5.49,,3.03,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,6/8/2025,Outpatient,Everolimus,104.6,103.1,39.2,8.4,141,4.2,26,16,9,108,65,15,7.2,5.1,1.4,1.7,6.3,13.8,256,4.72,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,6/9/2025,Outpatient,Everolimus,81.4,120.0,39.3,2.3,139,4.2,27,17,15,93,43,12,6.4,3.8,1.2,2.9,5.4,12.1,219,5.33,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,7/7/2025,Inpatient,Everolimus,140.7,71.8,36.6,9.7,135,3.9,21,29,31,101,83,20,6.9,4.3,1.4,2.6,9.1,13.2,311,4.53,,3.03,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,7/8/2025,Outpatient,Everolimus,118.9,99.4,38.6,3.7,140,4.5,22,26,26,80,52,16,6.5,4.7,1.0,1.8,6.2,13.4,251,5.43,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,7/9/2025,Outpatient,Everolimus,87.0,112.0,40.3,4.6,140,4.1,24,14,14,77,42,11,7.1,4.8,1.1,2.5,3.3,13.6,206,3.53,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,8/7/2025,Inpatient,Everolimus,112.2,74.2,36.3,11.1,142,4.5,23,18,30,91,76,22,6.1,3.3,1.7,2.5,7.5,12.9,276,4.66,,3.03,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,8/8/2025,Outpatient,Everolimus,101.8,96.5,37.7,6.4,137,4.3,22,13,30,91,58,15,5.8,3.3,1.2,3.0,6.9,12.9,192,4.35,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,8/9/2025,Outpatient,Everolimus,62.3,114.9,41.2,5.0,135,4.3,26,8,8,71,43,12,6.0,3.6,1.3,2.6,4.2,13.3,326,3.56,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,9/7/2025,Inpatient,Everolimus,120.8,53.4,35.7,7.7,139,4.1,25,17,24,113,68,14,6.9,4.8,1.0,2.4,6.6,11.5,304,4.18,,3.03,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,9/8/2025,Outpatient,Everolimus,92.5,96.8,38.8,6.0,139,4.6,25,22,22,112,59,8,5.8,3.4,1.2,2.6,6.0,14.1,223,5.47,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,9/9/2025,Outpatient,Everolimus,63.7,120.0,37.6,6.2,142,4.0,23,8,8,111,27,21,7.6,5.3,1.2,2.5,4.5,14.1,232,2.88,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,1/10/2025,Outpatient,Everolimus,75.6,54.7,41.6,7.3,140,4.3,25,37,34,68,70,16,5.3,2.8,1.2,2.7,5.6,12.9,275,5.51,,2.51,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,10/7/2025,Inpatient,Everolimus,121.7,54.5,36.7,8.0,136,3.9,26,19,31,122,76,19,6.9,4.8,1.1,2.1,7.5,12.5,176,4.24,,3.03,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,10/8/2025,Outpatient,Everolimus,111.2,84.3,40.5,5.5,139,4.3,24,12,13,62,84,17,7.9,6.1,1.0,1.6,7.0,11.6,207,4.26,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,10/9/2025,Outpatient,Everolimus,74.8,120.0,40.5,4.8,139,3.7,24,8,8,78,80,12,6.6,4.1,1.3,2.8,7.9,12.8,302,1.76,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,10/9/2025,Outpatient,Everolimus,74.0,59.7,41.7,2.3,137,4.7,25,23,21,93,28,18,6.4,4.3,1.4,1.6,7.6,13.4,287,2.82,,1.46,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,11/7/2025,Inpatient,Everolimus,117.3,86.6,37.2,7.5,139,4.8,23,32,16,112,71,8,6.7,4.5,1.0,2.7,8.6,13.6,270,4.28,,3.03,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,11/8/2025,Outpatient,Everolimus,100.2,108.4,40.2,6.7,135,4.1,27,23,8,107,94,15,5.8,3.6,1.0,2.6,6.8,12.9,286,6.41,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,11/9/2025,Outpatient,Everolimus,63.7,120.0,39.8,7.7,139,3.7,24,13,8,83,85,19,7.4,4.9,1.2,2.9,6.8,14.6,300,4.17,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,12/7/2025,Inpatient,Everolimus,130.7,59.4,35.4,8.3,135,5.1,22,19,17,102,77,15,6.9,4.8,1.0,2.4,8.0,12.1,211,3.76,,3.03,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,12/8/2025,Outpatient,Everolimus,90.1,93.4,39.2,5.5,140,3.6,22,21,32,81,51,16,7.0,4.9,1.1,2.3,7.3,15.0,270,2.64,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,12/9/2025,Outpatient,Everolimus,62.8,120.0,38.0,3.7,136,4.9,25,9,13,79,55,17,6.3,4.2,0.9,2.6,7.6,12.9,299,4.43,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,13/7/2025,Inpatient,Everolimus,128.8,85.2,37.4,6.3,138,3.7,23,23,20,90,60,15,5.3,2.9,1.3,2.4,8.0,12.4,283,3.76,,3.03,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,13/8/2025,Outpatient,Everolimus,85.8,95.6,40.3,4.1,142,4.7,24,12,28,85,86,14,7.5,5.5,1.0,2.3,7.1,12.3,321,4.3,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,13/9/2025,Outpatient,Everolimus,76.3,120.0,40.2,3.4,133,4.1,30,14,13,101,42,11,7.2,4.9,1.2,2.3,6.5,13.4,235,3.78,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,13/8/2025,Outpatient,Everolimus,114.5,82.4,40.3,5.2,136,4.2,24,32,26,50,78,6,6.0,4.0,1.1,1.9,6.4,13.9,275,4.93,,1.63,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,14/7/2025,Inpatient,Everolimus,110.7,63.2,35.7,7.6,140,3.9,26,40,20,69,40,14,6.2,4.1,1.2,2.0,6.4,12.7,229,4.55,,3.03,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,14/8/2025,Outpatient,Everolimus,82.5,91.1,40.7,7.2,138,4.2,24,21,8,99,69,8,7.4,5.1,1.1,2.4,6.0,11.3,244,3.06,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,14/9/2025,Outpatient,Everolimus,60.0,114.8,40.6,5.6,139,3.7,28,8,12,109,62,11,6.5,4.3,1.1,2.3,6.8,13.7,263,5.42,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,15/7/2025,Inpatient,Everolimus,125.8,84.2,36.5,8.2,136,4.7,25,13,25,141,66,16,7.1,4.8,1.1,2.8,7.9,12.4,195,6.25,,3.03,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,15/8/2025,Outpatient,Everolimus,60.0,120.0,39.7,6.3,138,4.3,25,24,21,108,91,15,6.4,4.1,1.3,2.4,4.2,14.5,310,6.1,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,15/9/2025,Outpatient,Everolimus,69.0,120.0,42.7,5.6,140,3.5,25,18,21,104,61,8,6.8,4.6,1.2,2.2,7.7,13.3,235,6.56,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,16/7/2025,Outpatient,Everolimus,120.7,70.0,40.7,7.7,137,4.8,19,24,23,97,33,10,6.1,4.4,1.2,1.2,7.1,12.6,279,6.98,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,16/8/2025,Outpatient,Everolimus,82.6,120.0,38.9,3.5,137,4.5,27,15,15,95,68,14,6.8,4.9,0.9,2.3,4.1,14.3,275,5.05,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,16/9/2025,Outpatient,Everolimus,60.0,120.0,41.1,4.8,139,4.2,28,12,8,57,96,11,6.6,4.2,1.1,2.7,8.0,12.5,271,3.67,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,16/7/2025,Outpatient,Everolimus,112.2,86.3,40.3,4.8,139,4.3,22,30,35,80,96,19,6.1,4.4,1.4,0.8,6.9,14.2,277,4.49,,2.21,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,17/7/2025,Outpatient,Everolimus,110.9,60.4,39.7,8.7,136,4.3,23,12,11,111,89,16,7.0,4.7,1.4,2.0,7.6,13.6,299,6.31,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,17/8/2025,Outpatient,Everolimus,83.5,120.0,39.2,7.1,137,4.3,23,16,18,104,96,7,7.0,4.8,1.0,2.6,5.8,14.2,173,4.35,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,17/9/2025,Outpatient,Everolimus,62.3,120.0,38.6,6.0,138,4.2,30,8,8,89,47,8,7.0,4.3,1.3,3.0,3.3,14.8,239,4.26,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,17/9/2025,Outpatient,Everolimus,102.1,77.3,40.1,4.2,136,4.8,25,14,32,142,49,9,7.1,5.4,0.9,1.9,6.1,14.7,303,2.16,,2.43,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,18/7/2025,Outpatient,Everolimus,125.0,56.7,39.1,7.7,134,4.2,22,34,24,118,79,11,6.5,4.9,1.0,1.3,3.5,12.9,306,5.87,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,18/8/2025,Outpatient,Everolimus,82.9,105.9,41.6,3.9,144,4.1,25,8,18,84,37,8,6.9,4.6,1.2,2.3,5.7,15.0,359,4.67,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,18/9/2025,Outpatient,Everolimus,60.2,120.0,40.9,5.9,142,3.9,26,16,18,105,64,8,6.9,4.7,1.3,2.1,5.1,12.3,197,2.28,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,19/7/2025,Outpatient,Everolimus,108.4,78.9,39.6,9.0,135,4.1,23,33,34,116,62,13,6.2,4.2,1.1,2.1,4.9,12.8,301,3.6,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,19/8/2025,Outpatient,Everolimus,103.6,93.0,40.4,6.3,140,4.3,26,27,14,77,73,20,6.8,4.6,1.2,2.4,5.6,12.3,319,5.75,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,19/9/2025,Outpatient,Everolimus,66.2,120.0,40.9,3.0,142,3.8,25,11,8,82,49,15,7.8,5.7,1.2,2.1,6.8,13.7,258,4.31,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,20/7/2025,Outpatient,Everolimus,121.7,65.9,39.4,5.7,140,4.2,25,18,19,90,76,12,6.6,4.5,0.8,2.8,6.7,13.8,229,4.46,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,20/8/2025,Outpatient,Everolimus,103.8,110.3,39.6,8.3,137,4.5,24,21,8,81,33,16,6.0,3.9,1.2,2.1,4.3,13.6,209,5.45,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,20/9/2025,Outpatient,Everolimus,61.3,120.0,40.9,2.0,137,3.5,26,18,8,124,81,13,6.4,4.4,1.2,1.7,7.0,14.7,197,5.22,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,20/8/2025,Outpatient,Everolimus,143.4,71.5,40.3,9.7,143,3.5,23,37,8,93,62,18,4.9,3.2,1.1,1.4,4.3,12.8,241,4.56,,2.45,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,21/7/2025,Outpatient,Everolimus,107.3,71.5,39.7,7.1,144,3.5,23,40,13,80,67,19,7.3,4.8,1.4,2.5,7.3,14.9,292,3.49,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,21/8/2025,Outpatient,Everolimus,86.6,93.0,38.9,8.9,140,4.3,24,9,16,117,59,11,6.8,4.1,1.4,2.9,5.2,12.1,309,5.77,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,21/9/2025,Outpatient,Everolimus,74.8,120.0,40.8,4.9,139,3.6,27,12,8,116,55,12,6.1,3.6,1.1,2.9,7.4,13.9,285,4.75,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,22/7/2025,Outpatient,Everolimus,111.8,81.4,41.1,7.0,134,4.0,25,11,18,87,92,11,5.8,4.2,1.1,1.3,7.4,14.1,267,4.55,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,22/8/2025,Outpatient,Everolimus,88.8,100.0,39.7,5.4,140,4.4,29,8,13,108,44,16,6.2,3.8,1.2,2.7,5.9,13.5,243,3.84,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,22/9/2025,Outpatient,Everolimus,64.0,120.0,38.6,3.9,137,3.8,26,8,8,92,55,12,6.5,4.3,1.2,2.3,6.4,14.5,216,2.73,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,23/7/2025,Outpatient,Everolimus,116.8,106.2,39.4,8.9,138,3.9,24,33,21,76,44,16,6.6,4.0,1.6,2.3,5.4,13.9,319,5.04,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,23/8/2025,Outpatient,Everolimus,80.4,115.6,39.9,7.2,137,3.8,23,14,21,99,81,16,7.0,4.8,1.3,2.1,7.6,14.5,315,7.31,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,23/9/2025,Outpatient,Everolimus,74.6,120.0,41.3,4.5,140,4.2,27,8,9,95,48,13,7.0,5.1,1.0,1.9,6.6,13.9,210,2.99,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,23/7/2025,Outpatient,Everolimus,120.6,74.7,43.2,10.5,143,4.5,26,42,15,88,87,9,5.3,2.7,1.4,2.7,4.4,11.8,188,4.82,,2.38,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,24/7/2025,Outpatient,Everolimus,119.3,73.2,40.2,4.9,140,3.9,26,37,19,107,35,15,7.8,5.6,1.0,2.7,7.5,14.3,311,5.49,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,24/8/2025,Outpatient,Everolimus,73.0,91.3,39.2,4.7,138,4.1,26,8,8,81,82,16,5.8,4.0,0.9,2.1,6.5,13.4,278,3.93,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,24/9/2025,Outpatient,Everolimus,60.0,120.0,40.1,3.1,138,4.1,25,8,8,82,38,14,6.9,4.6,1.1,2.5,7.7,14.4,205,3.74,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,24/9/2025,Outpatient,Everolimus,96.1,84.3,36.8,10.0,138,4.2,24,34,23,91,83,14,5.2,3.1,1.3,1.7,5.9,13.9,329,3.39,,2.52,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,25/7/2025,Outpatient,Everolimus,108.7,73.7,39.9,5.3,140,3.5,24,25,32,107,18,16,6.5,4.6,1.2,1.7,7.8,13.1,198,4.01,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,25/8/2025,Outpatient,Everolimus,89.1,111.4,39.9,3.1,140,4.1,22,23,19,61,42,16,5.7,3.6,1.4,1.6,7.4,13.4,230,3.79,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,25/9/2025,Outpatient,Everolimus,71.9,120.0,41.1,2.9,140,4.0,25,8,8,90,53,10,7.1,4.5,1.4,2.6,7.0,13.2,153,3.6,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,26/7/2025,Outpatient,Everolimus,114.9,79.8,40.1,8.3,140,4.4,26,19,27,93,52,15,6.9,4.8,0.9,2.7,7.1,13.6,276,4.21,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,26/8/2025,Outpatient,Everolimus,74.4,116.7,39.0,3.2,138,3.9,24,17,12,89,60,15,6.1,4.0,1.1,2.3,6.8,14.0,288,4.25,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,26/9/2025,Outpatient,Everolimus,60.0,120.0,39.6,4.6,137,3.9,25,8,8,95,17,11,7.1,4.8,1.2,2.4,5.1,13.1,177,3.81,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,27/7/2025,Outpatient,Everolimus,100.8,83.7,39.0,7.2,141,4.2,24,20,8,102,93,15,7.5,5.4,0.9,2.7,5.1,13.8,322,5.8,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,27/8/2025,Outpatient,Everolimus,69.4,102.6,37.4,2.3,140,3.6,25,16,9,93,55,9,6.7,4.6,1.4,1.7,4.4,13.3,289,3.91,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,27/9/2025,Outpatient,Everolimus,60.0,118.9,41.7,3.3,136,4.4,25,10,8,96,24,20,7.2,4.6,1.2,2.8,5.0,14.4,281,2.36,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,27/8/2025,Outpatient,Everolimus,78.6,68.5,40.1,3.4,141,4.3,25,20,31,83,61,19,5.0,2.9,1.4,1.5,8.7,11.2,311,4.01,,2.05,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,28/7/2025,Outpatient,Everolimus,105.8,74.6,40.9,9.0,137,4.0,22,15,12,108,78,19,7.1,5.0,1.2,2.0,6.4,15.1,262,5.82,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,28/8/2025,Outpatient,Everolimus,79.2,96.6,38.1,6.4,137,4.3,27,8,8,80,74,14,6.7,4.6,0.9,2.5,7.6,11.6,165,4.88,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,28/9/2025,Outpatient,Everolimus,60.0,120.0,39.5,2.9,138,4.4,27,8,8,107,66,15,7.5,5.1,1.0,3.1,5.9,14.2,256,4.04,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,29/7/2025,Outpatient,Everolimus,113.3,104.9,40.1,7.2,143,3.7,22,20,19,129,73,16,6.1,3.8,1.6,1.8,4.8,12.6,232,5.3,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,29/8/2025,Outpatient,Everolimus,77.2,102.7,39.3,4.1,134,4.2,24,19,22,56,81,11,6.2,4.1,1.1,2.3,3.2,13.7,241,3.08,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,29/9/2025,Outpatient,Everolimus,60.0,120.0,40.7,3.2,139,4.6,23,8,11,77,59,8,7.1,5.0,0.8,2.8,6.0,13.8,277,3.14,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,3/7/2025,Inpatient,Everolimus,125.2,48.2,35.0,8.0,134,5.4,24,35,30,88,119,14,6.4,4.2,0.9,2.9,5.1,12.9,235,3.73,,2.03,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,3/9/2025,Outpatient,Everolimus,106.4,86.2,40.3,7.6,145,4.1,22,34,40,82,67,13,6.3,4.2,1.0,2.5,6.6,13.2,236,4.3,,1.85,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,30/7/2025,Outpatient,Everolimus,98.3,101.5,39.2,5.7,140,4.4,22,13,22,119,50,22,7.1,4.8,0.9,3.0,4.4,13.0,234,7.28,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,30/8/2025,Outpatient,Everolimus,86.0,120.0,39.9,5.6,136,3.1,22,24,10,87,57,15,7.4,4.9,1.3,2.7,7.0,12.9,224,6.01,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,30/7/2025,Outpatient,Everolimus,94.7,68.3,37.7,2.2,138,4.1,23,53,18,98,57,17,5.7,3.6,1.0,2.3,6.7,13.8,254,3.15,,2.47,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,31/7/2025,Outpatient,Everolimus,82.7,79.8,39.6,6.0,136,4.4,27,28,18,90,76,18,6.4,3.9,1.3,2.8,7.5,15.3,288,5.4,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,31/8/2025,Outpatient,Everolimus,89.1,120.0,40.3,10.4,135,4.2,22,8,8,117,78,16,5.7,3.6,1.2,2.1,8.1,14.0,224,2.78,,2.62,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,4/7/2025,Inpatient,Everolimus,84.8,43.2,28.2,8.3,143,3.9,25,13,27,100,89,7,6.4,3.9,1.3,2.5,8.4,11.5,270,4.14,,3.23,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,5/7/2025,Inpatient,Everolimus,133.2,70.1,38.9,9.3,134,4.7,21,22,27,78,114,13,5.4,3.3,1.3,1.8,2.0,10.4,238,4.93,,2.02,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,6/7/2025,Inpatient,Everolimus,157.1,50.4,38.5,8.9,142,4.1,24,43,31,107,88,14,7.2,4.8,1.3,2.4,8.2,11.9,335,5.0,,1.85,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,6/8/2025,Outpatient,Everolimus,105.5,63.9,39.3,8.0,140,4.3,20,29,47,86,67,10,6.3,3.9,1.0,3.0,6.5,14.4,202,2.76,,2.69,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,7/7/2025,Inpatient,Everolimus,116.1,51.9,30.2,11.4,137,4.2,25,8,15,121,63,5,6.3,3.6,1.4,3.0,6.7,12.8,201,5.52,,1.91,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,8/7/2025,Inpatient,Everolimus,123.2,101.1,35.1,8.9,137,3.8,24,30,30,104,70,17,5.8,3.6,1.2,2.3,7.5,10.8,242,6.24,,2.59,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1019,7067A,Ananya Nair,2/7/2025,9/7/2025,Inpatient,Everolimus,102.3,54.2,38.5,9.2,142,3.9,25,25,26,108,70,21,5.1,2.9,1.4,1.9,6.5,13.4,242,4.95,,3.02,*3/*3,CC,58.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,1.75,3–8,0.75
RT1026,6370D,Chew Chen Xiao,4/6/2025,1/7/2025,Outpatient,Tacrolimus,116.0,93.5,41.3,9.0,140,3.9,22,17,20,77,64,15,5.0,3.2,1.3,1.0,5.3,13.7,197,9.33,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,1/8/2025,Outpatient,Tacrolimus,77.5,104.0,39.1,3.2,137,4.5,25,8,11,89,42,9,5.0,3.0,1.5,1.0,5.0,14.7,337,7.45,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,1/9/2025,Outpatient,Tacrolimus,60.0,120.0,41.5,4.5,133,4.2,27,8,8,89,60,10,5.5,3.3,1.5,1.7,7.5,12.0,311,11.1,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,2/7/2025,Outpatient,Tacrolimus,108.0,107.3,39.7,7.6,136,4.6,26,22,9,87,47,16,4.9,2.8,1.1,1.9,5.9,12.0,197,9.45,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,2/8/2025,Outpatient,Tacrolimus,76.3,114.6,39.5,3.1,138,3.4,25,31,8,132,47,12,4.8,2.5,1.4,2.0,3.0,14.1,225,7.7,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,3/7/2025,Outpatient,Tacrolimus,117.2,93.8,39.3,5.9,136,4.4,25,13,27,77,74,18,5.0,3.2,1.2,1.2,7.3,15.0,334,9.94,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,3/8/2025,Outpatient,Tacrolimus,60.0,120.0,40.0,6.1,141,4.3,27,29,10,88,45,18,5.3,3.0,1.4,2.0,5.0,12.2,319,7.61,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,4/6/2025,Inpatient,Tacrolimus,128.2,53.8,34.7,8.1,138,4.4,27,44,25,111,82,14,5.4,3.7,1.2,1.0,7.3,14.3,242,11.58,,4.65,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,4/7/2025,Outpatient,Tacrolimus,83.6,99.5,39.8,6.2,135,4.4,26,18,18,68,61,16,4.8,3.0,1.0,1.8,6.1,12.9,320,8.83,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,4/8/2025,Outpatient,Tacrolimus,85.9,119.2,39.3,5.2,136,3.9,27,15,9,109,55,15,4.8,3.0,1.1,1.5,2.6,14.0,216,8.14,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,5/6/2025,Inpatient,Tacrolimus,132.5,81.9,35.9,5.0,133,3.7,22,35,23,89,70,15,4.7,2.9,1.1,1.4,6.0,12.7,170,10.89,,4.65,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,5/7/2025,Outpatient,Tacrolimus,72.0,81.2,40.4,7.0,138,4.3,25,30,33,99,54,9,4.7,3.1,1.0,1.4,7.8,13.2,312,8.36,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,5/8/2025,Outpatient,Tacrolimus,69.8,120.0,39.6,6.2,138,4.1,26,8,11,105,58,11,4.9,2.8,1.5,1.2,6.9,13.0,267,11.2,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,6/6/2025,Inpatient,Tacrolimus,121.5,58.9,36.7,10.0,141,4.7,27,37,20,119,31,14,5.3,3.3,1.3,1.8,7.4,13.9,165,11.87,,4.65,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,6/7/2025,Outpatient,Tacrolimus,119.5,94.5,40.3,5.1,138,4.1,27,28,33,91,89,17,4.9,3.2,1.0,1.6,6.8,11.7,290,6.63,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,6/8/2025,Outpatient,Tacrolimus,70.3,107.2,39.2,6.1,141,4.8,25,9,19,89,54,14,5.2,3.2,1.2,1.8,4.0,14.9,200,10.29,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,7/6/2025,Inpatient,Tacrolimus,139.1,67.2,35.3,10.8,139,4.1,25,31,16,116,77,18,4.5,3.0,0.8,1.5,7.2,12.5,238,9.43,,4.65,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,7/7/2025,Outpatient,Tacrolimus,90.0,108.1,42.0,7.0,142,3.7,26,19,23,102,84,16,4.6,2.8,0.9,2.0,6.6,12.0,237,10.12,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,7/8/2025,Outpatient,Tacrolimus,67.5,109.2,40.3,5.1,138,4.2,24,9,11,91,93,14,4.9,3.2,1.1,1.4,8.0,13.2,252,7.88,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,8/6/2025,Inpatient,Tacrolimus,127.6,79.7,36.4,8.7,143,3.8,21,32,22,102,81,15,4.7,2.6,1.3,1.6,8.6,12.1,287,10.1,,4.65,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,8/7/2025,Outpatient,Tacrolimus,87.6,96.8,40.6,9.3,138,4.3,24,26,21,93,54,14,4.8,2.9,1.4,1.3,5.4,12.5,258,8.12,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,8/8/2025,Outpatient,Tacrolimus,79.5,108.3,40.1,6.1,137,3.8,24,8,10,91,59,17,4.6,3.0,1.0,1.3,5.2,12.5,233,8.56,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,9/6/2025,Inpatient,Tacrolimus,140.4,61.6,36.3,8.3,136,4.3,22,34,22,110,48,17,5.3,3.5,1.1,1.6,8.1,13.1,218,11.49,,4.65,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,9/7/2025,Outpatient,Tacrolimus,113.0,72.9,41.0,9.4,138,4.3,23,13,18,124,50,10,5.2,3.5,1.1,1.3,7.7,14.3,279,7.84,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,9/8/2025,Outpatient,Tacrolimus,80.9,120.0,41.2,5.3,143,3.8,24,14,14,68,54,15,5.4,3.5,1.4,1.1,7.3,12.6,268,7.97,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,1/7/2025,Outpatient,Tacrolimus,60.0,85.4,42.4,8.2,141,3.7,26,23,10,106,60,17,5.4,3.5,1.2,1.5,7.6,15.1,258,8.34,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,10/6/2025,Inpatient,Tacrolimus,115.0,72.5,37.4,7.5,140,4.1,20,19,25,115,31,20,4.9,3.3,1.1,1.2,7.0,12.8,240,9.73,,4.65,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,10/7/2025,Outpatient,Tacrolimus,111.5,100.2,40.3,8.1,139,4.0,22,34,27,79,94,9,5.5,3.4,1.3,1.8,5.6,12.4,206,7.92,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,10/8/2025,Outpatient,Tacrolimus,86.3,115.9,41.5,5.1,137,4.6,25,8,16,92,97,14,5.1,3.6,1.0,1.3,5.4,12.7,245,9.0,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,10/6/2025,Inpatient,Tacrolimus,121.5,69.5,39.8,4.7,137,4.4,24,41,41,113,90,12,5.0,3.3,0.7,2.0,7.5,12.4,212,8.83,,4.65,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,11/6/2025,Inpatient,Tacrolimus,126.7,65.2,36.1,6.5,138,3.3,26,32,29,99,99,9,4.8,2.6,1.6,1.5,8.4,14.3,277,10.96,,4.65,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,11/7/2025,Outpatient,Tacrolimus,106.1,85.9,39.5,4.9,135,3.8,23,24,24,97,73,19,5.6,3.5,1.3,1.6,4.2,12.5,216,6.3,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,11/8/2025,Outpatient,Tacrolimus,81.0,113.5,40.0,5.4,140,3.5,24,17,13,114,75,12,4.9,3.0,1.2,1.6,8.8,12.0,263,8.17,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,12/6/2025,Inpatient,Tacrolimus,138.5,61.5,37.1,9.6,136,3.8,21,30,30,101,70,21,5.0,3.1,1.1,1.7,5.5,13.3,273,9.68,,4.65,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,12/7/2025,Outpatient,Tacrolimus,97.7,94.7,38.7,7.2,139,3.8,25,22,18,62,21,19,5.7,3.6,1.2,1.8,7.3,13.6,227,10.56,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,12/8/2025,Outpatient,Tacrolimus,60.0,120.0,40.5,6.1,136,4.1,27,15,13,67,39,13,4.9,3.2,0.9,1.7,7.1,13.9,238,10.33,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,12/8/2025,Outpatient,Tacrolimus,75.6,91.8,38.1,5.0,141,5.4,23,25,19,93,48,15,4.9,3.3,1.0,1.4,4.5,14.2,146,8.55,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,13/6/2025,Inpatient,Tacrolimus,122.4,65.9,38.1,8.7,138,3.8,26,34,16,121,90,17,4.6,3.0,1.3,0.7,7.7,10.1,220,7.0,,4.65,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,13/7/2025,Outpatient,Tacrolimus,109.0,101.7,40.1,6.9,137,4.4,24,23,15,62,72,14,5.3,2.9,1.7,1.6,6.6,15.1,287,9.68,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,13/8/2025,Outpatient,Tacrolimus,66.5,120.0,39.3,7.4,140,4.1,29,10,8,57,51,16,5.0,2.9,1.3,1.6,4.3,13.8,253,9.08,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,14/6/2025,Inpatient,Tacrolimus,126.1,62.7,35.6,8.3,138,4.0,23,44,19,97,77,21,4.7,3.0,1.4,0.7,7.2,11.8,269,9.31,,4.65,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,14/7/2025,Outpatient,Tacrolimus,96.9,93.1,39.2,7.9,136,4.0,24,21,21,63,67,11,4.3,2.7,1.1,1.3,5.9,12.6,258,8.32,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,14/8/2025,Outpatient,Tacrolimus,60.0,120.0,40.4,3.7,134,3.6,25,13,8,94,37,6,4.7,3.1,0.8,1.7,6.4,13.1,239,9.4,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,15/6/2025,Inpatient,Tacrolimus,120.2,55.5,36.7,9.7,137,4.8,26,42,18,109,43,15,5.1,3.3,1.3,1.2,6.8,12.9,262,10.71,,4.65,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,15/7/2025,Outpatient,Tacrolimus,96.1,93.9,41.9,4.7,139,3.8,24,20,13,130,88,16,4.5,3.1,0.9,1.1,6.9,13.5,243,8.66,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,15/8/2025,Outpatient,Tacrolimus,63.1,110.8,41.1,4.9,140,3.7,26,8,19,110,62,19,5.5,3.7,1.1,1.5,7.9,13.7,222,9.65,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,15/7/2025,Outpatient,Tacrolimus,140.3,67.6,40.6,8.2,138,5.2,21,32,23,108,63,13,4.8,2.9,1.3,1.4,7.4,12.3,233,7.37,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,16/6/2025,Inpatient,Tacrolimus,120.8,70.5,38.0,9.6,140,3.6,26,54,26,102,33,17,4.8,2.9,1.2,1.6,7.2,13.1,232,9.03,,4.65,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,16/7/2025,Outpatient,Tacrolimus,88.1,107.2,41.0,6.0,138,4.1,28,26,8,91,96,9,4.4,2.7,1.2,1.3,6.7,12.1,150,10.74,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,16/8/2025,Outpatient,Tacrolimus,74.4,120.0,40.6,4.0,138,3.8,28,13,8,63,37,13,5.6,3.7,1.2,1.3,5.8,14.1,244,10.72,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,17/6/2025,Inpatient,Tacrolimus,125.7,70.8,36.9,9.1,142,4.1,22,16,30,103,47,14,5.3,3.2,1.4,1.5,9.1,13.2,168,11.9,,4.65,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,17/7/2025,Outpatient,Tacrolimus,92.1,106.7,39.6,7.6,137,3.9,26,13,22,53,59,17,5.7,3.9,1.2,1.4,5.9,13.1,290,8.49,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,17/8/2025,Outpatient,Tacrolimus,60.0,115.2,38.8,2.0,139,3.9,24,25,23,88,60,8,4.9,2.8,1.1,2.2,6.8,13.7,272,9.19,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,17/6/2025,Outpatient,Tacrolimus,90.6,85.0,42.2,9.0,137,4.1,25,29,17,90,29,12,5.2,3.2,1.1,1.9,6.0,14.3,206,5.33,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,18/6/2025,Outpatient,Tacrolimus,122.5,80.4,39.1,6.9,136,4.1,24,38,27,87,70,11,4.9,2.7,1.3,2.1,8.8,13.6,219,9.39,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,18/7/2025,Outpatient,Tacrolimus,95.5,81.3,41.0,7.0,141,3.7,25,26,24,76,51,16,4.6,2.7,1.3,1.4,7.0,14.5,188,8.56,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,18/8/2025,Outpatient,Tacrolimus,61.4,120.0,38.2,5.9,141,3.9,24,15,15,106,64,16,5.3,3.0,1.4,1.9,6.1,14.2,298,7.65,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,19/6/2025,Outpatient,Tacrolimus,123.7,59.7,39.9,8.2,139,4.9,23,47,22,61,63,15,5.3,3.6,1.0,1.5,8.4,14.1,316,11.28,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,19/7/2025,Outpatient,Tacrolimus,97.3,85.4,40.7,6.6,137,4.0,25,25,16,85,43,10,5.5,3.7,1.3,1.0,5.3,13.8,241,8.47,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,19/8/2025,Outpatient,Tacrolimus,72.2,120.0,39.7,2.3,136,3.4,25,8,8,81,54,7,4.6,2.8,1.1,1.7,7.7,12.7,266,9.43,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,19/8/2025,Outpatient,Tacrolimus,83.0,83.1,40.1,6.6,135,3.7,24,30,16,85,50,12,4.6,2.5,1.3,1.8,4.8,14.2,270,6.24,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,2/9/2025,Outpatient,Tacrolimus,95.0,49.3,37.6,5.0,139,4.3,25,32,25,99,79,16,4.1,2.0,1.3,1.8,6.4,12.8,272,6.99,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,20/6/2025,Outpatient,Tacrolimus,113.5,80.0,38.9,8.1,135,4.1,23,26,34,57,36,15,4.1,2.2,1.3,1.3,7.0,13.7,219,9.17,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,20/7/2025,Outpatient,Tacrolimus,97.8,99.7,41.3,3.4,135,4.3,22,28,25,96,47,15,4.8,2.7,1.3,1.9,4.8,14.0,330,8.33,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,20/8/2025,Outpatient,Tacrolimus,74.9,120.0,42.2,6.1,144,3.9,27,8,8,107,48,15,5.2,3.1,1.3,1.7,6.6,12.9,197,7.32,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,21/6/2025,Outpatient,Tacrolimus,128.3,82.0,40.9,7.4,140,4.4,25,30,10,109,71,12,5.7,4.2,1.0,1.2,5.2,13.6,373,8.53,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,21/7/2025,Outpatient,Tacrolimus,97.6,95.7,39.8,5.0,138,4.4,25,17,21,91,82,9,5.0,3.3,0.9,1.7,4.1,13.9,242,7.99,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,21/8/2025,Outpatient,Tacrolimus,60.0,108.5,39.1,3.3,140,3.7,24,10,12,104,40,14,5.2,3.3,1.2,1.3,6.1,13.9,323,9.32,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,22/6/2025,Outpatient,Tacrolimus,112.5,58.7,41.4,8.0,139,4.8,26,31,26,72,110,13,5.2,3.2,1.4,1.4,5.6,13.2,311,9.42,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,22/7/2025,Outpatient,Tacrolimus,88.2,98.9,40.8,5.3,144,3.9,22,22,12,88,65,13,5.4,3.6,1.1,1.5,5.3,12.4,278,11.77,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,22/8/2025,Outpatient,Tacrolimus,70.0,120.0,39.7,5.7,138,4.4,25,14,24,81,99,11,5.4,3.7,1.3,1.0,5.1,14.5,202,7.48,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,22/7/2025,Outpatient,Tacrolimus,77.9,67.3,36.7,7.3,134,4.5,23,30,25,98,68,22,4.1,2.3,1.4,1.0,6.8,12.3,258,7.91,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,23/6/2025,Outpatient,Tacrolimus,111.8,73.4,39.3,7.4,139,4.2,22,41,30,88,39,19,4.7,2.6,1.4,1.6,3.8,13.4,303,7.9,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,23/7/2025,Outpatient,Tacrolimus,79.7,111.2,40.3,7.4,138,4.4,25,20,20,64,59,9,5.0,3.4,1.1,1.2,6.4,13.9,273,7.78,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,23/8/2025,Outpatient,Tacrolimus,60.0,120.0,39.9,5.1,135,3.9,24,8,16,98,76,3,5.3,3.7,1.0,1.4,6.3,13.6,303,8.42,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,24/6/2025,Outpatient,Tacrolimus,110.6,66.3,38.0,3.8,136,4.3,21,17,19,94,69,17,4.7,3.0,1.1,1.2,7.8,12.4,240,8.18,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,24/7/2025,Outpatient,Tacrolimus,93.5,108.8,41.0,8.4,140,4.3,26,28,29,100,61,18,5.1,3.3,1.0,1.7,4.4,13.7,224,6.2,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,24/8/2025,Outpatient,Tacrolimus,60.0,120.0,39.9,2.0,143,3.4,24,17,8,103,44,10,5.4,4.2,0.6,1.4,3.9,13.8,299,7.4,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,24/6/2025,Outpatient,Tacrolimus,101.8,61.9,38.7,6.3,136,4.5,28,8,25,76,57,14,5.1,3.3,1.2,1.1,7.1,13.2,229,6.73,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,25/6/2025,Outpatient,Tacrolimus,97.1,71.1,40.9,6.2,138,4.2,24,31,25,84,24,21,5.4,3.0,1.5,1.8,5.5,13.3,345,12.17,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,25/7/2025,Outpatient,Tacrolimus,90.9,105.9,39.4,3.8,141,3.2,22,17,22,63,39,16,5.6,3.7,1.1,1.8,7.1,14.3,329,8.21,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,25/8/2025,Outpatient,Tacrolimus,60.0,120.0,40.6,5.5,139,3.7,25,10,11,94,44,12,5.6,3.7,1.1,1.6,6.1,14.6,274,10.51,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,26/6/2025,Outpatient,Tacrolimus,116.9,69.4,40.2,5.7,142,4.2,21,19,26,99,75,14,5.0,3.3,1.1,1.2,5.4,13.7,267,8.11,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,26/7/2025,Outpatient,Tacrolimus,60.0,102.2,39.8,7.6,138,3.3,27,14,13,96,38,17,4.7,2.9,1.1,1.4,7.7,13.5,221,8.86,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,26/8/2025,Outpatient,Tacrolimus,60.0,120.0,40.2,2.0,136,4.4,25,12,18,102,46,17,4.7,2.7,1.3,1.5,6.5,14.2,265,10.18,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,26/8/2025,Outpatient,Tacrolimus,102.4,57.1,41.3,3.0,140,4.0,26,8,26,93,84,10,5.1,3.2,1.2,1.7,5.5,13.3,272,8.84,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,27/6/2025,Outpatient,Tacrolimus,108.8,77.2,40.3,6.9,141,4.3,24,24,18,70,71,15,4.6,2.7,1.2,1.5,7.9,13.8,207,12.03,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,27/7/2025,Outpatient,Tacrolimus,94.6,93.6,40.7,5.8,137,4.4,25,20,12,95,20,10,5.0,3.0,1.5,1.2,7.0,13.8,230,8.74,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,27/8/2025,Outpatient,Tacrolimus,65.6,120.0,37.5,4.1,134,3.5,24,13,8,87,69,7,4.0,2.0,1.3,1.5,4.7,12.2,271,8.44,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,28/6/2025,Outpatient,Tacrolimus,90.3,92.2,38.7,9.2,137,3.9,27,25,15,63,70,18,5.2,3.2,1.3,1.6,7.5,12.7,288,9.27,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,28/7/2025,Outpatient,Tacrolimus,77.6,105.5,39.1,5.8,138,3.6,23,32,18,107,52,11,5.4,3.4,1.4,1.3,7.6,14.2,274,8.44,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,28/8/2025,Outpatient,Tacrolimus,60.0,120.0,39.9,5.8,138,4.6,23,10,11,97,91,16,6.1,4.3,1.2,1.4,6.0,13.8,231,10.44,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,29/6/2025,Outpatient,Tacrolimus,109.8,61.9,41.4,5.8,137,4.0,26,32,33,98,84,16,4.9,3.4,1.0,1.2,7.1,11.9,202,6.44,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,29/7/2025,Outpatient,Tacrolimus,89.9,120.0,39.9,4.7,139,4.5,24,10,27,80,46,15,4.5,2.6,1.4,1.1,6.7,13.7,196,11.35,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,29/8/2025,Outpatient,Tacrolimus,62.8,120.0,40.1,3.4,138,3.8,27,11,8,71,21,16,5.0,3.3,0.9,1.8,7.1,14.9,197,7.22,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,29/7/2025,Outpatient,Tacrolimus,81.7,96.4,41.0,9.5,137,4.4,22,25,27,121,41,17,5.4,3.5,1.1,1.6,7.7,13.1,302,9.98,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,30/6/2025,Outpatient,Tacrolimus,100.3,78.6,40.3,8.4,138,4.3,25,19,23,90,56,16,5.0,3.0,1.1,1.7,5.7,13.6,183,7.92,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,30/7/2025,Outpatient,Tacrolimus,74.9,106.8,38.9,6.1,138,4.4,25,12,8,111,45,13,5.3,3.2,1.2,2.0,6.3,13.6,238,6.56,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,30/8/2025,Outpatient,Tacrolimus,60.0,120.0,41.4,3.0,136,4.3,25,8,8,100,50,10,5.0,3.3,1.0,1.5,6.1,13.2,256,10.19,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,31/7/2025,Outpatient,Tacrolimus,68.9,120.0,39.4,2.6,135,4.6,22,11,14,51,58,14,5.0,3.2,1.1,1.5,3.9,11.3,327,8.44,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,31/8/2025,Outpatient,Tacrolimus,60.0,120.0,41.4,2.8,143,4.1,28,8,9,80,57,12,4.8,2.9,1.1,1.8,8.2,12.5,238,6.1,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,5/6/2025,Inpatient,Tacrolimus,137.9,65.0,39.6,8.5,143,4.9,27,63,12,61,111,27,4.9,3.1,1.1,1.5,7.9,13.9,308,8.4,,4.65,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,5/8/2025,Outpatient,Tacrolimus,104.2,85.9,42.5,5.4,138,4.9,26,39,23,142,31,10,4.9,2.8,1.2,2.1,8.4,13.8,239,8.01,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,6/6/2025,Inpatient,Tacrolimus,119.8,56.3,32.4,9.3,135,4.3,24,42,37,40,111,13,5.3,4.4,0.7,0.5,6.8,13.4,90,10.71,,4.65,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,7/6/2025,Inpatient,Tacrolimus,139.8,83.0,32.3,9.3,134,4.3,22,14,44,117,90,24,4.7,2.7,1.3,1.5,7.7,12.2,222,9.26,,4.65,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,8/6/2025,Inpatient,Tacrolimus,133.8,50.7,34.2,12.1,138,5.3,22,53,30,82,103,14,3.6,2.4,0.6,1.5,12.7,11.9,211,11.7,,4.65,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,8/7/2025,Outpatient,Tacrolimus,71.5,60.5,40.4,6.7,136,4.7,25,19,31,94,50,9,5.2,3.5,1.2,1.2,6.6,14.7,90,4.78,,4.02,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1026,6370D,Chew Chen Xiao,4/6/2025,9/6/2025,Inpatient,Tacrolimus,107.7,67.6,36.4,7.8,141,4.1,21,19,30,83,37,26,4.0,2.4,1.0,1.4,7.1,12.3,295,10.45,,4.65,*3/*3,CT,78.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1032,5804K,Tan Zhen Chen,19/6/2025,1/7/2025,Inpatient,Cyclosporin,129.8,68.1,37.4,6.6,138,3.9,23,42,23,76,51,16,4.6,2.9,1.3,0.8,8.0,13.8,243,235.9,1220.8,307.56,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,1/8/2025,Outpatient,Cyclosporin,79.8,96.2,42.7,5.3,139,4.3,23,30,22,50,96,7,5.0,2.9,1.4,1.4,6.7,14.3,242,178.18,835.22,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,1/9/2025,Outpatient,Cyclosporin,65.0,119.5,41.1,2.0,139,4.2,24,15,14,87,37,13,5.5,3.9,1.0,1.3,7.3,13.5,269,214.38,792.71,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,2/7/2025,Inpatient,Cyclosporin,126.9,82.5,36.5,7.9,139,4.2,24,36,30,91,109,18,4.5,2.7,1.0,1.7,7.0,13.0,276,201.27,1360.03,307.56,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,2/8/2025,Outpatient,Cyclosporin,92.3,76.4,38.1,7.5,136,4.3,22,13,14,74,57,13,4.7,2.7,1.1,1.8,8.3,13.5,256,231.78,1283.3,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,2/9/2025,Outpatient,Cyclosporin,60.0,120.0,39.3,6.1,139,4.3,24,18,29,60,46,11,4.6,2.9,1.0,1.7,5.9,15.3,191,164.48,1099.51,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,3/7/2025,Outpatient,Cyclosporin,116.9,66.9,41.5,5.7,141,4.0,23,31,18,99,58,14,4.7,3.3,1.1,0.6,4.3,13.4,238,185.44,1071.13,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,3/8/2025,Outpatient,Cyclosporin,77.5,116.8,40.1,7.3,139,3.7,24,17,30,71,108,10,4.5,2.4,1.3,1.7,6.1,14.0,288,273.1,894.69,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,3/9/2025,Outpatient,Cyclosporin,60.0,120.0,40.6,3.3,141,4.3,25,17,11,74,74,10,4.2,2.6,0.9,1.4,4.4,11.8,329,177.33,839.99,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,4/7/2025,Outpatient,Cyclosporin,105.7,70.4,40.7,8.4,141,4.0,25,37,18,99,62,15,5.0,3.0,1.3,1.4,7.5,13.8,284,197.92,802.03,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,4/8/2025,Outpatient,Cyclosporin,88.9,99.4,40.8,5.0,133,3.8,24,19,14,121,104,13,4.8,3.0,1.0,1.8,6.5,14.8,175,156.22,1177.5,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,4/9/2025,Outpatient,Cyclosporin,60.0,120.0,39.4,4.5,136,4.4,26,27,8,100,43,12,3.9,2.4,1.0,1.1,8.3,12.2,263,212.17,1048.01,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,5/7/2025,Outpatient,Cyclosporin,128.0,72.2,40.7,5.2,138,4.3,23,38,36,66,52,18,4.4,2.7,1.1,1.5,6.3,13.2,224,193.65,1298.38,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,5/8/2025,Outpatient,Cyclosporin,115.6,87.4,39.7,9.1,136,4.7,23,18,25,100,25,17,4.5,2.7,1.4,1.0,6.0,13.3,227,165.63,920.13,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,5/9/2025,Outpatient,Cyclosporin,76.5,104.3,41.2,4.6,139,4.2,25,8,13,92,40,14,4.5,2.7,1.1,1.4,6.0,14.0,282,122.19,799.47,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,6/7/2025,Outpatient,Cyclosporin,117.8,63.5,39.4,6.2,139,4.9,26,17,40,82,62,15,4.7,3.0,1.1,1.5,5.0,14.3,226,165.48,1009.8,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,6/8/2025,Outpatient,Cyclosporin,78.6,117.4,39.5,6.8,142,4.3,24,31,19,91,59,13,4.7,3.0,1.1,1.3,5.0,12.0,270,230.89,1126.7,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,6/9/2025,Outpatient,Cyclosporin,80.3,120.0,38.3,7.5,143,4.0,29,11,11,108,75,9,4.0,2.3,1.2,1.2,5.4,14.1,332,236.01,726.39,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,7/7/2025,Outpatient,Cyclosporin,113.4,77.1,40.5,7.5,138,3.8,22,33,30,72,74,15,4.3,2.8,1.3,0.6,5.9,13.8,278,172.34,1067.67,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,7/8/2025,Outpatient,Cyclosporin,82.1,120.0,40.3,7.1,136,4.6,25,23,21,71,73,15,3.9,2.1,1.2,1.3,6.0,14.5,137,197.83,883.88,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,7/9/2025,Outpatient,Cyclosporin,84.8,120.0,40.7,4.3,139,4.0,22,29,8,61,65,13,4.9,3.1,1.0,1.9,7.5,13.8,327,169.23,814.52,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,8/7/2025,Outpatient,Cyclosporin,124.4,76.2,40.4,9.2,142,4.2,23,27,36,81,91,15,4.8,2.9,1.1,1.7,7.6,12.6,278,184.06,943.7,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,8/8/2025,Outpatient,Cyclosporin,98.5,100.3,40.0,7.2,141,4.2,24,12,13,91,52,22,4.3,2.6,1.3,1.0,4.8,12.9,247,226.3,826.56,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,8/9/2025,Outpatient,Cyclosporin,60.0,120.0,38.9,2.9,141,4.0,23,8,18,99,53,11,5.1,2.7,1.4,2.2,3.1,11.9,245,195.77,781.89,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,9/7/2025,Outpatient,Cyclosporin,112.9,83.7,40.0,8.3,139,4.0,23,30,20,112,63,19,4.9,3.1,1.1,1.4,7.9,12.0,265,189.01,1293.56,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,9/8/2025,Outpatient,Cyclosporin,96.9,115.2,39.2,7.6,138,4.1,28,16,26,83,67,12,4.8,3.0,1.2,1.6,4.7,13.2,272,145.32,1011.93,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,9/9/2025,Outpatient,Cyclosporin,60.0,119.6,40.3,4.3,142,4.3,26,8,33,51,69,11,5.7,3.4,1.5,1.7,3.1,13.5,217,111.05,808.73,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,1/8/2025,Outpatient,Cyclosporin,89.3,69.2,35.9,6.6,136,4.3,26,32,20,89,56,12,4.3,2.5,1.2,1.1,6.7,12.3,197,195.62,1020.64,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,10/7/2025,Outpatient,Cyclosporin,113.7,82.0,41.3,6.4,138,4.2,25,28,37,89,60,20,5.0,3.1,1.3,1.3,7.4,13.7,202,183.19,660.61,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,10/8/2025,Outpatient,Cyclosporin,61.3,109.6,39.8,5.4,136,4.5,26,35,17,86,39,12,4.5,2.5,1.3,1.5,4.4,15.3,265,226.69,1154.35,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,10/9/2025,Outpatient,Cyclosporin,82.8,120.0,41.7,6.3,140,4.3,22,8,14,113,85,13,4.4,2.8,1.1,1.0,8.4,13.3,276,239.41,635.8,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,11/7/2025,Outpatient,Cyclosporin,121.2,79.6,39.7,8.4,137,4.1,25,27,26,73,96,12,4.7,2.8,1.2,1.4,7.0,13.8,231,174.2,1046.26,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,11/8/2025,Outpatient,Cyclosporin,84.7,87.9,39.4,5.4,139,4.2,24,27,24,106,65,18,4.5,2.4,1.3,1.7,5.9,14.0,190,165.15,1144.25,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,11/9/2025,Outpatient,Cyclosporin,71.4,120.0,40.4,5.7,141,3.7,21,15,8,107,60,14,4.9,3.0,1.0,1.9,7.0,11.3,231,80.0,862.7,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,11/7/2025,Outpatient,Cyclosporin,76.7,84.0,41.6,7.2,141,4.5,25,24,32,60,30,5,5.5,3.2,1.3,2.2,5.5,16.1,317,176.08,741.56,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,12/7/2025,Outpatient,Cyclosporin,119.4,59.5,41.1,6.4,136,4.3,23,9,29,81,59,11,4.5,2.9,1.1,1.0,5.5,15.2,283,221.4,818.99,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,12/8/2025,Outpatient,Cyclosporin,87.2,91.8,40.2,5.4,142,3.7,25,22,38,124,70,13,5.1,3.4,1.1,1.3,5.7,13.3,228,148.1,1102.28,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,12/9/2025,Outpatient,Cyclosporin,60.0,120.0,40.1,8.2,137,3.6,28,8,13,91,50,15,5.0,3.3,1.3,1.1,4.6,13.9,266,169.27,999.99,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,12/9/2025,Outpatient,Cyclosporin,101.3,76.3,38.6,6.9,135,3.9,24,29,11,87,60,16,5.1,3.2,1.2,1.5,5.8,16.7,200,146.72,795.23,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,13/7/2025,Outpatient,Cyclosporin,94.0,62.1,41.7,6.5,137,4.0,24,22,38,123,74,18,4.9,3.4,1.1,1.0,5.8,13.1,206,231.17,1005.48,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,13/8/2025,Outpatient,Cyclosporin,86.7,106.4,39.3,4.6,135,3.8,23,25,25,106,54,14,4.9,3.3,1.1,1.3,7.3,14.0,273,197.82,1030.9,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,13/9/2025,Outpatient,Cyclosporin,60.0,120.0,40.0,5.2,138,4.5,28,16,8,81,42,13,4.5,2.9,1.0,1.2,8.0,13.8,232,173.76,566.91,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,14/7/2025,Outpatient,Cyclosporin,113.9,79.9,40.6,8.8,140,4.9,22,30,23,100,72,17,4.9,3.2,1.2,1.1,7.2,12.9,299,176.46,1002.13,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,14/8/2025,Outpatient,Cyclosporin,93.2,104.1,39.2,3.2,139,4.0,25,17,20,99,39,17,5.4,3.9,0.8,1.5,6.8,13.5,284,121.86,848.4,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,14/9/2025,Outpatient,Cyclosporin,60.0,120.0,40.5,5.5,140,4.0,22,13,8,108,57,12,4.0,2.3,1.1,1.2,7.0,12.5,231,187.39,931.78,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,15/7/2025,Outpatient,Cyclosporin,108.5,65.6,38.6,3.6,134,4.6,24,33,27,97,79,16,5.1,3.1,1.2,1.8,5.5,13.9,139,219.59,874.42,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,15/8/2025,Outpatient,Cyclosporin,88.8,97.6,40.7,4.0,135,4.8,24,34,25,89,50,13,4.6,2.8,1.3,1.0,5.1,13.8,210,205.06,745.77,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,15/9/2025,Outpatient,Cyclosporin,60.0,120.0,41.6,3.7,140,3.6,27,8,8,69,54,7,4.5,2.6,1.3,1.3,8.8,13.2,181,148.24,903.32,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,15/8/2025,Outpatient,Cyclosporin,92.8,81.6,38.2,8.3,134,3.9,22,49,29,77,54,11,5.2,3.5,1.0,1.4,5.3,12.0,272,131.39,747.56,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,16/7/2025,Outpatient,Cyclosporin,104.4,61.3,38.7,6.2,137,4.1,23,35,35,102,57,14,4.7,3.2,1.0,1.1,5.4,15.3,318,309.93,1150.16,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,16/8/2025,Outpatient,Cyclosporin,70.0,103.3,40.0,4.4,139,3.9,26,8,20,104,83,8,4.9,2.9,1.4,1.4,5.1,12.4,350,152.12,1022.28,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,16/9/2025,Outpatient,Cyclosporin,60.0,115.3,38.8,3.7,140,4.0,25,22,13,70,49,8,5.0,2.9,1.4,1.4,4.6,13.7,174,139.43,757.21,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,17/7/2025,Outpatient,Cyclosporin,100.8,78.1,41.6,5.4,140,3.7,23,21,31,71,70,21,4.2,2.0,1.2,2.0,3.1,12.6,238,191.72,920.16,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,17/8/2025,Outpatient,Cyclosporin,95.1,94.7,40.1,7.2,140,4.0,28,21,27,85,82,12,4.2,2.3,1.1,1.6,6.9,13.4,251,140.46,775.72,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,18/7/2025,Outpatient,Cyclosporin,102.4,66.9,39.0,7.7,139,3.9,24,14,38,90,80,11,4.9,3.2,1.1,1.4,5.0,12.8,329,121.76,866.44,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,18/8/2025,Outpatient,Cyclosporin,74.4,97.0,39.2,3.5,138,4.3,24,9,25,122,39,11,4.8,3.1,0.9,1.6,4.4,12.2,245,209.2,992.32,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,18/7/2025,Outpatient,Cyclosporin,89.4,77.3,37.1,9.1,142,3.7,28,28,31,59,63,16,5.1,3.5,1.2,1.0,6.0,14.0,316,132.44,808.02,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,19/6/2025,Inpatient,Cyclosporin,138.0,37.1,36.4,9.8,138,4.7,21,39,37,70,75,17,4.9,3.3,1.1,1.1,8.8,12.4,208,231.71,938.08,307.56,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,19/7/2025,Outpatient,Cyclosporin,91.9,83.1,40.9,9.3,138,4.6,26,27,27,57,106,17,5.0,3.0,1.2,1.8,5.2,13.5,263,218.05,1038.74,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,19/8/2025,Outpatient,Cyclosporin,76.1,92.5,40.6,6.3,140,4.0,24,32,22,112,67,10,4.9,3.3,1.1,1.2,6.7,13.0,211,188.3,880.63,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,19/9/2025,Outpatient,Cyclosporin,72.8,68.3,41.4,7.4,140,3.5,28,23,8,80,53,4,5.4,3.7,1.1,1.5,9.2,14.1,257,129.8,729.98,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,20/6/2025,Inpatient,Cyclosporin,126.9,83.2,35.7,9.3,143,3.8,25,38,38,69,65,19,5.4,3.5,1.3,1.5,5.7,14.0,236,198.44,1151.64,307.56,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,20/7/2025,Outpatient,Cyclosporin,98.5,96.1,41.2,9.2,143,4.1,20,13,20,104,96,17,4.2,2.5,1.0,1.4,4.7,13.1,168,236.5,937.73,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,20/8/2025,Outpatient,Cyclosporin,87.3,120.0,40.8,4.7,137,3.9,27,20,19,79,21,11,4.2,2.5,1.2,1.1,6.3,13.8,237,180.2,986.67,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,20/6/2025,Inpatient,Cyclosporin,135.8,63.4,40.6,11.0,143,4.1,22,39,35,84,76,21,5.1,3.5,1.2,0.8,9.0,13.4,135,232.97,1059.63,307.56,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,21/6/2025,Inpatient,Cyclosporin,116.4,82.5,35.2,7.9,140,3.5,23,46,39,91,44,20,4.6,2.9,1.2,1.0,7.2,13.2,269,173.11,1249.84,307.56,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,21/7/2025,Outpatient,Cyclosporin,119.4,78.7,40.9,8.5,137,3.7,26,37,28,95,34,7,4.4,2.3,1.5,1.4,4.6,11.8,279,235.7,890.57,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,21/8/2025,Outpatient,Cyclosporin,90.1,113.5,40.2,2.9,141,3.7,26,26,17,80,63,15,5.1,3.4,1.2,1.2,6.3,12.6,144,180.58,784.08,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,21/6/2025,Inpatient,Cyclosporin,96.0,100.0,35.1,6.3,136,4.4,23,26,18,66,53,7,4.5,2.5,1.2,1.8,9.7,14.4,177,213.54,1252.93,307.56,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,22/6/2025,Inpatient,Cyclosporin,128.4,59.1,35.3,8.7,139,3.9,24,42,36,105,91,16,4.4,3.0,0.9,1.1,5.9,11.7,249,206.97,999.67,307.56,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,22/7/2025,Outpatient,Cyclosporin,107.1,84.7,38.2,8.1,137,4.5,25,18,27,86,88,7,5.1,3.3,1.2,1.3,8.0,11.8,237,239.78,860.07,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,22/8/2025,Outpatient,Cyclosporin,95.9,102.9,39.3,7.0,137,4.1,23,8,18,74,88,7,4.0,2.3,1.0,1.6,6.3,12.7,246,155.82,748.63,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,22/6/2025,Inpatient,Cyclosporin,77.3,85.2,39.8,7.8,143,3.9,28,43,15,55,35,19,4.9,3.4,1.2,0.6,9.1,13.5,179,200.65,1022.44,307.56,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,22/8/2025,Outpatient,Cyclosporin,82.1,66.3,37.1,8.6,142,4.5,23,35,32,111,81,9,5.5,3.7,1.3,1.2,3.0,15.0,219,194.12,968.4,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,23/6/2025,Inpatient,Cyclosporin,128.4,50.1,35.1,8.2,142,4.7,27,43,44,104,44,19,5.1,3.6,0.9,1.1,8.4,13.5,251,235.85,970.32,307.56,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,23/7/2025,Outpatient,Cyclosporin,101.8,95.0,39.4,9.5,136,4.2,26,12,19,99,66,12,4.2,2.5,1.0,1.7,7.5,13.9,202,186.29,1007.08,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,23/8/2025,Outpatient,Cyclosporin,89.0,105.7,41.6,5.6,140,4.4,24,11,8,99,22,12,4.5,2.7,1.0,1.8,5.9,13.8,197,156.76,506.21,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,23/6/2025,Inpatient,Cyclosporin,134.4,85.2,35.1,11.8,138,5.0,20,16,32,91,43,17,5.0,3.2,1.2,1.3,6.8,12.2,315,205.29,1115.71,307.56,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,24/6/2025,Inpatient,Cyclosporin,109.2,61.4,37.5,6.0,139,4.4,23,35,21,80,63,13,4.6,2.9,1.2,1.2,8.8,13.2,207,166.39,1103.66,307.56,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,24/7/2025,Outpatient,Cyclosporin,101.2,87.0,41.3,4.6,140,4.4,23,15,28,86,68,16,4.5,2.8,1.1,1.5,6.2,13.6,229,176.68,1009.18,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,24/8/2025,Outpatient,Cyclosporin,60.0,120.0,41.7,3.5,140,4.0,25,30,8,100,79,20,5.1,3.2,1.2,1.7,8.0,15.1,233,124.9,863.4,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,24/6/2025,Inpatient,Cyclosporin,114.9,48.2,34.9,9.3,143,4.0,22,42,24,121,26,17,5.1,2.8,1.7,1.4,3.7,12.2,234,203.25,940.71,307.56,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,25/6/2025,Inpatient,Cyclosporin,109.7,67.1,36.2,9.5,137,4.4,22,26,34,78,53,14,5.1,3.1,1.4,1.2,7.6,12.7,250,173.5,1082.02,307.56,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,25/7/2025,Outpatient,Cyclosporin,94.6,94.9,39.5,7.7,141,4.3,24,21,20,86,93,15,5.1,3.8,0.7,1.2,5.4,14.1,235,179.58,1212.9,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,25/8/2025,Outpatient,Cyclosporin,72.7,119.0,39.7,5.7,136,4.4,25,21,10,82,69,16,4.9,3.3,1.2,0.7,5.7,13.5,303,133.94,691.73,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,25/6/2025,Inpatient,Cyclosporin,95.9,80.0,36.8,9.2,136,4.4,24,32,22,103,58,12,5.1,3.0,1.2,2.0,11.2,13.7,262,184.79,1096.24,307.56,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,25/7/2025,Outpatient,Cyclosporin,101.0,96.9,40.1,12.2,141,4.1,24,26,24,112,44,9,4.6,2.5,1.2,2.0,5.7,14.6,213,151.57,593.62,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,26/6/2025,Inpatient,Cyclosporin,118.9,56.5,34.8,9.9,138,3.6,26,43,40,109,91,19,4.7,2.8,1.4,1.0,7.2,12.8,278,189.98,1226.01,307.56,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,26/7/2025,Outpatient,Cyclosporin,87.9,98.2,41.4,7.8,142,3.9,25,34,25,113,49,13,4.5,3.1,1.2,0.6,6.1,13.5,341,170.42,974.13,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,26/8/2025,Outpatient,Cyclosporin,83.6,120.0,37.9,5.1,142,4.9,25,12,11,83,62,10,4.4,2.5,1.3,1.4,7.4,13.9,216,80.0,941.74,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,26/6/2025,Inpatient,Cyclosporin,75.3,79.0,39.2,7.8,141,4.7,25,22,29,96,91,12,5.1,3.2,1.4,1.2,9.3,13.0,279,173.68,1317.55,307.56,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,27/6/2025,Inpatient,Cyclosporin,136.8,52.7,36.9,6.9,139,4.3,24,51,36,109,68,21,4.6,2.9,1.1,1.3,7.5,13.1,259,190.18,837.81,307.56,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,27/7/2025,Outpatient,Cyclosporin,92.9,80.0,42.0,6.7,138,4.2,25,24,31,125,65,14,4.3,2.9,1.1,0.8,5.7,12.0,211,170.94,954.68,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,27/8/2025,Outpatient,Cyclosporin,65.2,92.0,39.9,4.9,140,4.0,24,17,10,93,43,13,5.4,3.6,1.4,0.9,6.9,12.1,202,90.92,796.45,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,27/6/2025,Inpatient,Cyclosporin,90.5,85.4,39.0,8.5,142,3.9,23,49,32,111,83,19,4.0,2.0,1.2,1.6,8.2,11.9,90,170.58,1278.04,307.56,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,28/6/2025,Inpatient,Cyclosporin,121.8,54.1,38.5,7.1,136,4.1,24,41,19,98,62,11,4.3,2.8,0.8,1.5,7.3,11.9,226,185.57,993.87,307.56,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,28/7/2025,Outpatient,Cyclosporin,90.5,115.2,39.0,7.9,142,4.6,24,18,30,107,46,8,4.7,2.6,1.3,1.6,7.4,13.3,263,194.49,920.54,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,28/8/2025,Outpatient,Cyclosporin,60.0,120.0,40.2,6.4,139,4.4,25,15,9,109,34,13,5.0,3.2,1.0,1.7,7.7,13.0,257,188.31,875.42,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,29/6/2025,Inpatient,Cyclosporin,104.3,53.6,36.9,5.4,141,4.3,24,29,37,97,44,17,5.1,3.0,1.2,1.9,6.0,13.6,261,226.71,973.45,307.56,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,29/7/2025,Outpatient,Cyclosporin,85.9,93.0,39.8,9.5,138,4.5,26,16,20,116,26,19,4.4,2.7,0.8,2.0,6.0,13.6,258,180.01,962.85,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,29/8/2025,Outpatient,Cyclosporin,60.6,120.0,40.5,3.9,136,4.2,24,28,25,108,59,14,5.0,3.0,1.3,1.5,5.7,13.2,171,151.74,583.1,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,29/8/2025,Outpatient,Cyclosporin,100.7,42.7,38.5,6.7,136,4.6,23,33,25,106,43,15,3.5,2.0,1.3,0.6,8.5,13.3,284,100.87,730.33,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,30/6/2025,Inpatient,Cyclosporin,119.7,40.1,37.3,9.3,134,4.3,27,34,38,63,45,16,4.8,3.1,1.4,0.7,9.5,12.8,277,213.75,1151.1,307.56,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,30/7/2025,Outpatient,Cyclosporin,96.8,105.7,40.3,8.1,137,3.8,26,23,10,112,53,8,4.2,2.2,1.2,1.7,6.8,13.4,355,173.39,1067.88,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,30/8/2025,Outpatient,Cyclosporin,70.7,120.0,40.1,4.5,142,3.9,21,22,23,121,71,8,5.6,3.4,1.6,1.2,7.3,13.5,276,167.0,664.97,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,31/7/2025,Outpatient,Cyclosporin,74.8,105.2,37.8,6.0,139,4.4,23,19,23,90,72,19,4.5,2.4,1.3,1.5,6.9,14.7,235,207.07,1134.17,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,31/8/2025,Outpatient,Cyclosporin,74.7,120.0,41.1,5.5,139,4.1,23,18,22,76,82,14,3.9,2.1,1.3,1.2,5.5,11.4,174,161.42,900.0,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,4/7/2025,Outpatient,Cyclosporin,101.9,63.2,38.1,9.7,138,3.3,23,43,23,86,65,15,5.1,2.9,1.2,2.1,4.0,14.0,246,218.89,698.17,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,5/9/2025,Outpatient,Cyclosporin,110.8,100.6,41.5,7.4,138,4.3,23,21,27,87,53,18,4.9,3.0,1.1,1.8,7.8,14.2,335,155.7,816.46,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1032,5804K,Tan Zhen Chen,19/6/2025,8/8/2025,Outpatient,Cyclosporin,95.2,69.4,39.9,8.5,139,3.8,27,24,38,70,14,17,4.5,2.6,1.2,1.6,6.7,15.8,199,180.27,790.13,265.62,*3/*3,CC,69.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,240.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,1/8/2025,Outpatient,Cyclosporin,102.8,100.2,41.0,6.2,141,4.6,21,17,43,96,73,12,4.5,2.6,1.3,1.4,7.5,12.7,181,212.23,1007.31,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,1/9/2025,Outpatient,Cyclosporin,73.5,120.0,39.1,6.4,142,3.9,25,9,25,89,57,11,5.2,3.5,0.9,1.7,7.5,12.5,158,164.63,828.95,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,1/10/2025,Outpatient,Cyclosporin,60.0,120.0,40.1,2.0,141,4.5,27,8,8,68,50,11,5.1,3.3,1.3,1.1,8.9,11.8,367,168.05,882.52,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,2/8/2025,Outpatient,Cyclosporin,106.0,57.1,40.4,6.5,142,4.9,25,26,12,90,86,11,4.6,2.8,1.2,1.5,6.8,13.6,286,192.65,733.05,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,2/9/2025,Outpatient,Cyclosporin,76.0,110.8,38.2,5.6,139,4.2,24,13,28,107,66,14,5.3,3.3,1.2,1.6,3.6,12.6,227,123.05,940.66,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,2/10/2025,Outpatient,Cyclosporin,60.0,120.0,39.0,3.6,142,3.7,25,8,8,75,47,12,5.5,3.4,1.2,1.9,7.2,13.8,271,171.04,773.72,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,3/8/2025,Outpatient,Cyclosporin,101.2,83.1,41.6,6.2,139,4.5,23,25,23,113,73,17,5.5,3.2,1.6,1.6,7.4,13.6,354,255.51,1109.34,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,3/9/2025,Outpatient,Cyclosporin,61.4,120.0,39.6,5.6,135,4.1,28,11,12,106,49,6,5.0,3.1,1.2,1.6,4.9,12.5,168,170.15,677.86,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,3/10/2025,Outpatient,Cyclosporin,60.0,120.0,39.7,5.3,141,4.4,26,8,8,113,52,12,5.5,3.5,1.2,1.8,4.5,12.7,340,213.52,789.83,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,4/8/2025,Outpatient,Cyclosporin,109.7,96.3,40.9,8.1,140,4.3,22,28,8,84,70,15,4.8,2.9,1.2,1.6,6.3,13.2,299,205.75,874.11,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,4/9/2025,Outpatient,Cyclosporin,64.2,120.0,39.2,6.4,139,4.0,23,18,14,89,67,17,5.7,3.8,1.2,1.5,7.3,13.4,285,260.15,942.26,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,4/10/2025,Outpatient,Cyclosporin,60.0,120.0,41.2,3.2,143,4.1,26,8,8,108,26,9,4.6,2.8,1.2,1.3,7.8,14.1,220,161.1,883.89,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,5/8/2025,Outpatient,Cyclosporin,90.7,84.8,40.2,7.8,138,4.1,24,33,23,91,30,14,5.3,3.3,1.2,1.8,6.6,12.3,163,116.76,979.99,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,5/9/2025,Outpatient,Cyclosporin,80.9,120.0,39.6,4.4,137,4.0,27,20,15,65,54,15,4.9,2.8,1.3,1.7,4.2,13.3,267,162.44,1149.5,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,6/8/2025,Outpatient,Cyclosporin,96.8,96.8,39.9,8.2,137,3.9,25,39,19,106,78,17,5.1,3.7,0.8,1.2,6.4,12.9,184,253.07,1089.54,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,6/9/2025,Outpatient,Cyclosporin,79.7,120.0,41.7,6.9,136,4.3,26,22,8,78,65,13,4.4,2.5,1.2,1.6,5.3,13.6,202,172.18,631.75,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,7/7/2025,Inpatient,Cyclosporin,124.1,48.3,37.7,8.9,137,3.6,24,39,34,109,64,23,4.7,3.1,1.0,1.2,4.3,13.4,197,252.81,1132.5,342.32,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,7/8/2025,Outpatient,Cyclosporin,113.2,104.7,39.5,7.9,136,4.3,25,11,13,91,73,20,5.4,3.5,1.3,1.2,8.1,13.0,185,233.38,1133.1,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,7/9/2025,Outpatient,Cyclosporin,69.8,104.1,39.3,3.4,137,3.6,26,15,15,93,59,20,5.9,3.9,1.3,1.4,6.3,13.8,244,129.96,981.02,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,8/7/2025,Inpatient,Cyclosporin,118.1,55.6,36.6,8.9,136,4.6,23,32,32,109,58,12,4.7,2.9,1.4,1.0,7.7,14.8,235,194.53,1159.25,342.32,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,8/8/2025,Outpatient,Cyclosporin,86.0,89.5,37.5,5.0,139,3.9,23,20,27,52,64,12,5.1,2.8,1.6,1.6,5.9,13.8,207,279.61,1295.57,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,8/9/2025,Outpatient,Cyclosporin,74.7,120.0,40.3,5.6,140,4.2,25,16,10,98,44,10,4.5,2.6,1.0,1.8,7.0,11.8,163,201.03,961.16,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,9/7/2025,Inpatient,Cyclosporin,115.6,71.0,34.6,7.4,135,4.1,23,27,25,117,28,16,4.4,2.6,1.4,1.1,7.7,11.7,226,225.06,849.88,342.32,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,9/8/2025,Outpatient,Cyclosporin,91.3,98.1,39.4,6.2,140,3.9,23,33,34,103,35,13,5.1,3.4,1.2,1.0,6.7,14.6,226,241.23,1222.38,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,9/9/2025,Outpatient,Cyclosporin,71.6,120.0,39.5,4.1,136,4.6,26,20,13,107,50,11,5.6,3.6,1.4,1.4,8.1,12.9,270,111.89,973.63,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,10/7/2025,Inpatient,Cyclosporin,117.7,71.5,35.4,10.8,136,4.3,20,35,40,127,93,12,5.3,3.4,1.2,1.5,8.2,13.0,204,225.38,891.53,342.32,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,10/8/2025,Outpatient,Cyclosporin,78.2,87.5,39.7,5.7,137,3.9,22,31,24,102,63,13,5.3,3.0,1.2,2.4,7.8,12.9,266,186.76,841.35,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,10/9/2025,Outpatient,Cyclosporin,70.8,120.0,39.3,8.3,140,4.5,27,17,9,86,27,15,5.0,3.0,1.2,1.8,6.2,14.2,261,136.24,1166.63,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,10/7/2025,Inpatient,Cyclosporin,134.7,69.4,42.0,11.9,136,5.0,27,20,29,68,59,22,4.1,2.1,1.1,2.1,11.1,14.0,233,207.3,972.85,342.32,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,11/7/2025,Inpatient,Cyclosporin,136.2,54.4,34.8,7.1,137,3.9,24,32,20,65,94,14,4.5,3.2,0.8,1.3,8.1,11.4,226,227.02,946.83,342.32,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,11/8/2025,Outpatient,Cyclosporin,101.1,94.7,40.8,7.7,140,4.1,21,33,23,100,86,20,4.4,2.4,1.4,1.3,8.7,12.1,201,181.39,1058.47,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,11/9/2025,Outpatient,Cyclosporin,65.2,120.0,38.5,3.2,139,4.0,26,29,8,63,75,19,5.3,3.7,1.2,1.1,5.6,12.8,293,168.56,773.03,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,11/7/2025,Inpatient,Cyclosporin,118.1,75.9,39.3,6.3,134,4.0,25,52,17,98,82,14,4.7,3.3,0.9,1.1,8.0,14.0,262,213.68,963.35,342.32,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,12/7/2025,Inpatient,Cyclosporin,105.7,42.3,34.1,9.8,136,4.3,24,30,34,102,63,13,5.1,3.4,1.3,1.1,9.2,12.4,234,244.68,994.3,342.32,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,12/8/2025,Outpatient,Cyclosporin,89.8,99.5,41.1,8.7,139,4.3,21,22,27,115,75,16,5.1,3.3,1.2,1.3,5.7,13.2,281,184.06,863.05,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,12/9/2025,Outpatient,Cyclosporin,86.1,120.0,39.4,4.7,137,3.9,24,12,26,93,46,12,4.3,2.4,1.0,1.8,7.7,13.4,352,139.51,953.88,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,12/7/2025,Inpatient,Cyclosporin,110.1,34.4,34.4,8.0,135,4.0,25,17,25,40,57,24,5.0,3.6,1.1,0.8,13.0,13.5,311,163.29,1379.83,342.32,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,12/8/2025,Outpatient,Cyclosporin,78.6,61.2,41.0,5.9,144,3.7,26,26,25,107,73,9,5.0,3.5,1.2,0.8,3.6,13.5,332,221.03,836.35,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,13/7/2025,Inpatient,Cyclosporin,130.8,64.6,36.3,9.3,140,3.8,24,32,14,84,68,10,4.0,2.1,1.2,1.3,6.1,13.1,314,184.82,1383.35,342.32,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,13/8/2025,Outpatient,Cyclosporin,81.3,105.1,38.7,4.1,143,4.5,24,23,13,71,48,19,5.1,3.4,1.1,1.2,5.7,12.7,182,182.79,874.52,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,13/9/2025,Outpatient,Cyclosporin,60.0,109.6,40.0,4.0,138,4.2,24,8,8,81,92,9,4.7,2.9,1.2,1.5,6.0,13.1,276,158.05,896.55,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,13/7/2025,Inpatient,Cyclosporin,114.7,74.4,43.2,8.0,132,4.4,21,48,37,70,42,20,4.2,2.0,1.3,1.8,9.5,12.9,202,149.65,1190.71,342.32,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,14/7/2025,Inpatient,Cyclosporin,129.9,73.7,37.0,9.9,138,4.6,23,26,21,85,91,17,5.4,3.8,1.1,1.1,9.0,13.0,234,151.08,919.95,342.32,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,14/8/2025,Outpatient,Cyclosporin,86.0,108.2,37.6,2.7,140,4.6,25,8,28,112,47,14,5.0,2.9,1.2,1.9,5.5,14.0,235,145.56,805.45,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,14/9/2025,Outpatient,Cyclosporin,77.2,113.3,39.7,5.1,133,4.2,21,12,23,93,75,11,4.9,3.3,1.0,1.4,6.8,15.1,280,166.65,904.28,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,14/7/2025,Inpatient,Cyclosporin,125.3,29.4,39.2,3.1,137,4.6,24,19,40,152,59,10,5.0,3.0,1.4,1.3,10.3,11.2,159,252.12,1143.73,342.32,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,15/7/2025,Inpatient,Cyclosporin,112.0,64.1,36.4,6.0,138,3.4,22,37,26,107,88,16,4.7,3.1,1.1,1.2,7.6,11.8,179,176.15,1197.64,342.32,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,15/8/2025,Outpatient,Cyclosporin,98.1,100.3,40.0,9.2,136,4.3,23,20,22,77,73,16,5.7,4.0,1.2,1.3,7.2,14.0,297,122.73,917.34,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,15/9/2025,Outpatient,Cyclosporin,64.1,120.0,39.3,7.1,139,3.9,24,11,12,80,52,8,5.4,3.4,1.2,1.9,4.4,12.3,268,164.37,584.91,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,15/7/2025,Inpatient,Cyclosporin,143.2,66.5,38.4,8.5,141,4.9,24,29,32,107,85,19,4.1,3.0,0.7,0.8,6.6,10.6,217,213.39,1054.86,342.32,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,16/7/2025,Inpatient,Cyclosporin,127.9,69.3,36.0,6.3,141,3.3,20,21,31,111,90,15,4.8,3.0,1.2,1.3,7.4,13.6,261,268.59,942.13,342.32,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,16/8/2025,Outpatient,Cyclosporin,80.8,92.7,38.2,5.1,144,4.6,26,23,8,98,47,20,4.2,2.4,1.3,1.2,3.8,12.3,230,141.04,1132.0,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,16/9/2025,Outpatient,Cyclosporin,60.0,114.7,38.9,3.3,142,4.0,24,17,8,104,89,18,4.8,3.0,1.1,1.5,8.8,14.5,284,161.78,621.8,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,16/9/2025,Outpatient,Cyclosporin,91.2,81.3,41.5,7.3,137,4.7,26,17,36,133,46,18,3.6,1.9,1.2,1.2,6.2,14.9,285,155.4,631.76,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,17/7/2025,Inpatient,Cyclosporin,104.8,92.7,37.2,10.4,139,4.1,26,20,23,109,51,18,4.9,3.2,1.1,1.4,8.8,12.7,217,193.69,1258.38,342.32,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,17/8/2025,Outpatient,Cyclosporin,87.1,93.8,39.1,10.0,136,4.6,24,24,10,92,51,16,5.2,3.3,1.5,1.0,6.1,13.6,301,160.18,872.5,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,17/9/2025,Outpatient,Cyclosporin,73.1,120.0,39.3,3.0,135,4.4,25,8,8,86,66,12,4.8,2.8,1.3,1.6,6.7,13.9,196,175.21,974.91,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,18/7/2025,Inpatient,Cyclosporin,126.8,78.0,38.5,9.1,133,4.2,25,20,35,76,55,19,4.6,2.7,1.2,1.7,6.0,12.9,219,159.32,1138.63,342.32,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,18/8/2025,Outpatient,Cyclosporin,84.3,105.0,39.1,3.0,143,3.9,26,28,22,118,65,16,4.7,2.6,1.4,1.6,7.6,12.3,271,108.62,1066.33,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,18/9/2025,Outpatient,Cyclosporin,60.0,117.3,40.0,6.3,140,4.2,24,11,8,108,50,13,4.5,2.9,1.0,1.4,6.0,13.1,213,183.01,931.89,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,19/7/2025,Inpatient,Cyclosporin,121.6,58.3,36.1,9.2,138,3.8,24,23,17,127,61,19,5.0,3.3,1.1,1.1,8.6,11.6,206,214.94,1187.22,342.32,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,19/8/2025,Outpatient,Cyclosporin,81.2,110.6,40.8,5.6,140,4.0,24,26,11,100,59,20,5.1,3.2,1.3,1.4,5.6,11.7,253,171.86,963.08,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,19/9/2025,Outpatient,Cyclosporin,60.0,120.0,41.1,4.5,142,4.5,25,11,9,92,20,15,5.0,2.9,1.1,2.2,4.6,12.5,284,210.01,955.22,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,19/8/2025,Outpatient,Cyclosporin,107.7,91.9,38.1,7.0,137,4.1,22,28,17,67,55,10,4.5,2.5,1.2,1.9,9.3,14.5,296,155.59,761.56,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,2/9/2025,Outpatient,Cyclosporin,134.3,76.7,43.2,7.1,137,5.0,26,33,24,128,81,14,3.5,2.1,0.8,1.3,7.0,13.3,281,151.9,818.27,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,20/7/2025,Inpatient,Cyclosporin,118.4,66.7,35.0,7.6,137,3.9,25,27,28,95,57,24,5.2,3.4,1.4,0.6,8.1,13.5,278,193.29,1333.86,342.32,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,20/8/2025,Outpatient,Cyclosporin,88.5,110.8,40.6,7.1,135,4.7,25,8,16,119,92,18,6.2,4.3,1.1,1.7,6.7,12.1,325,211.99,796.96,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,20/9/2025,Outpatient,Cyclosporin,65.7,120.0,39.2,4.1,135,3.8,24,17,14,89,69,11,4.9,2.5,1.6,1.8,7.8,12.6,229,182.64,1026.49,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,21/7/2025,Outpatient,Cyclosporin,121.4,68.0,39.6,5.9,133,4.0,24,33,31,97,66,14,4.2,2.0,1.3,1.8,5.7,12.5,265,235.99,1105.25,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,21/8/2025,Outpatient,Cyclosporin,85.9,100.5,38.5,7.3,137,3.6,25,15,21,93,81,15,5.5,3.5,1.4,1.3,5.1,13.4,254,216.4,897.41,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,21/9/2025,Outpatient,Cyclosporin,72.7,120.0,40.0,4.0,141,4.3,27,8,19,100,72,9,5.2,3.2,1.2,1.8,8.7,11.5,314,160.78,847.12,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,22/7/2025,Outpatient,Cyclosporin,116.3,73.9,39.0,7.0,144,4.0,22,35,32,85,58,13,5.1,2.8,1.3,2.0,7.5,14.0,283,193.7,634.22,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,22/8/2025,Outpatient,Cyclosporin,80.2,101.8,40.8,6.2,137,4.8,21,16,9,129,50,9,4.0,2.0,1.4,1.5,7.1,13.3,157,176.92,968.51,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,22/9/2025,Outpatient,Cyclosporin,60.0,120.0,38.5,7.8,136,4.4,25,17,10,102,49,18,4.8,2.8,1.3,1.4,6.7,12.3,274,143.94,960.64,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,22/7/2025,Outpatient,Cyclosporin,100.2,83.2,40.2,7.7,136,4.2,26,20,28,91,34,10,4.3,2.8,0.9,1.4,5.2,13.4,256,199.34,879.1,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,23/7/2025,Outpatient,Cyclosporin,103.5,79.6,39.9,8.5,141,4.9,23,25,18,87,42,12,4.9,3.0,1.3,1.3,4.5,13.5,271,132.77,993.69,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,23/8/2025,Outpatient,Cyclosporin,84.7,97.9,40.0,5.6,141,3.7,26,9,23,58,75,10,4.9,3.1,1.1,1.5,7.4,13.9,271,199.62,753.57,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,23/9/2025,Outpatient,Cyclosporin,73.6,120.0,38.6,6.7,140,4.1,25,21,8,95,35,10,5.1,3.2,1.3,1.4,6.2,14.8,261,182.97,919.3,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,23/9/2025,Outpatient,Cyclosporin,96.0,59.6,37.9,8.1,141,4.1,26,23,15,61,63,18,4.9,3.2,1.0,1.5,6.2,14.4,284,223.07,872.56,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,24/7/2025,Outpatient,Cyclosporin,103.4,80.3,39.4,6.5,135,3.5,26,34,27,103,59,14,4.9,2.5,1.7,1.6,5.5,13.0,289,276.89,1060.53,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,24/8/2025,Outpatient,Cyclosporin,78.0,112.6,41.1,5.7,136,4.1,24,8,21,76,69,14,4.7,2.6,1.3,1.7,7.3,13.1,320,147.89,878.97,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,24/9/2025,Outpatient,Cyclosporin,75.6,120.0,39.9,4.7,140,3.8,26,8,8,83,77,14,5.3,3.5,1.1,1.6,7.5,13.9,352,203.36,788.85,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,25/7/2025,Outpatient,Cyclosporin,130.1,99.1,40.1,6.2,138,3.7,22,27,26,86,85,12,5.1,3.2,1.2,1.5,5.5,14.0,267,177.9,1079.34,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,25/8/2025,Outpatient,Cyclosporin,86.4,93.6,40.8,5.8,140,4.3,27,27,20,117,58,13,4.8,2.6,1.3,2.0,7.3,14.7,165,143.17,1026.47,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,25/9/2025,Outpatient,Cyclosporin,60.0,120.0,39.8,6.7,136,4.3,21,8,8,79,33,10,4.9,2.7,1.4,1.6,7.7,13.2,275,122.75,1170.36,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,26/7/2025,Outpatient,Cyclosporin,94.3,92.5,38.9,7.7,139,4.1,20,20,33,93,51,18,5.5,3.6,1.2,1.4,6.3,14.7,279,197.82,917.53,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,26/8/2025,Outpatient,Cyclosporin,77.0,120.0,38.7,9.3,136,3.8,23,29,26,72,75,13,5.7,3.6,1.2,1.7,5.8,13.6,275,145.53,825.7,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,26/9/2025,Outpatient,Cyclosporin,60.0,120.0,38.8,5.0,138,3.6,25,8,16,149,17,15,4.8,2.7,1.2,2.1,6.0,15.4,185,104.53,893.04,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,26/8/2025,Outpatient,Cyclosporin,78.0,79.8,41.5,6.8,134,4.8,22,20,13,104,33,18,5.7,4.0,1.1,1.2,7.7,12.7,193,90.84,885.92,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,27/7/2025,Outpatient,Cyclosporin,113.1,91.6,39.8,10.5,140,3.8,22,37,20,101,85,13,4.9,2.9,1.4,1.1,6.1,13.1,219,135.37,1411.91,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,27/8/2025,Outpatient,Cyclosporin,83.9,102.6,39.4,6.8,136,3.9,26,21,15,68,86,14,4.8,3.1,1.0,1.5,8.1,13.3,295,161.62,862.25,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,27/9/2025,Outpatient,Cyclosporin,61.9,120.0,39.8,6.0,138,4.2,23,8,17,59,62,13,4.9,2.5,1.6,1.8,8.9,13.3,195,114.2,782.62,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,28/7/2025,Outpatient,Cyclosporin,107.1,62.9,39.4,8.6,136,4.3,23,22,32,102,81,14,4.5,2.7,1.2,1.4,5.6,12.9,205,223.24,1096.36,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,28/8/2025,Outpatient,Cyclosporin,60.8,103.7,41.9,5.7,135,3.8,26,8,25,59,54,14,5.1,3.0,1.4,1.6,3.3,14.1,250,156.33,995.56,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,28/9/2025,Outpatient,Cyclosporin,60.0,120.0,38.9,2.0,137,4.0,23,18,12,81,66,11,5.0,3.3,1.1,1.1,7.7,14.1,188,142.57,636.07,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,29/7/2025,Outpatient,Cyclosporin,113.3,96.7,39.7,7.5,142,3.1,23,20,28,76,56,23,5.0,3.3,1.2,1.2,5.4,12.9,198,215.98,1354.22,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,29/8/2025,Outpatient,Cyclosporin,85.0,104.0,40.7,7.3,143,4.1,28,10,20,88,53,14,5.6,3.9,1.0,1.6,5.3,12.9,222,212.57,1236.53,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,29/9/2025,Outpatient,Cyclosporin,60.0,120.0,40.1,5.0,136,3.7,27,15,8,120,59,10,5.1,3.3,1.1,1.6,7.0,13.2,207,146.65,1049.46,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,29/7/2025,Outpatient,Cyclosporin,90.0,85.5,38.3,8.1,142,3.5,25,51,33,108,46,14,5.1,3.4,1.2,1.2,7.6,14.0,167,124.27,905.0,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,30/7/2025,Outpatient,Cyclosporin,121.0,80.6,39.1,10.2,141,4.5,26,17,17,83,100,18,5.3,3.7,1.1,1.4,3.3,13.0,240,199.18,915.7,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,30/8/2025,Outpatient,Cyclosporin,101.5,120.0,39.9,8.0,137,4.4,22,9,22,125,74,17,5.3,3.1,1.5,1.6,8.8,14.0,290,171.29,891.05,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,30/9/2025,Outpatient,Cyclosporin,70.4,120.0,40.0,7.0,139,3.5,26,8,11,111,17,12,5.0,3.3,1.1,1.3,9.5,14.0,269,225.64,587.81,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,30/9/2025,Outpatient,Cyclosporin,88.9,46.1,41.5,6.0,138,3.9,23,19,32,78,76,13,5.3,3.5,1.1,1.6,4.6,14.0,239,154.03,879.75,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,31/7/2025,Outpatient,Cyclosporin,106.2,80.8,42.0,4.8,142,4.1,27,29,22,73,49,20,5.2,3.6,1.2,0.9,6.5,13.1,190,209.34,1199.36,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,31/8/2025,Outpatient,Cyclosporin,75.6,120.0,40.4,8.2,134,4.5,24,16,29,63,57,13,4.1,2.2,1.1,1.8,3.3,14.3,234,197.14,933.52,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,5/8/2025,Outpatient,Cyclosporin,104.1,113.1,41.6,4.4,135,4.0,24,14,18,44,42,11,4.8,2.9,1.2,1.6,6.8,12.9,304,193.49,586.3,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,7/10/2025,Outpatient,Cyclosporin,101.0,65.8,39.8,5.8,139,4.2,27,22,27,67,15,14,5.0,2.8,1.5,1.5,5.5,14.1,254,166.57,751.86,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,8/7/2025,Inpatient,Cyclosporin,145.2,61.1,35.1,11.7,139,4.0,21,40,29,69,21,12,4.7,3.1,1.1,1.1,8.1,14.3,211,124.08,1084.5,342.32,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,9/7/2025,Inpatient,Cyclosporin,140.9,48.6,38.7,8.1,140,4.9,26,34,44,83,41,16,4.5,2.5,1.2,1.6,8.9,13.6,200,219.48,1273.26,342.32,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1037,1535C,Siti Binte Hassan,7/7/2025,9/9/2025,Outpatient,Cyclosporin,104.4,73.2,39.0,6.5,137,3.2,24,28,33,80,40,7,5.0,3.1,1.4,1.2,8.3,12.2,227,125.57,568.55,295.64,*1/*3,CC,77.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,270.0,100–200,0.75
RT1048,7588F,Lim Hui Xiao,30/7/2025,1/8/2025,Inpatient,Tacrolimus,143.3,73.7,36.9,9.4,140,4.2,24,35,26,91,74,13,4.2,2.4,1.2,1.4,9.4,14.3,304,8.54,,4.21,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,1/9/2025,Outpatient,Tacrolimus,92.2,81.7,39.4,6.7,141,3.7,28,14,22,103,75,14,4.8,2.4,1.5,2.0,4.9,13.9,315,8.53,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,1/10/2025,Outpatient,Tacrolimus,96.6,109.5,38.5,2.0,140,4.5,26,12,8,89,20,9,5.8,4.2,1.0,1.5,7.4,14.7,263,10.26,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,2/8/2025,Inpatient,Tacrolimus,125.9,75.5,35.9,8.1,139,4.2,22,41,30,112,66,6,4.9,3.2,1.2,1.1,10.0,12.5,201,10.3,,4.21,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,2/9/2025,Outpatient,Tacrolimus,106.5,71.3,41.4,7.7,142,3.5,23,22,9,99,61,15,5.3,3.6,1.2,1.3,6.3,14.2,308,6.82,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,2/10/2025,Outpatient,Tacrolimus,87.4,120.0,39.0,2.0,138,3.2,28,27,8,105,65,15,4.9,3.2,1.1,1.3,8.5,13.3,221,6.82,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,3/8/2025,Inpatient,Tacrolimus,117.6,43.6,36.6,9.2,140,4.2,21,21,22,69,60,12,5.7,3.8,1.2,1.6,9.6,13.3,250,10.43,,4.21,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,3/9/2025,Outpatient,Tacrolimus,91.2,95.3,41.4,5.6,144,4.7,23,9,10,63,29,19,5.2,3.1,1.4,1.7,6.3,12.8,186,9.8,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,3/10/2025,Outpatient,Tacrolimus,78.5,110.6,39.4,6.8,137,4.5,24,20,14,121,44,9,5.2,3.6,1.1,1.2,9.8,15.3,250,8.87,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,4/8/2025,Inpatient,Tacrolimus,125.2,44.4,37.0,4.2,136,3.8,21,24,42,65,33,12,4.6,3.4,0.8,1.0,7.2,13.0,236,9.9,,4.21,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,4/9/2025,Outpatient,Tacrolimus,127.3,106.3,40.3,5.6,139,3.6,22,33,13,88,97,12,4.6,2.7,1.3,1.5,8.5,14.8,301,8.41,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,4/10/2025,Outpatient,Tacrolimus,77.7,120.0,39.7,8.2,142,3.6,25,8,13,74,49,11,5.0,2.9,1.3,1.5,8.1,13.6,353,10.42,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,5/8/2025,Inpatient,Tacrolimus,140.9,85.4,36.2,12.3,141,3.9,22,47,12,89,91,17,5.4,3.8,1.0,1.3,9.5,12.6,303,8.34,,4.21,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,5/9/2025,Outpatient,Tacrolimus,95.4,86.9,40.3,7.8,143,3.3,22,12,23,71,53,17,5.1,3.1,1.2,1.8,5.6,13.7,233,7.75,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,5/10/2025,Outpatient,Tacrolimus,68.1,120.0,41.0,4.9,141,3.7,24,13,13,101,49,6,5.1,3.3,1.0,1.6,4.9,12.8,304,8.81,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,6/8/2025,Inpatient,Tacrolimus,147.1,63.7,35.7,11.3,133,4.5,26,25,35,113,41,12,5.5,3.8,1.1,1.4,9.6,13.6,245,8.94,,4.21,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,6/9/2025,Outpatient,Tacrolimus,94.7,85.3,41.5,8.4,140,4.2,23,27,15,56,56,16,5.0,3.2,1.2,1.5,3.7,11.9,207,7.98,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,6/10/2025,Outpatient,Tacrolimus,60.0,120.0,38.9,5.8,139,4.2,28,11,12,64,57,10,5.8,4.1,1.1,1.3,6.0,12.9,219,11.34,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,7/8/2025,Inpatient,Tacrolimus,130.6,67.3,38.5,9.6,136,4.0,23,28,29,97,101,13,4.9,2.8,1.2,1.8,8.2,12.7,209,10.16,,4.21,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,7/9/2025,Outpatient,Tacrolimus,105.3,90.5,41.2,5.6,139,3.9,25,30,30,105,61,13,4.2,2.3,1.4,1.1,7.9,12.8,202,7.92,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,7/10/2025,Outpatient,Tacrolimus,73.4,113.6,39.6,6.0,140,4.1,24,8,22,77,56,9,4.7,2.6,1.2,1.8,8.1,11.5,161,9.39,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,8/8/2025,Inpatient,Tacrolimus,113.3,52.1,36.8,6.0,135,4.2,26,36,30,100,65,17,5.2,3.5,1.0,1.4,8.7,11.5,172,8.53,,4.21,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,8/9/2025,Outpatient,Tacrolimus,85.9,94.8,38.9,8.5,139,3.7,23,14,32,101,74,14,5.1,3.6,0.8,1.5,4.5,12.7,224,9.07,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,8/10/2025,Outpatient,Tacrolimus,60.0,115.2,38.8,5.5,141,4.4,25,8,10,79,70,18,4.8,2.9,1.2,1.7,6.4,13.5,251,9.37,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,9/8/2025,Inpatient,Tacrolimus,121.8,66.5,36.6,6.6,139,4.5,24,27,26,57,45,19,5.4,3.0,1.6,1.8,7.7,12.4,289,9.51,,4.21,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,9/9/2025,Outpatient,Tacrolimus,104.9,108.6,40.9,4.8,138,3.9,25,8,18,110,76,8,4.5,2.6,1.3,1.3,7.7,12.8,267,9.36,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,9/10/2025,Outpatient,Tacrolimus,64.9,120.0,40.3,2.0,138,4.0,24,8,8,58,48,14,5.5,3.7,1.1,1.5,5.4,13.2,241,10.7,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,1/8/2025,Inpatient,Tacrolimus,146.6,115.8,36.1,7.5,142,3.5,21,28,29,129,74,21,5.8,4.5,0.7,1.1,7.4,11.2,195,8.55,,4.21,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,10/8/2025,Inpatient,Tacrolimus,121.6,71.7,38.7,6.0,140,4.2,24,12,28,95,101,18,5.4,3.4,1.3,1.6,9.4,13.9,262,8.88,,4.21,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,10/9/2025,Outpatient,Tacrolimus,95.9,88.6,39.8,5.0,142,3.9,22,17,15,86,79,13,4.4,3.0,1.0,1.0,5.3,12.7,295,8.64,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,10/10/2025,Outpatient,Tacrolimus,64.7,118.3,40.7,4.7,143,4.2,20,8,8,69,65,14,5.5,3.1,1.7,1.5,7.1,13.1,275,10.23,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,11/8/2025,Inpatient,Tacrolimus,117.7,62.4,36.1,8.0,139,4.1,22,25,28,57,77,16,4.5,2.6,1.3,1.2,9.8,13.3,233,9.74,,4.21,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,11/9/2025,Outpatient,Tacrolimus,103.2,104.8,40.6,5.7,137,4.4,28,12,33,81,86,11,5.8,4.2,0.9,1.5,7.7,14.2,312,7.38,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,11/10/2025,Outpatient,Tacrolimus,62.1,120.0,38.5,5.8,138,4.2,25,8,14,86,69,13,5.9,4.2,1.0,1.7,11.5,13.5,238,9.43,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,12/8/2025,Inpatient,Tacrolimus,122.2,80.0,37.0,6.3,137,4.5,24,43,14,57,53,13,5.5,3.7,1.1,1.6,7.3,12.8,215,6.59,,4.21,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,12/9/2025,Outpatient,Tacrolimus,113.3,105.9,39.0,4.8,140,3.4,24,8,13,103,73,3,4.6,2.3,1.3,2.1,7.5,15.3,321,8.08,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,12/10/2025,Outpatient,Tacrolimus,60.0,120.0,38.6,4.0,141,3.6,26,8,8,64,38,10,5.8,4.0,1.1,1.6,7.5,13.0,254,10.0,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,13/8/2025,Outpatient,Tacrolimus,105.2,70.6,39.6,6.7,141,4.8,23,19,18,96,71,17,4.9,3.1,1.2,1.6,4.6,13.2,158,11.42,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,13/9/2025,Outpatient,Tacrolimus,95.6,99.8,40.2,7.1,137,4.1,22,26,18,89,42,12,5.7,3.9,1.3,1.2,8.5,12.6,231,7.56,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,13/10/2025,Outpatient,Tacrolimus,60.0,120.0,39.5,6.5,136,3.8,22,8,14,100,72,8,5.7,3.9,1.2,1.2,7.9,13.1,309,8.22,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,13/9/2025,Outpatient,Tacrolimus,92.5,62.7,36.7,6.5,143,4.1,26,22,35,85,43,13,5.6,4.1,1.1,1.1,7.8,13.1,242,8.82,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,14/8/2025,Outpatient,Tacrolimus,109.9,72.9,39.5,7.8,134,4.2,26,14,15,71,73,17,5.3,3.4,1.3,1.3,5.7,13.0,222,8.84,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,14/9/2025,Outpatient,Tacrolimus,93.2,98.3,40.2,6.9,136,4.5,20,27,18,85,42,13,5.4,3.6,1.2,1.4,6.8,13.5,250,7.8,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,14/10/2025,Outpatient,Tacrolimus,71.4,120.0,39.6,4.3,140,3.6,22,10,8,127,59,13,5.1,2.8,1.4,1.8,6.3,12.9,235,5.98,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,15/8/2025,Outpatient,Tacrolimus,125.2,65.9,40.6,7.2,134,4.4,26,51,23,97,83,12,5.6,3.9,0.9,1.7,7.5,13.6,274,8.0,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,15/9/2025,Outpatient,Tacrolimus,97.6,90.0,39.9,4.1,139,4.0,21,26,14,113,75,20,5.2,3.5,1.1,1.4,8.6,12.6,127,9.04,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,15/10/2025,Outpatient,Tacrolimus,65.2,120.0,38.8,4.3,139,3.6,25,8,8,53,62,14,6.0,4.0,1.3,1.5,3.2,10.2,237,10.06,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,16/8/2025,Outpatient,Tacrolimus,110.6,61.9,40.0,9.2,140,4.1,22,29,33,97,20,17,4.6,2.7,1.3,1.4,6.4,13.4,343,10.22,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,16/9/2025,Outpatient,Tacrolimus,99.5,91.1,40.1,7.2,137,3.8,25,24,8,88,93,13,5.4,3.4,1.2,1.7,7.8,13.0,270,8.81,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,16/10/2025,Outpatient,Tacrolimus,75.1,120.0,42.7,5.7,138,4.7,21,8,10,102,34,13,5.3,3.3,1.2,1.7,7.8,12.4,243,10.35,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,16/8/2025,Outpatient,Tacrolimus,75.3,76.0,39.0,4.8,142,4.5,24,16,39,68,66,17,4.1,1.9,1.2,2.2,8.1,13.3,323,8.79,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,17/8/2025,Outpatient,Tacrolimus,128.3,75.2,41.6,4.2,138,4.2,23,34,26,95,42,13,5.0,3.0,1.1,2.1,6.0,12.6,240,9.52,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,17/9/2025,Outpatient,Tacrolimus,80.9,112.3,39.1,4.6,140,3.6,21,20,10,81,105,14,5.6,3.9,1.1,1.2,4.3,11.5,185,9.21,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,17/10/2025,Outpatient,Tacrolimus,75.5,120.0,40.8,3.0,136,4.6,23,15,17,59,22,8,5.0,2.9,1.3,1.7,5.8,12.4,204,11.82,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,18/8/2025,Outpatient,Tacrolimus,106.8,64.7,39.2,7.8,138,4.2,18,28,12,94,66,18,5.3,3.3,1.2,1.7,6.0,12.7,278,8.72,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,18/9/2025,Outpatient,Tacrolimus,86.5,106.0,38.0,4.7,139,3.6,23,8,8,107,40,21,5.2,3.2,1.4,1.4,7.9,12.2,233,8.16,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,18/10/2025,Outpatient,Tacrolimus,69.4,120.0,39.3,3.8,138,3.5,27,9,8,76,54,11,5.4,3.6,1.2,1.3,8.4,12.3,227,5.62,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,19/8/2025,Outpatient,Tacrolimus,126.2,64.6,40.8,4.9,137,4.2,21,32,20,78,55,15,5.1,3.1,1.3,1.5,5.7,13.9,331,9.36,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,19/9/2025,Outpatient,Tacrolimus,91.9,95.5,40.3,4.3,140,4.0,23,8,23,81,71,17,4.9,3.2,0.9,1.6,7.0,13.5,301,9.3,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,19/10/2025,Outpatient,Tacrolimus,61.5,120.0,40.3,4.8,134,3.6,24,8,8,88,70,13,5.6,3.6,1.2,1.6,9.3,13.7,242,8.76,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,2/8/2025,Inpatient,Tacrolimus,119.8,71.5,33.5,8.6,140,4.2,25,19,26,63,71,23,5.1,3.5,1.0,1.4,10.1,14.6,254,9.57,,4.21,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,20/8/2025,Outpatient,Tacrolimus,117.8,68.4,40.9,4.5,141,4.1,24,12,17,108,25,21,5.3,3.6,1.2,1.1,7.2,13.6,216,10.0,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,20/9/2025,Outpatient,Tacrolimus,92.4,91.4,41.1,7.6,136,4.4,25,19,8,78,49,15,5.4,3.5,1.1,1.8,8.3,14.2,244,10.71,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,20/10/2025,Outpatient,Tacrolimus,60.0,119.8,40.6,4.8,143,3.6,22,8,16,105,44,2,5.3,3.4,0.9,2.2,5.8,14.1,254,9.56,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,20/9/2025,Outpatient,Tacrolimus,99.7,65.0,39.8,5.7,147,4.3,20,27,32,99,50,16,5.3,3.2,1.5,1.4,4.9,14.8,131,8.87,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,21/8/2025,Outpatient,Tacrolimus,130.1,74.0,39.2,5.6,140,4.4,22,29,28,115,66,14,5.8,4.1,1.0,1.6,7.7,11.3,245,7.92,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,21/9/2025,Outpatient,Tacrolimus,83.7,108.1,38.3,6.1,137,4.2,27,8,12,93,70,10,5.5,3.7,1.4,1.0,6.6,13.0,325,7.51,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,21/10/2025,Outpatient,Tacrolimus,60.0,120.0,41.7,2.6,138,3.7,24,8,20,80,54,18,5.6,3.6,1.0,2.1,6.6,14.7,248,7.65,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,22/8/2025,Outpatient,Tacrolimus,122.7,67.7,41.1,8.9,136,3.9,26,17,28,89,76,20,5.3,3.3,1.4,1.4,7.9,15.4,260,9.66,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,22/9/2025,Outpatient,Tacrolimus,74.3,95.2,42.5,5.8,140,3.5,26,19,18,79,61,12,5.5,3.6,1.1,1.7,5.7,11.9,284,6.03,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,22/10/2025,Outpatient,Tacrolimus,60.0,120.0,40.4,3.6,139,3.8,23,21,8,68,73,3,5.2,3.2,1.2,2.0,9.1,12.5,309,6.48,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,23/8/2025,Outpatient,Tacrolimus,100.4,64.4,40.2,9.0,136,4.4,27,36,31,73,39,13,5.2,3.5,1.2,1.3,7.6,13.8,239,9.59,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,23/9/2025,Outpatient,Tacrolimus,71.3,114.6,40.4,6.8,138,3.8,28,24,24,78,27,15,4.6,3.0,1.1,1.3,9.5,13.2,328,7.94,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,23/10/2025,Outpatient,Tacrolimus,69.9,120.0,38.1,5.0,134,3.6,29,22,8,90,57,10,5.4,3.3,1.2,1.9,6.3,11.7,252,7.97,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,23/8/2025,Outpatient,Tacrolimus,81.1,65.2,37.9,5.8,142,4.8,26,33,11,65,41,16,5.3,3.5,1.2,1.3,7.0,13.6,257,4.48,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,24/8/2025,Outpatient,Tacrolimus,115.3,58.3,39.6,7.4,137,3.9,23,28,24,106,69,11,5.5,3.7,1.0,1.7,9.9,15.4,327,8.38,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,24/9/2025,Outpatient,Tacrolimus,86.8,112.6,40.1,5.1,139,4.1,25,9,8,124,63,15,5.4,3.2,1.4,1.8,7.8,13.4,303,8.19,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,24/10/2025,Outpatient,Tacrolimus,60.0,120.0,40.8,4.9,141,3.3,24,8,8,47,68,15,5.3,3.3,1.1,1.8,6.0,13.1,154,8.11,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,25/8/2025,Outpatient,Tacrolimus,115.1,90.8,41.1,9.8,138,4.0,24,34,20,78,61,14,5.0,3.2,1.1,1.5,8.3,13.1,304,11.31,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,25/9/2025,Outpatient,Tacrolimus,87.1,94.1,39.2,5.8,136,4.4,23,18,10,105,32,13,5.5,3.1,1.6,2.0,8.0,13.4,185,11.13,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,25/10/2025,Outpatient,Tacrolimus,71.2,120.0,41.7,3.8,141,4.1,21,8,8,75,62,12,5.5,3.3,1.2,2.0,7.0,14.5,190,8.46,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,26/8/2025,Outpatient,Tacrolimus,88.8,75.5,40.6,5.1,140,3.9,26,15,11,92,82,18,5.3,3.5,1.2,1.4,7.2,14.8,373,7.62,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,26/9/2025,Outpatient,Tacrolimus,87.2,114.3,41.5,4.3,139,4.6,24,17,12,74,82,7,5.7,3.8,1.1,1.7,7.9,13.4,302,8.9,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,26/10/2025,Outpatient,Tacrolimus,62.1,120.0,40.1,3.7,139,3.7,25,8,9,125,56,6,6.1,4.3,1.3,1.0,6.5,13.6,267,8.44,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,27/8/2025,Outpatient,Tacrolimus,109.0,90.0,39.5,5.3,142,4.2,23,8,17,58,82,12,4.7,2.7,1.4,1.3,7.4,15.3,211,9.33,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,27/9/2025,Outpatient,Tacrolimus,96.0,107.4,41.4,2.9,139,4.0,26,8,8,100,53,12,5.3,3.4,1.0,2.1,5.4,13.4,233,7.37,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,27/10/2025,Outpatient,Tacrolimus,60.0,120.0,39.5,3.6,138,3.7,24,8,8,93,46,10,5.1,3.0,1.3,1.9,5.8,11.6,258,6.7,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,27/9/2025,Outpatient,Tacrolimus,119.7,93.2,42.0,6.7,143,4.5,28,22,30,118,49,6,5.6,3.7,1.2,1.5,5.8,15.9,250,6.23,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,28/8/2025,Outpatient,Tacrolimus,120.6,80.5,40.9,4.5,137,4.2,23,27,11,61,67,15,4.5,2.5,1.3,1.5,6.1,13.7,217,10.88,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,28/9/2025,Outpatient,Tacrolimus,73.5,114.8,40.1,4.7,135,4.6,26,20,8,113,10,14,4.9,3.1,0.9,1.8,6.2,15.7,315,7.44,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,29/8/2025,Outpatient,Tacrolimus,124.0,65.2,38.8,6.0,142,4.6,22,22,9,118,40,15,5.5,3.8,1.1,1.3,5.6,14.2,300,10.59,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,29/9/2025,Outpatient,Tacrolimus,72.0,95.2,39.4,6.2,145,3.6,23,20,20,65,55,7,5.1,3.3,1.1,1.7,6.7,13.1,291,7.68,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,3/8/2025,Inpatient,Tacrolimus,125.6,79.9,39.2,8.4,135,4.2,18,35,20,74,54,20,5.1,3.7,1.2,0.7,8.5,12.2,230,10.31,,4.21,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,30/7/2025,Inpatient,Tacrolimus,129.1,58.7,36.5,9.2,137,3.9,25,25,38,96,73,15,4.6,2.7,1.2,1.7,8.2,13.4,213,12.76,,4.21,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,30/8/2025,Outpatient,Tacrolimus,112.6,83.7,39.6,8.0,138,4.2,25,12,8,68,80,17,4.9,2.9,1.2,1.8,8.2,11.7,286,8.0,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,30/9/2025,Outpatient,Tacrolimus,76.0,108.6,41.1,6.1,139,4.0,26,21,26,121,86,9,5.2,3.5,1.0,1.5,8.1,15.2,292,6.02,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,30/8/2025,Outpatient,Tacrolimus,91.1,79.6,39.2,5.9,135,4.3,21,29,39,58,58,17,4.6,2.7,1.4,1.2,9.3,15.6,266,8.57,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,31/7/2025,Inpatient,Tacrolimus,130.6,50.2,36.3,8.3,140,4.1,26,9,27,92,33,18,5.5,3.8,1.4,0.8,9.4,13.3,266,8.77,,4.21,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,31/8/2025,Outpatient,Tacrolimus,134.9,79.7,41.1,6.9,138,4.7,24,24,27,87,61,9,5.3,3.4,1.1,1.6,7.6,14.3,283,9.04,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,31/7/2025,Inpatient,Tacrolimus,121.4,57.6,32.9,9.0,135,4.0,25,56,31,52,48,24,5.0,3.7,0.8,1.0,5.0,13.8,273,8.9,,4.21,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,4/10/2025,Outpatient,Tacrolimus,109.4,92.7,37.3,8.7,135,4.7,25,15,15,63,40,7,5.0,3.3,1.3,0.9,11.3,15.1,269,7.28,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,4/8/2025,Inpatient,Tacrolimus,84.1,64.9,34.9,8.4,142,4.9,18,49,8,105,57,22,5.6,4.0,1.2,0.9,5.5,13.2,185,10.99,,4.21,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,5/8/2025,Inpatient,Tacrolimus,102.4,50.3,36.2,11.8,146,4.4,21,36,25,135,100,14,5.9,3.8,1.2,2.1,7.9,11.9,203,8.04,,4.21,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,6/8/2025,Inpatient,Tacrolimus,95.7,99.7,34.8,11.8,134,4.8,26,18,36,40,83,18,5.3,3.8,1.0,1.2,10.2,14.3,308,9.63,,4.21,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,6/9/2025,Outpatient,Tacrolimus,80.6,78.7,40.9,6.7,138,4.4,22,28,23,79,42,13,4.8,2.6,1.5,1.7,5.3,14.3,327,7.41,,3.64,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,7/8/2025,Inpatient,Tacrolimus,175.3,45.1,38.9,6.4,142,3.5,22,39,36,78,103,16,4.3,2.5,1.3,1.1,8.0,11.8,249,9.13,,4.21,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,8/8/2025,Inpatient,Tacrolimus,79.9,63.3,35.9,8.3,137,4.5,24,38,16,129,101,20,4.3,2.8,1.0,1.1,8.0,12.4,341,12.03,,4.21,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1048,7588F,Lim Hui Xiao,30/7/2025,9/8/2025,Inpatient,Tacrolimus,98.9,71.9,39.7,5.0,137,4.7,25,34,25,127,35,25,4.7,2.9,1.1,1.6,6.0,12.0,275,12.1,,4.21,*3/*3,CT,70.9,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,1/8/2025,Inpatient,Tacrolimus,115.2,60.0,35.3,7.5,139,3.7,26,43,52,69,85,12,4.4,2.3,1.3,1.7,4.8,14.3,190,7.96,,5.02,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,1/9/2025,Outpatient,Tacrolimus,86.8,92.8,39.5,6.2,138,3.5,23,23,29,73,81,7,4.8,2.6,1.3,2.0,6.0,11.9,333,8.58,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,1/10/2025,Outpatient,Tacrolimus,69.7,120.0,40.6,4.5,135,3.8,25,29,17,85,10,16,5.1,3.2,1.2,1.5,6.9,13.1,207,8.24,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,2/8/2025,Inpatient,Tacrolimus,118.4,48.2,39.1,10.0,138,3.8,27,40,44,69,60,16,4.0,1.8,1.5,1.6,9.5,13.5,264,9.8,,5.02,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,2/9/2025,Outpatient,Tacrolimus,88.2,92.6,39.6,4.1,141,4.0,22,23,32,103,68,5,4.4,2.5,1.5,1.0,7.5,15.2,206,8.31,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,2/10/2025,Outpatient,Tacrolimus,74.8,120.0,39.1,3.1,137,3.9,27,27,13,105,38,11,4.6,2.8,1.3,1.0,3.4,13.9,330,8.15,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,3/8/2025,Outpatient,Tacrolimus,124.8,74.4,40.5,7.4,139,4.4,24,35,33,81,107,23,4.9,3.1,1.4,1.1,7.3,13.1,203,10.66,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,3/9/2025,Outpatient,Tacrolimus,90.2,113.3,40.5,4.7,142,4.5,27,40,34,103,31,13,4.9,3.1,1.3,1.2,6.6,12.9,223,10.79,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,3/10/2025,Outpatient,Tacrolimus,71.0,120.0,40.2,2.5,137,3.8,27,22,28,57,104,17,4.4,2.5,1.2,1.6,4.3,14.0,301,4.49,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,4/8/2025,Outpatient,Tacrolimus,141.9,54.7,41.2,8.9,138,4.3,23,57,38,102,81,12,4.4,2.6,1.3,1.0,6.4,13.9,320,9.47,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,4/9/2025,Outpatient,Tacrolimus,107.1,97.9,39.4,5.4,132,4.0,25,26,34,58,40,13,5.3,3.3,1.4,1.4,7.3,13.7,321,9.02,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,4/10/2025,Outpatient,Tacrolimus,60.4,120.0,39.0,2.8,137,4.4,26,29,36,67,53,8,5.0,3.0,1.1,1.9,9.4,13.4,179,10.17,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,5/8/2025,Outpatient,Tacrolimus,106.6,66.6,38.2,7.8,139,4.3,26,50,45,112,63,18,4.7,3.0,1.2,1.1,8.4,14.4,190,10.64,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,5/9/2025,Outpatient,Tacrolimus,103.7,105.2,40.0,8.1,140,4.1,24,31,27,95,44,4,4.8,2.6,1.3,1.8,9.6,13.2,208,7.64,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,5/10/2025,Outpatient,Tacrolimus,71.8,120.0,39.6,4.2,139,3.8,23,28,18,92,72,10,5.5,3.4,1.1,2.1,6.0,13.7,238,3.71,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,6/8/2025,Outpatient,Tacrolimus,133.3,66.5,40.2,8.5,140,4.9,25,26,30,82,94,17,4.4,2.7,1.2,1.2,7.5,12.5,233,6.49,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,6/9/2025,Outpatient,Tacrolimus,91.7,89.5,39.8,8.0,140,4.1,24,23,32,85,72,10,4.2,2.7,1.0,1.1,5.6,15.2,123,9.65,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,6/10/2025,Outpatient,Tacrolimus,60.0,120.0,40.7,2.9,140,3.9,29,22,18,98,78,22,5.3,3.6,1.0,1.6,7.0,14.2,270,9.64,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,7/8/2025,Outpatient,Tacrolimus,120.7,57.2,40.6,6.7,138,3.9,23,28,41,98,51,12,5.0,3.2,1.2,1.4,7.8,13.0,321,9.73,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,7/9/2025,Outpatient,Tacrolimus,85.6,91.4,39.2,6.3,137,3.8,23,32,27,93,57,12,4.5,3.2,0.9,1.0,8.6,11.8,312,5.96,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,7/10/2025,Outpatient,Tacrolimus,60.0,120.0,41.1,3.9,143,4.3,25,23,10,54,82,12,4.6,2.6,1.3,1.5,6.2,14.4,243,10.88,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,8/8/2025,Outpatient,Tacrolimus,109.3,86.0,38.8,6.3,141,4.1,24,36,30,93,113,17,4.7,2.8,1.1,1.7,7.7,14.8,243,8.39,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,8/9/2025,Outpatient,Tacrolimus,103.3,107.2,41.0,7.0,139,3.6,22,19,38,78,58,16,5.4,3.7,1.0,1.5,8.9,13.0,288,10.32,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,8/10/2025,Outpatient,Tacrolimus,60.0,120.0,40.8,3.0,141,4.1,25,16,25,73,55,11,5.1,3.2,1.3,1.3,8.4,13.5,346,5.06,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,9/8/2025,Outpatient,Tacrolimus,117.8,83.2,39.5,5.9,141,4.0,25,33,33,78,56,18,4.0,2.1,1.2,1.7,6.3,11.9,249,7.67,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,9/9/2025,Outpatient,Tacrolimus,92.5,115.1,40.4,5.8,140,4.4,26,29,21,92,54,3,4.4,2.6,1.1,1.5,7.5,13.8,254,10.92,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,9/10/2025,Outpatient,Tacrolimus,61.4,120.0,39.4,4.7,138,4.6,23,19,15,118,59,10,4.5,2.7,1.4,0.8,5.5,11.6,262,6.22,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,10/8/2025,Outpatient,Tacrolimus,102.4,70.1,40.5,6.5,139,4.1,20,34,40,127,68,16,5.0,3.6,0.7,1.5,8.0,12.9,227,7.28,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,10/9/2025,Outpatient,Tacrolimus,75.8,106.2,39.2,8.1,138,3.7,25,24,30,130,42,11,5.2,2.9,1.4,1.8,6.8,12.0,343,10.48,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,10/10/2025,Outpatient,Tacrolimus,74.0,120.0,41.0,3.0,137,3.5,26,12,25,83,46,15,4.7,2.7,1.3,1.5,10.5,14.4,205,11.01,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,11/8/2025,Outpatient,Tacrolimus,106.0,82.0,39.3,7.2,136,4.0,23,28,43,89,57,10,4.8,3.6,0.9,0.8,7.5,13.6,341,10.6,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,11/9/2025,Outpatient,Tacrolimus,85.6,94.5,40.7,6.8,137,4.7,26,25,33,88,82,14,4.7,2.4,1.4,2.0,7.4,14.1,226,9.82,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,11/10/2025,Outpatient,Tacrolimus,60.0,120.0,40.2,6.4,134,4.2,26,27,15,83,66,20,5.1,3.4,1.1,1.3,6.9,14.8,308,5.4,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,11/9/2025,Outpatient,Tacrolimus,88.2,75.6,41.3,9.2,139,3.9,28,26,28,69,45,12,5.7,3.8,1.1,1.8,9.3,15.4,120,8.6,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,12/8/2025,Outpatient,Tacrolimus,116.7,89.2,40.4,8.0,137,4.0,24,34,37,119,44,15,5.5,3.9,1.1,1.0,7.3,14.1,182,7.39,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,12/9/2025,Outpatient,Tacrolimus,92.0,114.0,38.8,6.6,142,4.4,23,16,32,114,39,12,5.0,3.3,1.2,1.2,8.9,11.8,241,6.11,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,12/10/2025,Outpatient,Tacrolimus,60.0,120.0,40.5,7.1,140,3.7,23,8,9,86,61,13,5.2,3.5,1.0,1.6,8.0,11.4,252,7.29,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,13/8/2025,Outpatient,Tacrolimus,118.3,68.3,42.0,6.8,134,3.7,27,32,36,96,26,19,4.6,3.2,1.0,0.9,5.4,12.4,202,5.77,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,13/9/2025,Outpatient,Tacrolimus,90.5,107.6,39.3,5.8,141,3.9,23,29,29,107,50,11,5.4,3.8,1.0,1.6,9.0,14.3,189,8.43,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,13/10/2025,Outpatient,Tacrolimus,60.0,120.0,39.4,2.5,137,3.3,28,22,9,70,55,11,4.6,2.6,1.2,1.9,7.2,16.0,335,8.47,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,14/8/2025,Outpatient,Tacrolimus,112.8,87.6,39.9,5.9,137,4.2,25,46,38,96,58,9,5.7,3.8,1.2,1.5,5.1,12.4,374,10.29,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,14/9/2025,Outpatient,Tacrolimus,73.8,97.5,39.9,5.7,136,3.8,24,24,40,111,78,11,4.9,2.8,1.4,1.4,7.2,12.9,276,6.94,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,14/10/2025,Outpatient,Tacrolimus,76.9,120.0,40.6,2.8,136,4.1,27,16,15,87,52,8,4.9,2.8,1.3,1.6,7.4,13.0,209,8.64,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,14/8/2025,Outpatient,Tacrolimus,99.3,98.8,41.6,9.8,145,4.7,22,16,24,92,70,14,5.3,3.5,1.2,1.3,7.8,13.2,246,9.68,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,15/8/2025,Outpatient,Tacrolimus,109.1,73.0,39.0,4.9,137,4.4,23,32,24,88,68,17,5.0,2.7,1.5,1.6,8.8,15.2,282,8.04,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,15/9/2025,Outpatient,Tacrolimus,80.5,119.1,39.6,5.2,139,4.5,24,32,9,109,59,8,4.1,2.2,1.4,1.2,6.4,13.3,273,10.68,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,15/10/2025,Outpatient,Tacrolimus,75.7,120.0,41.1,2.6,136,3.8,23,30,20,95,59,13,4.8,3.0,1.1,1.5,3.7,12.9,214,8.88,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,16/8/2025,Outpatient,Tacrolimus,103.8,100.5,39.4,9.7,141,4.1,23,21,34,128,43,20,4.4,2.6,1.1,1.6,4.1,13.5,307,10.15,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,16/9/2025,Outpatient,Tacrolimus,83.3,115.5,41.9,4.0,141,4.3,22,19,21,74,57,20,4.7,2.7,1.2,1.8,6.0,14.5,318,7.7,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,16/10/2025,Outpatient,Tacrolimus,70.1,120.0,40.0,5.4,140,3.8,26,22,22,70,79,15,5.4,3.9,1.1,0.9,5.5,11.7,202,9.66,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,17/8/2025,Outpatient,Tacrolimus,112.7,86.4,40.3,9.7,144,3.7,25,29,33,101,79,17,4.4,2.6,0.9,1.9,6.6,13.5,226,8.96,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,17/9/2025,Outpatient,Tacrolimus,60.6,114.2,39.3,4.8,136,4.1,25,20,23,90,43,11,4.7,2.9,1.2,1.2,9.3,14.0,287,5.99,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,17/10/2025,Outpatient,Tacrolimus,60.0,120.0,39.8,3.1,137,5.0,28,9,12,91,38,10,5.1,3.0,1.4,1.6,8.6,14.3,311,7.6,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,18/8/2025,Outpatient,Tacrolimus,95.4,74.5,40.1,8.5,137,3.9,25,47,31,109,58,13,4.7,3.2,0.8,1.6,5.9,13.4,260,7.46,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,18/9/2025,Outpatient,Tacrolimus,81.5,104.8,39.5,6.9,139,4.1,26,30,14,107,37,17,5.5,3.2,1.3,2.0,7.9,12.0,288,7.88,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,18/9/2025,Outpatient,Tacrolimus,92.0,53.0,38.8,8.7,143,4.3,22,24,11,113,95,19,3.9,2.1,1.1,1.5,7.6,15.1,211,10.5,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,19/8/2025,Outpatient,Tacrolimus,98.6,89.8,41.1,5.7,139,4.6,24,45,33,88,63,12,4.5,3.0,1.0,1.1,9.8,14.7,336,10.83,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,19/9/2025,Outpatient,Tacrolimus,81.1,107.5,39.8,4.7,139,3.9,26,16,21,84,38,13,4.6,2.8,1.2,1.2,9.8,13.7,264,5.05,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,2/10/2025,Outpatient,Tacrolimus,139.3,65.8,41.3,5.9,139,3.7,28,35,29,142,61,7,5.7,3.5,1.1,2.3,9.4,13.7,289,11.38,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,20/7/2025,Inpatient,Tacrolimus,126.9,56.1,36.3,7.6,141,4.3,25,26,28,93,75,20,4.2,2.5,1.3,0.9,10.1,12.2,292,7.14,,5.02,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,20/8/2025,Outpatient,Tacrolimus,87.9,98.8,39.8,6.9,138,4.4,26,25,32,90,25,15,4.6,2.7,1.3,1.4,7.6,12.6,340,8.64,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,20/9/2025,Outpatient,Tacrolimus,79.6,111.2,40.5,9.4,138,3.2,23,25,21,94,90,13,4.4,2.8,1.2,0.9,6.5,12.0,196,7.68,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,21/7/2025,Inpatient,Tacrolimus,117.4,71.8,35.4,10.0,137,3.4,22,41,42,76,73,13,4.2,2.6,1.1,1.0,8.4,12.9,286,9.02,,5.02,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,21/8/2025,Outpatient,Tacrolimus,96.0,90.3,40.1,5.5,140,3.9,24,40,44,72,81,10,4.8,3.2,1.0,1.2,6.3,13.5,269,8.34,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,21/9/2025,Outpatient,Tacrolimus,85.9,119.7,39.1,7.9,141,3.7,26,8,11,91,42,15,5.1,3.3,1.2,1.4,8.5,14.7,238,7.1,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,21/7/2025,Inpatient,Tacrolimus,100.0,64.3,32.0,4.9,136,4.1,26,34,24,64,62,11,3.7,2.1,1.0,1.3,8.8,11.7,163,7.51,,5.02,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,21/8/2025,Outpatient,Tacrolimus,95.8,88.4,41.3,5.9,139,4.6,21,35,28,84,56,9,4.6,2.4,1.3,2.0,6.0,13.4,177,10.34,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,22/7/2025,Inpatient,Tacrolimus,134.1,42.6,35.2,7.7,141,4.4,25,49,40,112,78,14,4.7,2.7,1.4,1.4,8.3,10.6,251,8.02,,5.02,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,22/8/2025,Outpatient,Tacrolimus,131.8,105.6,41.3,9.0,140,4.2,24,27,33,105,70,19,4.2,2.4,1.0,1.7,6.4,13.2,198,8.12,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,22/9/2025,Outpatient,Tacrolimus,73.6,120.0,40.5,7.4,141,3.8,23,24,32,88,43,15,5.1,3.5,0.9,1.5,5.6,13.5,234,10.18,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,22/7/2025,Inpatient,Tacrolimus,128.4,31.5,36.1,12.3,137,4.4,23,35,20,101,67,20,5.2,3.4,1.1,1.4,9.6,12.4,228,11.56,,5.02,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,23/7/2025,Inpatient,Tacrolimus,124.2,42.2,36.8,8.6,135,3.8,24,53,43,59,65,17,4.4,2.3,1.3,1.9,8.2,12.7,190,11.64,,5.02,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,23/8/2025,Outpatient,Tacrolimus,85.9,93.6,41.6,6.9,142,4.3,23,33,16,88,55,13,4.1,2.2,1.3,1.3,7.2,12.9,209,9.48,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,23/9/2025,Outpatient,Tacrolimus,71.1,120.0,39.6,6.8,133,4.9,25,24,35,93,25,11,4.1,2.2,1.2,1.7,8.6,11.4,232,9.39,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,23/7/2025,Inpatient,Tacrolimus,125.7,55.5,38.6,11.8,136,4.7,25,41,17,116,68,18,5.6,3.8,1.1,1.5,7.9,14.6,307,10.28,,5.02,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,24/7/2025,Inpatient,Tacrolimus,126.0,61.6,37.0,10.4,139,4.7,22,40,41,99,79,15,5.0,3.1,1.3,1.2,10.3,12.3,211,11.53,,5.02,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,24/8/2025,Outpatient,Tacrolimus,104.7,102.5,39.4,5.0,144,4.6,22,40,21,79,35,12,4.7,2.6,1.4,1.6,7.9,13.5,278,6.74,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,24/9/2025,Outpatient,Tacrolimus,86.8,104.5,39.2,4.8,141,3.8,25,26,17,71,74,13,4.8,3.0,1.2,1.4,6.2,13.2,244,10.37,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,24/7/2025,Inpatient,Tacrolimus,90.3,70.5,38.6,9.5,141,4.6,22,39,26,125,114,23,4.9,3.3,1.2,0.9,10.1,13.7,276,13.19,,5.02,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,25/7/2025,Inpatient,Tacrolimus,138.6,58.5,36.9,10.7,141,3.9,24,58,45,94,63,17,4.5,2.6,1.3,1.3,7.8,12.5,212,8.61,,5.02,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,25/8/2025,Outpatient,Tacrolimus,109.2,91.2,40.0,5.9,139,4.1,25,22,24,94,86,18,5.4,3.4,1.4,1.5,9.2,15.1,260,8.07,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,25/9/2025,Outpatient,Tacrolimus,73.0,120.0,40.0,5.0,137,3.9,24,10,21,53,21,11,4.3,2.3,1.2,1.8,7.4,13.7,245,7.27,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,25/7/2025,Inpatient,Tacrolimus,89.0,89.5,32.8,8.5,135,4.7,23,47,27,78,70,29,5.8,3.9,0.9,2.4,6.6,12.3,188,14.09,,5.02,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,25/9/2025,Outpatient,Tacrolimus,88.8,49.7,41.7,6.9,134,4.0,25,31,31,62,64,11,4.8,3.4,0.9,1.2,7.7,14.7,141,10.46,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,26/7/2025,Inpatient,Tacrolimus,110.5,58.0,36.5,10.8,136,4.3,26,40,37,112,75,16,4.8,3.3,1.0,1.1,9.0,11.7,229,9.75,,5.02,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,26/8/2025,Outpatient,Tacrolimus,98.0,101.4,39.5,6.5,138,5.3,23,23,25,100,59,14,4.2,2.2,1.2,1.9,4.7,12.9,295,9.49,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,26/9/2025,Outpatient,Tacrolimus,63.7,116.8,40.8,4.3,139,4.0,25,31,23,90,25,19,4.5,2.5,1.3,1.5,7.0,15.2,201,6.83,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,26/7/2025,Inpatient,Tacrolimus,137.2,67.2,36.3,11.5,139,4.6,23,39,21,123,19,24,4.7,2.5,1.2,2.2,8.0,12.3,219,11.45,,5.02,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,27/7/2025,Inpatient,Tacrolimus,136.2,61.0,37.1,9.1,135,4.0,27,36,30,101,66,15,4.9,2.8,1.3,1.6,9.0,12.3,184,7.52,,5.02,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,27/8/2025,Outpatient,Tacrolimus,81.6,104.6,40.7,8.2,142,3.9,24,33,20,90,40,10,4.6,2.8,1.2,1.2,5.9,12.4,258,10.67,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,27/9/2025,Outpatient,Tacrolimus,76.3,112.3,39.7,6.6,137,4.5,27,33,18,95,20,16,5.7,3.9,1.4,0.9,8.1,11.7,274,6.27,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,27/7/2025,Inpatient,Tacrolimus,130.9,53.2,41.5,8.3,139,4.0,20,25,19,97,91,19,4.5,2.7,1.2,1.5,6.5,13.6,214,11.66,,5.02,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,28/7/2025,Inpatient,Tacrolimus,137.4,51.5,37.2,6.3,140,4.1,26,23,37,95,35,18,4.8,2.9,1.5,0.8,7.8,11.8,223,9.14,,5.02,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,28/8/2025,Outpatient,Tacrolimus,104.7,97.7,41.5,7.8,139,4.3,25,38,36,117,40,11,4.9,2.7,1.2,2.0,7.0,13.2,268,8.3,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,28/9/2025,Outpatient,Tacrolimus,66.9,111.9,41.2,5.6,145,4.2,23,26,37,109,49,18,4.5,2.7,1.0,1.8,7.2,12.0,274,6.85,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,28/7/2025,Inpatient,Tacrolimus,72.8,84.2,36.4,6.9,139,3.8,25,48,23,70,85,16,6.1,4.5,1.1,1.3,8.8,13.8,268,8.01,,5.02,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,28/8/2025,Outpatient,Tacrolimus,79.1,82.0,37.1,7.5,140,4.0,24,24,33,133,68,12,5.6,3.8,1.2,1.4,6.3,13.8,284,4.72,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,29/7/2025,Inpatient,Tacrolimus,107.2,54.8,38.2,7.3,135,4.0,25,48,33,96,39,12,4.8,3.2,1.1,1.2,6.2,13.7,318,10.39,,5.02,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,29/8/2025,Outpatient,Tacrolimus,104.0,100.9,39.2,7.3,141,4.3,21,46,33,112,24,13,5.2,3.5,1.0,1.4,6.6,13.3,185,5.89,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,29/9/2025,Outpatient,Tacrolimus,60.3,120.0,38.5,3.9,135,4.7,27,20,21,98,111,7,4.7,2.8,1.2,1.6,5.6,11.8,220,6.43,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,29/7/2025,Inpatient,Tacrolimus,140.3,80.1,41.4,9.6,142,3.9,24,31,21,87,39,18,5.2,3.4,1.1,1.7,8.1,14.9,332,11.08,,5.02,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,30/7/2025,Inpatient,Tacrolimus,110.9,69.1,38.4,9.4,141,3.5,21,45,31,77,83,15,4.2,2.3,1.4,1.1,7.9,11.8,239,9.88,,5.02,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,30/8/2025,Outpatient,Tacrolimus,99.8,83.1,41.0,8.2,138,4.1,21,40,26,83,75,13,3.6,2.0,1.1,1.2,7.5,13.7,228,7.21,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,30/9/2025,Outpatient,Tacrolimus,77.6,108.2,39.6,5.6,136,4.1,24,27,15,84,19,11,4.8,2.4,1.5,1.9,7.2,14.5,183,10.44,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,30/7/2025,Inpatient,Tacrolimus,112.1,75.3,42.7,8.4,132,3.8,24,44,27,93,69,18,4.4,2.6,1.0,1.8,10.7,14.8,230,10.55,,5.02,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,31/7/2025,Inpatient,Tacrolimus,98.3,89.0,35.8,8.1,138,3.8,23,50,51,112,14,15,5.3,3.4,1.1,1.7,7.0,11.1,223,8.11,,5.02,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,31/8/2025,Outpatient,Tacrolimus,96.7,91.2,39.4,10.1,138,4.2,25,23,30,96,68,11,4.3,2.6,0.9,1.8,8.5,13.7,303,10.01,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,31/7/2025,Inpatient,Tacrolimus,127.0,49.3,37.4,5.6,138,4.3,22,33,9,93,58,14,4.3,2.2,1.4,1.6,11.0,13.8,191,12.78,,5.02,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,4/9/2025,Outpatient,Tacrolimus,112.0,90.3,38.2,7.4,138,3.5,24,33,19,50,61,14,4.5,2.2,1.4,2.2,4.6,13.8,199,7.53,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,7/8/2025,Outpatient,Tacrolimus,114.7,65.7,37.4,7.5,135,4.1,21,34,27,62,80,20,5.1,2.6,1.7,1.8,5.4,13.4,90,6.75,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1049,8690T,Nadia Bin Hassan,20/7/2025,9/10/2025,Outpatient,Tacrolimus,99.0,85.9,39.6,4.7,135,4.7,22,34,34,107,63,16,4.4,2.5,1.3,1.2,5.5,13.3,226,8.93,,4.33,*1/*3,TT,56.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,1/8/2025,Outpatient,Tacrolimus,104.9,70.7,40.3,8.3,143,3.9,25,25,21,85,39,13,4.3,2.6,1.0,1.4,7.6,13.8,194,10.77,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,1/9/2025,Outpatient,Tacrolimus,74.6,109.0,40.4,5.8,140,4.6,23,20,17,66,37,15,4.7,3.0,1.1,1.4,6.8,11.5,296,10.09,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,1/10/2025,Outpatient,Tacrolimus,60.0,120.0,40.1,4.3,142,4.2,25,8,8,84,64,13,5.8,4.0,1.0,1.7,6.9,14.0,309,9.67,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,2/8/2025,Outpatient,Tacrolimus,97.4,88.4,39.1,7.9,138,4.0,22,21,31,99,38,10,4.9,3.3,1.2,1.0,8.4,14.5,214,8.98,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,2/9/2025,Outpatient,Tacrolimus,71.8,118.6,39.5,4.1,140,4.0,28,15,12,82,91,13,5.2,3.6,1.0,1.5,8.7,12.8,266,9.19,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,2/10/2025,Outpatient,Tacrolimus,60.0,120.0,39.4,2.2,137,4.4,25,8,8,90,48,11,4.6,2.4,1.5,1.5,6.1,12.9,360,7.54,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,3/8/2025,Outpatient,Tacrolimus,93.6,66.5,40.9,9.2,138,4.6,25,30,16,79,75,12,5.1,3.3,1.1,1.6,5.5,13.1,234,10.75,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,3/9/2025,Outpatient,Tacrolimus,69.3,119.1,39.0,7.5,137,4.5,29,15,8,61,63,18,4.4,2.2,1.4,1.7,8.5,14.1,221,4.85,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,3/10/2025,Outpatient,Tacrolimus,60.0,120.0,39.3,3.8,143,3.8,28,8,8,81,45,14,5.4,3.6,1.0,1.7,6.6,14.0,261,8.62,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,4/8/2025,Outpatient,Tacrolimus,115.5,96.2,40.0,6.4,142,4.4,25,29,14,94,56,15,5.3,3.4,1.2,1.6,7.0,12.2,186,6.82,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,4/9/2025,Outpatient,Tacrolimus,72.5,113.4,39.0,5.5,142,4.1,26,13,23,78,45,11,5.0,3.1,1.1,1.7,9.7,14.0,186,9.54,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,5/8/2025,Outpatient,Tacrolimus,99.1,83.7,40.9,7.2,141,4.8,26,28,31,93,78,18,5.3,3.8,0.9,1.5,7.9,13.0,262,11.23,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,5/9/2025,Outpatient,Tacrolimus,60.0,113.2,40.1,6.0,135,3.9,25,23,8,58,67,13,4.9,3.6,0.7,1.3,6.4,13.6,276,9.92,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,6/7/2025,Inpatient,Tacrolimus,135.6,33.6,37.0,9.1,141,3.9,22,22,9,91,103,15,6.0,3.7,1.4,1.9,9.3,11.7,192,9.58,,2.51,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,6/8/2025,Outpatient,Tacrolimus,101.2,84.5,40.1,7.6,140,4.0,23,29,21,64,50,17,4.7,2.6,1.4,1.8,7.0,14.5,264,6.57,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,6/9/2025,Outpatient,Tacrolimus,86.7,120.0,40.9,6.8,140,4.1,22,8,11,88,63,21,5.6,3.7,1.1,1.8,6.7,12.7,258,7.66,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,7/7/2025,Inpatient,Tacrolimus,124.4,77.6,35.8,7.8,138,3.7,23,37,28,100,66,17,4.6,2.7,1.2,1.7,7.2,12.3,301,10.31,,2.51,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,7/8/2025,Outpatient,Tacrolimus,107.8,82.9,38.7,4.4,140,3.8,24,16,29,60,75,15,4.2,2.2,1.1,1.9,11.1,13.1,164,8.97,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,7/9/2025,Outpatient,Tacrolimus,60.0,102.5,41.1,3.3,138,3.8,26,31,8,78,91,11,5.0,2.7,1.5,1.7,7.3,14.7,234,9.38,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,8/7/2025,Inpatient,Tacrolimus,123.2,61.2,36.9,9.6,138,4.3,24,36,33,91,61,18,4.3,2.7,1.0,1.2,7.0,12.4,273,10.06,,2.51,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,8/8/2025,Outpatient,Tacrolimus,110.3,91.3,38.4,4.4,141,4.5,24,29,26,60,59,10,4.8,3.4,0.9,1.1,5.3,13.3,239,7.06,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,8/9/2025,Outpatient,Tacrolimus,83.1,120.0,38.6,6.7,138,3.9,22,15,17,84,19,10,5.1,3.1,1.2,1.8,9.2,13.6,270,5.92,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,9/7/2025,Inpatient,Tacrolimus,131.9,59.7,36.0,5.4,140,4.1,23,43,27,106,68,20,4.4,2.6,1.1,1.5,7.2,11.9,207,9.34,,2.51,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,9/8/2025,Outpatient,Tacrolimus,110.2,102.7,43.0,4.9,138,4.6,20,34,24,72,88,20,5.0,3.5,1.1,1.0,7.7,13.4,295,8.07,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,9/9/2025,Outpatient,Tacrolimus,79.1,120.0,39.2,5.7,143,4.5,28,8,10,68,49,8,5.3,3.4,1.3,1.2,4.5,14.4,315,10.14,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,10/7/2025,Inpatient,Tacrolimus,124.5,64.2,35.6,8.7,137,3.8,25,25,25,82,112,19,5.0,3.0,1.3,1.7,7.6,12.8,226,7.38,,2.51,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,10/8/2025,Outpatient,Tacrolimus,106.3,93.5,41.4,5.5,136,3.7,28,37,16,94,35,21,4.7,2.8,1.2,1.6,3.1,13.1,215,10.3,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,10/9/2025,Outpatient,Tacrolimus,76.8,120.0,39.3,2.8,137,4.2,27,8,20,87,26,13,4.9,3.0,1.4,0.9,7.8,12.8,249,7.9,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,10/7/2025,Inpatient,Tacrolimus,134.6,86.5,39.0,8.7,137,4.8,26,20,22,51,60,13,3.9,2.3,1.0,1.3,4.2,12.8,90,10.39,,2.51,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,11/7/2025,Inpatient,Tacrolimus,147.5,87.3,37.4,9.0,138,4.2,24,45,18,72,43,11,5.2,3.4,1.1,1.6,6.4,12.4,217,10.67,,2.51,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,11/8/2025,Outpatient,Tacrolimus,86.1,68.8,39.9,9.0,139,4.5,24,20,15,105,61,14,5.2,3.3,1.2,1.6,8.4,14.2,236,9.52,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,11/9/2025,Outpatient,Tacrolimus,68.3,120.0,40.4,4.5,140,4.0,22,8,8,85,65,14,4.6,2.6,1.2,1.7,6.3,12.8,331,10.23,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,11/7/2025,Inpatient,Tacrolimus,121.4,97.4,38.1,6.9,139,3.6,24,29,23,101,98,12,5.6,4.1,0.9,1.3,6.4,13.9,148,10.04,,2.51,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,12/7/2025,Inpatient,Tacrolimus,131.0,67.1,37.8,8.1,138,3.9,25,39,25,91,36,15,4.9,3.1,1.1,1.6,6.8,10.9,262,9.43,,2.51,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,12/8/2025,Outpatient,Tacrolimus,116.6,94.8,40.5,8.5,134,5.2,28,24,9,102,29,5,4.9,3.1,1.3,1.2,4.7,14.0,246,10.68,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,12/9/2025,Outpatient,Tacrolimus,68.1,120.0,39.4,5.5,143,4.1,24,8,19,90,51,16,5.2,3.2,1.2,1.6,9.4,12.9,235,4.8,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,12/7/2025,Inpatient,Tacrolimus,108.1,71.8,33.4,7.3,144,5.2,23,12,27,100,65,8,5.4,3.5,1.2,1.4,10.3,15.0,244,9.96,,2.51,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,13/7/2025,Inpatient,Tacrolimus,114.9,75.4,37.4,7.5,141,4.6,23,26,32,96,50,16,4.8,3.2,1.0,1.3,7.3,14.2,221,8.62,,2.51,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,13/8/2025,Outpatient,Tacrolimus,92.6,108.2,40.2,7.7,138,3.6,25,25,21,82,71,7,4.8,3.0,1.2,1.4,5.7,12.7,122,6.72,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,13/9/2025,Outpatient,Tacrolimus,60.0,117.0,40.0,4.7,143,3.7,25,8,16,90,74,12,5.1,3.2,1.3,1.0,7.2,13.0,198,10.96,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,13/9/2025,Outpatient,Tacrolimus,108.0,56.4,37.6,8.1,143,4.2,22,17,32,89,54,13,5.2,3.1,1.4,1.8,5.4,11.8,318,10.04,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,14/7/2025,Inpatient,Tacrolimus,119.8,62.0,36.6,8.4,139,4.0,27,34,13,77,89,12,4.8,3.1,1.2,1.1,9.3,12.8,210,11.97,,2.51,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,14/8/2025,Outpatient,Tacrolimus,101.2,101.2,40.4,5.0,144,4.0,25,23,11,97,64,10,5.0,2.7,1.8,1.1,6.9,14.4,253,7.89,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,14/9/2025,Outpatient,Tacrolimus,71.3,118.6,39.3,6.3,140,4.5,23,11,10,93,40,11,5.7,3.8,1.0,2.0,5.4,14.2,338,10.64,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,15/7/2025,Inpatient,Tacrolimus,113.7,59.9,37.6,7.8,140,4.1,24,27,22,84,70,15,4.9,2.7,1.4,1.9,7.5,12.6,298,11.47,,2.51,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,15/8/2025,Outpatient,Tacrolimus,73.6,93.3,38.5,7.6,139,4.0,25,11,15,96,76,13,5.2,3.2,1.3,1.6,7.3,12.0,238,8.48,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,15/9/2025,Outpatient,Tacrolimus,79.9,120.0,41.5,4.6,139,4.5,25,8,12,88,56,5,4.4,2.6,0.9,1.9,5.7,12.6,274,10.06,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,16/7/2025,Inpatient,Tacrolimus,115.3,62.0,37.5,8.9,138,3.4,23,20,15,99,55,18,5.5,3.5,1.2,1.7,8.3,13.8,283,8.13,,2.51,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,16/8/2025,Outpatient,Tacrolimus,96.0,85.5,39.3,6.9,136,4.6,25,31,19,77,49,12,5.1,3.0,1.4,1.5,5.9,14.9,296,8.8,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,16/9/2025,Outpatient,Tacrolimus,60.0,120.0,40.8,5.3,140,4.4,24,8,18,75,39,16,5.3,2.9,1.5,2.1,8.8,13.9,217,7.41,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,16/8/2025,Outpatient,Tacrolimus,90.2,79.6,35.1,8.0,136,4.3,22,17,33,82,44,14,4.1,2.4,1.1,1.5,6.6,14.1,307,7.26,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,17/7/2025,Inpatient,Tacrolimus,126.2,69.4,37.9,7.9,141,4.0,23,24,29,95,53,10,4.5,2.9,1.1,1.1,7.6,11.2,205,10.6,,2.51,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,17/8/2025,Outpatient,Tacrolimus,90.3,98.4,38.6,7.6,139,4.7,26,10,13,69,58,14,4.5,2.8,1.1,1.4,6.7,12.2,237,7.85,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,17/9/2025,Outpatient,Tacrolimus,66.4,120.0,41.9,7.2,139,4.1,27,12,8,107,125,12,5.1,3.5,1.0,1.2,8.0,13.3,291,5.35,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,18/7/2025,Inpatient,Tacrolimus,110.9,80.4,38.0,7.4,143,4.1,24,32,35,103,66,15,4.9,3.6,0.7,1.3,9.4,14.7,239,10.65,,2.51,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,18/8/2025,Outpatient,Tacrolimus,92.1,85.1,41.1,5.4,142,3.7,26,13,14,104,31,22,5.0,3.3,1.1,1.5,5.3,12.1,298,8.04,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,18/9/2025,Outpatient,Tacrolimus,63.3,120.0,40.3,3.6,135,4.4,27,8,12,101,38,16,4.7,2.7,1.2,1.6,6.7,14.4,317,6.8,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,19/7/2025,Inpatient,Tacrolimus,109.6,68.2,36.9,7.5,141,4.0,23,38,35,104,73,10,5.3,3.2,1.3,1.8,7.2,13.6,173,8.56,,2.51,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,19/8/2025,Outpatient,Tacrolimus,88.3,103.7,39.2,8.0,135,4.2,23,21,24,86,87,11,4.5,2.9,1.1,1.0,6.8,12.1,294,10.41,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,19/9/2025,Outpatient,Tacrolimus,60.0,120.0,41.7,3.9,135,4.0,26,11,18,103,71,13,4.7,2.5,1.4,1.6,8.1,11.9,285,8.68,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,19/7/2025,Outpatient,Tacrolimus,106.1,76.4,37.3,4.5,142,4.2,24,32,35,105,52,12,5.8,4.2,1.1,1.3,5.6,14.5,263,8.4,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,2/8/2025,Outpatient,Tacrolimus,60.0,70.0,42.0,9.4,139,3.8,25,31,31,87,59,15,5.3,3.0,1.5,1.8,8.0,12.8,250,9.17,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,20/7/2025,Outpatient,Tacrolimus,118.2,82.8,40.1,7.7,138,4.6,21,33,38,79,91,22,4.7,2.8,1.4,1.0,7.3,13.1,223,8.26,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,20/8/2025,Outpatient,Tacrolimus,85.7,118.7,39.1,6.6,140,4.6,19,8,12,96,31,13,4.7,2.7,1.2,1.6,8.8,12.8,245,9.63,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,20/9/2025,Outpatient,Tacrolimus,83.3,116.2,38.6,9.0,140,3.2,26,10,12,66,75,10,4.5,2.5,1.2,1.7,5.6,13.0,165,8.16,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,20/9/2025,Outpatient,Tacrolimus,82.4,93.6,41.7,3.7,139,3.3,24,32,29,73,47,15,4.8,2.7,1.5,1.2,5.0,14.0,209,9.37,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,21/7/2025,Outpatient,Tacrolimus,112.7,57.2,40.2,7.2,140,4.6,24,25,25,111,67,15,5.1,3.1,1.4,1.6,4.9,15.7,187,7.31,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,21/8/2025,Outpatient,Tacrolimus,90.5,100.9,40.1,4.7,141,4.7,22,23,24,113,83,12,4.7,2.6,1.6,1.1,6.5,12.2,318,5.36,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,21/9/2025,Outpatient,Tacrolimus,60.0,120.0,40.3,2.9,138,3.4,23,8,8,89,35,17,5.0,3.4,1.0,1.3,6.7,12.6,262,4.99,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,22/7/2025,Outpatient,Tacrolimus,112.2,67.3,40.0,6.9,139,4.4,23,30,28,71,74,12,4.6,2.9,1.3,1.1,7.6,14.0,246,10.91,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,22/8/2025,Outpatient,Tacrolimus,75.3,77.2,39.6,6.8,140,3.9,24,19,19,99,81,12,4.9,3.0,1.3,1.5,8.0,12.2,238,8.92,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,22/9/2025,Outpatient,Tacrolimus,60.0,120.0,40.2,2.9,140,4.0,26,12,22,124,78,16,5.0,3.1,1.0,2.1,5.1,12.1,207,9.75,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,23/7/2025,Outpatient,Tacrolimus,124.5,73.9,40.1,8.2,135,4.0,23,19,21,82,39,12,5.4,3.5,1.3,1.3,6.2,13.0,155,7.84,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,23/8/2025,Outpatient,Tacrolimus,85.0,106.0,40.2,4.8,137,4.2,31,11,30,95,35,13,5.1,3.3,1.1,1.6,6.9,13.5,331,5.79,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,23/9/2025,Outpatient,Tacrolimus,79.1,120.0,39.2,2.0,138,4.3,26,11,26,69,37,12,5.2,3.7,0.9,1.2,6.6,14.3,287,8.44,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,23/8/2025,Outpatient,Tacrolimus,114.1,51.7,39.5,6.5,136,4.0,22,29,18,87,46,12,5.4,3.7,1.0,1.4,5.7,12.7,231,8.07,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,24/7/2025,Outpatient,Tacrolimus,112.5,85.4,39.5,7.8,138,4.2,26,40,30,115,71,10,4.5,2.4,1.4,1.6,5.6,13.7,264,10.26,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,24/8/2025,Outpatient,Tacrolimus,77.8,107.1,40.6,5.7,137,3.7,28,9,27,84,64,17,3.8,2.3,1.1,1.0,5.8,12.8,234,9.57,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,24/9/2025,Outpatient,Tacrolimus,60.0,119.8,39.5,5.6,146,3.9,25,17,8,103,41,7,5.2,3.1,1.2,1.9,5.4,13.1,304,9.03,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,25/7/2025,Outpatient,Tacrolimus,103.1,84.6,41.0,6.8,137,4.1,24,15,18,74,83,9,4.9,3.2,1.0,1.5,8.2,12.3,250,7.49,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,25/8/2025,Outpatient,Tacrolimus,85.0,95.1,39.4,5.8,141,3.8,25,28,16,111,80,16,4.9,3.3,1.0,1.3,5.8,12.6,321,7.91,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,25/9/2025,Outpatient,Tacrolimus,60.0,120.0,38.9,5.5,142,4.1,21,8,12,91,33,11,4.7,2.6,1.1,2.2,7.7,13.2,182,8.22,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,26/7/2025,Outpatient,Tacrolimus,118.0,81.1,39.5,5.5,137,4.2,25,18,28,82,92,13,5.1,2.9,1.5,1.5,7.8,14.9,208,7.41,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,26/8/2025,Outpatient,Tacrolimus,78.5,106.3,40.8,6.4,138,4.0,26,16,21,90,89,7,5.6,3.8,1.1,1.4,7.6,12.2,231,9.38,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,26/9/2025,Outpatient,Tacrolimus,60.0,120.0,41.0,3.4,140,4.3,26,11,20,103,35,12,5.9,3.8,1.3,1.8,7.3,13.9,258,7.48,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,26/7/2025,Outpatient,Tacrolimus,99.5,95.4,40.8,7.8,146,3.7,23,22,19,42,71,13,5.7,3.8,1.4,1.2,8.6,13.2,267,9.0,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,27/7/2025,Outpatient,Tacrolimus,107.1,84.3,40.0,9.2,142,3.8,26,29,26,73,10,16,4.8,3.1,1.2,1.3,8.5,13.6,245,8.04,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,27/8/2025,Outpatient,Tacrolimus,91.6,110.3,39.6,5.6,137,3.8,25,9,18,107,34,18,5.8,3.9,1.1,1.8,7.7,13.6,211,6.26,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,27/9/2025,Outpatient,Tacrolimus,60.0,120.0,40.9,4.0,141,3.4,27,11,10,102,73,7,5.0,3.1,1.3,1.3,6.6,14.2,249,7.48,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,27/9/2025,Outpatient,Tacrolimus,102.4,91.9,40.6,4.4,141,4.1,21,36,24,66,60,18,5.5,3.6,1.4,1.0,4.9,13.1,235,5.88,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,28/7/2025,Outpatient,Tacrolimus,105.9,61.5,38.1,7.9,141,4.0,24,26,15,85,76,16,5.5,3.4,1.2,1.9,2.8,13.9,248,10.61,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,28/8/2025,Outpatient,Tacrolimus,66.7,110.4,39.7,4.6,139,4.5,26,17,15,72,26,12,5.2,3.4,1.2,1.3,7.0,11.9,203,9.22,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,28/9/2025,Outpatient,Tacrolimus,60.0,120.0,40.1,3.0,137,3.9,24,11,8,85,48,7,4.9,2.7,1.3,1.8,7.2,13.6,372,8.36,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,29/7/2025,Outpatient,Tacrolimus,98.1,76.0,40.7,5.4,140,4.3,27,33,16,99,61,19,5.0,3.1,1.3,1.3,5.2,13.6,274,6.69,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,29/8/2025,Outpatient,Tacrolimus,76.7,105.4,39.2,6.2,145,3.2,25,15,9,68,68,11,4.6,2.7,1.1,1.6,8.7,13.7,236,8.28,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,29/9/2025,Outpatient,Tacrolimus,60.0,120.0,40.0,3.8,137,3.8,24,23,8,100,44,17,5.5,3.1,1.5,1.9,7.9,15.3,169,8.85,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,30/7/2025,Outpatient,Tacrolimus,105.7,69.2,40.2,6.1,140,4.5,26,29,21,56,43,15,6.0,4.1,1.3,1.2,9.1,16.0,329,8.06,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,30/8/2025,Outpatient,Tacrolimus,93.9,108.7,39.5,8.3,138,4.7,26,9,24,94,51,11,5.0,3.5,0.9,1.3,7.2,13.5,305,6.84,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,30/9/2025,Outpatient,Tacrolimus,60.0,120.0,41.5,3.1,139,4.5,22,8,8,80,68,14,5.3,3.6,1.0,1.6,7.2,13.9,196,8.92,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,30/8/2025,Outpatient,Tacrolimus,94.4,79.7,40.8,3.0,135,4.5,22,15,30,99,60,8,4.8,3.1,1.1,1.4,6.9,14.3,262,5.74,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,31/7/2025,Outpatient,Tacrolimus,108.7,71.7,39.9,7.3,140,3.8,24,37,21,90,91,17,5.4,3.8,1.2,1.1,6.6,12.4,154,8.65,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,31/8/2025,Outpatient,Tacrolimus,85.0,115.8,39.6,6.2,139,3.9,25,11,14,61,10,12,5.9,4.0,1.2,1.7,8.1,12.9,291,6.82,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,4/10/2025,Outpatient,Tacrolimus,103.6,68.2,40.6,8.1,136,4.9,23,17,40,70,59,16,5.2,3.7,1.1,1.1,6.3,12.7,207,6.8,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,6/9/2025,Outpatient,Tacrolimus,97.7,74.7,34.2,6.1,140,4.6,19,27,19,93,48,15,3.9,2.2,1.3,1.0,7.0,15.1,202,6.2,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,7/7/2025,Inpatient,Tacrolimus,85.2,72.8,34.1,7.5,135,4.1,22,54,40,80,74,19,4.7,3.0,1.3,0.8,8.1,14.4,236,7.51,,2.51,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,8/7/2025,Inpatient,Tacrolimus,121.9,62.4,35.3,5.8,136,3.9,21,44,28,64,73,6,4.1,2.7,0.8,1.2,8.4,12.9,247,8.32,,2.51,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,9/7/2025,Inpatient,Tacrolimus,129.4,76.1,31.5,4.3,137,3.7,26,40,24,62,56,13,4.8,3.0,1.3,1.2,10.0,12.3,242,10.37,,2.51,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1051,2799Y,Ng Ying Min,6/7/2025,9/8/2025,Outpatient,Tacrolimus,79.5,72.3,43.5,6.2,140,4.3,26,42,31,133,56,9,5.3,3.5,1.2,1.2,5.1,14.5,346,6.12,,2.17,*3/*3,TT,42.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.5,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,1/7/2025,Outpatient,Tacrolimus,111.7,85.0,40.2,9.1,138,4.0,24,35,26,96,60,16,4.7,3.0,1.1,1.4,8.3,12.3,203,10.48,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,1/8/2025,Outpatient,Tacrolimus,86.8,103.5,39.2,4.1,137,4.3,24,28,24,73,122,16,5.2,3.5,1.2,1.0,6.8,13.6,188,8.4,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,1/9/2025,Outpatient,Tacrolimus,60.0,120.0,39.7,4.8,136,4.3,25,32,12,113,68,12,4.1,2.4,1.2,1.2,5.8,13.8,277,8.73,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,2/7/2025,Outpatient,Tacrolimus,100.2,78.4,40.7,6.3,143,3.9,24,44,31,92,55,14,4.0,2.3,1.2,1.2,6.6,15.7,265,9.0,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,2/8/2025,Outpatient,Tacrolimus,69.1,115.8,40.6,6.5,141,4.1,24,18,27,88,51,7,4.8,3.1,1.3,1.1,5.5,12.6,231,9.55,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,2/9/2025,Outpatient,Tacrolimus,60.0,120.0,39.5,3.9,136,4.2,25,35,8,90,80,14,4.8,3.1,1.0,1.4,7.2,13.1,262,9.15,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,3/7/2025,Outpatient,Tacrolimus,106.2,82.2,41.3,9.6,138,3.5,21,50,32,105,43,13,4.4,2.6,1.2,1.3,4.2,12.6,292,6.43,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,3/8/2025,Outpatient,Tacrolimus,70.8,111.0,39.9,7.3,137,4.8,24,24,30,71,74,21,4.5,2.9,1.0,1.3,6.9,12.8,264,9.08,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,3/9/2025,Outpatient,Tacrolimus,60.0,120.0,41.5,3.6,136,4.2,24,18,21,53,38,17,4.5,2.3,1.5,1.5,4.0,12.9,269,9.58,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,4/7/2025,Outpatient,Tacrolimus,109.4,70.4,39.8,8.9,135,4.6,24,32,37,84,70,12,4.1,2.1,1.1,1.8,5.7,12.0,287,7.51,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,4/8/2025,Outpatient,Tacrolimus,61.6,110.0,40.2,8.6,137,4.8,24,25,23,118,83,11,4.0,2.7,1.0,0.7,7.5,14.0,314,8.62,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,4/9/2025,Outpatient,Tacrolimus,60.0,120.0,40.4,3.7,144,4.6,25,13,14,87,52,12,4.6,2.6,1.3,1.4,5.9,12.9,272,3.0,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,5/7/2025,Outpatient,Tacrolimus,83.7,83.9,39.4,8.8,137,4.6,23,42,25,101,50,18,4.0,2.2,1.3,1.3,6.2,12.9,290,7.92,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,5/8/2025,Outpatient,Tacrolimus,62.2,106.4,42.2,4.7,143,3.9,25,29,29,89,77,17,4.7,3.0,1.2,1.1,4.2,12.4,148,6.47,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,5/9/2025,Outpatient,Tacrolimus,60.0,120.0,40.8,4.1,136,4.4,23,15,15,78,36,12,4.2,2.3,1.3,1.3,8.6,12.5,218,7.22,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,6/7/2025,Outpatient,Tacrolimus,103.9,90.7,41.7,8.8,138,4.0,25,29,30,83,83,16,4.8,3.1,1.1,1.4,6.0,14.0,269,9.24,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,6/8/2025,Outpatient,Tacrolimus,75.2,108.3,39.2,7.4,136,4.3,27,38,38,104,41,17,4.6,3.0,1.1,1.2,5.3,13.0,255,7.65,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,6/9/2025,Outpatient,Tacrolimus,63.7,120.0,39.1,4.4,138,3.5,24,19,21,102,26,11,5.2,3.5,1.0,1.4,5.1,12.9,325,5.44,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,7/7/2025,Outpatient,Tacrolimus,89.8,99.3,39.9,8.6,136,4.0,22,39,37,61,69,15,4.7,3.3,0.8,1.4,6.7,14.4,301,8.54,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,7/8/2025,Outpatient,Tacrolimus,67.7,106.2,37.8,6.8,140,3.8,25,18,20,73,52,10,4.7,3.1,1.0,1.3,7.1,14.6,299,7.54,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,7/9/2025,Outpatient,Tacrolimus,60.0,120.0,39.3,3.6,139,4.5,28,28,19,69,70,11,5.0,3.6,0.9,1.2,7.2,13.1,218,10.02,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,8/7/2025,Outpatient,Tacrolimus,105.8,82.4,38.7,7.2,138,4.4,28,22,26,108,35,16,4.6,2.9,1.2,1.1,6.0,13.4,280,10.27,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,8/8/2025,Outpatient,Tacrolimus,67.2,87.1,41.1,4.9,139,4.3,26,32,31,91,48,11,4.8,2.8,1.4,1.3,7.4,13.0,182,9.91,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,8/9/2025,Outpatient,Tacrolimus,60.0,120.0,40.0,4.2,141,3.9,24,21,17,83,71,13,3.8,2.1,0.9,1.5,7.4,13.8,262,6.9,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,9/7/2025,Outpatient,Tacrolimus,104.8,81.2,39.4,5.8,143,4.4,23,25,35,77,63,12,5.4,4.0,1.1,0.6,7.0,12.9,217,7.98,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,9/8/2025,Outpatient,Tacrolimus,60.8,120.0,38.6,5.9,139,3.9,23,8,10,126,79,11,4.8,3.0,1.4,0.9,4.3,11.8,260,9.69,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,9/9/2025,Outpatient,Tacrolimus,60.0,120.0,39.4,4.4,135,4.2,27,25,13,101,81,10,4.8,2.9,1.2,1.6,7.0,15.9,284,9.19,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,10/7/2025,Outpatient,Tacrolimus,106.3,81.4,40.1,11.6,135,3.8,26,30,33,105,54,18,5.1,3.4,1.2,1.2,6.2,15.9,205,11.11,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,10/8/2025,Outpatient,Tacrolimus,86.0,106.8,39.5,4.1,139,3.5,23,34,25,74,79,11,4.8,3.4,1.0,1.1,4.9,12.5,207,8.62,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,10/9/2025,Outpatient,Tacrolimus,60.0,120.0,40.6,4.3,141,3.7,26,10,16,73,72,15,4.3,2.2,1.4,1.6,6.3,14.8,258,7.82,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,10/7/2025,Outpatient,Tacrolimus,103.2,65.0,38.0,6.9,144,4.1,23,19,27,95,54,7,4.9,3.2,1.2,1.2,10.2,13.5,271,6.23,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,11/7/2025,Outpatient,Tacrolimus,114.3,86.7,40.4,6.1,140,3.9,26,26,26,108,68,16,4.3,2.3,1.1,1.9,5.9,11.9,247,7.85,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,11/8/2025,Outpatient,Tacrolimus,79.4,120.0,39.1,5.0,141,3.9,27,26,24,85,73,14,4.6,2.7,1.2,1.6,5.9,14.3,243,7.98,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,11/9/2025,Outpatient,Tacrolimus,60.0,120.0,38.4,5.0,133,3.3,26,25,21,82,37,13,4.9,3.1,1.1,1.5,5.5,12.6,285,5.66,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,11/9/2025,Outpatient,Tacrolimus,60.0,81.6,39.6,4.9,140,4.6,26,24,23,79,50,19,5.2,3.6,0.9,1.7,8.5,15.0,208,9.38,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,12/7/2025,Outpatient,Tacrolimus,96.4,114.2,40.9,6.7,141,5.0,24,23,40,86,51,11,4.7,2.1,1.7,1.8,6.2,14.0,296,9.64,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,12/8/2025,Outpatient,Tacrolimus,63.6,120.0,41.4,5.3,133,4.7,22,10,25,119,71,16,3.8,1.8,1.1,1.9,6.1,12.9,302,9.32,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,13/7/2025,Outpatient,Tacrolimus,84.3,91.4,39.2,7.8,136,4.0,21,41,34,117,37,15,4.1,2.4,1.2,1.0,7.7,13.8,257,11.68,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,13/8/2025,Outpatient,Tacrolimus,67.2,120.0,39.7,6.9,136,4.4,26,16,28,88,55,14,4.2,2.5,0.9,1.8,5.3,15.7,335,9.68,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,14/6/2025,Inpatient,Tacrolimus,133.8,63.3,37.1,9.8,139,4.3,23,32,33,73,105,13,4.5,3.1,1.1,0.7,9.3,12.7,253,8.38,,6.26,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,14/7/2025,Outpatient,Tacrolimus,88.9,90.7,38.8,8.2,135,3.8,21,30,27,103,47,12,4.6,2.9,1.0,1.4,4.4,12.3,225,10.65,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,14/8/2025,Outpatient,Tacrolimus,62.6,119.5,40.3,5.9,137,4.6,25,26,40,94,82,8,4.3,2.4,1.1,2.0,6.0,12.3,336,8.31,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,14/8/2025,Outpatient,Tacrolimus,129.2,83.5,40.4,6.9,137,4.0,25,38,39,125,44,19,4.9,2.9,1.1,1.9,7.0,12.3,200,8.05,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,15/6/2025,Inpatient,Tacrolimus,133.1,68.5,37.6,10.0,137,4.3,26,39,36,96,75,13,4.9,3.5,1.1,0.7,8.8,12.1,242,11.43,,6.26,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,15/7/2025,Outpatient,Tacrolimus,99.8,97.7,38.8,7.8,135,3.9,19,41,22,92,29,15,5.5,3.8,1.1,1.4,6.8,13.1,292,7.58,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,15/8/2025,Outpatient,Tacrolimus,63.4,120.0,40.2,5.1,142,3.5,24,19,25,99,71,13,4.8,3.4,0.9,1.2,7.0,13.6,267,8.65,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,15/6/2025,Inpatient,Tacrolimus,140.5,49.1,33.7,9.7,135,3.9,24,15,30,121,51,20,3.8,2.5,0.8,1.2,7.3,13.3,319,10.73,,6.26,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,16/6/2025,Inpatient,Tacrolimus,117.3,46.5,37.6,7.6,137,4.4,20,26,36,88,68,17,4.4,2.5,1.1,1.7,8.2,11.7,209,11.06,,6.26,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,16/7/2025,Outpatient,Tacrolimus,94.7,105.6,40.8,7.0,138,4.2,25,43,37,109,81,11,4.8,3.1,1.1,1.4,9.9,13.3,238,11.12,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,16/8/2025,Outpatient,Tacrolimus,60.0,113.6,39.5,3.8,138,3.5,23,24,22,96,72,18,4.4,2.4,1.4,1.3,5.1,13.5,277,8.38,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,16/6/2025,Inpatient,Tacrolimus,124.1,60.2,34.7,7.0,131,3.7,24,38,40,70,89,21,4.7,2.8,1.1,1.7,7.3,15.1,267,8.5,,6.26,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,17/6/2025,Inpatient,Tacrolimus,125.1,72.0,34.0,8.6,140,4.8,24,46,41,69,76,12,4.8,3.0,1.2,1.5,11.6,12.8,266,10.01,,6.26,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,17/7/2025,Outpatient,Tacrolimus,84.5,106.4,40.2,5.7,138,4.3,25,33,38,78,29,13,4.6,2.5,1.6,1.3,4.9,12.2,226,5.15,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,17/8/2025,Outpatient,Tacrolimus,71.1,120.0,40.2,8.3,143,4.0,27,11,27,76,64,18,4.3,2.1,1.4,1.7,6.2,12.5,301,7.3,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,17/6/2025,Inpatient,Tacrolimus,101.8,43.2,38.1,7.7,139,4.3,27,29,35,125,80,19,5.0,3.0,1.2,1.8,4.9,12.7,244,10.99,,6.26,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,17/7/2025,Outpatient,Tacrolimus,107.6,76.8,37.3,6.4,135,4.5,24,27,20,62,39,16,5.7,3.5,1.4,1.9,7.2,12.4,199,6.18,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,18/6/2025,Inpatient,Tacrolimus,120.0,61.3,36.4,6.7,136,3.9,23,33,49,74,106,20,4.4,2.8,1.1,1.1,5.7,13.3,212,8.21,,6.26,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,18/7/2025,Outpatient,Tacrolimus,104.7,89.5,38.7,8.5,141,4.2,26,35,38,89,58,21,5.1,3.6,1.1,0.9,4.8,13.4,163,10.78,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,18/8/2025,Outpatient,Tacrolimus,67.6,120.0,40.3,5.0,137,4.1,25,9,28,94,41,15,3.9,1.6,1.6,1.6,6.8,11.1,335,8.43,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,18/6/2025,Inpatient,Tacrolimus,110.4,69.6,33.6,9.1,140,3.8,22,33,32,46,36,17,4.7,3.4,0.9,1.1,6.3,13.5,283,14.36,,6.26,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,19/6/2025,Inpatient,Tacrolimus,101.2,61.9,35.8,6.6,139,4.7,26,45,33,97,51,15,5.2,3.5,1.3,0.8,8.3,12.4,252,7.36,,6.26,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,19/7/2025,Outpatient,Tacrolimus,85.8,110.4,39.5,6.0,142,4.3,25,38,26,102,81,22,4.4,2.8,1.0,1.5,7.3,13.7,297,7.02,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,19/8/2025,Outpatient,Tacrolimus,60.0,120.0,40.8,6.5,139,4.2,26,32,20,102,57,12,5.0,2.9,1.4,1.5,7.9,13.2,245,9.32,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,19/6/2025,Inpatient,Tacrolimus,86.1,36.5,36.8,4.1,136,4.9,27,60,25,139,72,15,4.8,2.4,1.3,2.4,6.4,12.4,262,7.34,,6.26,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,20/6/2025,Inpatient,Tacrolimus,132.6,59.1,37.5,7.6,137,4.5,22,49,42,76,78,18,4.8,3.0,1.2,1.2,8.6,13.4,190,11.9,,6.26,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,20/7/2025,Outpatient,Tacrolimus,60.0,103.1,40.2,5.9,140,3.2,25,25,27,124,61,14,5.2,3.6,1.0,1.5,8.0,14.7,322,11.52,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,20/8/2025,Outpatient,Tacrolimus,60.0,115.0,38.6,5.7,140,4.3,25,16,21,83,75,8,4.9,2.7,1.5,1.5,7.4,12.8,200,7.1,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,20/6/2025,Inpatient,Tacrolimus,81.8,63.4,43.0,6.4,133,4.4,23,8,17,44,77,21,5.1,3.6,0.8,1.5,6.9,12.1,292,11.95,,6.26,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,21/6/2025,Inpatient,Tacrolimus,115.8,65.7,37.0,8.5,137,4.4,24,58,37,83,77,14,4.6,3.1,1.2,0.8,10.5,14.4,236,11.3,,6.26,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,21/7/2025,Outpatient,Tacrolimus,95.1,99.1,40.6,6.2,134,4.0,23,24,36,46,50,10,4.3,2.2,1.4,1.4,5.0,13.0,218,8.13,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,21/8/2025,Outpatient,Tacrolimus,60.0,120.0,41.8,4.1,135,4.2,25,15,22,63,63,12,4.4,2.4,1.4,1.4,7.6,14.1,205,7.95,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,21/6/2025,Inpatient,Tacrolimus,160.5,41.3,31.6,8.8,134,4.3,22,17,21,121,64,18,4.6,3.4,0.8,1.0,7.4,11.5,113,11.01,,6.26,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,21/8/2025,Outpatient,Tacrolimus,110.5,60.1,40.6,9.6,144,4.3,24,34,17,80,24,13,4.0,2.2,1.2,1.4,9.0,13.6,162,7.51,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,22/6/2025,Inpatient,Tacrolimus,123.3,71.6,36.2,10.4,141,4.2,24,30,44,106,48,14,5.2,3.4,1.2,1.4,8.0,12.6,268,9.01,,6.26,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,22/7/2025,Outpatient,Tacrolimus,61.6,104.3,40.1,7.4,134,4.0,24,29,28,80,81,17,4.6,3.2,0.8,1.4,7.9,13.1,242,9.95,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,22/8/2025,Outpatient,Tacrolimus,60.0,120.0,38.8,6.8,135,3.7,25,22,21,102,40,16,4.7,2.9,1.3,1.2,2.0,13.4,226,7.26,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,22/6/2025,Inpatient,Tacrolimus,126.5,87.6,35.0,5.9,137,4.8,19,24,30,80,70,27,4.5,2.6,1.2,1.7,9.7,12.7,257,9.17,,6.26,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,23/6/2025,Inpatient,Tacrolimus,116.4,61.3,37.5,7.9,141,4.2,26,35,35,85,54,20,4.2,2.5,1.3,1.1,4.2,12.6,224,7.29,,6.26,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,23/7/2025,Outpatient,Tacrolimus,83.2,108.0,39.5,8.5,137,3.9,23,34,32,85,39,12,4.3,2.6,1.0,1.4,6.9,14.9,307,7.92,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,23/8/2025,Outpatient,Tacrolimus,74.3,120.0,38.3,7.5,136,4.4,28,8,32,124,82,12,4.9,3.3,0.9,1.5,8.1,12.1,236,9.57,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,23/6/2025,Inpatient,Tacrolimus,132.3,46.6,34.5,11.2,137,4.5,25,42,25,60,55,9,6.3,4.4,1.1,1.7,7.6,12.0,173,12.48,,6.26,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,24/6/2025,Inpatient,Tacrolimus,128.5,55.2,37.8,10.2,137,4.7,21,51,36,85,71,15,4.6,3.1,1.1,0.9,7.1,13.4,383,8.83,,6.26,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,24/7/2025,Outpatient,Tacrolimus,92.0,99.0,38.9,8.3,140,4.3,27,26,27,100,59,13,4.8,3.2,1.3,0.6,5.6,13.5,189,8.96,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,24/8/2025,Outpatient,Tacrolimus,60.0,120.0,40.0,4.8,137,3.9,24,22,10,88,56,16,4.6,2.9,1.1,1.3,4.5,13.9,274,9.27,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,24/6/2025,Inpatient,Tacrolimus,82.0,85.1,32.4,4.1,135,4.4,23,12,34,116,43,26,4.6,2.8,1.2,1.2,7.0,13.2,236,10.11,,6.26,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,24/7/2025,Outpatient,Tacrolimus,99.4,60.1,41.1,3.7,137,3.8,25,23,31,58,58,14,4.5,3.0,1.0,1.3,6.9,12.8,258,11.98,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,25/6/2025,Inpatient,Tacrolimus,121.7,85.3,36.4,7.1,139,4.2,24,43,44,88,58,14,4.5,2.8,1.3,1.0,7.2,14.4,227,6.76,,6.26,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,25/7/2025,Outpatient,Tacrolimus,71.7,102.4,39.3,4.9,137,4.2,24,20,32,91,101,10,4.8,2.9,1.2,1.5,3.4,13.2,208,10.55,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,25/8/2025,Outpatient,Tacrolimus,60.0,116.4,40.9,4.9,141,3.9,21,22,27,91,42,13,4.9,3.2,1.0,1.7,5.6,14.1,202,5.8,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,25/6/2025,Inpatient,Tacrolimus,107.6,56.7,31.5,8.5,137,4.4,19,24,29,95,83,16,4.6,2.9,1.0,1.5,7.1,11.2,177,9.61,,6.26,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,26/6/2025,Inpatient,Tacrolimus,122.7,78.8,38.6,8.0,137,3.6,24,18,9,69,59,20,3.8,1.9,1.5,1.0,6.2,13.8,232,8.71,,6.26,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,26/7/2025,Outpatient,Tacrolimus,74.4,108.7,41.0,7.0,135,4.3,21,26,36,102,47,6,4.1,2.2,1.2,1.6,7.3,12.7,253,5.98,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,26/8/2025,Outpatient,Tacrolimus,60.0,120.0,43.0,3.2,140,4.2,25,22,23,56,59,11,4.7,2.7,1.3,1.6,7.0,15.0,299,8.68,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,26/6/2025,Inpatient,Tacrolimus,129.5,75.1,40.2,6.2,136,4.3,24,15,33,53,88,22,4.7,2.7,1.5,1.1,10.1,14.0,250,7.17,,6.26,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,27/6/2025,Inpatient,Tacrolimus,115.7,80.2,37.9,10.3,136,4.2,25,41,47,94,77,12,4.0,2.2,1.2,1.4,7.8,12.2,215,10.63,,6.26,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,27/7/2025,Outpatient,Tacrolimus,83.8,102.9,39.7,6.2,138,4.5,22,28,31,86,79,10,4.4,2.4,1.3,1.5,6.3,14.0,249,11.03,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,27/8/2025,Outpatient,Tacrolimus,60.0,120.0,39.6,7.0,137,4.5,24,11,30,54,42,12,4.4,2.6,1.2,1.6,5.6,13.3,204,8.36,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,28/6/2025,Outpatient,Tacrolimus,116.7,72.2,37.9,9.0,139,4.9,23,39,17,92,52,15,4.7,3.5,0.8,1.0,5.4,13.7,269,11.64,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,28/7/2025,Outpatient,Tacrolimus,76.9,95.6,41.0,6.1,139,3.4,24,24,34,104,94,11,4.9,2.9,1.4,1.4,8.0,14.4,382,10.86,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,28/8/2025,Outpatient,Tacrolimus,60.0,107.0,37.7,5.1,137,4.3,23,8,8,100,35,15,4.0,2.5,1.0,1.3,5.9,14.1,286,8.86,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,28/8/2025,Outpatient,Tacrolimus,102.0,79.6,38.8,8.7,147,4.2,23,15,44,88,26,14,4.3,2.1,1.3,1.9,6.6,13.4,290,7.79,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,29/6/2025,Outpatient,Tacrolimus,104.4,94.1,39.8,8.1,138,4.4,23,48,40,117,50,15,4.8,3.2,1.1,1.0,3.8,13.2,187,10.45,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,29/7/2025,Outpatient,Tacrolimus,89.3,118.0,40.0,7.1,140,4.1,23,20,15,73,69,10,4.5,2.9,0.9,1.5,7.1,15.0,253,9.05,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,29/8/2025,Outpatient,Tacrolimus,60.0,120.0,39.5,4.8,135,4.4,24,22,32,98,45,14,4.2,2.6,1.1,1.3,5.6,12.0,291,8.94,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,3/7/2025,Outpatient,Tacrolimus,121.2,65.5,41.2,8.8,141,4.0,23,25,30,102,71,5,5.7,4.1,1.1,1.1,4.9,14.5,288,6.57,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,30/6/2025,Outpatient,Tacrolimus,103.0,84.9,41.3,7.4,137,3.7,25,42,20,115,10,13,5.1,3.4,1.3,0.9,9.5,13.0,265,6.77,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,30/7/2025,Outpatient,Tacrolimus,77.7,111.7,40.3,5.6,141,4.6,25,30,32,66,56,14,4.3,2.5,1.1,1.3,6.7,12.6,258,8.65,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,30/8/2025,Outpatient,Tacrolimus,67.6,120.0,41.1,4.4,142,3.8,26,33,24,56,33,10,4.9,2.9,1.5,1.0,5.3,12.7,270,9.12,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,31/7/2025,Outpatient,Tacrolimus,77.6,110.2,41.1,6.2,139,4.1,25,32,22,93,60,14,4.6,2.5,1.5,1.2,6.2,15.7,225,9.46,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,31/8/2025,Outpatient,Tacrolimus,60.0,118.6,38.2,4.3,139,4.1,26,15,14,80,53,8,5.0,3.2,1.3,1.1,6.0,14.1,338,10.94,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,31/7/2025,Outpatient,Tacrolimus,105.9,60.2,41.4,6.9,139,4.0,27,21,34,105,67,19,3.9,1.8,1.3,1.8,6.7,14.4,274,5.35,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,4/9/2025,Outpatient,Tacrolimus,66.0,67.5,38.6,4.8,137,4.1,24,15,30,78,53,14,5.0,3.1,1.4,0.9,5.8,13.9,221,11.02,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1053,8950N,Amir Binte Ahmad,14/6/2025,7/8/2025,Outpatient,Tacrolimus,90.0,80.6,43.1,8.9,138,4.5,25,36,29,101,22,15,5.0,3.0,1.4,1.5,5.9,13.9,294,8.82,,5.41,*1/*3,CC,70.3,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1065,0498I,Arjun Iyer,2/6/2025,1/7/2025,Outpatient,Everolimus,99.9,52.4,40.7,4.7,137,4.3,22,20,19,67,45,8,6.3,4.3,1.0,2.0,9.1,12.6,377,6.15,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,1/8/2025,Outpatient,Everolimus,108.0,113.5,40.3,3.0,138,3.5,24,19,8,116,110,12,7.0,5.0,1.0,2.0,7.4,13.6,220,4.07,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,2/6/2025,Inpatient,Everolimus,139.2,60.1,36.1,9.7,138,3.8,23,40,28,84,33,13,6.0,3.7,1.2,2.2,8.3,13.5,258,3.86,,3.19,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,2/7/2025,Outpatient,Everolimus,101.2,100.6,39.6,6.7,137,4.7,24,22,21,97,17,15,6.7,4.6,1.3,1.8,6.8,15.8,265,5.77,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,2/8/2025,Outpatient,Everolimus,78.3,115.9,40.1,5.1,136,3.9,24,16,8,89,50,11,6.7,4.7,1.1,1.9,7.0,13.5,198,5.14,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,3/6/2025,Inpatient,Everolimus,142.4,60.7,35.3,9.4,139,4.2,24,48,32,122,67,19,6.3,4.4,1.3,1.6,8.0,12.6,194,6.63,,3.19,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,3/7/2025,Outpatient,Everolimus,89.1,93.2,40.7,7.4,142,5.0,26,18,27,70,55,15,6.6,4.3,1.1,2.7,4.4,15.5,297,5.7,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,3/8/2025,Outpatient,Everolimus,80.7,109.5,40.8,4.1,140,3.4,27,24,21,84,45,13,6.5,4.1,1.2,2.6,5.1,13.7,288,2.02,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,4/6/2025,Inpatient,Everolimus,143.8,56.8,35.2,7.9,142,4.0,23,31,31,116,95,16,5.1,3.3,0.7,2.4,6.7,12.3,320,4.06,,3.19,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,4/7/2025,Outpatient,Everolimus,100.9,82.2,39.4,5.7,137,3.9,22,31,27,121,65,9,6.4,4.1,1.4,2.0,6.2,15.3,279,5.75,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,4/8/2025,Outpatient,Everolimus,69.4,120.0,38.9,5.7,138,4.2,23,25,21,95,94,13,5.1,2.8,1.2,2.6,5.9,13.7,249,2.24,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,5/6/2025,Inpatient,Everolimus,136.3,58.3,35.4,8.7,139,4.2,22,39,30,81,86,17,5.7,3.6,1.1,2.1,10.1,13.8,173,5.59,,3.19,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,5/7/2025,Outpatient,Everolimus,117.6,82.8,39.6,6.6,137,3.9,25,28,25,86,86,14,5.4,3.1,1.4,1.8,6.8,12.7,224,5.44,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,5/8/2025,Outpatient,Everolimus,84.1,120.0,38.7,4.9,138,4.1,24,16,8,135,66,11,5.9,3.9,0.9,2.4,7.3,11.5,294,2.95,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,6/6/2025,Inpatient,Everolimus,115.2,70.2,35.9,8.5,140,3.9,24,42,23,92,70,22,6.6,4.4,1.3,2.1,7.1,13.7,213,6.58,,3.19,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,6/7/2025,Outpatient,Everolimus,101.4,71.4,39.0,8.4,138,4.9,25,37,32,113,69,11,5.6,3.4,1.1,2.5,7.1,13.3,171,5.65,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,6/8/2025,Outpatient,Everolimus,72.5,117.3,40.6,6.4,140,4.2,25,16,40,86,63,8,6.1,3.7,1.2,2.6,6.2,11.1,277,3.64,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,7/6/2025,Inpatient,Everolimus,127.1,74.2,35.9,8.2,139,4.5,24,37,32,83,87,23,6.5,4.5,1.2,1.8,9.2,14.0,159,4.1,,3.19,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,7/7/2025,Outpatient,Everolimus,105.3,81.8,40.4,4.1,142,4.0,28,19,24,70,59,11,6.4,4.0,1.2,2.8,5.8,13.4,320,4.78,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,7/8/2025,Outpatient,Everolimus,77.2,119.6,38.6,6.1,135,4.1,25,30,19,123,61,14,6.3,4.1,1.1,2.4,6.4,15.4,268,5.02,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,8/6/2025,Inpatient,Everolimus,140.7,48.6,36.4,9.7,135,4.7,25,42,35,119,55,18,6.1,3.9,1.5,1.8,8.8,11.4,298,4.3,,3.19,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,8/7/2025,Outpatient,Everolimus,103.7,109.6,39.7,7.7,135,4.9,26,22,21,64,76,15,6.4,4.6,0.9,1.8,9.4,14.1,217,6.44,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,8/8/2025,Outpatient,Everolimus,72.0,120.0,39.0,5.6,135,4.4,27,12,17,109,28,11,6.4,3.9,1.2,2.7,8.7,12.3,377,3.86,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,9/6/2025,Inpatient,Everolimus,134.0,56.4,37.6,9.3,139,4.5,20,46,33,116,51,17,5.7,3.3,1.5,1.9,6.6,13.1,252,5.28,,3.19,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,9/7/2025,Outpatient,Everolimus,120.0,120.0,41.4,5.6,139,4.4,25,20,20,50,35,11,6.2,4.0,1.1,2.5,8.3,12.1,294,4.28,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,9/8/2025,Outpatient,Everolimus,68.1,116.1,40.7,6.3,137,4.2,24,15,19,114,61,13,6.2,4.0,1.3,2.0,7.4,14.8,301,4.73,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,1/7/2025,Outpatient,Everolimus,90.9,113.4,42.2,6.2,145,3.6,26,13,23,84,63,18,4.8,2.8,1.1,2.0,9.9,13.0,262,2.83,,2.62,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,10/6/2025,Inpatient,Everolimus,136.8,67.1,38.0,7.2,137,4.3,25,15,40,94,62,15,5.8,3.3,1.4,2.5,7.6,11.7,267,2.41,,3.19,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,10/7/2025,Outpatient,Everolimus,106.0,107.9,40.4,3.9,138,4.2,19,22,22,99,56,13,6.4,3.9,1.4,2.5,6.7,12.9,303,3.22,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,10/8/2025,Outpatient,Everolimus,80.6,120.0,40.9,2.4,140,4.2,24,13,14,118,55,14,6.3,4.0,1.0,2.8,4.6,15.2,302,3.01,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,10/6/2025,Inpatient,Everolimus,80.6,70.7,42.4,4.7,140,4.7,20,49,34,139,63,12,5.3,3.4,0.9,2.1,8.2,13.6,241,5.94,,2.13,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,11/6/2025,Inpatient,Everolimus,135.6,57.4,36.9,8.3,139,4.1,25,34,46,82,43,13,6.2,3.9,1.2,2.3,11.2,11.6,154,3.82,,3.19,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,11/7/2025,Outpatient,Everolimus,101.2,100.7,39.5,6.3,137,3.8,24,20,11,105,83,18,6.7,4.7,1.1,2.1,5.4,13.4,291,7.14,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,11/8/2025,Outpatient,Everolimus,68.5,120.0,39.1,3.4,140,3.9,27,25,13,70,56,11,6.0,3.5,1.4,2.4,6.0,13.4,201,4.34,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,12/6/2025,Inpatient,Everolimus,140.8,54.1,37.0,6.7,141,4.2,21,40,30,84,65,13,5.8,3.5,1.5,1.6,8.8,12.9,211,6.02,,3.19,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,12/7/2025,Outpatient,Everolimus,111.0,76.8,40.5,5.8,136,4.6,22,26,21,105,99,17,5.9,3.8,0.9,2.8,5.4,13.5,207,4.84,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,12/8/2025,Outpatient,Everolimus,90.3,120.0,39.8,5.0,134,4.2,22,8,28,85,59,15,5.9,3.6,1.3,2.3,5.6,13.5,279,5.78,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,12/8/2025,Outpatient,Everolimus,110.4,69.8,34.9,9.4,141,4.5,23,24,16,76,47,16,6.5,4.7,0.9,2.1,6.8,13.8,176,5.16,,1.99,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,13/6/2025,Inpatient,Everolimus,141.2,79.0,36.9,10.1,142,3.8,21,34,26,89,105,20,5.2,3.1,1.3,1.8,7.6,12.4,158,5.35,,3.19,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,13/7/2025,Outpatient,Everolimus,95.7,86.9,41.1,7.2,133,4.2,25,29,21,109,73,17,5.7,3.5,1.1,2.4,6.4,14.4,201,4.24,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,13/8/2025,Outpatient,Everolimus,92.2,120.0,40.3,2.3,142,4.0,26,18,24,87,16,13,6.2,3.7,1.3,2.8,7.2,13.3,359,4.18,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,14/6/2025,Inpatient,Everolimus,143.1,75.8,36.6,9.4,139,4.1,26,37,37,78,84,18,6.6,4.9,1.0,1.7,6.5,11.1,229,4.63,,3.19,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,14/7/2025,Outpatient,Everolimus,82.2,80.7,40.1,6.7,137,4.1,21,17,21,97,33,13,5.5,3.3,1.1,2.3,6.8,13.3,248,3.83,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,14/8/2025,Outpatient,Everolimus,69.8,120.0,39.9,2.7,141,3.6,26,18,23,63,29,13,6.5,4.3,1.3,2.0,7.9,13.3,315,6.44,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,15/6/2025,Inpatient,Everolimus,131.9,63.2,37.9,7.0,139,4.3,26,37,28,100,65,5,6.2,4.3,1.1,1.9,7.1,12.2,265,4.34,,3.19,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,15/7/2025,Outpatient,Everolimus,91.8,101.0,40.6,4.5,136,3.6,25,22,28,93,78,11,6.0,3.7,0.9,3.0,5.0,14.5,341,3.98,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,15/8/2025,Outpatient,Everolimus,60.0,98.4,39.4,4.6,135,4.1,23,24,11,88,38,13,6.4,4.1,1.4,2.0,7.7,12.6,310,5.14,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,15/7/2025,Outpatient,Everolimus,142.1,52.4,40.1,4.6,140,5.0,22,37,22,92,50,15,5.8,3.8,1.1,2.0,3.9,12.9,223,4.17,,2.16,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,16/6/2025,Outpatient,Everolimus,124.6,52.0,38.5,7.5,140,4.6,26,25,24,79,64,11,5.1,2.7,1.4,2.1,5.7,14.3,196,4.58,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,16/7/2025,Outpatient,Everolimus,110.8,98.7,40.3,7.5,137,3.9,25,22,25,78,57,13,6.7,4.5,1.3,2.0,7.0,12.8,322,4.11,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,16/8/2025,Outpatient,Everolimus,85.7,120.0,39.1,4.8,144,4.4,25,12,20,58,56,16,6.0,4.0,0.9,2.2,7.8,13.0,250,4.92,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,17/6/2025,Outpatient,Everolimus,119.2,72.0,38.1,8.5,139,4.0,24,46,33,97,43,17,4.8,2.9,1.1,1.9,2.9,13.5,219,5.5,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,17/7/2025,Outpatient,Everolimus,104.9,91.9,40.0,7.3,138,4.4,24,27,19,111,60,11,6.4,4.1,1.1,2.6,5.0,14.5,271,3.26,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,17/8/2025,Outpatient,Everolimus,63.6,113.0,40.7,5.1,138,3.5,22,8,10,93,46,7,6.5,4.6,0.8,2.4,6.8,17.4,220,3.47,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,17/6/2025,Outpatient,Everolimus,114.2,55.2,39.6,8.2,139,4.0,24,23,32,101,58,7,6.2,3.7,1.4,2.3,5.5,11.6,241,3.8,,2.1,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,18/6/2025,Outpatient,Everolimus,127.4,65.0,38.7,7.5,140,4.4,19,45,37,90,74,15,5.2,3.6,0.8,1.8,3.7,13.8,250,3.86,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,18/7/2025,Outpatient,Everolimus,99.3,87.4,39.2,5.6,138,4.7,24,27,23,83,39,13,6.4,4.0,1.0,3.1,8.1,13.2,200,6.41,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,18/8/2025,Outpatient,Everolimus,72.3,120.0,41.4,2.8,139,4.0,23,32,20,40,72,17,6.9,4.7,1.0,2.5,7.7,13.1,247,4.7,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,19/6/2025,Outpatient,Everolimus,104.8,76.6,40.5,6.7,139,3.5,26,20,42,63,76,16,5.9,4.0,1.0,2.0,6.3,14.5,310,5.32,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,19/7/2025,Outpatient,Everolimus,111.7,101.6,39.2,6.3,137,4.1,26,21,12,90,62,17,6.7,4.1,1.4,2.7,5.1,14.9,133,2.97,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,19/8/2025,Outpatient,Everolimus,76.7,106.3,40.0,2.0,134,4.2,24,15,8,97,49,14,6.3,4.2,1.2,2.1,7.6,13.3,205,4.41,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,19/8/2025,Outpatient,Everolimus,91.3,78.0,41.5,8.3,142,4.3,25,13,32,140,50,13,6.3,4.4,1.1,1.6,6.8,11.2,184,2.98,,2.37,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,2/9/2025,Outpatient,Everolimus,88.5,76.4,39.8,7.4,139,4.2,24,39,30,53,39,12,5.5,3.4,1.2,1.9,5.7,12.7,208,6.19,,2.5,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,20/6/2025,Outpatient,Everolimus,130.4,82.6,39.7,9.5,139,3.6,22,18,30,114,87,12,5.1,3.2,1.0,2.1,7.8,12.9,190,4.26,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,20/7/2025,Outpatient,Everolimus,104.3,85.1,39.6,7.0,137,4.2,22,23,21,96,63,15,6.5,4.8,1.0,1.7,6.2,13.2,282,4.41,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,20/8/2025,Outpatient,Everolimus,70.2,120.0,38.5,4.0,140,3.5,26,28,8,89,91,12,5.7,3.4,0.9,3.1,9.4,13.2,310,3.64,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,21/6/2025,Outpatient,Everolimus,122.7,66.7,39.1,6.7,137,4.0,23,34,31,129,48,14,7.0,5.0,1.2,1.7,3.6,13.0,347,5.17,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,21/7/2025,Outpatient,Everolimus,90.0,93.4,39.6,4.5,135,4.1,26,30,19,72,62,11,6.5,4.6,1.1,1.9,5.7,14.2,108,4.84,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,21/8/2025,Outpatient,Everolimus,70.0,120.0,38.7,4.5,142,3.6,26,22,21,96,49,11,6.7,4.6,1.0,2.6,7.1,14.0,236,4.92,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,22/6/2025,Outpatient,Everolimus,122.5,68.2,38.9,5.5,134,4.0,23,36,33,73,77,11,5.4,3.4,1.1,2.1,8.1,13.6,281,6.05,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,22/7/2025,Outpatient,Everolimus,93.4,115.0,40.2,6.7,138,4.4,23,27,32,84,81,13,5.9,3.7,1.1,2.5,4.9,12.6,217,5.09,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,22/8/2025,Outpatient,Everolimus,60.0,120.0,40.9,5.7,142,4.4,25,18,11,80,31,16,6.9,4.5,1.5,2.2,6.6,14.2,244,2.63,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,22/7/2025,Outpatient,Everolimus,84.9,116.8,38.3,9.5,138,4.0,25,30,11,133,44,11,5.1,3.2,1.0,1.9,6.4,12.3,239,2.04,,2.03,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,23/6/2025,Outpatient,Everolimus,142.9,81.4,39.8,6.9,138,3.5,25,37,36,94,39,12,6.6,4.5,1.2,2.1,4.9,13.4,194,5.19,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,23/7/2025,Outpatient,Everolimus,101.9,106.0,38.4,4.9,140,4.1,23,11,14,85,66,13,6.2,4.2,1.1,2.1,5.6,14.3,237,5.84,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,23/8/2025,Outpatient,Everolimus,60.0,120.0,38.8,3.8,142,3.8,28,14,19,97,10,13,5.8,3.6,1.4,1.7,3.9,13.7,361,4.31,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,24/6/2025,Outpatient,Everolimus,116.6,65.0,38.8,8.0,136,4.3,22,20,21,93,40,16,5.9,3.6,1.1,2.8,5.7,13.0,333,4.04,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,24/7/2025,Outpatient,Everolimus,85.6,95.5,39.9,4.3,132,4.0,27,17,21,79,63,12,7.3,5.3,0.9,2.5,7.6,13.1,269,3.81,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,24/8/2025,Outpatient,Everolimus,64.7,120.0,40.0,6.5,143,4.3,25,8,8,93,42,9,7.2,4.8,1.4,2.3,9.5,13.2,316,4.36,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,24/6/2025,Outpatient,Everolimus,109.8,58.8,40.6,9.7,137,4.5,26,22,8,118,47,7,6.4,4.3,0.8,2.8,6.5,12.4,299,3.45,,2.85,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,25/6/2025,Outpatient,Everolimus,95.6,70.9,40.3,5.6,140,4.3,23,22,33,124,96,14,6.4,3.9,1.4,2.4,5.5,14.2,170,3.64,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,25/7/2025,Outpatient,Everolimus,76.3,100.6,41.0,8.9,139,4.6,24,18,16,114,51,11,6.2,4.2,1.3,1.6,6.3,14.4,280,4.56,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,25/8/2025,Outpatient,Everolimus,68.3,120.0,39.0,2.6,138,4.6,28,8,25,79,37,14,6.4,3.9,1.3,2.6,6.1,14.1,269,3.67,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,26/6/2025,Outpatient,Everolimus,124.5,93.2,38.3,8.5,139,4.3,24,37,24,105,46,13,5.7,3.6,1.2,2.1,7.0,14.3,179,4.38,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,26/7/2025,Outpatient,Everolimus,104.5,100.8,40.0,6.7,140,3.4,23,26,28,119,71,8,5.9,3.7,0.9,2.9,3.1,13.2,211,6.2,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,26/8/2025,Outpatient,Everolimus,65.2,120.0,40.4,5.1,141,4.3,28,14,16,73,37,12,6.7,4.7,1.0,2.4,5.4,13.1,305,4.96,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,26/8/2025,Outpatient,Everolimus,98.7,80.2,37.3,8.0,144,4.2,24,28,27,70,39,12,5.8,3.7,1.2,2.1,6.2,13.4,232,5.2,,1.72,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,27/6/2025,Outpatient,Everolimus,122.9,78.6,39.8,7.1,142,3.8,23,40,28,110,86,13,6.4,4.2,1.1,2.4,7.7,13.5,211,5.67,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,27/7/2025,Outpatient,Everolimus,95.6,97.9,40.9,4.8,143,4.1,26,28,21,70,66,13,6.3,3.9,1.0,3.1,5.4,11.8,269,3.9,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,27/8/2025,Outpatient,Everolimus,70.4,120.0,37.9,2.0,138,4.1,25,10,8,63,89,11,6.7,4.1,1.5,2.5,6.1,12.4,207,4.45,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,28/6/2025,Outpatient,Everolimus,128.2,78.2,39.0,9.2,142,3.8,25,28,25,85,85,14,6.2,4.0,1.2,2.3,7.2,14.3,293,4.32,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,28/7/2025,Outpatient,Everolimus,75.4,108.8,40.6,6.6,136,4.7,27,27,19,94,41,7,6.6,4.3,1.4,2.1,7.3,13.0,261,3.92,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,28/8/2025,Outpatient,Everolimus,60.0,120.0,40.0,5.2,138,4.4,25,18,11,74,21,14,6.6,4.1,1.5,2.2,8.6,14.7,257,4.07,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,29/6/2025,Outpatient,Everolimus,124.5,71.3,39.8,5.4,134,4.1,21,41,24,95,42,15,6.2,3.9,1.4,1.9,6.9,13.3,235,5.8,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,29/7/2025,Outpatient,Everolimus,89.7,113.4,39.6,6.5,138,3.9,26,13,24,87,83,9,5.7,3.6,1.2,2.0,7.0,12.1,348,4.1,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,29/8/2025,Outpatient,Everolimus,78.6,120.0,40.0,3.1,141,4.2,28,8,8,74,78,7,6.3,3.8,1.5,2.0,4.9,12.9,263,4.47,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,29/7/2025,Outpatient,Everolimus,103.6,88.0,40.4,8.6,137,4.1,23,19,28,53,78,13,5.1,3.0,1.1,2.0,7.1,13.4,333,4.38,,2.59,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,3/6/2025,Inpatient,Everolimus,145.6,40.5,33.3,9.4,134,4.6,24,43,22,82,29,24,6.1,4.3,0.9,2.0,4.3,13.4,292,6.11,,2.67,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,30/6/2025,Outpatient,Everolimus,110.5,97.4,40.7,8.2,141,4.8,22,25,32,66,63,15,5.9,3.3,1.3,2.9,7.3,12.5,286,4.95,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,30/7/2025,Outpatient,Everolimus,80.7,91.0,41.9,3.1,143,3.3,22,12,10,73,62,12,5.8,3.0,1.6,2.8,6.8,16.2,282,2.83,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,30/8/2025,Outpatient,Everolimus,60.0,120.0,38.9,4.9,137,3.8,23,20,8,88,36,10,5.6,3.4,1.1,2.4,8.2,14.2,183,3.65,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,31/7/2025,Outpatient,Everolimus,74.2,120.0,40.4,6.1,135,4.0,26,19,24,106,20,11,5.9,3.5,1.2,2.6,6.0,13.3,364,6.04,,2.75,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,4/6/2025,Inpatient,Everolimus,132.7,62.1,34.1,8.0,136,4.1,23,58,23,64,63,14,5.7,3.6,1.2,2.1,8.7,12.3,198,5.42,,2.63,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,5/6/2025,Inpatient,Everolimus,109.4,57.2,32.5,6.6,135,3.7,22,21,35,99,82,16,6.1,3.9,0.9,2.7,7.8,12.9,278,5.5,,2.38,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,5/8/2025,Outpatient,Everolimus,100.1,75.2,38.6,6.5,141,4.0,24,30,32,71,57,11,5.8,3.2,1.7,2.0,6.3,13.7,195,5.09,,1.99,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,6/6/2025,Inpatient,Everolimus,118.8,85.8,36.7,8.2,133,3.5,22,43,35,120,65,12,5.5,3.3,1.1,2.3,6.7,12.5,203,4.47,,3.24,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,7/6/2025,Inpatient,Everolimus,141.6,77.5,34.3,7.1,137,3.5,19,10,24,130,80,12,4.9,2.9,1.0,2.2,9.8,12.5,148,5.87,,2.29,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,8/6/2025,Inpatient,Everolimus,84.0,74.0,38.5,5.8,132,4.1,23,27,27,87,71,19,5.1,3.4,1.0,1.4,9.9,10.5,202,5.03,,2.13,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,8/7/2025,Outpatient,Everolimus,105.5,63.1,37.4,9.5,139,4.6,25,32,16,79,47,17,5.4,3.1,0.8,3.3,6.7,12.5,291,3.72,,2.29,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1065,0498I,Arjun Iyer,2/6/2025,9/6/2025,Inpatient,Everolimus,146.9,63.0,37.4,6.5,136,4.3,20,24,27,96,76,14,6.4,4.2,1.0,2.6,8.5,13.5,217,4.36,,2.29,*3/*3,CC,63.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,2.0,3–8,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,1/7/2025,Inpatient,Sirolimus,123.5,56.7,36.0,9.0,137,4.3,24,20,28,113,88,17,5.5,3.6,1.0,2.0,6.1,14.3,289,6.41,,3.96,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,1/8/2025,Outpatient,Sirolimus,91.1,88.0,39.8,8.2,139,4.4,22,16,32,96,67,11,6.4,4.2,1.1,2.4,4.0,12.3,268,9.47,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,1/9/2025,Outpatient,Sirolimus,70.7,117.6,39.7,7.0,137,3.9,25,8,17,68,60,2,6.0,3.9,1.3,1.8,3.1,14.5,270,8.23,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,2/7/2025,Inpatient,Sirolimus,128.7,69.6,37.4,10.6,140,3.8,24,25,21,93,54,16,5.8,4.2,1.2,1.0,7.4,13.3,251,6.88,,3.96,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,2/8/2025,Outpatient,Sirolimus,91.3,88.1,39.2,8.5,139,3.9,24,19,21,61,66,14,7.0,4.8,1.2,2.4,4.5,13.4,264,7.89,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,2/9/2025,Outpatient,Sirolimus,60.0,116.3,40.7,5.7,140,4.0,24,10,11,59,53,13,6.0,4.0,1.1,2.0,5.5,12.7,280,8.15,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,3/7/2025,Inpatient,Sirolimus,110.8,60.8,37.4,7.4,136,3.7,23,26,30,90,50,16,5.9,4.1,1.0,1.6,6.7,15.2,280,9.2,,3.96,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,3/8/2025,Outpatient,Sirolimus,84.8,84.8,41.3,5.6,138,4.6,20,25,11,100,63,12,6.6,4.5,1.1,2.1,6.6,14.3,208,6.43,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,3/9/2025,Outpatient,Sirolimus,63.1,117.6,40.3,2.6,136,4.0,23,23,9,106,34,18,5.5,3.3,1.0,2.8,6.4,13.5,307,4.33,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,4/7/2025,Inpatient,Sirolimus,132.1,64.1,35.7,6.9,137,4.2,22,29,32,89,110,17,5.2,2.8,1.5,1.9,6.2,11.6,253,6.89,,3.96,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,4/8/2025,Outpatient,Sirolimus,84.0,105.1,39.9,8.2,141,4.2,24,22,17,77,20,17,6.6,4.5,1.2,1.9,6.2,13.3,203,7.82,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,4/9/2025,Outpatient,Sirolimus,69.0,120.0,38.4,3.3,138,3.6,27,22,20,70,10,16,6.4,4.3,1.0,2.6,5.4,14.0,152,6.65,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,5/7/2025,Inpatient,Sirolimus,111.9,69.6,36.4,8.1,142,4.4,26,33,26,110,33,24,5.9,4.2,1.1,1.4,7.6,12.6,215,7.91,,3.96,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,5/8/2025,Outpatient,Sirolimus,96.2,104.1,40.1,6.9,137,4.2,23,21,22,95,56,9,6.2,4.1,1.4,1.5,3.6,13.7,253,9.14,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,5/9/2025,Outpatient,Sirolimus,60.0,120.0,40.8,4.6,137,3.5,22,18,8,62,52,10,6.4,4.4,1.4,1.2,6.6,13.4,309,6.71,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,6/7/2025,Inpatient,Sirolimus,121.1,86.2,37.2,10.7,140,4.2,25,29,20,135,69,17,5.4,2.9,1.4,2.3,6.5,13.3,301,6.26,,3.96,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,6/8/2025,Outpatient,Sirolimus,85.6,89.1,39.6,5.2,139,4.4,24,16,25,98,53,9,5.5,4.0,1.1,1.0,5.7,11.7,225,7.38,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,6/9/2025,Outpatient,Sirolimus,60.0,120.0,38.8,5.4,139,4.1,28,18,8,109,73,12,5.4,3.1,1.3,2.4,4.8,12.9,190,9.9,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,7/7/2025,Inpatient,Sirolimus,133.5,81.5,35.9,9.2,135,4.4,22,33,20,60,53,15,5.4,3.4,1.2,1.8,3.4,11.5,222,7.78,,3.96,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,7/8/2025,Outpatient,Sirolimus,84.0,101.9,40.8,6.0,140,3.8,24,14,29,61,45,16,6.0,3.6,1.4,2.4,5.0,14.1,149,4.82,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,7/9/2025,Outpatient,Sirolimus,60.0,120.0,40.0,8.2,140,3.1,25,12,8,83,59,11,6.0,3.7,1.2,2.5,4.9,13.1,261,5.43,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,8/7/2025,Inpatient,Sirolimus,134.5,74.9,35.2,7.5,138,3.9,24,22,20,121,27,10,6.0,3.7,1.3,2.1,5.6,13.5,227,7.4,,3.96,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,8/8/2025,Outpatient,Sirolimus,85.5,112.0,40.8,6.2,138,3.9,27,8,22,62,50,16,5.5,3.3,1.2,2.2,6.1,11.5,328,5.7,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,8/9/2025,Outpatient,Sirolimus,60.6,120.0,40.3,8.5,139,3.8,27,19,22,109,67,17,6.5,4.5,1.1,2.0,4.0,12.9,300,4.78,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,9/7/2025,Inpatient,Sirolimus,116.4,73.2,36.0,8.6,140,4.3,24,25,27,115,55,17,6.6,4.3,1.1,2.5,3.6,12.5,198,6.81,,3.96,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,9/8/2025,Outpatient,Sirolimus,82.5,87.7,39.9,4.1,142,4.0,25,16,29,78,74,19,6.6,4.8,0.9,2.0,6.5,14.4,323,7.02,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,9/9/2025,Outpatient,Sirolimus,60.0,120.0,38.7,3.6,138,4.3,25,14,14,83,56,12,5.7,3.3,1.3,2.5,2.7,13.1,187,8.42,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,1/7/2025,Inpatient,Sirolimus,95.7,54.6,39.9,9.2,136,4.4,20,44,8,97,80,8,5.1,2.9,1.2,2.0,6.6,11.7,259,10.57,,4.44,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,10/7/2025,Inpatient,Sirolimus,108.8,75.0,39.3,6.4,141,3.7,25,35,19,77,126,19,5.8,3.1,1.4,2.9,9.2,13.7,243,7.39,,3.96,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,10/8/2025,Outpatient,Sirolimus,89.0,99.0,40.0,6.8,139,4.6,23,30,26,78,30,16,5.9,4.1,0.7,2.6,5.6,12.7,143,4.79,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,10/9/2025,Outpatient,Sirolimus,60.0,120.0,38.4,6.3,140,4.2,25,26,16,86,63,11,6.4,4.0,1.2,2.7,3.3,13.5,195,7.71,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,10/8/2025,Outpatient,Sirolimus,60.0,46.0,40.9,8.9,136,4.5,24,9,13,93,82,19,4.9,2.5,1.3,2.5,7.8,12.9,363,6.27,,4.56,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,11/7/2025,Inpatient,Sirolimus,108.3,76.2,35.8,7.7,135,3.7,21,22,33,95,76,23,5.9,3.8,1.3,1.6,5.1,13.0,329,7.29,,3.96,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,11/8/2025,Outpatient,Sirolimus,72.9,103.8,41.6,7.1,137,3.7,22,8,14,113,103,11,5.7,3.4,1.3,2.3,2.7,13.2,292,5.79,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,11/9/2025,Outpatient,Sirolimus,60.0,120.0,39.6,5.9,137,4.3,24,14,8,90,38,10,5.7,3.5,1.4,1.7,2.0,13.4,331,7.86,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,12/7/2025,Inpatient,Sirolimus,100.5,98.4,37.4,7.2,139,4.0,24,27,18,87,78,13,5.1,2.8,1.6,1.6,5.4,12.4,295,8.84,,3.96,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,12/8/2025,Outpatient,Sirolimus,85.9,109.1,42.1,5.2,140,4.1,25,26,12,82,93,18,7.1,5.0,1.1,2.2,4.3,14.6,332,7.89,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,12/9/2025,Outpatient,Sirolimus,60.0,120.0,39.1,4.8,137,4.3,24,8,8,57,63,12,5.2,2.6,1.3,2.9,5.6,13.5,305,4.34,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,13/7/2025,Outpatient,Sirolimus,102.5,68.7,39.6,9.4,136,3.5,24,24,35,111,45,17,5.9,3.6,1.4,2.1,4.7,14.0,324,8.42,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,13/8/2025,Outpatient,Sirolimus,94.6,108.3,39.2,8.3,137,4.4,26,29,10,87,35,16,6.2,3.9,1.4,2.1,3.3,13.5,200,6.96,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,13/9/2025,Outpatient,Sirolimus,60.0,120.0,39.1,5.2,136,3.8,28,11,8,92,42,15,6.0,3.0,1.4,3.5,5.5,14.9,270,7.38,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,13/7/2025,Outpatient,Sirolimus,91.6,81.8,42.5,5.8,141,4.1,25,17,28,97,44,11,6.7,4.5,1.2,2.2,7.8,14.7,319,7.2,,4.65,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,14/7/2025,Outpatient,Sirolimus,117.3,100.4,40.4,8.7,142,4.0,22,33,41,90,52,23,5.9,4.0,1.3,1.2,3.9,13.8,255,7.8,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,14/8/2025,Outpatient,Sirolimus,77.7,103.3,40.5,5.4,137,4.2,23,21,23,93,28,17,5.5,3.5,0.8,2.6,3.2,13.9,262,10.67,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,14/9/2025,Outpatient,Sirolimus,60.0,120.0,39.8,6.4,136,3.7,24,14,8,84,70,13,6.6,4.3,1.2,2.5,4.2,12.7,282,5.6,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,14/9/2025,Outpatient,Sirolimus,99.7,85.0,41.1,8.9,139,4.0,23,40,39,74,92,20,5.7,3.4,1.4,1.9,5.4,12.7,226,9.34,,2.66,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,15/7/2025,Outpatient,Sirolimus,134.2,72.7,39.5,6.9,143,4.3,23,32,22,78,48,19,6.3,4.3,1.0,2.2,3.9,13.5,168,8.31,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,15/8/2025,Outpatient,Sirolimus,64.5,100.4,40.8,4.9,139,4.0,23,16,16,100,19,16,5.3,3.3,0.9,2.3,5.7,15.7,195,3.82,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,15/9/2025,Outpatient,Sirolimus,60.0,120.0,40.9,3.8,143,4.3,23,8,11,64,29,7,5.1,2.9,1.1,2.4,5.0,12.8,226,6.88,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,16/7/2025,Outpatient,Sirolimus,95.8,79.8,40.5,6.7,139,4.2,25,19,23,89,73,15,6.6,4.9,1.0,1.7,6.2,13.8,208,7.31,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,16/8/2025,Outpatient,Sirolimus,91.8,106.3,39.1,10.0,142,4.6,23,28,16,64,82,14,6.1,4.0,1.1,2.1,5.7,13.9,210,8.15,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,16/9/2025,Outpatient,Sirolimus,60.0,120.0,40.6,5.9,140,3.3,27,10,12,94,38,8,5.5,3.4,1.2,2.0,5.1,15.0,254,8.8,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,17/7/2025,Outpatient,Sirolimus,106.9,89.2,39.6,6.2,138,4.0,25,37,27,109,52,12,6.4,4.7,0.9,1.8,3.3,14.7,223,6.77,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,17/8/2025,Outpatient,Sirolimus,80.4,105.2,39.0,6.2,142,4.5,23,21,21,68,66,16,5.6,3.6,1.1,2.2,5.5,13.8,158,6.68,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,17/9/2025,Outpatient,Sirolimus,60.0,120.0,42.7,4.2,136,4.1,26,9,26,79,56,18,6.2,4.0,1.0,2.4,6.2,13.1,283,5.94,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,17/8/2025,Outpatient,Sirolimus,102.5,74.3,42.4,6.8,143,3.8,25,35,42,78,53,13,5.6,3.9,1.0,1.6,6.2,12.2,327,6.13,,4.26,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,18/7/2025,Outpatient,Sirolimus,104.2,57.1,39.7,8.3,140,4.2,22,20,20,109,81,14,6.3,4.3,1.0,2.1,4.6,14.4,362,5.39,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,18/8/2025,Outpatient,Sirolimus,69.3,101.3,39.1,6.7,138,3.9,26,15,9,56,89,14,5.2,3.1,1.3,1.9,5.5,12.2,266,9.44,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,18/9/2025,Outpatient,Sirolimus,60.0,120.0,40.4,3.5,137,3.9,27,8,8,49,65,10,7.3,5.5,0.8,2.2,3.7,12.8,241,6.18,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,19/7/2025,Outpatient,Sirolimus,106.6,88.4,40.9,8.6,142,4.4,26,25,26,71,70,19,6.4,3.8,1.4,2.6,7.0,14.0,213,7.37,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,19/8/2025,Outpatient,Sirolimus,80.2,112.6,41.3,6.4,138,3.6,25,19,17,92,48,12,6.1,4.4,1.2,1.1,4.9,12.2,284,7.67,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,19/9/2025,Outpatient,Sirolimus,60.0,120.0,40.7,2.0,142,4.5,22,9,13,95,54,13,5.8,3.4,1.5,2.2,4.4,12.7,174,6.37,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,2/7/2025,Inpatient,Sirolimus,109.3,105.7,35.0,10.1,136,4.4,25,14,54,105,30,12,6.1,3.6,1.3,2.6,7.6,13.7,269,7.1,,4.51,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,20/7/2025,Outpatient,Sirolimus,84.1,92.5,40.4,9.1,141,3.9,23,28,20,97,95,14,6.0,3.2,1.5,2.7,5.6,12.8,290,6.16,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,20/8/2025,Outpatient,Sirolimus,60.4,116.4,42.3,5.7,133,4.0,25,8,9,121,68,13,6.0,3.6,1.2,2.4,3.2,14.0,215,5.97,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,20/9/2025,Outpatient,Sirolimus,60.0,118.9,39.7,2.4,134,4.1,25,8,8,77,54,19,5.9,3.3,1.3,2.7,7.3,14.1,293,8.04,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,20/7/2025,Outpatient,Sirolimus,108.7,79.9,38.5,7.3,143,4.3,25,12,28,40,76,11,6.3,4.4,1.2,1.5,8.0,13.7,266,8.45,,3.2,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,21/7/2025,Outpatient,Sirolimus,89.0,86.9,38.9,6.0,134,3.7,25,36,8,80,83,23,5.9,3.9,1.0,2.0,6.7,13.1,252,8.25,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,21/8/2025,Outpatient,Sirolimus,66.4,120.0,39.2,7.5,138,4.2,26,13,13,74,34,18,5.2,3.2,0.9,2.5,4.4,12.8,284,5.4,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,21/9/2025,Outpatient,Sirolimus,60.0,120.0,39.4,2.6,142,4.0,25,9,8,86,30,12,6.5,4.4,1.0,2.2,5.1,13.7,255,6.29,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,21/9/2025,Outpatient,Sirolimus,103.8,61.3,38.2,7.6,140,4.2,26,20,19,72,65,16,5.2,3.1,1.2,1.9,8.2,13.3,168,8.75,,2.96,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,22/7/2025,Outpatient,Sirolimus,98.4,91.6,40.8,6.1,139,4.6,24,28,27,86,81,9,6.4,4.0,1.3,2.3,8.1,13.6,306,5.01,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,22/8/2025,Outpatient,Sirolimus,71.6,120.0,40.0,4.7,137,3.1,29,12,13,54,14,14,6.4,4.5,1.0,2.1,5.0,13.5,285,4.26,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,22/9/2025,Outpatient,Sirolimus,60.0,120.0,39.3,2.5,139,3.8,25,8,8,60,25,9,7.1,5.1,0.7,2.8,6.3,12.8,260,8.02,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,23/7/2025,Outpatient,Sirolimus,102.9,94.7,41.0,6.9,138,4.1,25,28,34,120,50,10,5.6,3.3,1.1,2.4,4.3,15.7,317,8.61,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,23/8/2025,Outpatient,Sirolimus,89.5,101.0,40.6,6.7,142,3.9,22,8,11,86,100,13,6.8,4.9,1.0,1.9,6.0,13.0,200,7.11,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,23/9/2025,Outpatient,Sirolimus,60.0,120.0,40.3,5.0,142,3.7,23,13,14,95,58,12,6.4,4.4,1.3,1.6,4.7,12.7,209,6.47,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,24/7/2025,Outpatient,Sirolimus,95.3,76.9,42.5,9.1,136,4.2,21,35,26,97,106,21,6.5,4.4,1.1,1.9,4.0,12.2,192,5.68,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,24/8/2025,Outpatient,Sirolimus,69.9,114.8,39.8,4.1,138,3.4,26,18,8,91,83,13,6.7,4.4,1.3,2.3,3.3,14.3,381,7.57,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,24/9/2025,Outpatient,Sirolimus,60.0,120.0,39.3,3.9,137,4.0,23,8,8,90,39,12,4.6,2.4,1.1,2.2,3.2,12.4,325,6.64,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,24/8/2025,Outpatient,Sirolimus,113.2,75.4,40.1,5.8,136,4.6,23,29,24,92,84,19,5.6,3.2,1.7,1.7,8.6,14.7,255,6.1,,4.64,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,25/7/2025,Outpatient,Sirolimus,101.4,91.5,39.3,8.6,140,4.5,24,21,15,63,87,21,6.2,4.5,0.8,2.0,5.5,15.0,192,8.38,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,25/8/2025,Outpatient,Sirolimus,70.6,120.0,42.1,5.2,139,3.7,25,21,22,71,99,10,6.3,4.1,1.2,2.2,5.1,13.2,263,8.14,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,25/9/2025,Outpatient,Sirolimus,60.0,120.0,39.2,4.6,141,4.0,25,8,8,103,30,10,6.7,4.3,1.3,2.4,2.7,13.6,294,4.54,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,26/7/2025,Outpatient,Sirolimus,86.7,114.9,39.8,9.1,142,4.0,26,27,9,96,35,17,5.8,3.6,1.3,1.9,5.2,15.0,254,5.65,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,26/8/2025,Outpatient,Sirolimus,78.6,116.3,40.1,4.3,139,3.5,26,8,13,53,82,11,5.9,3.6,1.1,2.5,8.3,15.3,280,5.96,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,26/9/2025,Outpatient,Sirolimus,60.0,120.0,40.4,6.3,139,3.9,27,8,18,62,67,8,6.8,5.0,1.0,1.8,4.5,12.2,242,7.49,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,27/7/2025,Outpatient,Sirolimus,106.9,89.7,41.2,7.0,140,3.8,23,18,12,89,53,14,6.2,3.7,1.4,2.2,6.3,13.1,243,6.54,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,27/8/2025,Outpatient,Sirolimus,72.2,116.8,38.7,8.3,145,4.5,25,8,12,134,90,12,5.5,3.6,1.1,1.7,4.3,12.0,219,5.73,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,27/7/2025,Outpatient,Sirolimus,101.2,80.6,39.7,6.0,136,3.8,24,29,39,92,62,18,6.2,3.9,1.2,2.5,7.5,12.6,285,10.96,,3.45,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,28/7/2025,Outpatient,Sirolimus,77.3,96.6,42.2,7.8,139,4.3,20,24,14,101,98,17,6.1,4.0,1.3,1.9,6.2,12.6,265,5.71,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,28/8/2025,Outpatient,Sirolimus,60.5,120.0,39.7,6.6,144,3.7,26,11,8,50,68,16,5.4,3.3,1.2,2.1,5.0,13.4,287,7.74,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,28/9/2025,Outpatient,Sirolimus,85.0,73.3,41.5,5.9,139,5.0,24,30,24,104,52,12,5.7,4.0,1.2,1.2,7.0,12.2,259,5.54,,2.61,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,29/6/2025,Inpatient,Sirolimus,115.5,76.6,38.1,6.3,138,4.5,24,22,23,90,42,14,5.5,3.2,1.3,2.3,6.0,12.6,237,7.26,,3.96,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,29/7/2025,Outpatient,Sirolimus,99.1,107.8,38.6,5.6,137,4.0,24,39,21,49,39,11,6.4,4.5,1.1,1.7,4.3,11.9,394,8.43,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,29/8/2025,Outpatient,Sirolimus,60.0,120.0,40.0,4.5,135,4.2,25,12,8,92,49,9,6.2,3.5,1.5,2.5,3.3,13.3,275,7.7,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,3/7/2025,Inpatient,Sirolimus,111.3,68.2,33.3,15.0,142,4.5,22,18,25,96,55,15,5.6,3.3,0.9,2.9,7.2,12.7,361,10.43,,3.21,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,3/8/2025,Outpatient,Sirolimus,72.0,67.5,42.0,4.0,135,4.8,25,38,27,92,78,12,5.8,3.9,1.0,2.1,7.2,13.3,284,9.87,,3.96,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,30/6/2025,Inpatient,Sirolimus,140.9,71.3,35.5,8.3,138,4.4,23,21,38,102,41,19,5.3,3.2,1.2,2.1,7.8,12.8,215,8.12,,3.96,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,30/7/2025,Outpatient,Sirolimus,93.2,85.4,39.4,5.4,139,4.3,20,10,27,95,73,19,5.2,3.2,1.0,2.2,5.9,12.3,269,6.72,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,30/8/2025,Outpatient,Sirolimus,62.7,110.8,38.3,4.0,136,4.0,26,9,8,75,25,10,6.2,4.6,0.9,1.7,2.6,15.1,346,8.27,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,30/6/2025,Inpatient,Sirolimus,136.8,50.9,33.2,11.3,138,3.5,22,43,29,90,90,12,6.3,4.6,1.1,1.3,6.4,11.3,286,7.28,,3.53,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,31/7/2025,Outpatient,Sirolimus,110.5,98.9,40.1,6.7,140,4.5,25,27,17,73,54,10,6.4,4.2,1.3,2.0,4.2,12.8,279,7.88,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,31/8/2025,Outpatient,Sirolimus,80.5,117.9,39.1,6.9,142,3.8,23,8,10,97,43,14,5.8,3.5,1.3,2.2,5.3,13.3,225,4.75,,3.42,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,31/8/2025,Outpatient,Sirolimus,95.5,73.7,43.1,7.8,142,4.3,24,13,13,93,50,14,5.6,3.4,1.3,1.9,7.0,13.3,318,5.3,,3.24,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,4/7/2025,Inpatient,Sirolimus,103.9,75.9,37.0,5.9,141,4.2,25,44,23,74,78,10,6.3,4.9,1.1,0.6,6.7,13.4,221,6.34,,5.3,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,5/7/2025,Inpatient,Sirolimus,95.2,93.0,36.0,5.9,139,5.0,23,10,22,98,78,10,6.1,3.8,1.2,2.6,7.8,13.0,328,10.95,,4.05,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,6/7/2025,Inpatient,Sirolimus,94.2,78.3,33.6,7.6,136,4.2,19,41,19,103,36,14,6.3,4.5,0.9,2.0,5.1,11.5,304,7.65,,5.36,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1066,5819X,Ng Chen Min,29/6/2025,7/9/2025,Outpatient,Sirolimus,82.4,88.1,39.1,8.3,139,4.1,23,23,14,93,50,10,5.9,3.5,1.5,2.1,6.4,14.2,225,5.79,,3.74,*3/*3,TT,91.6,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,4.0,5–15,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,1/8/2025,Outpatient,Cyclosporin,109.4,72.3,39.5,6.6,137,4.5,25,50,30,70,16,17,5.2,3.6,1.0,1.5,5.5,13.5,247,174.0,1090.79,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,1/9/2025,Outpatient,Cyclosporin,108.7,110.7,40.1,3.5,138,3.8,24,25,19,84,67,15,4.7,3.1,1.0,1.3,8.0,13.9,220,180.88,1051.44,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,1/10/2025,Outpatient,Cyclosporin,78.0,120.0,39.9,5.9,140,3.7,24,12,18,69,54,12,4.9,3.1,1.3,1.1,8.1,13.6,209,187.27,1169.07,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,2/8/2025,Outpatient,Cyclosporin,118.2,91.4,40.6,6.7,137,4.1,23,45,53,152,91,11,4.5,2.7,1.0,1.8,8.5,13.6,182,224.08,1102.74,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,2/9/2025,Outpatient,Cyclosporin,74.2,103.3,41.0,8.5,137,3.9,26,21,31,89,39,15,4.1,2.6,0.9,1.4,7.5,13.6,256,199.72,899.26,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,2/10/2025,Outpatient,Cyclosporin,61.7,120.0,40.1,6.9,141,4.0,27,14,12,123,69,10,5.0,3.3,1.2,1.2,9.7,13.1,296,150.61,665.89,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,3/8/2025,Outpatient,Cyclosporin,118.1,83.0,39.5,7.3,139,3.9,24,19,23,70,49,10,4.7,2.7,1.3,1.6,10.1,12.7,189,184.68,988.15,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,3/9/2025,Outpatient,Cyclosporin,92.2,114.6,39.7,5.5,136,3.9,21,42,22,105,59,16,5.2,3.7,0.8,1.5,9.1,13.7,202,173.23,764.45,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,3/10/2025,Outpatient,Cyclosporin,60.0,120.0,40.6,2.8,136,4.7,22,26,23,103,27,15,5.1,3.5,1.0,1.3,7.0,14.6,233,118.91,815.25,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,4/8/2025,Outpatient,Cyclosporin,134.2,77.0,39.0,7.9,140,3.6,25,47,22,91,92,20,4.7,2.8,1.2,1.5,7.6,12.6,201,171.11,1052.81,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,4/9/2025,Outpatient,Cyclosporin,97.1,109.5,39.6,4.9,137,4.2,23,21,30,65,48,7,4.4,2.4,1.4,1.5,7.4,14.1,249,224.38,841.73,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,4/10/2025,Outpatient,Cyclosporin,60.0,120.0,38.7,3.1,143,3.6,24,15,16,75,10,10,4.6,2.9,1.0,1.5,7.8,13.2,257,227.77,680.03,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,5/8/2025,Outpatient,Cyclosporin,115.8,82.6,40.0,8.7,140,3.7,26,35,37,73,79,18,4.3,2.5,1.2,1.3,5.9,13.8,234,161.92,840.47,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,5/9/2025,Outpatient,Cyclosporin,85.3,118.5,39.0,6.4,134,3.8,25,26,24,72,10,15,4.9,3.1,1.1,1.7,7.2,11.9,288,172.91,1188.07,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,5/10/2025,Outpatient,Cyclosporin,60.0,120.0,41.2,5.9,142,3.5,25,27,11,84,63,6,4.8,2.8,1.4,1.4,7.3,12.6,271,158.4,785.05,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,6/8/2025,Outpatient,Cyclosporin,105.8,97.5,41.6,5.9,138,4.5,27,32,37,93,54,11,4.8,3.0,1.2,1.2,8.2,12.2,351,179.73,1000.58,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,6/9/2025,Outpatient,Cyclosporin,89.8,106.5,39.2,5.0,138,4.3,23,21,35,113,34,13,4.2,2.4,1.4,0.9,9.0,12.9,219,113.83,798.44,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,6/10/2025,Outpatient,Cyclosporin,60.0,116.5,40.0,3.9,134,3.8,26,17,10,87,38,9,5.1,3.1,1.4,1.2,8.4,13.7,158,215.3,1134.98,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,7/8/2025,Outpatient,Cyclosporin,113.8,71.5,41.8,5.2,136,4.1,24,43,34,63,74,17,5.2,3.4,1.4,1.0,7.4,13.0,171,259.02,796.84,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,7/9/2025,Outpatient,Cyclosporin,90.4,94.0,39.8,6.4,135,4.3,24,28,28,92,80,12,4.6,3.1,1.0,1.0,7.8,13.3,244,157.2,885.84,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,7/10/2025,Outpatient,Cyclosporin,60.0,120.0,38.6,6.9,136,4.0,25,20,28,82,35,12,5.0,3.2,1.3,1.2,6.2,13.6,192,113.88,1103.05,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,8/8/2025,Outpatient,Cyclosporin,116.3,88.3,41.7,7.6,133,3.9,22,29,36,109,57,11,4.7,2.3,1.5,2.1,8.5,11.7,328,291.12,1174.1,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,8/9/2025,Outpatient,Cyclosporin,73.2,120.0,39.7,5.7,137,4.1,25,23,25,101,78,16,4.6,2.9,1.1,1.3,6.2,14.3,302,165.52,918.62,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,8/10/2025,Outpatient,Cyclosporin,64.6,120.0,39.2,2.8,139,3.5,27,8,27,61,78,11,4.7,2.6,1.2,2.0,7.5,12.9,282,190.72,899.61,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,9/8/2025,Outpatient,Cyclosporin,129.4,83.0,38.6,8.0,135,4.1,24,34,28,78,49,14,3.8,1.7,1.5,1.3,5.7,15.0,253,193.89,1013.15,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,9/9/2025,Outpatient,Cyclosporin,72.7,111.4,40.8,5.7,141,4.0,25,28,12,86,45,9,4.7,2.8,1.3,1.3,9.0,13.9,282,224.66,999.62,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,9/10/2025,Outpatient,Cyclosporin,60.0,120.0,39.4,5.6,141,4.4,27,19,27,77,36,11,5.6,3.8,1.1,1.4,6.3,13.8,309,165.19,639.78,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,10/8/2025,Outpatient,Cyclosporin,99.0,71.8,39.1,5.7,140,4.1,25,37,32,91,76,17,4.2,2.5,1.2,0.9,6.2,13.7,227,155.76,1098.41,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,10/9/2025,Outpatient,Cyclosporin,77.9,114.9,41.2,6.7,136,3.6,25,32,25,70,52,13,4.4,2.1,1.5,1.7,8.3,13.0,277,208.75,922.74,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,10/10/2025,Outpatient,Cyclosporin,60.0,120.0,41.3,3.4,138,4.0,24,12,25,117,33,7,5.9,3.8,1.5,1.4,6.6,13.7,224,130.95,780.9,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,11/8/2025,Outpatient,Cyclosporin,103.8,79.7,39.4,8.1,134,4.1,24,41,24,110,10,19,4.6,2.6,1.4,1.2,5.9,12.9,307,147.19,1052.64,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,11/9/2025,Outpatient,Cyclosporin,90.2,116.5,39.1,7.4,139,3.9,25,11,16,65,53,20,4.2,2.7,1.1,1.0,8.8,13.8,173,248.56,669.31,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,11/10/2025,Outpatient,Cyclosporin,68.2,120.0,39.0,2.4,142,3.9,23,21,34,81,60,7,4.6,2.9,1.1,1.2,8.9,14.0,275,91.75,699.35,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,11/9/2025,Outpatient,Cyclosporin,97.8,73.9,36.4,4.4,135,3.7,25,37,19,99,56,11,4.2,2.2,1.3,1.5,5.9,11.5,327,74.13,983.74,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,12/8/2025,Outpatient,Cyclosporin,107.4,82.3,39.5,6.9,140,3.4,25,34,32,125,60,19,3.7,1.9,1.3,1.0,8.5,13.4,202,203.31,1011.41,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,12/9/2025,Outpatient,Cyclosporin,95.4,114.8,40.9,4.0,137,4.3,23,21,12,79,64,12,4.3,2.1,1.4,1.7,5.6,14.4,272,159.14,1271.54,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,12/10/2025,Outpatient,Cyclosporin,60.0,120.0,40.4,4.5,141,3.5,23,20,8,104,65,7,4.8,3.1,1.2,1.1,7.6,13.0,222,115.01,713.01,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,13/8/2025,Outpatient,Cyclosporin,98.0,95.1,40.8,4.9,139,4.0,26,33,27,94,86,16,4.6,2.7,1.1,1.5,8.1,14.5,347,215.13,1007.33,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,13/9/2025,Outpatient,Cyclosporin,84.8,114.4,42.6,5.4,140,4.2,27,29,26,74,28,13,4.7,2.1,1.7,1.9,6.0,12.8,240,222.41,982.51,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,14/8/2025,Outpatient,Cyclosporin,118.1,101.6,39.0,5.1,138,4.6,26,48,46,105,47,10,4.8,3.3,1.0,1.1,7.4,12.3,324,172.45,919.44,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,14/9/2025,Outpatient,Cyclosporin,86.1,103.1,41.1,7.7,138,4.2,26,14,23,94,39,12,4.9,3.1,1.0,1.6,6.4,12.6,259,135.24,997.98,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,14/8/2025,Outpatient,Cyclosporin,119.0,97.6,41.6,8.5,133,4.0,26,22,23,90,58,18,4.3,2.7,1.1,1.2,4.5,14.2,317,145.47,631.42,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,15/7/2025,Inpatient,Cyclosporin,144.4,51.0,35.2,4.8,135,4.1,22,44,44,108,59,16,4.1,2.4,1.2,1.2,7.5,13.2,318,261.64,1239.28,235.4,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,15/8/2025,Outpatient,Cyclosporin,101.4,99.6,39.7,4.1,140,3.9,27,32,30,129,47,17,4.8,2.8,1.4,1.3,9.0,12.3,238,161.46,907.48,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,15/9/2025,Outpatient,Cyclosporin,67.5,113.6,39.0,5.2,140,4.1,20,28,22,76,49,9,4.7,2.8,1.4,1.2,7.8,12.8,263,141.34,984.17,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,16/7/2025,Inpatient,Cyclosporin,154.8,68.1,36.3,6.5,138,4.5,25,47,36,120,106,16,4.2,2.4,1.0,1.7,9.1,13.3,271,182.5,1088.35,235.4,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,16/8/2025,Outpatient,Cyclosporin,99.6,101.7,39.9,9.0,138,3.8,24,25,27,91,66,16,4.8,3.1,1.2,1.3,8.0,15.1,212,133.3,933.02,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,16/9/2025,Outpatient,Cyclosporin,60.0,114.7,39.4,7.3,142,3.6,25,23,18,108,58,12,4.5,2.1,1.6,1.9,7.9,13.0,217,198.63,710.35,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,16/7/2025,Inpatient,Cyclosporin,102.7,53.4,37.3,6.4,140,3.6,23,48,41,103,79,15,5.2,3.6,1.1,1.1,4.9,11.9,257,146.4,1078.82,235.4,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,17/7/2025,Inpatient,Cyclosporin,122.9,53.3,35.7,7.4,136,4.4,22,38,41,79,66,17,3.8,2.1,1.3,0.9,9.7,11.1,306,215.14,1017.98,235.4,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,17/8/2025,Outpatient,Cyclosporin,107.9,83.3,40.5,4.9,141,3.8,23,22,31,74,79,13,4.7,3.2,0.9,1.4,6.6,14.8,200,182.72,963.97,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,17/9/2025,Outpatient,Cyclosporin,84.1,120.0,39.2,3.8,143,3.8,25,12,22,98,47,18,4.8,2.8,1.4,1.3,6.2,11.6,154,183.02,915.92,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,17/7/2025,Inpatient,Cyclosporin,70.0,50.3,30.7,10.9,137,3.9,24,41,38,110,95,21,5.9,4.5,0.9,1.1,7.0,10.6,262,243.98,1224.66,235.4,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,18/7/2025,Inpatient,Cyclosporin,118.8,55.5,36.7,7.2,134,3.5,24,36,27,64,96,18,5.0,3.6,1.1,0.8,9.2,12.5,236,211.63,946.41,235.4,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,18/8/2025,Outpatient,Cyclosporin,89.0,97.8,39.9,6.8,139,4.5,22,25,25,78,27,14,4.8,2.9,1.2,1.5,7.4,13.3,253,180.67,1194.84,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,18/9/2025,Outpatient,Cyclosporin,84.6,120.0,41.4,6.0,141,3.9,24,22,18,84,61,14,4.2,2.5,1.0,1.6,8.1,13.4,373,178.22,899.92,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,18/7/2025,Inpatient,Cyclosporin,99.4,92.6,35.9,7.8,138,3.4,26,28,32,119,57,14,4.7,2.6,1.4,1.6,4.7,11.2,154,197.22,1097.96,235.4,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,18/9/2025,Outpatient,Cyclosporin,135.2,56.1,40.3,2.8,141,5.0,23,22,8,109,67,15,5.5,3.0,1.5,2.4,5.5,13.4,162,142.52,954.03,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,19/7/2025,Inpatient,Cyclosporin,141.6,70.0,36.2,7.3,142,4.4,23,34,38,95,58,16,4.5,2.7,1.3,1.2,9.7,13.2,231,215.8,975.36,235.4,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,19/8/2025,Outpatient,Cyclosporin,88.8,102.3,40.0,9.3,140,5.1,25,44,26,93,100,18,5.1,3.5,1.1,1.1,7.4,12.4,244,200.08,1023.21,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,19/9/2025,Outpatient,Cyclosporin,60.0,120.0,38.8,5.6,139,3.8,27,33,15,99,62,14,4.8,3.2,1.1,1.0,7.0,12.3,192,152.06,891.18,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,19/7/2025,Inpatient,Cyclosporin,119.6,88.7,30.4,7.6,140,3.8,20,47,23,75,60,6,4.5,2.6,1.4,0.9,6.8,13.8,273,209.98,945.15,235.4,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,2/10/2025,Outpatient,Cyclosporin,93.2,89.0,42.0,4.4,142,4.4,24,27,8,90,56,8,4.2,1.9,1.4,1.8,7.0,13.2,226,217.87,721.49,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,20/7/2025,Inpatient,Cyclosporin,124.6,69.4,36.6,4.9,139,3.7,27,33,41,122,71,19,5.2,3.1,1.6,1.1,8.6,13.0,156,226.24,1003.02,235.4,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,20/8/2025,Outpatient,Cyclosporin,108.0,90.8,40.2,6.5,141,4.3,24,25,32,80,61,11,4.9,3.4,1.0,1.1,5.9,12.8,247,130.73,1178.84,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,20/9/2025,Outpatient,Cyclosporin,74.1,117.9,40.1,4.1,140,3.3,24,29,23,85,32,12,4.3,2.6,1.0,1.5,7.2,14.8,215,172.72,690.31,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,20/7/2025,Inpatient,Cyclosporin,107.9,68.7,35.8,10.8,137,4.1,24,20,16,72,30,19,5.1,3.9,1.0,0.5,6.9,16.0,258,218.05,813.49,235.4,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,21/7/2025,Inpatient,Cyclosporin,125.6,73.8,35.4,7.7,137,4.1,22,42,50,118,51,18,5.1,3.2,1.0,1.9,8.6,12.4,185,212.42,1143.85,235.4,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,21/8/2025,Outpatient,Cyclosporin,108.6,85.2,41.8,7.1,135,3.8,26,40,34,83,78,13,4.5,2.5,1.3,1.5,7.1,13.1,300,135.34,848.94,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,21/9/2025,Outpatient,Cyclosporin,78.2,119.2,39.2,5.8,138,4.3,28,22,21,86,48,13,4.9,3.4,1.1,1.0,8.8,13.2,156,204.8,761.53,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,21/7/2025,Inpatient,Cyclosporin,70.0,48.2,35.8,7.4,142,4.1,22,15,14,129,62,17,3.8,2.2,1.2,0.7,9.1,12.9,239,171.91,964.86,235.4,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,21/8/2025,Outpatient,Cyclosporin,87.4,75.7,38.5,6.2,137,4.4,24,22,34,68,58,12,4.8,2.6,1.3,1.9,7.3,13.4,279,112.12,786.31,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,22/7/2025,Inpatient,Cyclosporin,123.0,59.9,36.2,9.7,136,3.8,20,41,38,94,48,18,3.8,1.8,1.4,1.2,6.9,11.7,212,210.72,1059.55,235.4,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,22/8/2025,Outpatient,Cyclosporin,105.0,108.7,39.1,6.0,140,3.5,25,29,27,92,79,5,5.0,3.7,0.9,1.0,6.9,12.9,231,154.29,1008.17,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,22/9/2025,Outpatient,Cyclosporin,64.4,112.2,41.2,3.7,139,4.0,25,18,25,112,65,15,5.4,3.5,1.2,1.5,6.6,12.7,202,189.79,893.97,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,22/7/2025,Inpatient,Cyclosporin,160.1,103.0,35.6,8.5,145,4.4,23,18,21,40,63,11,5.0,3.1,1.2,1.6,6.1,12.5,285,164.6,1076.23,235.4,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,23/7/2025,Inpatient,Cyclosporin,128.8,72.5,36.4,8.6,140,5.1,27,50,39,89,40,26,4.6,3.3,0.9,0.8,10.7,12.5,278,215.78,975.17,235.4,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,23/8/2025,Outpatient,Cyclosporin,80.8,82.8,41.1,3.6,137,4.4,23,38,30,113,30,15,4.7,3.3,0.9,1.2,5.9,13.0,298,209.14,1052.86,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,23/9/2025,Outpatient,Cyclosporin,82.5,119.7,39.8,6.0,141,3.8,23,11,11,67,89,15,5.2,3.4,1.3,1.2,7.4,13.1,291,189.58,851.6,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,23/7/2025,Inpatient,Cyclosporin,122.1,78.2,34.6,9.3,141,4.5,19,34,31,116,33,17,4.0,2.2,1.1,1.7,8.5,13.8,215,250.33,1123.81,235.4,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,24/7/2025,Inpatient,Cyclosporin,122.3,66.0,35.4,5.0,137,3.8,25,34,26,69,90,19,5.3,3.8,0.9,1.2,6.3,14.1,228,206.1,1130.19,235.4,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,24/8/2025,Outpatient,Cyclosporin,98.5,105.3,40.7,9.1,139,4.6,26,39,26,42,72,15,4.6,2.7,1.1,1.6,8.1,13.6,359,166.23,1200.65,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,24/9/2025,Outpatient,Cyclosporin,60.0,99.9,39.8,2.6,135,4.2,24,13,16,93,29,7,5.1,2.7,1.6,1.8,7.2,12.5,183,201.52,841.31,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,24/7/2025,Inpatient,Cyclosporin,144.5,93.2,34.5,7.7,138,4.4,24,45,30,147,35,12,5.5,4.3,0.7,0.9,7.2,14.2,243,102.97,1153.95,235.4,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,25/7/2025,Inpatient,Cyclosporin,121.9,59.0,37.5,7.9,137,4.1,26,51,33,93,100,13,4.2,2.1,1.4,1.5,7.8,11.9,276,259.1,1271.5,235.4,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,25/8/2025,Outpatient,Cyclosporin,92.6,99.6,40.3,5.4,143,4.4,23,33,28,88,68,13,5.3,2.9,1.5,1.9,8.7,13.5,340,240.72,1157.5,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,25/9/2025,Outpatient,Cyclosporin,73.0,120.0,39.3,4.6,138,3.9,27,18,30,89,53,14,5.4,3.7,1.2,1.2,8.7,14.3,258,153.02,955.89,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,25/9/2025,Outpatient,Cyclosporin,84.1,88.7,34.1,5.6,146,3.9,23,22,21,110,69,11,5.5,3.5,1.3,1.5,7.2,14.3,259,177.6,816.96,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,26/7/2025,Inpatient,Cyclosporin,94.7,74.3,37.3,4.5,136,4.8,23,37,50,75,63,22,5.0,3.4,1.1,1.2,8.5,12.4,200,164.73,988.41,235.4,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,26/8/2025,Outpatient,Cyclosporin,95.6,87.3,42.4,9.5,140,4.1,21,34,43,97,50,12,5.2,3.3,1.2,1.5,7.7,13.3,283,177.85,1004.6,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,26/9/2025,Outpatient,Cyclosporin,71.7,97.5,39.7,6.3,140,3.8,24,22,8,72,56,10,4.5,2.7,1.2,1.6,5.7,14.2,300,100.82,818.76,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,27/7/2025,Inpatient,Cyclosporin,107.4,67.6,38.4,9.5,137,4.0,24,37,43,128,53,16,5.1,3.0,1.4,1.6,6.5,13.6,174,211.45,1281.6,235.4,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,27/8/2025,Outpatient,Cyclosporin,88.8,103.0,41.4,4.4,135,4.1,21,24,15,89,57,17,4.5,2.7,1.3,0.9,7.3,11.9,178,136.84,1022.38,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,27/9/2025,Outpatient,Cyclosporin,65.4,120.0,37.8,7.8,140,4.4,25,18,31,112,51,15,4.7,3.3,1.0,1.0,8.5,14.1,266,124.4,521.13,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,28/7/2025,Inpatient,Cyclosporin,121.9,65.2,37.8,6.4,142,4.2,24,21,32,102,59,22,3.7,1.5,1.4,1.6,6.4,13.0,152,192.7,963.7,235.4,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,28/8/2025,Outpatient,Cyclosporin,85.5,106.2,41.4,4.7,141,3.5,25,43,40,65,49,16,4.4,2.7,1.4,0.9,7.7,13.1,261,185.98,1331.87,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,28/9/2025,Outpatient,Cyclosporin,70.5,120.0,42.0,6.5,138,4.3,25,8,30,95,59,7,4.4,2.9,0.8,1.6,6.2,13.3,229,161.64,795.87,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,28/8/2025,Outpatient,Cyclosporin,128.1,97.5,38.4,7.2,141,4.2,25,26,32,104,46,20,5.2,3.5,0.9,1.7,6.7,13.3,285,124.55,861.28,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,29/7/2025,Outpatient,Cyclosporin,123.1,61.6,41.1,7.2,136,4.4,24,43,27,91,82,16,4.8,2.9,1.2,1.4,5.1,13.9,327,144.47,1235.78,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,29/8/2025,Outpatient,Cyclosporin,89.7,113.8,39.2,4.3,137,4.6,21,24,26,88,103,8,4.6,3.1,1.1,0.9,8.6,14.9,222,156.75,1177.22,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,29/9/2025,Outpatient,Cyclosporin,69.2,118.4,40.0,3.7,140,4.6,23,26,23,80,15,15,4.0,2.1,1.2,1.4,6.3,15.9,323,160.93,1091.99,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,30/7/2025,Outpatient,Cyclosporin,121.9,58.8,38.6,6.2,139,3.8,21,39,38,88,51,10,4.2,2.9,0.9,1.1,7.5,15.3,290,163.5,1114.3,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,30/8/2025,Outpatient,Cyclosporin,84.2,103.8,39.1,5.8,139,3.8,24,40,25,122,42,16,4.8,3.0,1.2,1.2,8.8,13.8,239,123.43,758.76,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,30/9/2025,Outpatient,Cyclosporin,64.0,115.7,38.8,3.6,139,3.7,24,13,28,66,47,12,4.7,2.8,1.4,0.9,8.7,15.2,218,165.52,802.15,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,31/7/2025,Outpatient,Cyclosporin,118.9,65.2,40.2,10.1,140,3.7,21,34,33,92,57,18,3.8,2.3,1.1,0.9,6.1,11.9,313,237.3,1192.42,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,31/8/2025,Outpatient,Cyclosporin,88.4,109.2,40.0,6.7,134,3.5,28,21,24,141,43,20,4.4,2.7,1.2,1.2,7.5,13.1,269,219.74,919.28,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,31/7/2025,Outpatient,Cyclosporin,110.7,90.0,39.2,7.9,135,4.4,23,22,16,85,50,14,5.1,3.1,1.1,2.0,4.9,13.4,290,170.72,753.48,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,4/9/2025,Outpatient,Cyclosporin,84.4,67.7,43.4,5.9,137,4.6,23,28,17,98,83,12,5.6,3.9,1.1,1.4,6.5,12.2,306,160.68,811.29,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,7/8/2025,Outpatient,Cyclosporin,60.0,72.7,41.6,9.2,138,3.7,20,39,34,83,46,14,4.1,2.1,1.3,1.5,6.4,13.3,281,243.9,930.05,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1068,3072F,Yap Kai Kai,15/7/2025,9/10/2025,Outpatient,Cyclosporin,62.3,89.3,40.6,8.0,133,4.3,22,41,16,55,23,14,4.3,2.9,0.7,1.4,7.5,12.2,155,194.72,859.85,203.3,*3/*3,CT,53.5,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,190.0,100–200,0.75
RT1071,3159W,Ng Zhen Jia,27/7/2025,1/8/2025,Inpatient,Tacrolimus,119.5,53.1,36.3,10.0,137,4.8,23,27,33,92,50,13,4.7,2.6,1.2,1.9,7.4,14.5,270,10.39,,5.95,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,1/9/2025,Outpatient,Tacrolimus,99.4,89.1,39.7,4.8,141,3.8,27,22,15,80,26,9,4.9,3.1,1.1,1.5,6.6,14.9,260,11.58,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,1/10/2025,Outpatient,Tacrolimus,79.1,114.2,41.5,5.8,140,3.5,24,8,17,66,73,10,4.9,3.2,1.1,1.5,6.0,11.0,271,5.3,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,2/8/2025,Inpatient,Tacrolimus,120.3,70.3,36.6,8.1,139,3.8,23,31,33,107,117,16,5.6,3.6,1.2,1.8,7.9,14.3,211,7.51,,5.95,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,2/9/2025,Outpatient,Tacrolimus,103.3,93.9,39.3,4.9,139,4.1,26,34,21,100,56,15,5.5,3.6,1.1,1.8,5.4,14.1,186,6.56,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,2/10/2025,Outpatient,Tacrolimus,70.3,113.9,40.3,3.6,133,4.4,24,8,17,82,79,10,5.6,3.7,1.0,1.8,4.2,13.7,254,10.37,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,3/8/2025,Inpatient,Tacrolimus,113.1,73.8,35.2,6.4,142,4.0,24,29,26,120,108,19,5.5,3.8,1.2,1.3,5.7,14.5,254,8.28,,5.95,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,3/9/2025,Outpatient,Tacrolimus,103.8,105.4,39.7,6.5,135,4.5,23,37,22,89,42,13,4.8,3.0,1.2,1.3,7.3,14.6,217,9.93,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,3/10/2025,Outpatient,Tacrolimus,60.0,120.0,39.9,5.0,137,4.1,23,8,8,91,48,15,4.7,2.8,1.1,1.7,7.6,13.4,255,7.66,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,4/8/2025,Inpatient,Tacrolimus,117.2,58.6,36.7,11.2,141,4.8,24,25,24,95,72,12,5.6,4.2,0.8,1.4,7.9,13.2,145,8.45,,5.95,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,4/9/2025,Outpatient,Tacrolimus,87.0,80.8,41.1,7.5,134,4.0,24,11,24,89,72,18,5.0,2.9,1.4,1.5,7.1,13.3,267,8.25,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,4/10/2025,Outpatient,Tacrolimus,60.7,118.1,39.0,3.5,136,5.0,24,8,11,101,81,16,5.3,3.3,1.2,1.7,5.0,12.9,234,9.75,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,5/8/2025,Inpatient,Tacrolimus,122.9,80.9,37.6,9.1,139,4.0,19,34,33,79,23,21,5.3,3.3,1.4,1.4,6.4,12.3,177,9.03,,5.95,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,5/9/2025,Outpatient,Tacrolimus,84.9,107.6,38.4,4.5,135,4.1,28,18,11,101,54,12,4.9,2.9,1.1,1.8,6.2,14.2,328,8.18,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,5/10/2025,Outpatient,Tacrolimus,60.0,120.0,39.5,5.8,142,4.5,27,12,8,99,63,14,5.5,3.5,1.1,1.9,9.0,12.6,303,8.19,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,6/8/2025,Inpatient,Tacrolimus,108.0,99.3,36.2,8.4,138,3.8,23,25,29,95,103,14,5.3,3.2,1.4,1.6,7.3,14.1,194,9.06,,5.95,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,6/9/2025,Outpatient,Tacrolimus,73.7,109.2,39.8,7.0,137,4.1,27,16,30,75,60,15,5.0,3.6,0.8,1.2,7.5,11.7,301,10.54,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,6/10/2025,Outpatient,Tacrolimus,68.1,120.0,40.4,3.9,137,3.7,22,23,18,116,36,6,5.5,3.9,0.9,1.8,8.7,13.7,223,9.15,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,7/8/2025,Inpatient,Tacrolimus,108.7,83.2,37.2,10.3,139,4.1,26,36,17,116,71,20,5.4,3.1,1.3,2.0,6.2,12.4,234,7.95,,5.95,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,7/9/2025,Outpatient,Tacrolimus,81.3,90.1,38.8,9.0,134,4.1,24,20,23,59,86,14,4.8,3.0,1.1,1.4,7.1,13.6,230,6.63,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,7/10/2025,Outpatient,Tacrolimus,60.0,120.0,41.6,3.3,137,4.4,28,19,8,79,106,10,5.6,3.8,1.2,1.4,5.6,12.1,289,9.43,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,8/8/2025,Inpatient,Tacrolimus,99.4,80.2,37.0,8.3,140,4.5,24,33,24,84,63,11,4.7,3.2,1.1,0.9,7.6,12.3,209,9.47,,5.95,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,8/9/2025,Outpatient,Tacrolimus,90.5,109.6,41.0,7.0,139,3.7,23,18,8,88,64,13,5.4,3.6,1.3,1.2,8.5,14.2,232,9.85,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,8/10/2025,Outpatient,Tacrolimus,61.5,120.0,39.5,4.3,142,3.5,27,8,15,66,23,14,6.0,4.1,1.2,1.7,4.6,13.5,347,8.55,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,9/8/2025,Inpatient,Tacrolimus,118.6,58.2,35.2,7.5,139,3.8,28,30,32,84,32,19,5.1,3.0,1.3,1.5,8.8,12.3,206,10.53,,5.95,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,9/9/2025,Outpatient,Tacrolimus,75.8,101.4,40.2,6.6,139,4.0,20,16,25,67,39,16,4.7,3.2,1.1,1.1,7.8,12.7,223,8.45,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,9/10/2025,Outpatient,Tacrolimus,60.0,120.0,39.1,5.9,141,4.4,23,9,8,73,64,6,5.8,4.0,1.1,1.7,4.8,12.5,277,7.06,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,1/8/2025,Inpatient,Tacrolimus,111.5,85.1,38.4,8.6,136,5.9,24,50,23,112,120,12,5.3,2.6,1.6,2.4,4.6,14.5,317,11.78,,5.95,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,10/8/2025,Outpatient,Tacrolimus,125.0,84.0,39.5,8.1,141,4.0,24,34,23,98,72,18,6.0,4.3,1.0,1.8,6.4,13.6,221,11.04,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,10/9/2025,Outpatient,Tacrolimus,72.8,98.3,40.4,5.2,139,4.3,23,26,21,92,119,18,5.6,3.3,1.4,1.9,5.9,14.3,349,11.21,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,10/10/2025,Outpatient,Tacrolimus,61.8,120.0,39.5,3.5,142,3.7,27,22,8,81,66,11,4.7,2.7,1.2,1.7,9.2,13.4,368,6.18,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,10/8/2025,Outpatient,Tacrolimus,82.1,68.1,39.3,9.1,141,4.3,25,38,32,63,25,15,4.8,2.8,1.2,1.9,7.5,13.2,266,10.07,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,11/8/2025,Outpatient,Tacrolimus,99.7,55.8,40.1,4.9,137,3.7,26,34,28,93,57,10,5.7,3.7,1.4,1.5,5.6,13.5,170,9.58,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,11/9/2025,Outpatient,Tacrolimus,79.0,102.4,40.9,8.3,144,3.9,26,8,22,84,62,13,4.6,2.3,1.4,2.0,8.2,13.3,184,8.15,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,11/10/2025,Outpatient,Tacrolimus,75.2,120.0,40.6,5.4,137,4.2,26,10,8,58,52,13,5.4,3.4,1.3,1.5,8.0,12.9,278,5.27,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,12/8/2025,Outpatient,Tacrolimus,128.6,75.6,39.5,7.8,138,4.4,24,16,8,93,54,14,3.9,1.7,1.4,1.8,8.1,13.5,202,7.94,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,12/9/2025,Outpatient,Tacrolimus,78.7,99.8,39.1,4.7,139,4.1,26,20,15,136,49,16,5.1,3.3,1.2,1.4,4.3,13.9,258,6.99,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,12/10/2025,Outpatient,Tacrolimus,78.3,120.0,40.8,3.6,137,3.5,26,8,9,78,52,17,4.9,3.0,1.2,1.7,6.2,13.7,255,8.13,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,13/8/2025,Outpatient,Tacrolimus,108.7,63.1,39.6,8.9,139,4.4,24,28,12,81,39,16,5.3,3.4,1.2,1.6,8.0,12.4,255,9.13,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,13/9/2025,Outpatient,Tacrolimus,80.3,109.7,40.4,6.7,134,4.0,22,8,19,68,37,16,5.5,4.0,0.8,1.6,8.2,13.6,230,6.45,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,13/10/2025,Outpatient,Tacrolimus,60.0,120.0,43.4,4.9,136,3.6,24,8,8,81,53,13,5.5,3.4,1.0,2.3,4.8,13.0,260,9.06,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,14/8/2025,Outpatient,Tacrolimus,120.4,76.7,40.4,7.6,140,3.9,25,30,32,90,92,13,5.3,3.7,1.1,1.2,6.1,13.7,140,7.91,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,14/9/2025,Outpatient,Tacrolimus,80.8,120.0,39.5,6.5,148,4.4,24,22,8,83,48,10,4.8,2.2,1.5,2.4,7.0,14.1,144,9.7,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,14/10/2025,Outpatient,Tacrolimus,60.0,120.0,38.6,7.1,141,3.8,30,20,8,79,38,12,5.6,3.4,1.3,1.8,8.4,13.2,114,7.68,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,14/9/2025,Outpatient,Tacrolimus,70.8,81.2,42.3,9.3,140,4.5,26,33,21,93,52,14,5.4,3.6,1.0,1.6,5.6,12.4,254,9.13,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,15/8/2025,Outpatient,Tacrolimus,112.0,84.2,39.1,6.5,137,4.5,23,8,33,109,55,15,4.7,2.9,1.1,1.7,7.8,14.4,249,7.07,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,15/9/2025,Outpatient,Tacrolimus,77.2,119.7,39.6,6.2,138,4.2,26,18,8,78,40,20,5.3,3.4,1.2,1.7,7.6,12.9,232,5.47,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,15/10/2025,Outpatient,Tacrolimus,60.7,120.0,39.6,5.9,135,4.3,28,15,8,92,41,14,5.3,3.4,1.1,1.6,8.0,13.3,249,9.33,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,16/8/2025,Outpatient,Tacrolimus,122.3,87.4,41.0,7.5,137,4.1,25,23,14,82,44,17,5.0,3.4,1.0,1.3,5.8,15.2,141,10.98,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,16/9/2025,Outpatient,Tacrolimus,68.4,102.2,38.9,5.9,140,4.4,22,11,15,63,59,18,5.3,3.2,1.3,1.7,4.8,13.5,258,7.62,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,16/10/2025,Outpatient,Tacrolimus,60.0,119.1,40.8,4.6,139,4.3,27,9,8,81,33,17,5.7,3.6,1.4,1.4,6.4,14.2,257,7.2,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,17/8/2025,Outpatient,Tacrolimus,97.2,102.8,38.9,8.9,137,3.6,24,15,35,118,48,16,5.2,3.3,1.1,1.5,8.3,14.2,243,8.79,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,17/9/2025,Outpatient,Tacrolimus,70.3,114.3,40.3,7.0,134,4.0,27,8,8,100,86,12,4.8,2.9,1.3,1.1,8.0,13.5,305,7.62,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,17/10/2025,Outpatient,Tacrolimus,66.2,120.0,40.1,4.6,138,4.0,24,8,8,104,18,15,5.5,3.5,1.3,1.7,7.0,12.7,274,4.93,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,17/8/2025,Outpatient,Tacrolimus,83.4,85.6,37.2,7.6,140,4.4,25,35,40,117,55,13,4.6,2.6,1.3,1.4,7.1,13.1,283,9.12,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,18/8/2025,Outpatient,Tacrolimus,130.8,89.6,38.8,6.2,134,5.1,25,20,10,87,30,17,4.8,2.6,1.3,1.8,7.2,12.3,300,7.64,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,18/9/2025,Outpatient,Tacrolimus,104.1,102.5,41.1,4.4,143,4.7,24,9,10,85,61,10,5.0,3.0,1.2,1.9,8.6,11.6,369,6.47,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,18/10/2025,Outpatient,Tacrolimus,60.0,120.0,41.4,4.6,140,3.9,25,8,13,59,30,13,5.5,3.8,1.0,1.5,7.3,13.1,292,8.71,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,19/8/2025,Outpatient,Tacrolimus,117.7,81.1,39.8,8.6,136,4.1,25,22,18,63,53,18,4.8,3.0,1.2,1.5,6.6,14.4,250,7.04,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,19/9/2025,Outpatient,Tacrolimus,88.1,120.0,41.2,5.6,138,3.5,26,15,21,92,79,14,5.1,3.2,1.2,1.5,5.9,14.1,371,8.42,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,19/10/2025,Outpatient,Tacrolimus,60.0,120.0,38.3,3.1,136,4.2,27,8,10,94,60,8,5.4,3.4,1.4,1.4,7.4,13.9,332,8.0,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,2/8/2025,Inpatient,Tacrolimus,177.5,84.1,35.7,8.5,143,3.5,19,25,29,114,117,21,5.1,3.3,1.3,1.1,8.1,13.2,267,10.86,,5.95,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,20/8/2025,Outpatient,Tacrolimus,109.6,59.2,38.6,6.6,135,4.4,18,22,21,92,73,20,5.1,3.2,1.3,1.3,7.9,11.7,272,6.35,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,20/9/2025,Outpatient,Tacrolimus,60.0,107.7,37.3,4.1,137,3.3,25,18,10,90,103,10,5.3,2.9,1.4,2.2,5.7,13.9,253,7.42,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,20/10/2025,Outpatient,Tacrolimus,60.0,120.0,38.5,6.7,134,4.2,28,15,12,117,10,11,5.0,3.0,1.1,1.9,7.6,12.3,215,9.09,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,21/8/2025,Outpatient,Tacrolimus,105.9,78.8,39.3,7.5,138,4.8,21,23,15,64,115,15,4.7,3.0,1.1,1.2,7.4,13.8,240,10.88,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,21/9/2025,Outpatient,Tacrolimus,72.4,109.9,41.5,5.6,140,3.9,24,18,8,104,77,13,5.3,3.3,1.4,1.3,7.7,12.3,224,9.82,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,21/10/2025,Outpatient,Tacrolimus,60.0,120.0,38.6,3.4,138,4.3,25,15,8,66,61,21,5.1,2.9,1.2,1.9,9.4,13.0,246,5.71,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,21/9/2025,Outpatient,Tacrolimus,73.1,61.2,39.5,7.0,135,4.1,23,33,17,109,67,16,4.2,2.2,1.2,1.9,5.6,11.5,319,7.23,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,22/8/2025,Outpatient,Tacrolimus,94.9,77.2,40.7,7.1,140,4.3,24,28,21,128,68,13,5.8,4.1,1.1,1.3,7.0,13.8,235,8.55,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,22/9/2025,Outpatient,Tacrolimus,90.2,109.8,38.8,2.9,139,3.9,23,8,26,82,73,14,5.2,3.3,1.0,2.1,6.8,13.7,227,8.4,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,22/10/2025,Outpatient,Tacrolimus,60.0,120.0,39.5,6.2,138,4.3,24,8,8,82,45,16,5.2,2.9,1.1,2.5,7.2,13.8,280,6.97,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,23/8/2025,Outpatient,Tacrolimus,92.3,77.2,40.1,6.9,142,4.5,26,37,17,81,38,14,5.6,3.7,1.2,1.5,7.0,13.6,341,7.34,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,23/9/2025,Outpatient,Tacrolimus,69.4,93.1,39.6,4.8,137,4.2,24,15,8,85,92,14,4.8,3.0,1.0,1.6,6.3,14.4,283,7.33,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,23/10/2025,Outpatient,Tacrolimus,60.0,120.0,39.4,7.0,140,3.8,24,8,14,96,32,13,5.8,3.9,1.1,1.7,6.7,14.6,297,7.82,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,24/8/2025,Outpatient,Tacrolimus,95.0,90.5,40.5,6.5,137,3.7,26,22,9,99,67,18,5.2,3.1,1.3,1.8,9.4,14.8,259,8.23,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,24/9/2025,Outpatient,Tacrolimus,69.4,113.3,38.5,5.7,143,4.4,26,8,14,77,37,20,5.4,3.6,1.1,1.5,6.9,12.3,274,8.71,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,24/10/2025,Outpatient,Tacrolimus,60.0,120.0,38.1,3.7,140,3.9,25,17,8,79,50,12,5.7,3.5,1.3,2.1,7.1,12.7,266,7.23,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,24/8/2025,Outpatient,Tacrolimus,111.8,96.8,37.7,9.8,138,4.0,25,25,25,86,10,17,4.5,2.7,1.1,1.6,7.6,12.8,218,6.99,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,25/8/2025,Outpatient,Tacrolimus,108.8,87.1,42.4,7.8,138,4.7,24,23,9,86,98,14,5.0,3.1,1.2,1.4,5.9,13.4,243,8.38,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,25/9/2025,Outpatient,Tacrolimus,81.9,110.4,43.1,7.4,140,4.5,23,27,14,67,36,14,5.4,3.2,1.4,1.8,5.8,13.5,307,4.74,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,26/8/2025,Outpatient,Tacrolimus,110.2,79.8,39.8,5.5,138,3.8,23,19,13,90,56,11,5.2,3.4,1.1,1.6,7.1,14.0,250,10.7,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,26/9/2025,Outpatient,Tacrolimus,85.9,120.0,40.1,4.9,141,3.6,26,13,18,112,46,13,5.7,3.8,1.4,1.3,6.0,13.5,237,7.67,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,26/10/2025,Outpatient,Tacrolimus,88.1,89.5,37.0,9.5,137,4.0,24,27,29,66,62,12,5.2,3.0,1.1,2.3,7.5,14.0,151,7.09,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,27/7/2025,Inpatient,Tacrolimus,106.3,72.0,37.2,8.6,133,4.2,24,36,36,66,85,14,5.2,3.4,1.3,1.2,7.0,12.5,274,11.24,,5.95,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,27/8/2025,Outpatient,Tacrolimus,105.6,109.6,40.3,4.6,144,3.7,23,22,25,115,72,21,6.2,4.7,1.0,1.0,6.8,14.4,241,7.23,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,27/9/2025,Outpatient,Tacrolimus,69.1,118.0,40.6,6.1,142,4.7,25,12,17,78,82,12,5.1,3.1,1.2,1.9,6.9,14.0,247,8.6,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,28/7/2025,Inpatient,Tacrolimus,145.6,62.8,35.4,6.5,136,4.7,24,35,27,106,64,21,4.7,3.1,1.1,1.2,7.5,12.6,116,8.45,,5.95,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,28/8/2025,Outpatient,Tacrolimus,100.7,89.6,40.3,7.9,137,4.1,21,19,28,70,36,17,4.8,3.1,1.0,1.5,6.2,14.1,234,8.88,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,28/9/2025,Outpatient,Tacrolimus,69.7,120.0,41.1,5.7,140,3.9,23,33,12,76,96,13,4.9,3.1,1.4,1.0,4.7,13.2,257,9.7,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,28/7/2025,Inpatient,Tacrolimus,105.0,76.8,33.4,2.3,136,4.0,24,43,36,122,98,24,4.8,2.7,1.3,1.7,8.5,12.4,309,9.56,,5.95,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,28/9/2025,Outpatient,Tacrolimus,136.2,87.8,39.5,8.2,138,4.3,26,22,11,83,76,7,5.1,3.1,1.1,2.1,6.0,11.5,226,7.88,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,29/7/2025,Inpatient,Tacrolimus,121.4,71.9,36.7,8.8,139,3.7,25,18,21,75,66,13,5.8,4.1,1.0,1.5,7.5,14.3,173,10.96,,5.95,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,29/8/2025,Outpatient,Tacrolimus,86.9,95.9,40.7,5.6,141,3.9,24,18,16,71,34,21,5.8,3.8,1.2,1.9,9.6,12.2,272,9.29,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,29/9/2025,Outpatient,Tacrolimus,60.0,120.0,40.3,4.8,139,4.4,27,8,12,87,48,14,5.1,3.4,1.0,1.4,7.7,13.1,257,10.9,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,29/7/2025,Inpatient,Tacrolimus,132.4,79.3,37.4,9.7,137,4.3,25,22,41,72,51,15,3.3,1.7,1.0,1.3,5.4,13.9,272,9.31,,5.95,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,3/8/2025,Inpatient,Tacrolimus,137.7,71.9,38.9,7.2,142,4.7,21,18,19,132,58,12,3.5,1.5,1.2,1.8,5.4,14.6,233,9.94,,5.95,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,30/7/2025,Inpatient,Tacrolimus,129.0,71.4,37.7,7.1,138,4.7,26,33,11,112,63,18,4.5,3.0,0.9,1.3,6.0,11.9,350,8.92,,5.95,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,30/8/2025,Outpatient,Tacrolimus,115.9,87.2,39.2,4.7,137,3.8,24,20,15,81,58,21,5.6,3.5,1.2,2.1,6.3,14.0,216,10.3,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,30/9/2025,Outpatient,Tacrolimus,85.9,120.0,40.8,7.6,135,3.7,24,8,15,72,59,5,5.2,3.1,1.3,1.8,6.0,12.1,255,8.5,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,30/7/2025,Inpatient,Tacrolimus,155.0,32.9,32.1,7.7,139,4.3,27,51,39,124,81,17,4.6,2.9,1.3,0.8,7.7,12.7,178,9.66,,5.95,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,31/7/2025,Inpatient,Tacrolimus,110.6,54.1,37.1,7.2,138,4.2,21,28,38,76,80,16,4.4,2.6,1.1,1.4,6.8,13.2,207,11.13,,5.95,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,31/8/2025,Outpatient,Tacrolimus,87.1,90.6,39.7,6.2,142,4.3,28,34,13,70,83,10,5.4,3.5,1.3,1.5,3.3,12.4,244,9.4,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,31/7/2025,Inpatient,Tacrolimus,134.5,46.8,34.9,6.5,138,4.6,24,44,31,139,103,8,5.0,3.1,1.1,1.7,9.9,12.4,120,12.56,,5.95,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,31/8/2025,Outpatient,Tacrolimus,113.9,62.9,38.9,7.1,140,4.1,22,35,20,104,36,9,4.5,2.8,0.8,2.0,7.3,13.9,262,8.42,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,5/10/2025,Outpatient,Tacrolimus,73.6,67.4,39.2,9.5,140,3.7,26,12,26,98,71,7,5.6,3.9,1.1,1.3,9.4,13.0,254,12.65,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1071,3159W,Ng Zhen Jia,27/7/2025,7/9/2025,Outpatient,Tacrolimus,77.5,75.9,37.9,8.0,143,3.5,26,15,32,56,58,18,4.8,2.6,1.6,1.3,6.9,14.8,241,10.17,,5.14,*1/*3,CC,66.8,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,6.0,5–12,0.8
RT1072,6300Q,Chua Kai Hui,12/6/2025,1/7/2025,Outpatient,Cyclosporin,104.8,74.9,40.4,7.9,140,3.6,22,27,43,130,71,17,4.4,2.6,1.2,1.2,8.4,13.2,235,153.99,940.78,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,1/8/2025,Outpatient,Cyclosporin,78.9,108.3,39.0,4.2,137,4.1,28,21,12,103,52,10,4.5,2.5,1.2,1.7,5.8,12.8,321,221.75,816.52,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,1/9/2025,Outpatient,Cyclosporin,60.0,120.0,39.5,3.6,142,4.3,28,22,10,85,65,12,4.1,1.8,1.6,1.5,4.6,13.2,243,180.46,682.41,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,2/7/2025,Outpatient,Cyclosporin,105.9,74.7,38.5,6.8,138,4.3,22,36,24,87,39,11,4.1,2.3,1.2,1.4,8.1,14.1,240,160.39,1107.76,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,2/8/2025,Outpatient,Cyclosporin,82.1,104.2,39.5,8.2,138,4.3,23,10,8,76,27,22,4.7,2.7,1.3,1.6,10.0,13.1,295,224.07,1056.07,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,2/9/2025,Outpatient,Cyclosporin,75.3,120.0,38.5,5.7,137,4.5,24,8,15,68,49,13,4.1,2.6,1.1,1.1,6.4,15.0,162,123.8,870.79,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,3/7/2025,Outpatient,Cyclosporin,116.4,73.5,39.2,6.9,142,3.8,26,27,35,132,70,16,3.6,1.9,1.0,1.5,7.1,11.1,223,189.99,1070.63,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,3/8/2025,Outpatient,Cyclosporin,73.5,117.1,40.7,4.8,141,3.8,24,44,21,57,46,14,4.9,3.4,1.1,1.0,3.5,13.2,185,219.81,645.56,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,3/9/2025,Outpatient,Cyclosporin,60.0,120.0,41.1,2.0,134,4.1,27,8,16,82,63,17,4.6,2.9,1.0,1.4,6.9,13.5,230,174.53,835.7,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,4/7/2025,Outpatient,Cyclosporin,113.7,77.1,40.0,7.0,140,3.5,22,34,42,111,57,13,4.3,2.7,1.0,1.4,2.8,12.6,242,184.51,1086.63,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,4/8/2025,Outpatient,Cyclosporin,97.6,93.9,40.4,9.8,140,4.1,25,21,9,67,58,12,4.8,2.9,1.2,1.5,7.4,12.6,254,164.24,1080.46,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,4/9/2025,Outpatient,Cyclosporin,60.0,120.0,40.2,2.7,137,4.0,26,16,8,133,52,15,4.4,2.8,1.1,1.0,7.7,13.1,305,128.19,945.32,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,5/7/2025,Outpatient,Cyclosporin,114.9,85.5,41.0,7.3,138,3.8,26,10,28,96,32,16,4.1,2.1,1.4,1.3,4.6,13.8,272,204.2,970.39,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,5/8/2025,Outpatient,Cyclosporin,80.9,120.0,39.8,6.1,138,3.9,24,10,8,83,37,17,3.9,1.9,1.5,1.3,7.9,13.1,252,174.58,1039.11,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,5/9/2025,Outpatient,Cyclosporin,60.0,120.0,40.5,3.3,143,3.8,23,12,12,100,80,10,4.5,2.4,1.4,1.4,7.4,14.4,242,185.35,963.4,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,6/7/2025,Outpatient,Cyclosporin,106.8,94.4,41.4,5.7,140,3.8,27,13,15,79,121,14,3.9,2.5,0.9,1.1,7.5,12.3,309,214.71,827.95,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,6/8/2025,Outpatient,Cyclosporin,64.2,109.3,39.8,7.8,140,4.3,27,18,11,88,63,13,4.3,2.6,1.3,0.9,3.4,14.3,247,129.08,774.3,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,6/9/2025,Outpatient,Cyclosporin,60.0,120.0,40.0,2.9,138,4.3,26,8,9,65,28,9,4.7,3.2,1.0,1.1,4.0,13.1,279,147.4,747.2,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,7/7/2025,Outpatient,Cyclosporin,104.5,90.3,38.9,5.8,136,4.2,27,25,32,112,89,14,4.0,2.5,0.9,1.3,5.4,12.9,190,185.76,1228.33,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,7/8/2025,Outpatient,Cyclosporin,86.9,108.3,39.5,5.6,139,3.9,24,9,16,102,90,13,4.4,2.5,1.3,1.3,9.6,13.4,229,249.53,823.47,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,7/9/2025,Outpatient,Cyclosporin,60.0,120.0,38.8,3.0,142,4.4,25,8,17,118,41,5,4.4,2.6,1.2,1.3,7.1,12.4,253,128.92,805.18,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,8/7/2025,Outpatient,Cyclosporin,123.0,76.7,40.3,6.7,138,3.8,24,18,20,93,80,19,4.5,2.7,1.1,1.5,4.3,13.2,279,162.11,938.27,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,8/8/2025,Outpatient,Cyclosporin,82.2,120.0,39.6,6.6,132,3.9,23,19,11,106,59,11,4.4,2.3,1.3,1.8,2.0,13.1,301,186.44,908.97,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,8/9/2025,Outpatient,Cyclosporin,60.0,120.0,39.3,5.6,140,3.8,27,13,13,69,60,13,5.1,3.1,1.3,1.6,5.5,14.4,258,159.79,409.42,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,9/7/2025,Outpatient,Cyclosporin,110.4,85.9,40.3,8.7,136,4.3,25,21,22,108,45,15,4.3,2.4,1.4,1.3,3.3,12.5,192,166.27,905.55,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,9/8/2025,Outpatient,Cyclosporin,71.7,111.8,40.7,4.2,138,4.1,24,20,8,104,37,11,3.6,1.7,1.1,1.9,5.5,13.4,282,179.25,1033.46,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,9/9/2025,Outpatient,Cyclosporin,60.0,120.0,40.6,4.6,138,3.6,24,8,8,76,57,11,4.7,2.6,1.5,1.2,6.7,13.7,263,163.97,580.98,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,1/7/2025,Outpatient,Cyclosporin,124.4,63.0,41.7,6.1,141,4.6,23,24,26,64,66,19,4.9,3.6,1.0,0.9,8.8,13.5,219,167.08,1001.88,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,10/7/2025,Outpatient,Cyclosporin,106.1,72.2,37.2,5.8,134,4.2,26,21,27,104,83,15,4.7,3.3,0.9,1.2,4.5,13.7,235,226.96,703.43,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,10/8/2025,Outpatient,Cyclosporin,82.7,106.0,39.7,5.6,138,3.1,26,12,8,86,34,12,4.8,3.3,1.2,0.7,6.0,12.3,272,171.89,668.48,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,11/7/2025,Outpatient,Cyclosporin,110.5,91.5,40.4,7.3,138,4.4,25,8,29,88,90,2,4.8,2.6,1.5,1.3,7.0,14.2,309,200.03,960.46,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,11/8/2025,Outpatient,Cyclosporin,64.5,108.1,39.9,6.8,140,3.9,22,8,11,74,14,11,4.5,2.9,1.1,1.0,4.6,14.2,383,160.63,917.76,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,12/6/2025,Inpatient,Cyclosporin,126.1,52.3,38.1,10.8,140,3.9,26,44,39,59,95,18,4.1,2.4,1.1,1.2,9.8,12.4,209,226.73,1200.26,258.28,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,12/7/2025,Outpatient,Cyclosporin,98.6,71.6,39.5,5.6,135,4.3,26,27,11,91,42,18,3.9,2.0,1.2,1.6,6.7,13.0,247,152.86,1022.02,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,12/8/2025,Outpatient,Cyclosporin,82.0,108.8,40.2,4.9,140,4.0,24,8,15,92,62,16,5.1,3.0,1.3,1.7,8.2,15.9,264,188.9,832.43,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,12/8/2025,Outpatient,Cyclosporin,87.0,74.1,40.7,6.2,141,4.6,24,48,25,123,33,10,3.3,1.6,1.2,1.1,4.3,11.9,118,131.3,812.81,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,13/6/2025,Inpatient,Cyclosporin,100.5,73.7,35.3,11.8,134,3.7,25,41,39,104,74,15,4.3,2.4,1.2,1.4,6.1,13.3,117,194.56,1037.97,258.28,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,13/7/2025,Outpatient,Cyclosporin,94.5,100.6,39.1,9.1,138,3.7,24,26,15,108,66,19,4.4,2.9,0.9,1.4,2.9,13.1,247,170.4,889.32,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,13/8/2025,Outpatient,Cyclosporin,70.9,114.1,37.5,7.4,138,4.1,22,17,23,72,53,14,4.5,2.5,1.2,1.6,6.5,15.0,313,201.2,710.85,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,13/6/2025,Inpatient,Cyclosporin,126.2,83.8,34.4,8.2,139,4.4,23,60,8,65,72,18,5.1,3.5,1.1,1.2,7.2,12.8,217,199.95,1000.88,258.28,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,14/6/2025,Inpatient,Cyclosporin,122.6,72.5,36.8,9.6,140,3.6,22,39,35,109,50,13,4.8,3.1,1.3,0.9,8.7,11.5,173,182.92,1120.43,258.28,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,14/7/2025,Outpatient,Cyclosporin,67.7,86.9,39.6,4.7,140,4.2,23,29,26,74,41,11,4.5,2.5,1.2,1.7,7.8,14.2,218,194.01,841.83,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,14/8/2025,Outpatient,Cyclosporin,81.4,119.2,40.2,6.1,136,4.2,23,8,21,98,61,16,4.8,2.8,1.2,1.7,6.2,12.7,298,205.59,722.07,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,14/6/2025,Inpatient,Cyclosporin,138.4,65.4,36.1,13.5,134,4.4,17,25,35,65,71,16,4.3,2.3,1.4,1.4,7.7,14.5,399,153.12,1109.7,258.28,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,15/6/2025,Inpatient,Cyclosporin,137.1,63.2,37.0,7.9,138,4.0,23,23,30,88,67,14,4.8,2.7,1.4,1.3,7.8,14.0,262,181.95,1082.9,258.28,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,15/7/2025,Outpatient,Cyclosporin,117.0,87.7,40.7,5.6,137,3.6,24,29,27,70,65,12,3.5,1.5,1.2,1.9,6.4,13.2,225,218.57,1018.37,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,15/8/2025,Outpatient,Cyclosporin,76.5,120.0,40.4,2.8,136,4.0,27,21,29,93,74,13,4.8,3.2,1.0,1.2,7.5,14.7,256,216.87,817.94,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,15/6/2025,Inpatient,Cyclosporin,123.6,63.5,33.9,8.3,138,3.9,27,16,29,84,79,28,6.0,4.2,1.2,1.4,9.4,12.1,233,244.47,1207.57,258.28,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,15/7/2025,Outpatient,Cyclosporin,122.8,81.9,38.6,3.1,137,4.2,24,22,26,47,77,21,4.6,2.9,1.1,1.4,7.7,14.1,204,133.25,852.87,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,16/6/2025,Inpatient,Cyclosporin,115.6,65.5,33.5,8.8,138,4.5,25,38,32,97,61,10,4.5,2.5,1.3,1.6,6.7,11.7,243,181.55,1044.99,258.28,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,16/7/2025,Outpatient,Cyclosporin,95.2,89.2,40.5,5.6,138,3.5,25,34,19,103,88,14,4.2,2.4,1.1,1.7,6.4,15.4,205,172.62,1197.8,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,16/8/2025,Outpatient,Cyclosporin,60.0,120.0,40.0,7.0,138,4.1,28,11,8,113,45,17,4.0,2.2,1.2,1.3,7.0,14.8,231,191.53,785.48,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,16/6/2025,Inpatient,Cyclosporin,115.3,86.9,31.7,10.3,140,4.7,23,31,44,127,11,24,3.8,1.9,1.2,1.5,9.6,13.6,170,196.24,1262.11,258.28,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,17/6/2025,Inpatient,Cyclosporin,130.9,82.2,36.0,11.9,139,4.4,25,32,18,81,82,18,4.3,2.5,1.4,0.9,6.6,13.2,180,180.96,1029.29,258.28,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,17/7/2025,Outpatient,Cyclosporin,88.9,110.8,39.3,5.1,137,3.8,24,33,21,75,88,9,4.2,2.2,1.3,1.6,3.0,12.3,292,197.64,877.38,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,17/8/2025,Outpatient,Cyclosporin,60.0,112.3,41.6,6.0,141,4.4,26,14,14,91,42,14,5.1,3.4,1.3,0.8,6.2,13.8,282,136.89,1109.55,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,17/6/2025,Inpatient,Cyclosporin,84.6,76.5,30.4,8.9,133,3.9,26,23,15,88,51,21,5.0,3.5,0.8,1.6,5.3,15.9,297,223.52,1461.88,258.28,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,18/6/2025,Inpatient,Cyclosporin,112.7,61.8,36.9,8.5,141,4.0,24,25,33,85,80,20,4.0,1.9,1.5,1.4,7.4,13.9,195,179.64,1306.9,258.28,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,18/7/2025,Outpatient,Cyclosporin,81.2,92.2,38.5,8.4,137,4.2,25,19,18,75,47,10,4.7,2.9,1.3,1.2,5.8,13.5,263,174.83,890.97,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,18/8/2025,Outpatient,Cyclosporin,61.6,120.0,40.1,6.2,139,4.3,25,13,12,104,87,15,4.7,2.9,1.2,1.2,6.7,12.8,304,165.59,772.99,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,18/6/2025,Inpatient,Cyclosporin,146.1,75.3,37.8,7.0,135,4.3,26,44,35,108,72,15,5.2,3.5,1.2,1.2,9.8,13.9,165,159.28,1140.04,258.28,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,19/6/2025,Inpatient,Cyclosporin,125.2,65.6,36.4,6.7,139,4.0,23,32,34,120,64,22,4.5,2.9,1.2,1.0,7.3,14.4,265,219.93,1442.55,258.28,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,19/7/2025,Outpatient,Cyclosporin,102.9,85.4,41.5,6.8,137,3.5,25,19,14,61,77,11,4.4,2.4,1.4,1.3,5.6,12.8,300,154.5,910.21,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,19/8/2025,Outpatient,Cyclosporin,60.0,116.3,40.4,2.7,138,4.2,27,9,16,40,69,12,4.4,2.5,1.2,1.3,6.4,13.3,308,179.98,706.06,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,19/6/2025,Inpatient,Cyclosporin,70.0,47.8,35.3,6.5,139,4.8,26,52,13,47,29,19,4.0,1.8,1.4,1.6,6.1,13.8,287,177.66,983.04,258.28,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,19/8/2025,Outpatient,Cyclosporin,60.0,110.2,38.3,6.1,138,4.5,23,19,35,90,51,16,4.6,3.0,1.0,1.2,5.6,16.3,305,174.67,494.98,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,2/9/2025,Outpatient,Cyclosporin,96.2,84.3,39.4,6.1,137,4.0,26,24,24,83,34,16,4.7,3.2,1.2,0.7,6.0,13.3,349,168.3,742.53,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,20/6/2025,Inpatient,Cyclosporin,125.6,65.2,37.1,6.9,139,3.6,22,31,32,67,50,14,3.9,2.1,1.0,1.8,5.5,13.3,181,183.66,1074.41,258.28,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,20/7/2025,Outpatient,Cyclosporin,84.3,95.4,38.7,6.3,139,3.7,23,10,37,66,36,19,3.8,2.0,1.2,1.4,7.2,13.6,161,155.15,869.18,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,20/8/2025,Outpatient,Cyclosporin,63.0,120.0,41.6,2.5,134,4.1,23,9,16,86,48,11,4.0,2.0,1.5,1.1,6.3,11.8,219,150.72,986.56,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,20/6/2025,Inpatient,Cyclosporin,127.6,53.8,34.8,7.6,133,4.4,23,25,9,69,136,17,3.9,1.8,1.5,1.4,7.3,13.8,222,206.48,810.75,258.28,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,21/6/2025,Inpatient,Cyclosporin,123.4,70.8,37.7,9.5,137,3.8,22,37,33,96,95,16,3.9,2.3,1.2,0.9,6.9,13.6,246,249.21,1096.96,258.28,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,21/7/2025,Outpatient,Cyclosporin,79.0,72.9,39.5,6.2,140,3.5,24,17,20,104,56,16,4.2,2.8,0.9,1.1,5.9,13.7,159,183.73,739.01,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,21/8/2025,Outpatient,Cyclosporin,90.7,120.0,38.9,5.8,139,4.3,23,13,8,75,82,10,3.7,1.9,1.2,1.4,4.4,13.4,212,188.13,1040.11,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,21/6/2025,Inpatient,Cyclosporin,98.2,69.8,35.6,6.6,134,4.4,22,17,29,101,115,13,4.7,3.4,0.8,1.0,6.4,14.3,337,188.63,939.52,258.28,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,22/6/2025,Inpatient,Cyclosporin,130.0,67.4,37.4,6.9,140,3.9,23,23,20,77,75,19,4.9,3.1,1.2,1.1,6.9,13.4,171,298.72,1192.83,258.28,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,22/7/2025,Outpatient,Cyclosporin,89.1,101.2,40.0,7.9,140,3.9,24,13,26,91,44,14,4.6,2.5,1.5,1.4,4.9,12.9,337,151.3,819.78,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,22/8/2025,Outpatient,Cyclosporin,73.3,120.0,41.5,5.0,140,4.9,27,13,13,59,27,11,4.5,3.0,1.0,1.1,7.7,12.7,261,160.37,771.99,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,22/6/2025,Inpatient,Cyclosporin,121.9,75.6,35.3,7.2,134,4.3,27,35,21,93,44,17,4.8,3.4,1.0,0.8,7.4,13.1,312,161.41,1071.18,258.28,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,22/7/2025,Outpatient,Cyclosporin,104.1,62.5,39.5,10.4,135,4.0,27,23,18,101,36,15,5.1,3.6,1.1,0.8,6.3,13.2,317,93.48,847.83,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,23/6/2025,Inpatient,Cyclosporin,101.2,81.7,37.9,6.3,134,5.0,25,33,29,80,64,18,3.8,1.7,1.4,1.6,3.2,13.3,268,191.13,907.25,258.28,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,23/7/2025,Outpatient,Cyclosporin,83.0,114.2,39.3,6.2,139,4.1,23,19,25,91,74,16,4.3,2.7,1.2,1.0,6.0,13.2,239,205.0,784.59,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,23/8/2025,Outpatient,Cyclosporin,60.0,119.8,39.8,5.4,137,4.1,23,9,16,81,57,19,3.9,2.1,1.3,1.1,6.9,13.1,217,148.43,1229.12,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,23/6/2025,Inpatient,Cyclosporin,85.1,51.0,32.7,3.4,138,4.6,23,24,32,96,18,18,4.3,2.4,1.4,1.0,6.1,14.3,279,218.96,1336.28,258.28,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,24/6/2025,Inpatient,Cyclosporin,105.8,80.1,35.5,7.9,138,4.9,26,26,24,111,106,23,4.7,3.3,0.9,0.9,9.8,13.7,211,213.04,1247.53,258.28,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,24/7/2025,Outpatient,Cyclosporin,87.9,97.9,40.0,8.1,139,4.2,24,31,8,96,92,12,4.5,2.6,1.2,1.5,5.9,13.0,238,209.55,1153.3,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,24/8/2025,Outpatient,Cyclosporin,70.0,120.0,39.8,6.3,138,3.3,25,8,8,83,79,15,4.9,3.4,0.9,1.2,6.3,13.2,250,248.18,874.87,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,24/6/2025,Inpatient,Cyclosporin,76.7,108.1,35.3,9.7,137,3.0,21,29,39,97,97,15,4.2,3.0,1.0,0.5,10.5,13.0,229,111.05,853.33,258.28,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,25/6/2025,Inpatient,Cyclosporin,120.0,76.9,35.0,7.5,137,4.2,22,33,32,98,106,14,4.3,2.5,1.2,1.3,6.5,12.5,261,155.11,1163.92,258.28,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,25/7/2025,Outpatient,Cyclosporin,77.0,95.2,40.1,7.9,133,3.9,26,9,19,92,68,10,4.1,2.8,0.9,0.9,7.7,13.3,231,194.41,877.11,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,25/8/2025,Outpatient,Cyclosporin,60.0,115.3,38.6,6.7,140,4.0,26,16,8,111,34,11,4.4,2.3,1.2,1.8,6.9,12.3,235,137.89,920.25,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,26/6/2025,Outpatient,Cyclosporin,130.3,82.5,39.2,9.2,143,3.8,24,33,31,83,46,19,4.7,3.4,0.8,1.1,4.4,13.7,260,206.11,1135.27,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,26/7/2025,Outpatient,Cyclosporin,93.0,86.3,39.1,5.6,139,4.0,23,29,12,92,89,12,4.3,2.7,1.0,1.3,7.1,12.9,233,157.1,774.53,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,26/8/2025,Outpatient,Cyclosporin,72.5,120.0,39.3,6.8,136,4.2,23,11,8,79,59,15,5.1,3.0,1.0,2.3,4.9,13.8,112,142.55,894.72,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,26/8/2025,Outpatient,Cyclosporin,116.2,85.1,40.6,6.2,136,4.8,22,25,26,119,58,17,4.9,3.4,0.9,1.4,7.9,15.4,211,172.77,597.59,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,27/6/2025,Outpatient,Cyclosporin,109.7,56.6,38.9,6.5,136,4.3,23,27,29,108,82,10,4.3,2.4,1.3,1.4,6.8,13.2,242,203.63,1009.26,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,27/7/2025,Outpatient,Cyclosporin,93.1,92.2,41.1,6.8,140,4.0,23,29,26,89,27,19,4.4,2.4,1.3,1.6,7.8,15.2,228,270.85,792.79,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,27/8/2025,Outpatient,Cyclosporin,60.0,120.0,38.2,4.0,136,4.5,25,17,9,101,70,7,4.1,2.3,1.2,1.2,7.9,13.8,260,132.36,876.91,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,28/6/2025,Outpatient,Cyclosporin,119.0,72.9,40.5,4.6,141,4.4,23,32,25,111,62,9,4.4,2.9,1.0,1.3,2.7,13.3,283,194.04,702.24,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,28/7/2025,Outpatient,Cyclosporin,99.0,114.2,39.9,7.5,138,4.5,20,26,14,81,59,10,4.6,2.8,1.1,1.8,5.1,15.0,235,175.13,1184.21,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,28/8/2025,Outpatient,Cyclosporin,61.5,120.0,40.5,2.6,138,4.8,23,22,8,81,69,13,3.6,1.8,1.2,1.1,7.4,13.3,221,212.67,801.56,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,29/6/2025,Outpatient,Cyclosporin,116.4,79.2,38.6,6.7,140,4.0,24,37,35,81,49,14,3.9,2.2,1.3,1.0,8.8,16.0,270,167.65,1276.71,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,29/7/2025,Outpatient,Cyclosporin,94.0,107.8,40.8,4.7,141,3.7,27,22,18,90,47,11,4.0,2.5,0.9,1.3,6.4,12.6,232,186.48,910.91,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,29/8/2025,Outpatient,Cyclosporin,60.0,116.9,40.3,4.7,141,4.0,24,16,17,71,60,10,4.5,2.9,0.9,1.7,8.2,14.2,207,189.35,1199.68,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,29/7/2025,Outpatient,Cyclosporin,105.6,52.3,37.7,8.2,139,4.3,27,26,21,89,60,11,5.9,4.1,1.1,1.5,8.0,15.5,218,191.08,877.16,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,30/6/2025,Outpatient,Cyclosporin,130.0,76.4,40.2,9.8,138,4.9,23,16,8,61,93,24,4.5,2.8,1.1,1.3,7.8,12.2,272,209.73,1082.98,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,30/7/2025,Outpatient,Cyclosporin,81.4,104.0,39.4,3.8,140,4.1,23,10,16,99,74,21,4.6,2.9,1.1,1.3,6.3,13.5,383,143.24,940.18,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,30/8/2025,Outpatient,Cyclosporin,60.0,120.0,41.6,3.0,138,3.9,26,18,12,60,32,12,3.7,2.1,1.1,1.0,7.4,13.1,243,102.11,797.39,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,31/7/2025,Outpatient,Cyclosporin,84.4,108.2,39.5,7.8,137,4.4,26,20,15,88,70,20,4.5,2.7,1.3,1.3,3.5,12.8,275,183.58,864.46,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,31/8/2025,Outpatient,Cyclosporin,64.0,120.0,40.3,2.6,138,3.9,24,9,15,117,34,13,4.1,2.2,1.2,1.6,5.8,12.6,203,132.91,810.96,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,5/8/2025,Outpatient,Cyclosporin,110.9,82.1,38.3,6.1,139,4.5,24,35,39,104,85,11,5.6,4.1,1.1,0.8,6.0,12.8,154,148.73,764.21,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,8/7/2025,Outpatient,Cyclosporin,118.4,55.7,41.5,6.0,138,4.5,24,12,25,117,59,11,5.6,3.9,1.2,1.1,4.6,14.8,269,100.86,988.89,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1072,6300Q,Chua Kai Hui,12/6/2025,9/9/2025,Outpatient,Cyclosporin,107.4,73.7,39.5,5.2,135,4.0,23,8,26,84,70,13,3.5,1.1,1.3,2.3,4.8,14.6,207,122.61,836.46,223.06,*3/*3,CC,58.7,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,210.0,100–200,0.75
RT1078,7600H,Lee Hui Chen,15/6/2025,1/7/2025,Outpatient,Tacrolimus,118.0,72.6,40.0,6.4,134,4.1,24,33,42,100,79,8,5.1,3.3,1.2,1.4,5.4,12.5,210,8.79,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,1/8/2025,Outpatient,Tacrolimus,89.6,104.4,40.7,7.2,137,4.2,22,23,16,99,75,15,5.1,3.4,1.1,1.6,8.4,13.3,235,7.36,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,1/9/2025,Outpatient,Tacrolimus,68.4,120.0,39.1,5.0,139,3.6,25,19,21,58,34,12,5.3,3.0,1.5,1.8,3.7,12.3,298,6.16,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,2/7/2025,Outpatient,Tacrolimus,116.3,77.0,37.6,7.9,138,3.6,22,28,29,87,75,18,5.2,2.9,1.5,1.7,6.3,12.2,179,8.35,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,2/8/2025,Outpatient,Tacrolimus,98.6,103.8,40.5,6.4,136,4.2,24,21,18,97,61,10,4.5,2.4,1.3,1.7,5.9,14.1,198,8.86,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,2/9/2025,Outpatient,Tacrolimus,68.8,119.0,41.3,5.7,143,4.1,26,13,8,91,39,17,5.5,3.8,1.0,1.4,6.5,13.6,157,9.16,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,3/7/2025,Outpatient,Tacrolimus,117.5,60.0,41.7,7.6,136,4.0,26,36,8,96,75,17,4.9,3.5,0.9,1.1,4.4,12.2,250,7.28,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,3/8/2025,Outpatient,Tacrolimus,88.7,101.8,41.7,6.5,140,4.4,27,21,12,105,71,12,4.5,2.9,0.9,1.5,6.1,13.8,256,11.09,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,3/9/2025,Outpatient,Tacrolimus,64.5,120.0,40.3,5.3,139,4.2,26,15,16,86,51,10,6.6,4.7,1.1,1.7,7.5,13.1,287,9.65,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,4/7/2025,Outpatient,Tacrolimus,102.2,76.5,39.8,8.6,137,4.3,23,30,39,92,51,14,4.5,2.7,1.0,1.8,6.4,14.3,318,11.79,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,4/8/2025,Outpatient,Tacrolimus,87.2,111.7,41.9,6.4,137,4.2,24,8,25,113,64,16,4.7,2.7,1.1,1.9,4.8,13.9,406,12.0,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,4/9/2025,Outpatient,Tacrolimus,60.0,120.0,38.0,3.5,140,4.1,26,13,8,106,54,10,5.2,3.3,1.0,2.0,4.5,13.4,261,10.88,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,5/7/2025,Outpatient,Tacrolimus,121.7,77.0,36.3,8.3,131,4.4,25,19,18,139,84,8,5.1,2.7,1.5,2.0,5.7,13.5,252,5.04,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,5/8/2025,Outpatient,Tacrolimus,78.6,104.3,40.3,4.8,141,4.1,23,19,8,99,86,18,5.5,3.7,1.1,1.6,8.7,15.3,197,8.9,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,5/9/2025,Outpatient,Tacrolimus,63.2,120.0,38.9,4.9,134,3.7,23,8,8,80,26,8,5.4,3.5,1.0,2.0,9.0,12.1,213,8.76,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,6/7/2025,Outpatient,Tacrolimus,113.4,64.8,39.8,7.3,140,3.9,25,16,26,91,55,17,5.0,3.1,1.1,2.0,6.1,12.7,301,6.78,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,6/8/2025,Outpatient,Tacrolimus,78.4,103.2,39.1,4.0,137,4.8,26,30,19,67,63,8,6.2,4.2,1.1,1.9,7.3,12.1,219,10.05,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,6/9/2025,Outpatient,Tacrolimus,79.2,120.0,41.6,2.0,139,4.1,24,8,21,75,66,17,5.2,3.0,1.3,1.9,4.8,13.1,296,8.14,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,7/7/2025,Outpatient,Tacrolimus,117.5,91.0,39.3,8.8,138,3.6,26,19,19,89,74,14,4.9,2.9,1.0,2.3,4.1,14.7,227,7.42,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,7/8/2025,Outpatient,Tacrolimus,90.1,112.0,39.6,7.5,140,3.8,25,16,17,66,68,17,5.1,3.3,1.1,1.6,4.2,13.8,260,8.82,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,7/9/2025,Outpatient,Tacrolimus,60.0,120.0,41.1,3.5,137,4.2,26,9,8,112,37,5,5.4,3.6,1.3,1.2,8.1,13.0,295,7.2,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,8/7/2025,Outpatient,Tacrolimus,94.1,75.8,39.3,7.3,142,4.0,23,35,16,71,83,13,4.8,3.2,1.1,1.2,5.2,13.2,225,8.69,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,8/8/2025,Outpatient,Tacrolimus,85.2,113.4,40.2,5.0,135,4.6,28,8,16,72,97,11,5.1,3.4,1.0,1.4,5.7,13.3,288,8.96,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,8/9/2025,Outpatient,Tacrolimus,60.0,120.0,40.3,6.5,140,4.0,26,8,8,55,33,10,5.0,3.1,1.4,1.2,8.6,12.2,250,9.01,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,9/7/2025,Outpatient,Tacrolimus,109.9,91.7,40.2,8.6,141,4.7,24,28,14,87,49,11,4.9,3.5,1.2,0.5,9.4,13.7,209,7.0,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,9/8/2025,Outpatient,Tacrolimus,91.4,120.0,40.1,9.9,139,3.5,25,8,12,75,51,20,5.5,3.5,1.2,1.6,5.9,13.7,224,3.98,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,9/9/2025,Outpatient,Tacrolimus,63.8,115.8,40.5,3.3,135,4.8,26,9,11,79,55,15,5.2,3.5,0.9,1.7,3.8,13.9,155,9.02,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,10/7/2025,Outpatient,Tacrolimus,114.0,85.3,40.2,7.9,137,3.3,21,18,40,95,43,18,4.7,3.1,1.1,1.2,6.9,14.3,281,8.84,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,10/8/2025,Outpatient,Tacrolimus,88.4,120.0,39.6,5.3,143,4.0,27,27,17,93,61,9,5.3,3.6,1.0,1.4,5.5,14.6,283,7.6,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,10/9/2025,Outpatient,Tacrolimus,60.0,120.0,40.7,4.9,132,3.9,25,8,8,79,52,7,5.8,3.9,1.2,1.5,6.6,12.6,237,9.97,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,10/7/2025,Outpatient,Tacrolimus,68.5,70.4,37.1,7.6,143,4.5,26,26,24,82,56,11,4.8,2.6,1.5,1.8,7.0,13.0,241,10.32,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,11/7/2025,Outpatient,Tacrolimus,113.3,87.5,40.2,10.7,136,3.7,27,23,27,105,69,12,5.2,3.2,1.2,1.8,6.8,13.9,289,9.87,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,11/8/2025,Outpatient,Tacrolimus,89.8,106.3,38.6,7.4,141,3.7,26,27,13,82,36,13,5.6,3.6,1.4,1.3,8.2,12.4,356,7.51,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,11/9/2025,Outpatient,Tacrolimus,60.0,120.0,40.2,6.3,144,3.9,27,13,8,71,65,10,4.8,2.6,1.4,1.6,5.8,14.2,189,4.87,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,11/9/2025,Outpatient,Tacrolimus,101.8,66.1,38.5,7.4,139,4.6,22,27,26,95,55,10,4.5,2.3,1.4,1.6,5.4,14.1,309,3.98,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,12/7/2025,Outpatient,Tacrolimus,114.1,73.4,39.6,8.1,138,4.2,24,25,21,79,28,17,5.5,3.7,1.1,1.5,5.2,13.4,259,11.77,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,12/8/2025,Outpatient,Tacrolimus,84.5,101.3,38.4,7.2,139,3.9,23,8,8,75,21,14,5.8,3.8,1.1,2.0,5.5,13.2,254,8.03,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,12/9/2025,Outpatient,Tacrolimus,60.0,120.0,39.7,3.6,140,4.0,23,16,8,81,52,20,5.2,3.3,1.3,1.4,6.8,12.3,213,10.72,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,13/7/2025,Outpatient,Tacrolimus,104.4,86.5,37.9,8.5,138,4.0,25,34,23,110,63,11,5.1,3.3,1.1,1.4,6.1,11.5,281,8.93,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,13/8/2025,Outpatient,Tacrolimus,68.0,105.8,40.2,4.2,141,3.9,26,8,18,58,81,14,4.3,2.6,1.1,1.3,7.3,13.1,302,10.27,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,14/7/2025,Outpatient,Tacrolimus,89.8,104.4,40.0,6.9,139,3.3,23,26,16,92,73,3,4.6,2.5,1.3,1.8,5.7,14.1,247,8.58,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,14/8/2025,Outpatient,Tacrolimus,84.6,112.4,40.1,3.9,138,4.5,24,8,15,82,104,16,4.8,3.0,1.2,1.4,5.8,13.3,115,9.96,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,14/8/2025,Outpatient,Tacrolimus,121.1,85.4,40.8,7.0,147,3.9,24,14,40,121,70,8,4.5,2.4,1.3,1.8,6.8,15.1,195,4.96,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,15/6/2025,Inpatient,Tacrolimus,124.4,56.0,35.0,6.7,137,3.9,29,32,22,91,76,18,5.5,3.5,1.2,1.7,7.0,13.7,214,6.77,,4.0,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,15/7/2025,Outpatient,Tacrolimus,106.3,71.9,39.0,8.1,137,4.1,22,22,18,70,55,17,5.1,3.5,1.0,1.3,7.7,10.9,182,10.32,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,15/8/2025,Outpatient,Tacrolimus,83.0,105.6,40.8,4.7,135,3.8,25,20,8,80,62,10,4.9,2.7,1.3,1.8,5.4,13.4,257,6.64,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,16/6/2025,Inpatient,Tacrolimus,137.2,63.0,37.6,8.7,134,4.1,23,39,22,77,94,10,4.7,2.7,1.2,1.7,6.4,12.3,217,11.15,,4.0,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,16/7/2025,Outpatient,Tacrolimus,102.9,78.6,40.9,7.9,139,3.7,23,27,35,72,61,13,5.6,3.8,1.2,1.2,6.6,13.3,137,9.29,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,16/8/2025,Outpatient,Tacrolimus,60.0,120.0,40.0,6.4,140,4.5,25,20,17,101,94,16,4.7,2.9,1.1,1.6,4.4,14.4,312,7.92,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,16/6/2025,Inpatient,Tacrolimus,133.7,72.4,32.5,10.2,138,4.7,21,22,30,68,48,11,3.9,1.8,1.1,2.1,7.0,12.4,303,12.03,,4.0,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,17/6/2025,Inpatient,Tacrolimus,145.2,46.9,34.8,8.6,143,4.2,27,31,29,131,72,12,4.9,3.1,1.2,1.4,7.6,13.0,282,12.19,,4.0,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,17/7/2025,Outpatient,Tacrolimus,99.2,84.4,40.7,6.6,138,3.8,27,30,10,100,54,10,5.0,3.4,1.1,1.0,7.0,13.0,309,8.58,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,17/8/2025,Outpatient,Tacrolimus,77.2,108.4,39.6,3.4,141,4.1,26,18,8,105,46,8,5.0,3.3,1.0,1.5,6.8,14.9,213,8.11,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,17/6/2025,Inpatient,Tacrolimus,109.8,39.4,35.6,7.1,137,5.6,24,36,36,104,100,18,5.6,3.7,1.2,1.5,7.5,13.2,282,11.28,,4.0,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,17/7/2025,Outpatient,Tacrolimus,100.1,76.5,40.9,9.8,140,3.7,22,36,18,108,50,6,5.2,3.3,1.1,1.7,6.7,12.8,280,8.45,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,18/6/2025,Inpatient,Tacrolimus,134.3,61.5,35.1,10.0,141,4.4,24,35,21,117,69,20,5.0,3.0,1.1,1.7,7.0,11.7,253,9.75,,4.0,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,18/7/2025,Outpatient,Tacrolimus,115.6,96.1,38.9,6.9,136,3.9,24,12,21,83,72,16,4.5,2.7,1.2,1.3,5.3,13.2,203,10.32,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,18/8/2025,Outpatient,Tacrolimus,87.6,120.0,40.4,6.0,143,3.9,25,8,20,49,91,14,4.3,2.2,1.3,1.9,6.8,13.9,230,7.63,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,18/6/2025,Inpatient,Tacrolimus,107.9,66.5,38.1,9.5,135,4.2,21,32,19,125,37,14,5.5,4.0,0.8,1.5,4.0,13.3,198,8.99,,4.0,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,19/6/2025,Inpatient,Tacrolimus,133.1,41.3,35.7,9.8,140,3.8,25,25,32,106,85,12,5.1,3.2,1.2,1.5,6.5,11.2,229,9.41,,4.0,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,19/7/2025,Outpatient,Tacrolimus,105.3,84.9,40.2,5.8,140,4.4,22,8,14,79,52,15,5.0,3.4,0.9,1.5,5.8,12.9,289,10.11,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,19/8/2025,Outpatient,Tacrolimus,70.0,119.5,40.7,5.8,139,3.7,29,8,17,97,58,11,4.8,2.6,1.3,1.9,8.4,13.2,173,7.26,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,19/6/2025,Inpatient,Tacrolimus,124.7,84.4,37.0,12.8,140,4.4,23,43,42,95,75,15,5.2,3.7,1.0,1.2,8.3,12.7,178,11.17,,4.0,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,20/6/2025,Inpatient,Tacrolimus,143.6,67.1,36.2,7.4,142,4.4,25,24,36,62,52,14,5.6,3.8,1.0,1.7,8.5,14.6,256,10.45,,4.0,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,20/7/2025,Outpatient,Tacrolimus,94.9,83.6,40.8,7.1,136,4.7,23,19,9,46,42,9,5.0,3.2,1.0,1.8,5.8,15.0,208,8.85,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,20/8/2025,Outpatient,Tacrolimus,78.0,103.5,40.0,6.7,140,4.0,26,22,8,91,67,13,5.0,3.1,1.4,1.0,5.5,12.8,217,9.7,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,20/6/2025,Inpatient,Tacrolimus,140.2,62.3,38.2,4.8,139,4.9,21,44,21,67,29,18,4.8,3.2,1.2,1.1,9.0,12.5,216,12.67,,4.0,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,21/6/2025,Inpatient,Tacrolimus,123.2,77.0,37.4,5.4,137,3.9,26,25,32,101,41,14,4.9,3.0,1.5,1.1,7.6,12.2,250,9.46,,4.0,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,21/7/2025,Outpatient,Tacrolimus,79.5,84.9,39.9,3.2,136,4.4,25,29,17,91,24,14,5.2,3.1,1.4,1.6,6.8,13.7,270,7.81,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,21/8/2025,Outpatient,Tacrolimus,66.2,114.5,40.6,5.3,137,4.3,22,8,11,102,37,13,4.7,3.0,0.9,1.7,6.9,12.4,337,7.42,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,21/6/2025,Inpatient,Tacrolimus,140.2,90.3,31.6,13.1,134,4.4,23,37,28,158,98,17,4.2,2.4,1.3,0.9,5.5,13.8,257,10.4,,4.0,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,21/8/2025,Outpatient,Tacrolimus,112.4,57.9,39.2,7.9,135,4.2,27,33,16,82,51,7,5.2,3.1,1.5,1.4,6.8,16.0,197,8.75,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,22/6/2025,Inpatient,Tacrolimus,146.1,63.5,35.5,8.5,141,4.3,23,30,21,105,42,19,5.7,3.9,1.0,1.7,8.1,11.8,287,6.26,,4.0,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,22/7/2025,Outpatient,Tacrolimus,110.3,104.8,40.2,9.0,137,4.0,23,14,20,79,34,19,5.1,3.0,1.4,1.5,6.4,14.2,289,11.16,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,22/8/2025,Outpatient,Tacrolimus,75.4,120.0,40.4,5.8,137,4.1,23,19,20,68,56,13,4.6,2.3,1.6,1.5,6.6,14.0,286,7.82,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,22/6/2025,Inpatient,Tacrolimus,119.5,46.9,37.0,6.2,142,4.4,22,48,39,144,84,13,4.8,2.3,1.4,2.4,8.3,13.4,314,9.75,,4.0,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,23/6/2025,Inpatient,Tacrolimus,108.8,68.5,37.2,6.7,137,3.9,25,23,15,104,76,14,4.6,2.6,1.4,1.3,6.8,13.0,197,11.07,,4.0,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,23/7/2025,Outpatient,Tacrolimus,114.6,89.7,41.1,8.0,136,4.0,21,33,24,100,29,10,5.7,3.9,1.2,1.4,5.9,14.0,244,10.09,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,23/8/2025,Outpatient,Tacrolimus,66.1,120.0,39.8,7.2,142,4.3,22,8,8,81,67,14,4.6,2.9,1.2,1.0,5.3,13.0,295,10.04,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,23/6/2025,Inpatient,Tacrolimus,101.7,68.0,35.7,7.0,137,4.5,24,27,30,86,117,19,5.2,3.7,1.0,1.2,5.2,12.1,223,14.24,,4.0,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,24/6/2025,Inpatient,Tacrolimus,101.0,66.7,35.6,9.6,140,4.0,26,17,15,85,82,19,5.1,3.1,1.3,1.4,6.8,12.1,227,10.92,,4.0,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,24/7/2025,Outpatient,Tacrolimus,100.6,97.6,40.4,6.5,140,4.2,24,11,16,78,90,13,5.6,3.4,1.4,1.8,5.8,12.9,231,8.67,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,24/8/2025,Outpatient,Tacrolimus,60.0,120.0,40.2,5.4,136,3.8,26,20,11,75,66,19,5.1,3.1,1.3,1.8,9.2,13.7,282,7.77,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,24/6/2025,Inpatient,Tacrolimus,129.2,60.1,37.7,7.3,140,4.8,17,30,20,114,13,20,4.0,2.2,1.2,1.3,12.9,15.1,228,8.98,,4.0,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,24/7/2025,Outpatient,Tacrolimus,68.4,81.4,38.0,3.5,133,4.3,25,21,22,70,65,15,5.8,4.4,0.8,1.2,6.0,13.3,136,8.04,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,25/6/2025,Inpatient,Tacrolimus,120.9,59.6,36.7,7.4,139,4.6,26,45,24,86,59,17,4.7,3.1,1.0,1.5,6.3,12.2,299,9.25,,4.0,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,25/7/2025,Outpatient,Tacrolimus,95.1,75.7,41.3,8.5,140,3.8,24,25,17,109,63,17,4.6,2.5,1.2,1.9,4.9,12.1,290,7.9,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,25/8/2025,Outpatient,Tacrolimus,65.5,120.0,40.4,6.5,138,4.7,26,9,9,50,67,11,4.4,2.3,1.2,2.1,4.5,13.3,195,5.68,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,25/6/2025,Inpatient,Tacrolimus,111.0,93.5,35.3,10.1,140,3.9,26,44,31,45,35,20,5.2,3.5,0.9,1.6,7.5,13.1,227,11.73,,4.0,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,26/6/2025,Inpatient,Tacrolimus,134.9,79.4,36.2,6.7,138,4.0,23,15,30,109,45,10,5.4,3.4,1.4,1.3,7.8,12.3,274,10.34,,4.0,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,26/7/2025,Outpatient,Tacrolimus,111.9,94.2,41.4,8.6,138,4.9,25,15,9,87,32,21,4.5,3.2,0.8,1.2,7.7,14.2,198,10.34,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,26/8/2025,Outpatient,Tacrolimus,60.0,120.0,38.7,5.4,137,3.5,26,8,15,41,78,14,4.9,3.2,1.3,1.1,4.8,14.6,226,10.47,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,26/6/2025,Inpatient,Tacrolimus,109.0,80.1,33.5,5.6,136,4.2,25,42,45,122,91,20,5.0,3.1,1.2,1.4,8.6,13.2,105,7.6,,4.0,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,27/6/2025,Inpatient,Tacrolimus,115.0,70.9,38.2,11.2,138,4.1,26,34,36,101,66,9,4.2,2.7,1.1,0.9,7.0,12.1,198,4.69,,4.0,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,27/7/2025,Outpatient,Tacrolimus,79.9,98.4,39.5,6.7,138,4.7,22,12,9,65,57,11,4.3,2.4,1.4,1.2,7.1,14.2,316,9.96,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,27/8/2025,Outpatient,Tacrolimus,71.5,120.0,40.9,4.0,140,4.4,24,8,8,91,39,6,5.0,2.9,1.3,1.8,6.6,13.2,283,9.14,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,28/6/2025,Inpatient,Tacrolimus,111.6,64.6,38.6,8.9,139,3.6,25,28,18,73,112,14,5.4,3.8,1.2,1.0,9.0,13.6,227,10.95,,4.0,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,28/7/2025,Outpatient,Tacrolimus,98.6,83.0,38.3,6.7,140,4.0,27,8,10,81,51,17,5.4,3.8,1.2,1.1,6.5,13.6,278,6.2,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,28/8/2025,Outpatient,Tacrolimus,60.0,120.0,39.6,7.2,134,3.7,26,8,14,87,64,18,4.9,2.7,1.4,1.8,5.8,13.3,279,6.44,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,28/8/2025,Outpatient,Tacrolimus,85.9,62.8,41.9,7.1,139,3.2,22,31,23,112,35,12,5.3,3.3,1.0,2.2,8.0,15.1,204,7.9,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,29/6/2025,Outpatient,Tacrolimus,120.6,59.0,41.1,8.5,136,3.4,24,25,22,59,65,18,5.2,3.4,1.3,1.3,8.1,13.3,252,9.92,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,29/7/2025,Outpatient,Tacrolimus,113.7,97.7,41.3,8.2,144,4.1,23,20,21,81,43,13,5.1,3.3,1.2,1.4,2.9,14.4,262,9.14,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,29/8/2025,Outpatient,Tacrolimus,60.0,117.6,38.6,6.2,139,4.4,24,8,8,90,82,17,5.1,3.0,1.3,1.7,6.8,12.1,181,6.3,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,3/7/2025,Outpatient,Tacrolimus,92.0,59.4,41.8,9.6,143,4.7,23,30,34,140,45,13,6.1,4.4,1.2,1.0,5.6,14.9,230,7.64,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,30/6/2025,Outpatient,Tacrolimus,118.5,82.8,40.1,4.4,138,3.9,25,32,31,96,80,18,5.1,3.3,1.3,1.1,6.0,13.9,285,10.26,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,30/7/2025,Outpatient,Tacrolimus,82.9,97.4,40.8,4.0,142,3.9,25,13,19,87,85,14,4.8,2.5,1.5,1.7,5.4,13.4,283,10.4,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,30/8/2025,Outpatient,Tacrolimus,60.0,120.0,38.5,3.2,136,3.4,25,15,8,83,74,14,5.4,3.3,1.1,2.4,7.2,13.0,269,4.39,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,31/7/2025,Outpatient,Tacrolimus,86.2,75.5,39.1,6.5,137,4.0,23,15,17,128,56,14,5.3,3.4,1.1,1.6,7.9,12.3,234,8.3,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,31/8/2025,Outpatient,Tacrolimus,61.2,120.0,39.5,5.7,141,4.1,25,8,8,93,52,14,5.5,4.1,0.7,1.5,6.7,12.8,231,7.16,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,31/7/2025,Outpatient,Tacrolimus,95.7,79.4,39.0,5.9,139,4.3,24,29,33,81,49,13,4.8,3.2,1.1,1.3,5.6,13.4,166,7.03,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,4/9/2025,Outpatient,Tacrolimus,109.7,71.2,38.3,8.2,141,5.0,25,33,33,52,45,5,4.6,2.7,1.4,1.2,4.8,13.3,280,6.02,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1078,7600H,Lee Hui Chen,15/6/2025,7/8/2025,Outpatient,Tacrolimus,94.8,95.3,42.9,5.9,140,3.8,20,38,23,101,47,9,4.5,2.9,0.9,1.4,6.8,13.9,290,6.8,,3.45,*3/*3,CT,67.3,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1079,6238N,Farah Binte Ahmad,25/5/2025,1/6/2025,Inpatient,Cyclosporin,125.9,76.9,37.4,7.4,135,4.6,23,41,24,83,74,14,5.3,3.3,1.2,1.7,7.7,13.4,256,132.34,1098.8,356.4,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,1/7/2025,Outpatient,Cyclosporin,100.0,90.2,41.8,7.7,139,4.9,20,21,12,65,58,6,5.8,3.7,1.2,1.9,10.7,13.3,273,185.82,936.05,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,1/8/2025,Outpatient,Cyclosporin,60.4,112.2,39.8,6.1,141,3.8,24,14,20,90,45,11,6.4,4.3,1.2,2.1,6.7,13.5,225,171.39,757.37,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,2/6/2025,Inpatient,Cyclosporin,116.4,69.5,37.4,8.5,140,4.4,27,47,30,71,74,16,5.7,4.0,1.3,1.0,9.4,12.1,209,197.64,1116.29,356.4,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,2/7/2025,Outpatient,Cyclosporin,114.5,95.2,39.7,6.7,139,4.3,25,24,13,99,39,15,5.3,2.9,1.5,2.0,7.9,13.5,232,217.38,1032.31,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,2/8/2025,Outpatient,Cyclosporin,81.6,120.0,39.6,3.0,141,4.7,25,17,9,77,28,15,5.6,3.7,1.2,1.7,6.3,14.3,177,171.05,864.68,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,3/6/2025,Inpatient,Cyclosporin,122.3,77.6,35.6,8.5,141,4.4,24,31,35,127,62,19,5.7,3.7,1.2,1.8,5.3,12.9,229,200.98,1039.85,356.4,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,3/7/2025,Outpatient,Cyclosporin,91.8,109.7,40.8,5.2,139,3.9,24,30,20,96,73,14,6.5,4.3,1.6,1.2,6.7,11.8,244,229.83,1304.61,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,3/8/2025,Outpatient,Cyclosporin,61.4,120.0,40.6,6.7,135,4.1,25,20,13,108,44,5,5.7,3.8,1.3,1.3,8.8,12.0,265,187.73,597.19,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,4/6/2025,Inpatient,Cyclosporin,112.1,68.1,37.2,8.3,141,4.2,23,28,32,60,46,17,5.9,4.0,1.2,1.6,8.3,11.8,262,188.92,1025.84,356.4,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,4/7/2025,Outpatient,Cyclosporin,94.3,105.0,38.4,5.1,140,4.0,21,18,19,99,96,15,5.5,3.6,1.1,1.7,8.4,12.9,202,192.29,913.63,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,4/8/2025,Outpatient,Cyclosporin,64.2,117.0,38.9,4.9,140,4.5,28,8,8,56,36,15,5.6,3.6,1.2,1.9,7.4,13.7,287,163.34,682.15,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,5/6/2025,Inpatient,Cyclosporin,109.0,79.4,37.3,9.6,141,3.6,24,26,27,109,58,13,5.9,4.0,1.1,1.8,5.1,12.1,210,208.18,1289.31,356.4,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,5/7/2025,Outpatient,Cyclosporin,78.4,98.9,39.6,6.9,139,3.8,24,8,20,80,28,6,5.6,3.7,1.3,1.4,7.1,13.4,272,177.93,983.95,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,5/8/2025,Outpatient,Cyclosporin,60.0,117.3,39.5,5.9,140,4.0,28,16,13,84,36,13,5.0,3.2,1.0,1.8,5.6,13.6,259,184.01,707.79,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,6/6/2025,Inpatient,Cyclosporin,104.1,72.0,38.8,10.9,134,3.6,26,28,36,118,92,14,5.6,3.7,1.1,1.8,9.8,13.2,379,206.04,1019.55,356.4,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,6/7/2025,Outpatient,Cyclosporin,93.0,90.0,40.8,5.1,139,4.1,25,23,19,118,76,14,5.1,3.1,1.3,1.7,6.7,13.4,126,197.32,1064.95,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,6/8/2025,Outpatient,Cyclosporin,62.4,109.2,39.0,2.2,140,4.0,26,15,8,94,52,9,6.1,4.6,0.8,1.7,4.7,11.7,223,176.72,587.05,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,7/6/2025,Inpatient,Cyclosporin,125.4,70.7,37.1,5.6,138,4.1,24,35,26,102,75,18,6.3,4.3,1.2,1.7,7.7,12.7,172,162.37,1156.56,356.4,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,7/7/2025,Outpatient,Cyclosporin,84.4,113.4,40.7,10.1,140,4.1,21,18,19,74,66,15,5.6,3.5,1.2,2.0,4.8,12.9,163,190.13,1020.05,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,7/8/2025,Outpatient,Cyclosporin,60.0,120.0,39.1,4.4,136,3.9,24,15,16,50,92,12,5.9,3.5,1.6,1.9,7.0,14.1,186,173.75,1005.39,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,8/6/2025,Outpatient,Cyclosporin,120.1,93.4,39.8,7.1,142,4.8,25,24,32,123,58,13,5.7,3.8,1.2,1.7,5.6,13.9,244,225.44,1048.54,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,8/7/2025,Outpatient,Cyclosporin,81.2,94.8,39.2,6.6,139,4.2,25,17,18,98,66,18,5.6,3.6,1.2,1.9,5.9,13.0,186,120.36,1023.21,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,8/8/2025,Outpatient,Cyclosporin,60.0,120.0,41.2,2.8,141,3.8,25,11,21,103,32,14,6.1,4.2,1.1,1.7,5.5,13.1,345,196.28,739.57,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,9/6/2025,Outpatient,Cyclosporin,125.2,64.8,39.4,7.5,136,4.4,24,30,17,85,60,18,5.0,3.1,1.3,1.3,8.8,11.8,164,186.47,1064.38,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,9/7/2025,Outpatient,Cyclosporin,91.4,99.3,40.2,5.4,137,3.9,24,18,8,90,46,14,5.4,3.0,1.5,1.8,4.5,13.7,302,229.55,978.37,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,9/8/2025,Outpatient,Cyclosporin,60.0,120.0,40.0,3.5,138,4.1,27,8,16,99,60,11,6.3,4.5,1.1,1.7,6.5,14.2,233,131.4,954.38,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,1/6/2025,Inpatient,Cyclosporin,123.1,14.9,34.7,8.3,140,4.6,23,42,39,102,88,24,3.9,2.4,0.9,1.4,7.2,13.3,220,146.46,1222.9,356.4,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,1/8/2025,Outpatient,Cyclosporin,100.5,89.2,37.9,6.6,141,4.2,24,31,39,50,39,12,6.0,4.3,1.1,1.5,5.4,12.5,291,133.37,724.5,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,10/6/2025,Outpatient,Cyclosporin,118.6,107.3,39.7,8.2,140,3.9,25,27,24,79,88,21,5.7,3.7,1.2,1.8,6.9,13.2,303,198.92,1225.03,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,10/7/2025,Outpatient,Cyclosporin,76.6,96.6,38.5,5.1,137,3.8,27,20,16,92,76,12,5.7,4.0,1.1,1.3,7.2,14.3,209,189.2,748.18,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,10/8/2025,Outpatient,Cyclosporin,60.0,120.0,40.7,4.3,132,4.0,30,15,8,84,65,15,5.9,3.9,1.3,1.5,8.9,12.8,262,198.68,771.71,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,11/6/2025,Outpatient,Cyclosporin,102.5,71.1,40.7,8.0,143,4.0,23,32,26,69,75,16,5.7,3.5,1.3,2.0,6.7,13.8,245,169.5,1173.54,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,11/7/2025,Outpatient,Cyclosporin,89.7,104.2,39.8,6.4,138,4.2,23,15,15,102,55,11,5.7,3.9,1.1,1.6,8.6,12.2,286,180.98,993.27,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,11/8/2025,Outpatient,Cyclosporin,63.6,120.0,38.9,6.1,134,4.0,24,10,15,101,59,14,5.1,3.2,1.1,2.0,4.8,11.9,253,179.39,736.75,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,11/7/2025,Outpatient,Cyclosporin,152.7,81.8,38.3,6.7,137,4.1,25,23,22,104,31,15,4.1,1.9,1.4,1.6,6.5,15.4,261,104.96,801.87,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,12/6/2025,Outpatient,Cyclosporin,120.3,82.0,39.9,6.9,142,3.6,25,26,24,97,59,15,5.7,3.7,1.4,1.3,6.3,13.0,182,225.65,1037.97,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,12/7/2025,Outpatient,Cyclosporin,64.7,95.2,39.3,5.2,142,4.4,28,25,15,108,46,13,6.1,4.4,1.0,1.5,5.1,12.3,269,198.55,596.14,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,12/8/2025,Outpatient,Cyclosporin,60.0,120.0,40.6,3.6,140,3.8,25,10,8,82,69,15,5.6,3.4,1.3,2.1,6.0,15.4,176,189.39,703.31,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,13/6/2025,Outpatient,Cyclosporin,110.7,75.3,39.0,8.0,139,4.0,25,27,34,82,72,14,5.2,3.2,1.3,1.5,4.9,14.1,228,209.13,1096.24,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,13/7/2025,Outpatient,Cyclosporin,83.7,104.6,38.2,5.0,138,3.3,27,15,36,111,69,14,5.6,3.7,1.1,1.9,4.4,13.3,321,214.19,1057.93,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,13/8/2025,Outpatient,Cyclosporin,60.0,120.0,41.0,3.9,138,4.1,24,8,10,114,10,12,5.6,3.3,1.3,2.2,6.6,15.1,297,158.02,706.93,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,13/6/2025,Outpatient,Cyclosporin,60.0,78.4,40.1,6.1,141,4.8,25,43,37,125,51,15,4.9,3.0,1.3,1.4,7.3,12.2,274,184.96,723.01,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,14/6/2025,Outpatient,Cyclosporin,109.6,98.9,40.1,6.4,140,3.6,27,18,36,85,62,12,6.1,4.4,1.1,1.4,6.0,14.6,303,150.62,1062.05,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,14/7/2025,Outpatient,Cyclosporin,79.3,119.2,40.6,5.0,144,4.0,26,15,8,91,62,12,5.7,3.3,1.4,2.2,7.5,12.7,228,156.32,916.93,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,14/8/2025,Outpatient,Cyclosporin,68.0,120.0,40.3,3.5,140,3.9,26,8,26,88,89,9,5.7,3.9,1.1,1.5,8.6,12.4,213,146.72,767.96,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,15/6/2025,Outpatient,Cyclosporin,100.9,96.6,39.0,6.4,142,4.3,24,39,19,101,104,14,5.6,3.5,1.2,2.1,5.0,13.7,291,172.84,1193.58,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,15/7/2025,Outpatient,Cyclosporin,71.7,87.8,40.9,6.8,140,3.7,28,9,21,106,72,16,5.5,3.6,1.2,1.7,6.2,14.4,99,213.6,1174.01,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,15/8/2025,Outpatient,Cyclosporin,60.0,120.0,40.8,3.4,139,4.0,23,23,24,76,55,11,5.6,3.8,1.1,1.4,8.1,12.7,345,216.16,883.55,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,15/8/2025,Outpatient,Cyclosporin,76.9,58.6,40.8,7.2,136,4.3,27,17,29,83,59,16,4.7,3.3,1.0,0.8,6.6,13.5,262,96.72,888.42,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,16/6/2025,Outpatient,Cyclosporin,108.4,94.3,40.7,5.9,136,4.1,24,34,21,101,56,11,5.6,3.9,0.8,1.8,6.2,11.8,301,231.94,1052.89,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,16/7/2025,Outpatient,Cyclosporin,101.7,107.0,40.2,3.8,139,4.7,28,13,12,89,87,13,5.2,3.6,0.8,1.8,6.5,13.0,267,180.47,855.68,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,16/8/2025,Outpatient,Cyclosporin,60.0,120.0,40.1,2.8,141,4.4,23,8,8,98,10,13,6.6,4.6,1.1,1.7,11.1,12.8,265,192.77,772.81,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,17/6/2025,Outpatient,Cyclosporin,109.5,64.3,41.4,6.6,142,4.5,25,23,22,116,37,10,5.5,3.7,1.0,1.6,8.4,13.3,251,215.95,1041.44,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,17/7/2025,Outpatient,Cyclosporin,76.7,108.8,38.3,6.3,139,3.9,25,28,25,52,49,13,5.6,3.8,0.9,1.8,6.3,12.6,201,232.88,963.87,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,17/8/2025,Outpatient,Cyclosporin,60.0,120.0,38.3,3.8,137,4.4,25,8,11,61,74,17,5.3,3.2,1.4,1.6,3.2,14.0,267,183.05,726.15,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,18/6/2025,Outpatient,Cyclosporin,99.8,84.7,40.3,8.3,136,4.6,25,23,21,68,70,11,5.6,3.8,1.0,1.6,5.6,14.1,294,139.23,1119.4,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,18/7/2025,Outpatient,Cyclosporin,80.1,120.0,40.9,4.7,140,4.4,27,31,9,130,59,14,6.4,4.5,1.2,1.5,7.1,12.0,204,228.74,869.29,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,18/8/2025,Outpatient,Cyclosporin,60.0,120.0,39.9,4.5,140,3.9,23,8,10,54,68,13,5.5,3.6,1.3,1.4,6.6,15.0,225,152.15,683.33,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,18/7/2025,Outpatient,Cyclosporin,83.4,91.8,39.7,8.8,137,3.9,23,29,17,114,23,8,5.7,3.5,1.4,1.8,6.3,14.2,161,142.92,658.89,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,19/6/2025,Outpatient,Cyclosporin,109.5,87.7,38.2,6.7,141,4.5,23,32,34,70,94,11,6.4,4.6,1.3,1.4,8.0,14.2,304,195.06,1197.66,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,19/7/2025,Outpatient,Cyclosporin,72.5,112.6,41.9,5.9,137,4.3,24,22,13,83,57,20,5.8,3.7,1.4,1.4,5.4,13.9,220,197.51,1049.04,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,19/8/2025,Outpatient,Cyclosporin,60.0,119.3,40.9,2.5,136,4.4,25,8,24,103,69,11,6.2,4.0,1.4,1.7,4.6,12.7,262,223.23,647.23,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,2/6/2025,Inpatient,Cyclosporin,90.9,67.3,38.8,11.5,133,4.0,19,22,8,76,78,16,4.5,2.9,1.0,1.3,4.7,11.4,186,229.38,988.24,356.4,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,20/6/2025,Outpatient,Cyclosporin,101.9,74.1,39.4,7.3,138,4.3,22,38,20,63,76,13,5.4,3.1,1.2,2.4,5.6,13.6,299,111.57,1146.62,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,20/7/2025,Outpatient,Cyclosporin,77.7,113.1,40.7,4.0,139,3.8,26,19,8,120,81,15,5.1,3.2,1.4,1.1,8.4,13.3,248,101.85,725.37,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,20/8/2025,Outpatient,Cyclosporin,60.0,120.0,40.7,3.5,142,4.2,22,9,8,57,50,9,5.8,3.8,1.2,1.9,6.0,13.2,257,137.73,1115.35,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,20/6/2025,Outpatient,Cyclosporin,114.8,56.8,38.9,7.6,147,3.9,24,34,22,93,40,16,4.5,3.1,1.0,1.0,6.8,13.8,305,181.3,825.85,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,21/6/2025,Outpatient,Cyclosporin,105.8,84.2,39.2,7.5,139,4.5,22,11,20,62,81,18,6.4,4.4,1.0,2.2,6.5,14.2,223,206.1,1345.57,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,21/7/2025,Outpatient,Cyclosporin,79.5,111.3,41.2,5.4,139,4.1,24,19,8,97,56,13,5.2,3.3,1.3,1.5,5.6,15.6,288,136.56,762.02,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,21/8/2025,Outpatient,Cyclosporin,60.0,120.0,40.5,2.9,135,4.4,20,8,12,91,80,9,5.6,4.1,0.9,1.5,6.0,13.8,294,158.87,777.35,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,22/6/2025,Outpatient,Cyclosporin,96.1,73.1,40.2,8.8,138,3.8,23,26,31,66,46,12,5.0,3.1,1.1,1.8,5.3,12.9,284,153.49,1018.64,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,22/7/2025,Outpatient,Cyclosporin,79.9,120.0,39.6,5.8,136,4.2,23,18,18,120,32,13,5.1,3.0,1.3,1.7,6.0,14.0,319,151.01,921.59,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,22/8/2025,Outpatient,Cyclosporin,64.4,120.0,39.2,4.4,141,4.2,26,14,8,104,63,7,6.1,4.1,1.3,1.4,8.1,14.2,295,173.76,525.8,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,22/8/2025,Outpatient,Cyclosporin,82.4,81.6,39.4,7.0,138,4.8,21,25,31,62,33,10,5.5,3.8,1.2,1.1,6.8,13.2,305,180.08,563.7,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,23/6/2025,Outpatient,Cyclosporin,98.1,80.5,41.6,7.0,142,4.0,25,22,16,97,96,7,6.2,4.1,1.2,1.7,7.0,14.3,289,193.08,1137.55,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,23/7/2025,Outpatient,Cyclosporin,60.0,120.0,38.4,5.6,138,4.2,24,18,19,108,47,20,5.3,2.9,1.3,2.3,4.9,14.9,240,179.65,985.56,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,24/6/2025,Outpatient,Cyclosporin,92.6,94.3,40.5,9.8,136,3.7,24,25,20,88,40,17,5.6,3.7,1.0,1.8,4.7,13.4,328,129.79,923.32,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,24/7/2025,Outpatient,Cyclosporin,77.3,120.0,41.0,5.1,143,4.2,24,15,15,96,73,15,6.1,3.8,1.4,2.1,7.7,13.4,325,187.83,910.92,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,25/5/2025,Inpatient,Cyclosporin,131.0,58.4,36.7,8.4,140,4.4,26,38,27,102,69,19,6.0,3.7,1.8,1.3,5.6,14.3,261,195.06,1114.61,356.4,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,25/6/2025,Outpatient,Cyclosporin,102.7,91.1,41.6,4.5,140,4.6,21,27,35,78,45,15,5.4,3.4,1.3,1.7,3.9,13.8,297,185.8,1086.65,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,25/7/2025,Outpatient,Cyclosporin,78.6,120.0,39.6,5.6,142,4.4,23,38,12,127,96,12,6.0,3.9,1.0,2.2,7.7,13.6,177,181.83,1185.63,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,25/7/2025,Outpatient,Cyclosporin,60.0,62.3,37.1,8.5,138,3.9,27,29,46,119,52,14,4.7,2.6,1.3,1.7,5.4,13.9,297,211.15,1254.55,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,26/5/2025,Inpatient,Cyclosporin,142.8,67.8,35.5,9.2,139,4.0,24,46,31,74,41,12,6.3,4.6,1.1,1.4,9.6,11.9,253,221.26,1225.24,356.4,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,26/6/2025,Outpatient,Cyclosporin,117.8,67.7,41.3,6.9,137,3.9,24,18,14,115,64,20,5.1,3.1,1.2,1.8,5.2,11.3,249,137.22,889.99,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,26/7/2025,Outpatient,Cyclosporin,61.4,105.7,41.4,6.4,139,4.1,25,16,22,89,71,10,5.5,3.5,1.2,1.7,7.0,14.0,264,152.93,916.67,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,26/5/2025,Inpatient,Cyclosporin,109.8,60.2,32.1,5.7,141,4.0,22,8,16,63,59,25,4.7,2.8,1.1,1.7,7.1,11.3,327,167.38,963.47,356.4,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,27/5/2025,Inpatient,Cyclosporin,137.2,59.6,35.6,11.3,142,4.1,25,29,24,96,58,18,5.0,2.8,1.3,1.8,6.8,13.4,152,178.9,1496.58,356.4,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,27/6/2025,Outpatient,Cyclosporin,97.4,96.0,38.8,8.1,139,4.4,24,34,35,98,62,12,5.6,3.7,0.8,2.2,9.4,12.3,372,235.62,966.91,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,27/7/2025,Outpatient,Cyclosporin,84.8,116.0,40.2,4.5,140,3.8,25,24,13,87,63,11,5.4,3.5,1.3,1.3,7.5,12.1,250,184.95,798.22,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,27/5/2025,Inpatient,Cyclosporin,102.6,38.4,36.1,9.9,135,4.5,25,16,29,78,89,19,4.7,3.4,0.7,1.3,6.6,13.8,188,198.81,1285.98,356.4,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,27/6/2025,Outpatient,Cyclosporin,131.6,67.2,39.7,6.1,138,4.6,24,18,34,123,61,18,4.0,2.2,1.3,1.2,7.5,13.0,234,110.77,1027.11,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,28/5/2025,Inpatient,Cyclosporin,128.4,68.9,35.6,4.7,135,3.8,23,41,29,60,62,14,5.5,3.7,1.1,1.5,9.6,13.5,290,206.13,907.03,356.4,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,28/6/2025,Outpatient,Cyclosporin,84.9,87.8,40.7,6.9,137,4.0,27,36,19,98,56,18,6.1,4.2,1.1,1.5,5.3,13.1,224,184.75,1035.15,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,28/7/2025,Outpatient,Cyclosporin,69.7,120.0,40.1,4.9,139,4.7,21,20,24,101,38,15,5.5,3.7,1.2,1.2,8.6,13.4,213,124.04,1046.01,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,28/5/2025,Inpatient,Cyclosporin,83.1,79.1,33.6,6.9,138,4.0,21,14,28,165,88,13,4.7,3.1,1.0,1.4,9.0,11.1,221,150.42,1143.89,356.4,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,29/5/2025,Inpatient,Cyclosporin,116.0,75.3,35.2,4.5,139,4.0,23,35,20,102,63,13,5.8,3.7,1.1,2.2,4.7,11.8,282,222.32,1024.27,356.4,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,29/6/2025,Outpatient,Cyclosporin,96.8,104.2,39.5,8.0,137,4.0,24,17,28,88,68,14,6.0,4.2,1.0,1.8,6.9,13.5,309,153.07,1021.73,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,29/7/2025,Outpatient,Cyclosporin,67.5,118.7,38.8,5.8,139,3.2,27,13,13,123,71,15,6.1,4.5,0.9,1.5,8.9,13.1,192,161.3,644.48,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,29/5/2025,Inpatient,Cyclosporin,142.3,79.6,36.7,7.5,134,4.0,22,24,30,90,96,10,4.8,3.4,0.8,1.0,5.0,13.3,218,235.13,1148.25,356.4,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,3/6/2025,Inpatient,Cyclosporin,125.0,66.4,39.6,7.4,133,4.4,22,23,8,83,66,19,4.3,2.4,1.2,1.7,8.2,14.5,228,223.43,1079.62,356.4,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,30/5/2025,Inpatient,Cyclosporin,110.6,57.8,35.2,4.8,141,3.6,22,43,25,125,66,17,5.8,3.8,1.1,1.9,7.5,12.7,257,237.23,1030.99,356.4,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,30/6/2025,Outpatient,Cyclosporin,110.0,92.3,40.6,8.4,139,3.8,28,24,26,77,120,13,5.3,3.5,1.1,1.6,6.0,13.4,327,205.54,1003.39,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,30/7/2025,Outpatient,Cyclosporin,64.6,99.6,39.8,2.3,142,3.8,24,24,8,90,66,15,5.7,3.8,1.0,2.0,5.3,13.6,154,134.89,804.49,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,30/5/2025,Inpatient,Cyclosporin,153.3,50.7,36.5,8.4,142,4.6,22,39,18,115,118,5,4.6,3.0,0.9,1.6,4.1,14.1,205,130.88,1252.04,356.4,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,31/5/2025,Inpatient,Cyclosporin,126.3,52.4,35.8,9.9,140,4.2,26,11,24,148,59,24,5.8,3.8,1.1,2.0,9.4,13.3,170,223.86,950.15,356.4,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,31/7/2025,Outpatient,Cyclosporin,74.1,120.0,38.6,5.0,139,4.5,25,24,18,90,51,13,5.4,3.5,1.3,1.3,8.1,12.8,218,190.4,780.51,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,31/5/2025,Inpatient,Cyclosporin,121.8,67.6,34.2,9.8,139,4.0,18,36,27,67,71,13,5.3,3.7,1.0,1.3,5.9,13.0,218,232.84,1076.34,356.4,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,4/6/2025,Inpatient,Cyclosporin,93.4,72.7,36.0,8.6,140,5.3,20,49,40,58,21,21,4.2,2.9,0.8,1.1,7.5,11.6,215,146.89,1121.91,356.4,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,4/7/2025,Outpatient,Cyclosporin,102.8,58.2,39.9,7.9,136,4.5,21,22,29,111,72,12,5.6,3.8,1.3,1.2,8.3,12.6,260,128.33,817.72,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,5/6/2025,Inpatient,Cyclosporin,111.9,90.3,38.6,2.0,139,4.7,26,8,25,47,85,17,3.9,2.3,1.2,1.0,7.0,12.3,214,266.05,1001.4,356.4,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,6/6/2025,Inpatient,Cyclosporin,123.0,37.4,39.6,6.2,137,4.3,26,36,22,60,84,19,5.2,3.2,1.4,1.4,5.6,11.9,312,230.37,520.41,356.4,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1079,6238N,Farah Binte Ahmad,25/5/2025,8/8/2025,Outpatient,Cyclosporin,116.4,68.6,42.0,8.7,137,4.2,21,22,18,87,47,12,4.5,2.7,1.1,1.6,5.7,13.2,267,121.39,1138.93,307.8,*3/*3,CC,81.0,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,280.0,100–200,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,1/7/2025,Outpatient,Sirolimus,87.4,88.1,41.3,10.5,140,4.2,25,19,14,109,52,13,5.3,3.4,1.3,1.5,6.2,13.1,237,8.26,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,1/8/2025,Outpatient,Sirolimus,91.3,119.9,39.5,7.5,141,4.3,24,9,10,110,49,13,4.9,2.9,1.3,1.7,6.5,14.2,282,5.65,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,1/9/2025,Outpatient,Sirolimus,61.8,120.0,39.8,4.4,135,4.0,25,8,8,102,111,14,5.3,3.2,1.1,2.5,6.2,13.0,239,8.38,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,2/7/2025,Outpatient,Sirolimus,111.8,94.8,38.4,8.2,140,4.6,21,21,27,101,70,14,5.6,3.5,1.1,2.0,8.9,14.9,306,3.62,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,2/8/2025,Outpatient,Sirolimus,76.4,97.8,39.6,3.8,136,4.2,21,18,10,65,72,14,5.0,2.8,1.0,2.7,4.8,13.0,266,6.78,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,2/9/2025,Outpatient,Sirolimus,60.0,120.0,38.0,5.1,137,4.6,23,8,8,111,54,10,6.7,4.4,1.5,1.9,6.3,13.6,358,7.48,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,3/7/2025,Outpatient,Sirolimus,89.5,82.7,37.8,6.0,139,4.6,22,16,24,109,69,17,5.4,3.2,1.4,1.9,6.5,13.9,293,8.2,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,3/8/2025,Outpatient,Sirolimus,64.5,106.5,39.6,5.5,141,4.4,24,22,8,71,45,8,6.1,3.6,1.3,2.7,5.9,12.2,294,5.4,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,3/9/2025,Outpatient,Sirolimus,60.0,119.5,40.5,2.7,140,4.9,26,8,8,75,61,3,5.4,3.4,1.1,2.1,3.2,14.0,235,5.38,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,4/7/2025,Outpatient,Sirolimus,101.6,79.9,42.2,4.8,136,3.6,24,29,19,124,99,22,5.6,3.6,1.3,1.7,7.6,12.5,227,8.55,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,4/8/2025,Outpatient,Sirolimus,79.8,110.4,39.7,4.7,135,3.9,26,25,18,57,76,16,5.2,3.2,1.1,2.0,6.7,13.7,227,6.59,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,4/9/2025,Outpatient,Sirolimus,62.9,120.0,38.9,5.7,141,3.9,24,8,8,111,53,12,6.7,4.2,1.3,2.6,8.0,13.2,286,7.44,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,5/7/2025,Outpatient,Sirolimus,94.2,89.6,40.3,8.9,137,3.9,26,10,19,84,74,14,6.3,4.2,1.2,2.1,9.0,14.1,228,7.77,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,5/8/2025,Outpatient,Sirolimus,77.2,120.0,41.2,3.1,134,4.1,23,18,17,65,43,9,6.5,4.2,1.4,2.1,7.3,13.5,213,5.59,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,5/9/2025,Outpatient,Sirolimus,60.0,120.0,40.6,2.0,143,4.3,26,8,21,88,38,14,5.5,3.2,1.3,2.2,6.7,12.0,149,8.13,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,6/7/2025,Outpatient,Sirolimus,85.0,96.1,39.5,3.5,144,3.6,22,32,22,103,92,22,5.0,2.8,1.3,1.8,6.9,11.9,166,8.37,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,6/8/2025,Outpatient,Sirolimus,86.7,111.0,41.0,3.1,137,3.8,28,16,12,87,36,8,5.5,2.9,1.4,2.5,7.9,13.8,184,7.37,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,6/9/2025,Outpatient,Sirolimus,60.0,120.0,39.5,2.0,138,3.6,24,8,8,118,37,17,5.9,3.8,1.0,2.2,5.0,13.8,288,6.92,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,7/7/2025,Outpatient,Sirolimus,98.1,101.1,40.7,5.3,139,4.6,24,27,19,75,74,16,6.5,4.3,1.3,1.9,6.4,13.3,232,8.6,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,7/8/2025,Outpatient,Sirolimus,65.6,112.2,40.3,2.9,139,4.0,23,17,8,64,40,2,5.5,3.2,1.2,2.5,6.5,13.5,278,6.54,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,8/7/2025,Outpatient,Sirolimus,103.7,104.1,38.0,8.0,136,4.1,29,26,17,98,80,19,6.4,4.6,1.1,1.7,8.5,12.3,241,6.07,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,8/8/2025,Outpatient,Sirolimus,81.1,108.8,40.8,4.7,139,4.0,22,15,11,63,93,11,5.1,3.3,1.0,1.6,4.9,11.7,314,8.58,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,9/6/2025,Inpatient,Sirolimus,127.9,81.7,36.2,9.8,136,3.9,25,34,36,117,83,20,4.8,3.0,1.0,1.8,7.8,12.1,228,9.24,,5.31,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,9/7/2025,Outpatient,Sirolimus,96.5,74.7,39.1,8.9,137,4.2,24,23,19,81,49,15,5.4,3.3,1.3,1.6,5.7,14.6,126,6.12,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,9/8/2025,Outpatient,Sirolimus,72.2,97.7,39.8,7.7,135,4.0,24,15,18,89,66,14,5.3,3.3,1.2,1.6,6.5,13.1,228,5.48,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,10/6/2025,Inpatient,Sirolimus,134.5,60.4,35.3,8.3,140,4.1,22,22,39,104,75,14,5.3,3.6,0.9,1.5,9.5,13.2,271,6.97,,5.31,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,10/7/2025,Outpatient,Sirolimus,110.1,94.7,39.3,6.3,138,4.1,24,10,18,50,82,14,5.5,3.7,1.1,1.5,6.7,12.3,259,8.36,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,10/8/2025,Outpatient,Sirolimus,75.1,109.3,39.0,5.0,145,4.4,23,10,14,95,31,9,5.3,3.4,1.0,1.9,7.8,13.4,265,9.32,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,10/6/2025,Inpatient,Sirolimus,117.2,39.3,34.4,6.2,137,4.3,20,41,38,113,66,18,5.9,3.7,1.1,2.3,5.5,11.7,222,3.5,,3.81,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,10/8/2025,Outpatient,Sirolimus,87.1,67.2,41.6,7.0,142,4.0,25,33,27,92,54,12,6.1,4.1,1.2,1.8,5.5,13.9,192,7.71,,3.7,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,11/6/2025,Inpatient,Sirolimus,113.2,62.2,37.0,9.0,137,4.2,25,36,13,87,76,14,5.4,3.6,1.2,1.3,8.7,13.6,250,9.15,,5.31,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,11/7/2025,Outpatient,Sirolimus,101.6,91.1,39.5,6.2,140,4.1,24,24,8,97,48,9,6.0,4.5,1.0,1.1,7.6,14.5,332,5.26,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,11/8/2025,Outpatient,Sirolimus,60.4,120.0,41.9,6.5,139,3.9,23,16,8,103,88,17,5.7,3.7,1.0,2.2,6.9,14.1,271,5.23,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,11/6/2025,Inpatient,Sirolimus,83.6,83.9,37.0,8.1,141,4.3,19,18,17,93,60,16,6.4,3.9,1.1,3.0,6.8,12.6,206,10.11,,4.18,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,12/6/2025,Inpatient,Sirolimus,110.0,62.2,36.9,9.3,137,4.1,24,25,19,93,73,11,5.8,3.9,1.0,2.0,7.0,14.5,287,6.81,,5.31,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,12/7/2025,Outpatient,Sirolimus,86.4,94.7,39.5,5.5,139,4.0,27,20,23,128,62,11,6.1,4.2,1.0,2.0,8.3,14.4,301,7.57,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,12/8/2025,Outpatient,Sirolimus,73.9,120.0,40.6,5.7,138,4.0,26,8,14,106,34,13,6.2,4.2,1.0,2.1,4.8,15.2,297,5.61,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,12/6/2025,Inpatient,Sirolimus,140.8,86.9,30.1,8.2,136,5.1,22,39,41,110,76,10,6.9,5.3,1.1,1.1,5.8,12.9,268,10.17,,2.92,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,13/6/2025,Inpatient,Sirolimus,118.8,63.0,38.0,9.1,138,4.4,22,30,18,78,79,14,5.8,4.1,1.3,1.0,7.6,12.7,230,8.84,,5.31,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,13/7/2025,Outpatient,Sirolimus,94.4,88.4,41.1,7.5,140,4.3,24,20,8,91,74,15,4.8,2.9,0.9,2.3,6.4,13.6,316,7.91,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,13/8/2025,Outpatient,Sirolimus,75.0,120.0,41.2,5.0,139,3.9,24,8,11,87,92,7,5.7,3.9,0.9,2.0,10.9,14.8,334,4.63,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,13/6/2025,Inpatient,Sirolimus,134.9,110.6,36.5,6.8,142,4.8,24,37,35,93,107,19,6.4,4.3,0.9,2.8,7.5,15.5,218,8.32,,5.35,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,13/7/2025,Outpatient,Sirolimus,95.6,66.7,38.1,8.9,140,4.3,25,37,19,86,59,15,6.0,3.6,1.3,2.4,6.4,12.5,308,5.9,,4.6,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,14/6/2025,Inpatient,Sirolimus,118.0,73.4,37.1,10.6,138,4.8,23,40,30,124,95,11,4.7,2.7,1.2,1.8,9.1,13.2,200,8.45,,5.31,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,14/7/2025,Outpatient,Sirolimus,92.3,101.1,38.9,7.7,134,4.4,26,29,20,110,67,17,5.6,3.9,1.0,1.6,4.3,13.1,306,7.01,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,14/8/2025,Outpatient,Sirolimus,62.9,115.4,39.5,3.6,138,4.2,27,9,10,96,54,11,5.0,3.0,1.3,1.7,7.7,14.0,343,6.73,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,14/6/2025,Inpatient,Sirolimus,78.5,68.7,33.6,7.9,137,3.5,27,21,32,101,61,20,5.6,4.0,1.0,1.4,11.2,11.6,190,9.32,,5.06,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,15/6/2025,Inpatient,Sirolimus,111.4,75.0,38.1,9.1,136,3.8,22,17,35,70,65,17,5.5,3.7,0.9,2.0,8.1,12.1,294,9.71,,5.31,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,15/7/2025,Outpatient,Sirolimus,85.4,109.6,39.5,7.2,140,4.5,22,21,11,77,59,15,5.1,3.5,1.0,1.5,5.1,13.5,259,6.3,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,15/8/2025,Outpatient,Sirolimus,60.0,120.0,40.8,5.7,140,4.4,21,15,12,109,71,14,6.7,4.6,1.1,2.2,7.4,13.3,220,4.45,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,15/6/2025,Inpatient,Sirolimus,129.2,68.3,30.9,11.5,131,5.1,26,37,24,124,71,9,6.4,5.0,0.7,1.8,6.9,11.3,209,6.47,,3.01,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,16/6/2025,Inpatient,Sirolimus,145.4,61.1,35.9,9.0,140,4.6,23,31,34,119,74,16,4.5,2.6,1.2,1.5,7.7,13.9,206,8.96,,5.31,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,16/7/2025,Outpatient,Sirolimus,94.1,89.2,40.4,6.5,138,3.6,24,23,14,99,43,14,5.1,3.2,1.2,1.6,8.3,14.3,232,9.02,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,16/8/2025,Outpatient,Sirolimus,79.1,120.0,38.5,7.4,142,3.3,28,8,15,70,75,8,5.8,3.4,1.6,1.7,8.7,14.3,234,7.07,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,17/6/2025,Inpatient,Sirolimus,112.0,49.6,36.2,8.7,139,4.1,24,36,14,91,59,17,5.6,3.2,1.4,2.3,8.7,13.4,214,8.03,,5.31,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,17/7/2025,Outpatient,Sirolimus,104.3,94.4,40.9,7.6,143,4.0,26,8,17,92,43,15,5.8,3.6,1.5,1.7,8.4,15.0,274,7.05,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,17/8/2025,Outpatient,Sirolimus,63.6,115.9,41.5,6.8,141,4.1,24,11,9,92,65,13,6.6,4.5,1.3,1.9,6.8,12.4,247,7.13,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,17/8/2025,Outpatient,Sirolimus,103.9,91.3,39.3,5.6,140,4.3,24,26,25,118,41,13,6.3,4.0,0.9,3.2,5.7,12.7,238,7.54,,4.74,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,18/6/2025,Inpatient,Sirolimus,121.1,82.9,35.8,8.1,142,4.5,23,18,29,94,58,18,6.2,4.3,1.2,1.6,9.6,11.2,204,8.41,,5.31,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,18/7/2025,Outpatient,Sirolimus,94.5,105.1,40.0,8.0,138,4.1,25,15,15,90,52,6,6.1,4.2,1.0,1.9,5.3,15.9,220,9.07,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,18/8/2025,Outpatient,Sirolimus,60.0,120.0,40.6,5.2,138,3.8,25,10,9,90,56,9,5.9,3.2,1.5,2.6,9.1,14.3,187,6.25,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,19/6/2025,Inpatient,Sirolimus,122.6,71.9,38.1,8.6,140,4.2,22,29,38,83,71,18,5.2,3.0,1.4,1.8,8.4,10.9,221,5.05,,5.31,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,19/7/2025,Outpatient,Sirolimus,101.0,86.8,39.4,7.6,140,4.2,24,22,14,80,55,20,5.1,3.1,1.3,1.5,6.9,12.5,258,5.32,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,19/8/2025,Outpatient,Sirolimus,60.0,120.0,38.1,2.0,139,3.8,25,22,8,104,93,14,6.4,4.7,1.2,1.2,6.8,15.2,357,5.66,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,20/6/2025,Inpatient,Sirolimus,99.7,76.3,37.2,7.6,137,4.5,24,24,19,67,37,16,6.4,4.5,1.1,1.6,8.9,11.3,176,6.06,,5.31,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,20/7/2025,Outpatient,Sirolimus,82.8,101.1,38.8,6.1,139,3.9,22,20,8,103,45,14,5.0,3.0,1.3,1.6,7.6,12.8,260,7.1,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,20/8/2025,Outpatient,Sirolimus,60.0,120.0,40.1,5.2,136,4.0,26,21,18,77,22,12,5.9,3.8,1.2,2.1,8.1,14.4,248,9.41,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,20/7/2025,Outpatient,Sirolimus,124.4,62.2,39.5,7.5,137,5.1,22,29,21,101,48,13,5.5,3.4,0.9,2.8,5.9,12.5,330,4.57,,2.52,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,21/6/2025,Inpatient,Sirolimus,107.8,76.9,37.3,7.6,136,4.5,20,17,20,110,82,15,5.4,3.4,1.1,2.0,9.9,15.1,169,8.76,,5.31,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,21/7/2025,Outpatient,Sirolimus,73.1,104.9,39.6,5.5,141,4.1,24,18,16,113,51,9,5.9,3.9,1.2,1.8,7.5,12.5,253,9.34,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,21/8/2025,Outpatient,Sirolimus,60.0,120.0,39.5,5.3,134,3.7,27,9,8,78,74,10,5.5,3.5,1.3,1.6,6.6,12.7,176,5.49,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,22/6/2025,Inpatient,Sirolimus,126.6,72.8,37.5,5.6,133,4.1,23,41,36,88,51,12,5.1,2.7,1.2,2.5,9.5,11.5,182,8.67,,5.31,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,22/7/2025,Outpatient,Sirolimus,95.9,89.3,41.1,6.6,138,3.8,25,20,23,89,93,7,4.0,2.2,1.1,1.4,4.8,12.5,275,8.0,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,22/8/2025,Outpatient,Sirolimus,60.0,120.0,37.4,3.9,139,4.0,27,12,8,82,39,4,4.9,2.9,1.2,1.8,5.1,11.7,202,7.35,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,22/6/2025,Outpatient,Sirolimus,93.2,54.2,39.8,5.2,143,3.9,25,11,42,108,69,13,5.8,3.8,0.9,2.6,4.8,12.1,223,8.03,,4.47,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,23/6/2025,Outpatient,Sirolimus,137.5,75.2,41.0,7.4,138,4.4,24,20,37,83,74,13,4.9,2.5,1.4,2.2,7.6,12.5,274,7.79,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,23/7/2025,Outpatient,Sirolimus,84.9,90.4,40.8,6.4,141,3.8,22,13,16,90,34,15,5.4,2.9,1.4,2.5,7.8,14.0,266,5.04,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,23/8/2025,Outpatient,Sirolimus,60.0,120.0,41.1,4.6,142,4.1,27,8,14,85,70,14,6.1,4.3,1.1,1.4,7.4,12.5,285,3.09,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,24/6/2025,Outpatient,Sirolimus,109.0,71.5,38.8,5.5,139,3.8,21,22,28,94,73,12,5.3,3.8,0.8,1.5,8.3,12.1,194,6.19,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,24/7/2025,Outpatient,Sirolimus,84.8,99.6,40.2,6.9,139,5.0,23,16,23,66,59,13,5.9,4.2,1.0,1.6,7.8,13.0,214,7.63,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,24/8/2025,Outpatient,Sirolimus,64.3,120.0,40.7,7.1,138,4.4,24,10,17,60,80,8,5.5,3.3,1.4,1.7,5.8,13.8,275,6.24,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,24/8/2025,Outpatient,Sirolimus,81.5,71.7,37.6,9.6,138,4.4,21,16,43,48,48,18,6.9,4.3,1.3,2.8,8.4,11.6,284,8.32,,3.49,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,25/6/2025,Outpatient,Sirolimus,106.1,86.7,39.5,7.3,146,4.2,25,41,29,122,81,12,6.4,4.3,1.5,1.4,4.6,11.6,221,8.51,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,25/7/2025,Outpatient,Sirolimus,66.6,96.6,40.3,9.0,138,4.6,27,28,20,121,40,11,6.1,3.7,1.2,2.6,5.3,13.3,296,7.93,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,25/8/2025,Outpatient,Sirolimus,60.0,120.0,39.7,4.0,140,3.7,26,19,8,106,72,10,5.4,3.3,1.4,1.5,8.7,14.6,240,7.29,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,26/6/2025,Outpatient,Sirolimus,100.8,78.0,41.1,7.8,138,4.3,23,26,24,57,70,17,4.6,3.0,0.9,1.5,7.7,12.3,240,9.01,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,26/7/2025,Outpatient,Sirolimus,92.6,94.1,40.9,6.2,134,4.4,23,29,11,81,60,13,6.4,4.2,1.3,1.9,5.4,13.8,247,6.7,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,26/8/2025,Outpatient,Sirolimus,61.4,120.0,39.3,5.4,135,4.7,28,11,8,115,35,10,5.8,3.6,1.1,2.5,7.0,12.2,305,7.04,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,27/6/2025,Outpatient,Sirolimus,121.7,81.6,39.0,6.9,136,4.1,25,31,18,109,58,15,5.3,3.4,1.0,2.0,5.8,15.5,246,8.78,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,27/7/2025,Outpatient,Sirolimus,76.8,80.7,40.7,6.5,138,4.2,26,26,28,65,96,19,5.5,3.1,1.3,2.4,6.5,14.2,246,4.23,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,27/8/2025,Outpatient,Sirolimus,60.0,120.0,39.6,2.9,141,3.4,26,8,8,104,63,15,6.6,4.2,1.4,2.1,5.3,13.7,180,4.42,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,27/7/2025,Outpatient,Sirolimus,91.3,68.7,37.9,6.9,132,4.3,27,29,22,71,52,21,5.3,3.0,1.5,1.8,7.6,13.4,217,6.2,,4.24,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,28/6/2025,Outpatient,Sirolimus,104.7,68.2,39.1,9.0,138,4.4,25,18,32,66,68,15,6.0,3.9,1.1,2.2,6.7,12.7,298,8.43,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,28/7/2025,Outpatient,Sirolimus,60.0,110.3,41.7,4.9,139,3.8,23,21,8,87,79,10,5.3,3.7,1.0,1.3,6.1,12.6,287,5.05,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,28/8/2025,Outpatient,Sirolimus,60.0,120.0,40.3,7.9,134,4.2,24,8,12,81,32,12,6.6,3.9,1.4,2.7,8.2,14.8,261,7.68,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,29/6/2025,Outpatient,Sirolimus,110.3,79.3,39.9,7.9,135,5.0,20,21,13,91,71,14,5.2,3.6,0.9,1.6,6.1,12.7,304,8.16,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,29/7/2025,Outpatient,Sirolimus,93.0,106.4,40.8,4.3,135,3.8,25,19,14,101,110,10,6.3,4.5,0.8,2.2,8.9,13.4,216,7.94,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,29/8/2025,Outpatient,Sirolimus,60.0,120.0,38.8,2.2,135,3.8,24,8,8,91,60,12,5.5,3.4,1.4,1.7,6.1,14.8,325,5.68,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,29/6/2025,Outpatient,Sirolimus,97.7,90.3,42.3,5.6,137,4.4,24,24,23,113,53,16,5.5,3.0,1.2,2.9,5.2,13.4,360,9.44,,2.41,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,3/8/2025,Outpatient,Sirolimus,123.6,56.5,35.8,5.2,143,4.3,25,29,24,84,13,12,5.9,4.3,1.1,0.9,5.0,13.9,325,5.27,,2.46,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,30/6/2025,Outpatient,Sirolimus,114.1,84.8,38.9,7.1,137,4.1,24,32,16,109,71,17,5.3,3.3,1.3,1.7,6.5,11.9,286,4.89,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,30/7/2025,Outpatient,Sirolimus,88.1,106.6,40.7,5.6,141,4.2,26,15,13,73,54,13,6.3,4.3,1.1,1.8,5.4,14.3,299,8.96,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,30/8/2025,Outpatient,Sirolimus,60.0,120.0,41.2,6.9,141,4.6,28,12,8,110,48,16,5.7,3.4,1.6,1.5,6.1,13.6,224,7.25,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,31/7/2025,Outpatient,Sirolimus,71.3,105.7,38.5,5.9,134,4.5,24,16,13,80,83,17,5.7,3.5,1.5,1.5,6.3,12.3,215,6.33,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,31/8/2025,Outpatient,Sirolimus,60.0,120.0,39.7,5.6,141,3.4,26,8,11,78,41,12,5.8,3.8,1.1,1.7,6.5,14.6,220,7.97,,4.59,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,31/8/2025,Outpatient,Sirolimus,77.6,77.6,43.2,5.6,135,4.0,23,23,25,73,45,16,5.0,2.7,1.7,1.1,6.2,14.7,313,8.76,,4.68,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,6/7/2025,Outpatient,Sirolimus,116.0,74.5,40.4,9.1,140,4.3,24,28,37,102,50,11,6.5,4.6,1.0,2.0,6.6,14.4,233,6.49,,4.75,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1088,9118M,Teo Ying Hui,9/6/2025,7/9/2025,Outpatient,Sirolimus,90.8,57.8,42.6,6.2,134,4.0,29,42,19,95,79,15,6.8,4.0,1.7,2.5,5.3,12.0,228,6.38,,3.16,*1/*3,CT,69.7,,Expresser (functional),Normal (*1/*1),P-gp high (lower absorption),1.78,3.0,5–15,0.75
RT1091,7008C,Yap Wei Zhen,25/6/2025,1/7/2025,Inpatient,Tacrolimus,141.9,73.6,36.1,6.4,138,4.1,24,33,28,79,43,16,4.2,2.8,0.9,1.0,9.9,11.7,243,11.79,,4.09,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,1/8/2025,Outpatient,Tacrolimus,90.1,91.1,39.0,5.8,140,3.9,24,22,8,68,87,17,4.6,2.9,1.1,1.3,6.4,12.6,220,9.63,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,1/9/2025,Outpatient,Tacrolimus,60.0,111.5,39.0,2.9,138,4.2,23,17,14,83,112,15,5.2,3.0,1.4,1.7,5.7,13.0,332,6.28,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,2/7/2025,Inpatient,Tacrolimus,126.3,62.6,35.6,7.8,138,4.4,22,28,25,86,70,14,4.3,2.5,1.0,1.9,5.1,13.3,240,8.76,,4.09,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,2/8/2025,Outpatient,Tacrolimus,88.6,97.6,40.7,6.6,137,4.3,25,8,8,91,62,16,4.7,2.6,1.4,1.4,6.8,16.4,319,8.78,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,2/9/2025,Outpatient,Tacrolimus,61.8,120.0,40.3,4.1,137,3.3,27,8,19,115,75,15,4.8,2.8,1.2,1.7,7.3,13.6,267,7.94,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,3/7/2025,Inpatient,Tacrolimus,101.0,58.8,37.0,11.6,140,4.1,25,26,15,97,92,15,5.1,3.0,1.1,2.1,7.2,14.0,326,8.94,,4.09,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,3/8/2025,Outpatient,Tacrolimus,102.0,93.2,39.1,7.0,141,4.2,26,18,14,86,70,14,5.2,3.2,1.1,2.1,5.9,13.8,286,7.06,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,3/9/2025,Outpatient,Tacrolimus,72.2,120.0,39.9,3.3,140,3.8,25,16,8,88,53,15,4.3,2.4,1.1,1.8,4.9,13.6,207,7.62,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,4/7/2025,Inpatient,Tacrolimus,107.7,81.0,37.8,9.3,136,4.2,23,35,30,109,57,15,5.4,3.5,1.2,1.6,7.1,12.1,256,11.1,,4.09,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,4/8/2025,Outpatient,Tacrolimus,112.4,112.2,39.1,4.7,139,4.6,24,26,23,101,71,21,5.6,3.8,1.1,1.4,7.9,12.4,308,7.33,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,4/9/2025,Outpatient,Tacrolimus,64.6,120.0,41.2,5.9,140,4.2,29,14,15,88,89,15,5.2,3.3,1.3,1.3,4.4,14.4,238,9.4,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,5/7/2025,Inpatient,Tacrolimus,108.1,57.0,38.1,7.3,138,4.0,26,24,15,72,57,14,4.6,2.6,1.2,1.6,8.4,12.1,236,11.2,,4.09,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,5/8/2025,Outpatient,Tacrolimus,87.6,98.5,39.6,4.2,140,4.5,28,19,21,104,66,14,5.0,3.2,1.0,1.8,6.6,12.8,251,8.64,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,5/9/2025,Outpatient,Tacrolimus,65.9,120.0,41.9,4.4,134,3.7,27,13,8,74,87,11,4.4,2.7,1.1,1.3,5.6,13.9,196,8.84,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,6/7/2025,Inpatient,Tacrolimus,115.7,57.4,36.9,7.3,138,4.6,27,22,26,79,94,17,5.3,3.1,1.4,1.8,7.7,13.2,231,5.73,,4.09,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,6/8/2025,Outpatient,Tacrolimus,84.9,103.5,40.3,5.3,136,4.3,21,18,12,117,74,12,4.6,2.8,1.3,1.1,7.1,13.3,251,6.4,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,6/9/2025,Outpatient,Tacrolimus,60.0,120.0,40.5,8.3,140,3.9,27,8,8,104,62,18,5.5,3.7,1.1,1.5,5.8,12.5,324,7.64,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,7/7/2025,Inpatient,Tacrolimus,101.7,75.2,37.4,9.5,135,4.4,24,32,26,70,85,16,4.5,2.5,1.2,1.8,8.3,13.5,274,11.93,,4.09,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,7/8/2025,Outpatient,Tacrolimus,73.6,92.2,39.8,7.6,137,3.8,25,13,15,100,84,12,5.3,3.6,1.3,0.9,6.2,11.0,277,9.16,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,7/9/2025,Outpatient,Tacrolimus,60.0,117.3,39.5,3.3,137,4.1,24,10,9,114,47,16,5.6,3.9,1.3,1.1,8.6,14.1,170,10.28,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,8/7/2025,Inpatient,Tacrolimus,115.5,65.5,36.9,8.4,140,4.2,23,15,10,110,18,15,5.0,3.0,1.2,1.7,5.4,13.6,191,8.91,,4.09,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,8/8/2025,Outpatient,Tacrolimus,102.0,110.0,40.7,5.4,140,4.0,23,28,27,114,81,18,4.5,2.7,1.3,1.3,7.3,13.7,262,8.87,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,8/9/2025,Outpatient,Tacrolimus,60.0,120.0,41.0,5.5,140,4.5,25,15,8,105,56,8,4.4,2.7,0.9,1.6,8.2,12.5,162,7.81,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,9/7/2025,Outpatient,Tacrolimus,116.6,85.2,40.2,10.8,134,4.7,25,36,27,80,55,15,5.1,3.1,1.3,1.5,6.8,15.2,247,10.97,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,9/8/2025,Outpatient,Tacrolimus,81.3,96.6,40.7,6.8,138,4.4,24,16,11,82,69,8,5.0,3.3,0.9,1.8,6.7,14.1,287,10.01,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,9/9/2025,Outpatient,Tacrolimus,60.0,120.0,39.4,3.3,142,3.9,26,9,18,63,61,13,6.0,4.2,1.1,1.5,6.3,11.9,307,6.12,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,1/7/2025,Inpatient,Tacrolimus,106.0,30.0,36.1,7.5,136,4.0,21,22,28,83,35,22,4.7,2.5,1.2,2.0,9.0,12.9,208,8.42,,4.09,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,10/7/2025,Outpatient,Tacrolimus,146.9,84.2,40.5,6.9,141,4.4,27,34,18,88,59,12,5.4,3.3,1.4,1.8,7.2,12.8,301,9.01,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,10/8/2025,Outpatient,Tacrolimus,91.5,107.1,42.3,5.1,138,4.5,24,16,13,114,78,17,4.8,2.7,1.4,1.3,5.7,13.3,175,7.61,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,10/9/2025,Outpatient,Tacrolimus,73.6,120.0,40.4,5.8,136,4.4,26,8,8,93,46,13,4.6,2.8,1.0,1.8,5.7,14.6,190,8.0,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,11/7/2025,Outpatient,Tacrolimus,104.5,68.1,41.2,4.9,139,4.2,25,25,24,78,74,13,4.2,2.3,1.3,1.4,5.6,13.0,269,7.2,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,11/8/2025,Outpatient,Tacrolimus,92.5,101.2,39.9,5.2,141,3.8,24,19,17,55,80,15,4.8,2.9,1.1,1.8,8.6,13.1,328,6.63,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,11/9/2025,Outpatient,Tacrolimus,60.0,120.0,39.1,5.9,136,4.1,26,15,11,84,19,5,4.8,2.5,1.4,2.1,7.7,13.8,249,8.67,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,12/7/2025,Outpatient,Tacrolimus,116.4,87.3,41.0,9.1,137,3.7,25,24,26,101,70,16,5.0,3.0,1.1,2.1,5.6,13.6,291,11.33,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,12/8/2025,Outpatient,Tacrolimus,96.8,89.7,42.1,5.4,142,3.2,23,15,20,100,49,16,4.9,3.3,1.1,1.3,7.9,13.7,164,5.52,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,12/9/2025,Outpatient,Tacrolimus,60.0,120.0,41.2,2.7,139,4.2,25,8,8,69,26,9,5.2,3.3,1.2,1.5,7.6,13.3,274,4.63,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,12/8/2025,Outpatient,Tacrolimus,115.0,70.2,38.5,5.1,131,4.7,24,23,14,105,62,17,4.5,2.5,1.1,2.1,8.8,14.1,247,6.31,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,13/7/2025,Outpatient,Tacrolimus,122.2,70.3,41.7,8.9,134,4.3,26,24,24,90,71,14,5.0,3.1,1.3,1.4,7.3,13.7,312,12.97,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,13/8/2025,Outpatient,Tacrolimus,79.0,107.7,40.2,3.8,139,3.6,24,17,14,61,64,11,4.9,3.2,1.1,1.2,8.7,13.2,269,11.11,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,13/9/2025,Outpatient,Tacrolimus,60.0,120.0,41.9,2.0,137,4.1,26,13,8,67,74,17,4.6,3.0,1.0,1.2,5.6,13.7,191,6.88,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,14/7/2025,Outpatient,Tacrolimus,103.2,79.4,40.4,6.6,137,4.3,27,28,12,115,65,20,4.4,2.5,1.2,1.5,6.9,14.0,286,9.69,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,14/8/2025,Outpatient,Tacrolimus,95.2,96.4,38.5,6.8,142,4.2,25,15,31,94,69,19,4.8,3.1,1.1,1.3,8.6,14.1,303,8.09,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,14/9/2025,Outpatient,Tacrolimus,60.0,116.5,41.1,6.9,143,3.3,24,25,8,101,64,12,4.8,3.1,1.1,1.3,9.5,15.5,360,5.18,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,15/7/2025,Outpatient,Tacrolimus,96.2,60.2,39.0,7.3,139,4.2,23,29,24,116,78,10,5.4,3.5,1.3,1.4,8.0,12.0,190,9.79,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,15/8/2025,Outpatient,Tacrolimus,81.2,112.6,40.3,6.4,137,4.2,26,20,20,69,38,10,5.7,3.8,1.2,1.5,7.6,12.8,231,8.38,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,15/9/2025,Outpatient,Tacrolimus,60.0,117.1,40.5,5.2,136,4.2,24,8,8,115,57,13,5.4,3.8,1.0,1.3,7.1,12.9,210,8.88,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,15/7/2025,Outpatient,Tacrolimus,84.6,80.7,40.5,8.2,143,4.3,27,27,22,127,60,11,6.0,4.2,1.0,1.6,3.7,12.9,290,10.43,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,16/7/2025,Outpatient,Tacrolimus,100.7,82.3,40.0,7.0,135,4.1,23,13,26,81,59,13,5.6,3.2,1.7,1.7,7.7,14.0,335,8.51,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,16/8/2025,Outpatient,Tacrolimus,85.5,114.3,40.6,4.8,137,4.0,25,27,14,80,59,16,5.2,2.9,1.3,2.0,6.1,15.6,271,7.92,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,16/9/2025,Outpatient,Tacrolimus,63.1,120.0,39.3,5.2,138,4.0,25,8,8,105,68,15,5.1,3.8,0.8,1.1,4.6,13.3,275,8.24,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,16/9/2025,Outpatient,Tacrolimus,104.4,70.5,42.9,9.2,139,3.9,24,48,20,69,48,8,6.2,4.4,1.1,1.6,7.0,15.5,325,7.77,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,17/7/2025,Outpatient,Tacrolimus,115.5,69.7,41.1,9.4,140,3.4,27,19,26,94,77,17,5.0,3.4,1.1,0.9,6.0,13.9,329,10.24,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,17/8/2025,Outpatient,Tacrolimus,92.5,120.0,39.6,7.8,133,3.7,23,16,24,105,65,17,4.4,2.7,1.0,1.6,5.8,13.2,287,11.55,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,17/9/2025,Outpatient,Tacrolimus,61.9,120.0,40.0,3.8,143,4.2,26,11,12,96,69,13,5.4,3.8,1.0,1.3,4.2,14.0,323,8.03,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,18/7/2025,Outpatient,Tacrolimus,117.4,96.2,41.1,10.2,141,4.7,26,21,16,91,46,16,4.6,2.8,1.1,1.5,6.3,15.3,249,11.15,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,18/8/2025,Outpatient,Tacrolimus,81.0,106.4,39.3,4.9,140,4.1,25,21,17,96,67,16,4.8,3.2,1.3,0.9,5.9,13.8,300,8.6,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,18/9/2025,Outpatient,Tacrolimus,60.0,120.0,39.6,4.0,140,3.9,26,15,8,59,54,12,5.2,3.4,1.0,1.9,8.3,13.5,279,9.55,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,19/7/2025,Outpatient,Tacrolimus,118.0,83.3,40.5,8.1,138,3.9,23,10,19,126,46,19,5.2,3.3,1.1,1.8,5.5,15.0,306,10.1,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,19/8/2025,Outpatient,Tacrolimus,73.7,100.0,40.9,4.4,143,4.4,26,20,9,110,48,18,4.8,3.0,1.1,1.5,5.4,12.1,338,6.65,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,19/9/2025,Outpatient,Tacrolimus,60.0,120.0,40.4,2.8,138,3.7,26,8,8,76,56,12,5.6,3.6,1.3,1.5,5.3,13.2,249,6.14,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,19/8/2025,Outpatient,Tacrolimus,73.6,47.3,39.2,6.2,136,3.7,25,28,23,107,68,13,4.8,2.4,1.3,2.5,8.5,14.3,186,8.08,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,2/9/2025,Outpatient,Tacrolimus,131.7,78.8,39.5,2.0,140,4.9,22,41,24,69,66,4,5.4,3.8,1.0,1.2,7.3,13.3,284,8.06,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,20/7/2025,Outpatient,Tacrolimus,101.6,65.8,39.4,3.9,139,3.6,21,24,15,75,84,19,4.2,1.9,1.6,1.6,7.2,12.6,345,8.03,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,20/8/2025,Outpatient,Tacrolimus,66.1,120.0,40.3,6.6,139,3.6,23,8,18,124,49,12,5.3,3.3,1.3,1.5,9.1,14.7,324,8.26,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,20/9/2025,Outpatient,Tacrolimus,60.0,120.0,40.0,4.4,137,4.1,26,8,8,92,29,12,5.6,3.7,1.2,1.5,7.7,12.2,343,6.63,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,21/7/2025,Outpatient,Tacrolimus,101.7,80.3,41.0,7.5,140,4.2,28,11,27,91,59,7,5.1,3.2,1.1,1.8,5.5,14.0,317,8.9,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,21/8/2025,Outpatient,Tacrolimus,63.5,120.0,39.8,6.9,136,3.5,26,15,11,106,55,15,5.2,3.3,1.3,1.4,7.9,13.9,117,9.1,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,21/9/2025,Outpatient,Tacrolimus,60.0,120.0,39.1,2.0,141,3.4,27,8,15,73,31,14,5.3,3.4,1.1,1.7,4.8,14.7,236,6.08,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,22/7/2025,Outpatient,Tacrolimus,110.6,103.1,40.0,9.2,135,4.5,23,22,15,89,47,16,4.5,2.6,1.5,0.8,5.5,13.0,308,8.28,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,22/8/2025,Outpatient,Tacrolimus,89.6,105.4,39.5,3.7,143,4.0,24,38,11,45,81,15,5.1,3.1,1.2,1.6,7.4,14.0,233,7.23,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,22/9/2025,Outpatient,Tacrolimus,60.0,120.0,39.5,3.2,134,3.9,26,14,15,88,23,15,4.9,3.1,1.4,0.9,4.7,12.9,230,6.69,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,22/7/2025,Outpatient,Tacrolimus,131.0,60.2,41.5,4.1,138,4.9,22,43,14,100,26,14,5.4,3.4,1.1,2.1,6.7,14.9,214,8.95,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,23/7/2025,Outpatient,Tacrolimus,121.1,84.5,38.6,6.1,137,4.1,27,10,23,69,45,16,6.4,4.8,1.1,1.1,6.6,13.9,322,8.73,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,23/8/2025,Outpatient,Tacrolimus,65.6,107.7,38.9,6.5,136,3.7,25,8,9,65,66,24,5.6,4.1,1.2,0.8,6.4,14.0,261,8.7,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,23/9/2025,Outpatient,Tacrolimus,84.9,61.5,39.3,7.8,141,3.4,24,37,29,71,22,14,4.8,2.9,1.3,1.3,5.5,12.6,208,8.05,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,24/7/2025,Outpatient,Tacrolimus,88.5,89.2,40.8,7.2,138,3.8,25,17,13,81,84,17,5.1,3.4,1.1,1.4,5.8,12.4,169,8.19,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,24/8/2025,Outpatient,Tacrolimus,74.1,102.7,40.3,6.0,136,3.5,28,8,9,76,51,19,5.3,3.4,1.0,1.9,7.8,13.9,234,10.26,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,25/6/2025,Inpatient,Tacrolimus,128.1,66.3,35.3,9.2,136,4.2,21,41,23,128,49,17,5.1,3.5,1.0,1.2,5.3,11.0,206,10.15,,4.09,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,25/7/2025,Outpatient,Tacrolimus,98.8,86.1,39.1,8.9,141,4.0,23,16,16,77,59,11,5.4,3.5,1.3,1.3,6.0,12.8,246,8.92,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,25/8/2025,Outpatient,Tacrolimus,67.2,110.9,41.4,9.6,141,3.9,24,9,15,82,87,15,5.6,3.8,1.2,1.5,6.9,11.8,266,9.75,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,26/6/2025,Inpatient,Tacrolimus,132.4,49.2,35.2,9.2,132,3.7,23,36,34,95,78,14,4.9,3.0,1.3,1.4,6.6,12.5,290,8.77,,4.09,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,26/7/2025,Outpatient,Tacrolimus,104.2,97.8,41.9,6.0,140,3.9,24,28,14,99,59,18,5.7,3.9,1.0,1.9,9.4,14.2,256,9.83,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,26/8/2025,Outpatient,Tacrolimus,84.6,120.0,39.8,4.5,135,4.5,23,22,16,70,51,14,5.2,3.4,1.1,1.5,7.2,13.0,244,6.52,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,26/6/2025,Inpatient,Tacrolimus,107.2,66.7,37.1,10.2,140,4.3,23,43,15,69,67,24,5.1,3.3,1.0,1.7,7.9,14.2,178,12.31,,4.09,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,26/8/2025,Outpatient,Tacrolimus,102.6,66.0,41.2,5.2,139,4.8,24,8,28,73,61,5,5.2,2.9,1.7,1.3,8.8,13.1,268,9.99,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,27/6/2025,Inpatient,Tacrolimus,118.6,60.6,36.5,7.8,140,4.0,26,19,27,91,70,13,5.1,3.3,1.1,1.4,8.4,12.1,317,10.36,,4.09,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,27/7/2025,Outpatient,Tacrolimus,94.4,102.2,40.6,4.2,142,4.5,23,26,19,134,36,23,4.5,2.6,1.2,1.7,8.8,14.4,260,8.46,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,27/8/2025,Outpatient,Tacrolimus,78.4,119.2,40.6,2.9,138,3.2,24,24,10,101,59,13,4.9,2.7,1.4,1.7,6.9,13.9,232,7.88,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,27/6/2025,Inpatient,Tacrolimus,133.5,33.8,36.1,9.1,136,4.2,21,36,41,111,51,15,5.0,3.1,1.1,1.7,7.4,9.5,199,13.69,,4.09,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,28/6/2025,Inpatient,Tacrolimus,127.8,70.8,37.1,5.6,140,4.6,23,30,33,99,86,12,4.5,2.4,1.3,1.6,7.1,12.7,271,9.9,,4.09,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,28/7/2025,Outpatient,Tacrolimus,95.3,77.9,40.3,9.0,137,4.2,26,14,26,79,75,12,5.4,3.7,1.1,1.4,5.9,13.3,263,7.14,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,28/8/2025,Outpatient,Tacrolimus,73.7,120.0,39.3,7.4,141,4.3,23,13,8,69,87,11,4.8,3.2,1.0,1.3,7.7,13.7,164,4.66,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,28/6/2025,Inpatient,Tacrolimus,128.9,47.8,36.2,10.3,142,3.9,21,49,24,60,62,23,5.4,3.1,1.3,2.2,4.5,14.2,221,12.78,,4.09,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,29/6/2025,Inpatient,Tacrolimus,130.2,61.5,36.1,6.2,134,4.2,23,28,23,82,40,12,5.3,3.6,1.2,1.3,8.8,12.3,233,7.83,,4.09,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,29/7/2025,Outpatient,Tacrolimus,81.8,68.2,40.2,6.2,145,4.2,25,36,22,68,60,14,5.0,3.2,1.1,1.5,5.2,13.3,337,11.38,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,29/8/2025,Outpatient,Tacrolimus,65.8,120.0,40.0,6.3,137,4.3,25,21,13,75,80,13,5.4,3.1,1.5,1.8,6.8,14.2,273,8.28,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,29/6/2025,Inpatient,Tacrolimus,116.1,26.8,31.0,3.5,141,4.5,25,49,37,72,103,23,6.3,4.7,1.1,1.3,8.0,12.5,204,11.52,,4.09,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,29/7/2025,Outpatient,Tacrolimus,60.0,72.6,39.0,6.5,140,4.5,25,34,26,69,55,9,4.6,2.9,1.0,1.6,6.2,14.3,254,7.29,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,30/6/2025,Inpatient,Tacrolimus,122.2,71.4,36.1,6.6,138,4.2,22,21,31,100,80,17,5.4,3.7,1.2,1.2,8.8,13.0,179,12.52,,4.09,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,30/7/2025,Outpatient,Tacrolimus,110.1,102.6,39.1,6.2,138,4.8,23,13,28,112,103,12,4.7,2.8,1.1,1.7,7.3,13.6,237,7.21,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,30/8/2025,Outpatient,Tacrolimus,62.8,114.0,38.8,5.2,144,3.8,25,13,9,109,25,11,5.6,3.6,1.1,1.9,4.3,14.6,239,6.84,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,30/6/2025,Inpatient,Tacrolimus,89.9,15.4,35.9,7.5,138,3.5,25,8,9,91,58,13,4.2,2.6,0.9,1.5,6.3,15.1,233,8.46,,4.09,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,31/7/2025,Outpatient,Tacrolimus,93.8,77.7,37.2,7.6,141,3.3,25,22,19,83,59,12,4.7,2.9,1.1,1.5,7.1,10.6,293,9.16,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,31/8/2025,Outpatient,Tacrolimus,60.0,112.1,41.6,4.5,140,4.0,27,8,38,107,70,14,5.9,4.0,1.1,1.6,8.4,11.6,135,6.48,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,5/8/2025,Outpatient,Tacrolimus,60.7,116.1,37.5,9.2,143,4.2,25,24,25,81,77,16,4.3,2.5,1.1,1.5,5.5,13.1,247,7.78,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,8/7/2025,Outpatient,Tacrolimus,99.8,58.5,38.8,4.9,136,4.8,24,32,20,121,47,15,4.6,2.5,1.5,1.4,5.8,12.5,259,7.71,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
RT1091,7008C,Yap Wei Zhen,25/6/2025,9/9/2025,Outpatient,Tacrolimus,84.8,82.1,41.6,3.8,137,3.7,21,22,30,76,60,11,4.4,2.5,1.3,1.2,7.2,12.8,208,7.24,,3.53,*3/*3,CC,68.8,,Non-expresser (loss-of-function),Normal (*1/*1),P-gp high (lower absorption),1.05,6.0,5–12,0.8
